Studies on the regulatory mechanisms of Fcγ receptor function by Bournazos, Stylianos
St u d ies  on  t h e  R eg u la to ry  M ec h a n ism s  of 
Fey R ecep to r  Fu n ctio n
S t y l ia n o s  B o u r n a z o s
Doctor of Philosophy 
The University of Edinburgh 
2010
Volume II
D e c l a r a t io n
This thesis and the research described herein is solely my own work. All work 
presented in this thesis was, unless otherwise acknowledged, initiated and 
executed by myself. All sources of information in the text have been 
acknowledged by reference. No part of this work has been, or is submitted for 
any other degree qualification.
Stylianos Bournazos
T a b l e  o f  C o n t e n t s
1. A b stra ct......................................................................................................................1
2. Fc Receptors.............................................................................................................. 4
2.1. Immunoglobulins.............................................................................................. 4
2.2. Fc Receptor C lasses...........................................................................................7
2.2.1. The Fey Receptor Fam ily .............................................................................................................................................................................................................................7
2.2.2. The Fee Receptor Fam ily ......................................................................................................................................................................................................................13
2.2.3. Receptors fo r  IgM and IgA .............................................................................................................................................................................................................17
2.3. Fc Receptor Function.......................................................................................19
2.3.1. Signalling and Function o f Activatory Fc Receptors ...........................................................................................19
2.3.2. Cellular Effects of Activatory Fc Receptor Signalling ........................................................................................25
2.3.3. Signalling and Biological Effects o f Non-Activatory Fc Receptors  26
3. Neutrophil G ran u lo cyte s..................................................................................... 30
3.1. Features and Role............................................................................................30
3.1.1. Pathogen Recognition  -  Role o f Fey Receptors ................................................................................................................31
3.1.2. Effector Functions and Cellular Responses ..................................................................................................................................33
3.2. Neutrophil Apoptosis-Opsonisation and Clearance...................................37
4. Clearance of Apoptotic Neutrophils: Role of C D 3 2 ........................................ 47
4.1. Introduction.....................................................................................................47
4.2. Results...............................................................................................................48
4.2.1. Apoptotic neutrophils display Increased binding o flg G  complexes to 
CD32 ...............................................................................................................................................................................................................................................................................................................................................48
4.2.2. IgG complex binding of apoptotic neutrophils increases macrophage- 
mediated apoptotic cell phagocytosis .....................................................................................................................................................................................57
4.2.3. M acrophage CD64 and CD32 mediate uptake o f IgG-opsonised  
apoptotic neutrophils ................................................................................................................................................................................................................................................................65
4.2.4. IgG opsonisation o f apoptotic neutrophils augments their phagocytosis 
by TNF-a and LPS-treated m acrophages ......................................................................................................................................................................... 71
4.2.5. Phagocytosis o f IgG opsonised apoptotic neutrophils suppresses LPS- 
induced pro-inflam m atory cytokine release ...........................................................................................................................................................75
4.2.6. Phagocytosis o f IgG opsonised apoptotic neutrophils enhances the 
clearance o f non-opsonlsed apoptotic neutrophils ..........................................................................................................................78
4.3. Discussion................................................................................  86
5. M yeloid-Specific Suppression of CD32 Ligand Binding A ctiv ity ...................96
5.1. Introduction..................................................................................................... 96
5.2. Results............................................................................................................... 97
5.2.1. Differential regulation o f IgG complex binding to CD32 receptor in 
various cell types ......................................................................................................................................................................................................................................................................................97
5.2.2. Neutrophil activation has no effect on CD32-mediated immune 
complex b ind ing ...................................................................................................................................................................................................................................................................................108
5.2.3. Immune complex binding to CD32 is increased follow ing treatment 
with serine proteases ...........................................................................................................................................................................................................................................................112
5.2.4. Inhibition o f N-linked glycosylation and removal o f surface sialic acid 
residues increases CD32-mediated IgG complex b ind ing ........................................................................................123
5.2.5. Removal o f GPI-anchored molecules by PI-PLC significantly upregulates 
CD32-mediated immune complex b ind ing ...........................................................................................................................................................130
5.2.6. CD16 has no regulatory role in the CD32-mediated IgG complex 
bin d in g ..............................................................................................................................................................................................................................................................................................................................135
5.2.7. Suppressed CD32 ligand binding activity on neutrophils results in 
impaired IgG-mediated reactive oxygen species production ........................................................................ 144
5.3. Discussion....................................................................................................... 148
6 . Role of Lipid Rafts in IgG Binding to C D 3 2 ......................................................154
6.1. Lipid Rafts....................................................................................................... 154
6.1.1. Lipid Rafts: Properties and Characteristics ............................................................................................................................154
6.1.2. Role o f Lipid Rafts in Receptor Function .........................................................................................................................................160
6.2. Introduction.................................................................................................... 164
6.3. Results.............................................................................................................166
6.3.1. Disruption o f lipid rafts reduces CD32-mediated IgG complex binding 
 166
6.3.2. IgG complex binding to CD32 induces receptor translocation to lipid 
rafts .............................................................................................................................................................................................................................................................................................................................................180
6.3.3. Exclusion o f CD32 from  lipid rafts results in decreased IgG complex 
b in d in g ..............................................................................................................................................................................................................................................................................................................................183
6.3.4. Palmitoylation o f CD32 promotes association with lipid rafts and 
regulates IgG complex binding .................................................................................................................................................................................................................192
6.3.5. Constitutively lipid raft associated CD32 displays increased IgG 
complex b ind ing ...................................................................................................................................................................................................................................................................................203
6.4. Discussion....................................................................................................... 215
7. Idiopathic Pulm onary F ib ro sis ..........................................................................225
7.1. Clinical Features and Diagnostic Criteria ...................................................225
7.2. Pathogenic Mechanisms............................................................................... 231
7.2.1. Role o f Inflammatory Processes .............................................................................................................................................................................231
7.2.2. Role o f Immune Complexes as Initiators o f Lung Injury ...................................................................237
7.3. Genetic Determinants of IP F .........................................................................240
7.3.1. Familial Forms o f IP F ................................................................................................................................................................................................................................240
7.3.2. Sporadic IPF Cases ............................................................................................................................................................................................................................................242
8 . Fc Receptor Genetic Variation........................................................................... 246
8.1. Types of Genetic Variants.............................................................................. 246
8.1.1. Single Nucleotide Polymorphisms (SN Ps) ..................................................................................................................................246
8.1.2. Copy Number Variation ....................................................................................................................................................................................................................253
8.2. Fc Receptor Genetic Variants as Risk Factors for Chronic Inflammatory 
Diseases................................................................................................................. 258
9. Fey Receptor Genetic Variants as Risk Factors for IP F ................................. 266
9.1. Introduction.................................................................................................... 266
9.2. Results.............................................................................................................268
9.2.1. IPF is associated with increased frequency o f the NA1 a lle le .......................................268
9.2.2. NA1/2 polymorphisms have no effect on IPF disease progression  274
9.2.3. FcyRlla R131H polymorphism does not confer susceptibility to IPF ...279
9.2.4. The FcyRlla FH31 variant is associated with more severe pulm onary 
function at presentation ...............................................................................................................................................................................................................................................282
9.2.5. R131FI polymorphism is associated with IPF disease progression  287
9.2.6. Copy number variation o f FCGR3B is associated with susceptibility to 
IP F ...................................................................................................................................................................................................................................................................................................................................................292
9.2.7. FCGR3B copy number variation is correlated with FcyRlllb surface 
expression levels ....................................................................................................................................................................................................................................................................................302
9.2.8. FCGR3B copy num ber variation does not influence IPF disease 
progression ............................................................................................................................................................................................................................................................................................................304
9.3. Discussion....................................................................................................... 308
10. Sum m ary and Conclusions...............................................................................317
11. M aterials and M e th o d s................................................................................... 323
11.1. Antibodies, Reagents and Culture M edia................................................. 323
11.2. Bacterial Strains........................................................................................... 329
11.3. Plasmid Constructs......................................................................................329
11.4. Clinical Study Subjects................................................................................ 331
11.5. Cell Isolation and Culture............................................................................ 332
v
11.5.1. Cell Lines and Culture .......................................................................................................................................................................................................................332
11.5.2. Leukocyte Isolation ...................................................................................................................................................................................................................................334
11.5.3. Generation o f Human M onocyte-Derived M acrophages ...................................................335
11.6. ¡mmunolabelling and Flow Cytom etry......................................................336
11.7. IV.3 (anti-CD32a) Antibody Purification.....................................................337
11.8. Protein Biotinylation................................................................................... 339
11.9. CD32 Immunoprecipitation and Immunoblotting.................................... 339
11.10. Immune (IgG) Complex Binding Assay.....................................................341
11.10.1. Generation o f Immune Com plexes ....................................................................................................................................................341
11.10.2. M easurement o f Immune Complex B inding ..........................................................................................................342
11.11. Induction and Assessment of Neutrophil Apoptosis............................. 342
11.12. Macrophage Phagocytosis Assay............................................................. 343
11.12.1. Cell Labelling fo r Phagocytosis A ssa y ........................................................................................................................................343
11.12.2. Flow Cytometry-based Apoptotic Cell Phagocytosis Assay .......................................344
11.12.3. Microscopy-based Apoptotic Cell Phagocytosis A ssa y .........................................................346
11.13. Cytokine Measurement.............................................................................347
11.14. Measurement of NADPH Oxidase Activity.............................................. 348
11.14.1. M easurement o f Intracellular ROS leve ls ......................................................................................................................348
11.14.2. Superoxide Release Assay ..............................................................................................................................................................................................349
11.15. Analysis of CD32 Tyrosine Phosphorylation............................................350
11.16. Nucleic Acid Purification...........................................................................351
11.16.1. M olecular Biology-grade Bacterial Plasmid DNA Extraction  351
11.16.2. Transfection-grade Bacterial Plasmid DNA Extraction .........................................................352
11.16.3. Purification o f PCR Products ..................................................................................................................................................................................353
11.16.4. Genomic DNA Extraction ................................................................................................................................................................................................. 354
11.17. Bacterial Transformation...........................................................................355
11.18. Short Hairpin RNA (shRNA)-Mediated CD32 Expression Knock-Down .357
11.19. Site-Directed Mutagenesis....................................................................... 357
11.19.1. Design o f Mutagenic Primer Pairs ....................................................................................................................................................... 357
11.19.2. Site-Directed M utagenesis ........................................................................................................................................................................................358
11.19.3. Plasmid DNA sequencing ................................................................................................................................................................................................. 359
11.20. Generation of GPI-anchored CD32 .......................................................... 360
11.20.1. Design o f the GPI-anchored CD 32 ....................................................................................................................................................... 360
11.20.2. Cloning o f the CD32/55 Chimaeric Protein ................................................................................................................361
11.21. Generation of Transgene-Expressing Cell Lines...................................... 364
11.21.1. Cell Transfection .........................................................................................................................................................................................................................................364
11.21.2. Cell Se lection ........................................................................................................................................................................................................................................................366
11.21.3. Cell So rtin g .................................................................................................................................................................................................................................................................366
11.22. Assessment of CD32-Lipid Raft Interactions...........................................367
11.22.1. Detergent-Resistant M embrane Fractionation and A nalysis  367
11.22.2. Confocal Immunofluorescence M icroscopy .............................................................................................................369
11.23. Measurement of Cellular Cholesterol......................................................370
11.24. SNP Genotyping......................................................................................... 371
11.24.1. Allele-specific PCR A m plification .............................................................................................................................................................371
11.24.2. DNA Sequencing o f PCR Products ..........................................................................................................................................................373
11.24.3. Allotype-specific Neutrophil Immunolabelling and Flow Cytometry 
..................................................................................................................................................................................................................................................................................................................................................................374
11.25. Measurement of FCGR3B Copy Number Variation.................................375
11.25.1. Quantification o f FCGR3B Copy Num ber by Quantitative Real-Time 
PCR (qPCR) ..............................................................................................................................................................................................................................................................................................................375
11.25.2. Bioinformatics Analysis o f Array Comparative Genome Hybridization 
(aCGH) D a ta .....................................................................................................................................................................................................................................................................................................377
11.26. Data Analysis............................................................................................. 378
11.26.1. Statistical A nalysis ................................................................................................................................................................................................................................378
11.26.2. Pulmonary Function Data Analysis ....................................................................................................................................................378
11.26.3. Genetic Analysis -  S N P ...........................................................................................................................................................................................................379
11.26.4. Genetic Analysis -  CNV ..........................................................................................................................................................................................................380
12. A cknow ledgem ents...........................................................................................382
13. R e fe re n ce s..........................................................................................................385
14. List of A bbreviations......................................................................................... 467
15. A p p e n d ice s .........................................................................................................474
15.1 Plasmid Maps and Sequences................................................................... 474
15.1.1. pSELECT-neo-mcs-FCGR2A ................................................................................................................................................................................................. 474
15.1.2. pSELECT-neo-mcs-FCGR2A X h o l .........................................................................................................................................................................477
15.1.3. pSELECT-neo-mcs-FCGR2A A 224S ................................................................................................................................................................480
15.1.4. pSELECT-neo-mcs-FCGR2A C 2 4 1 A .............................................................................................................................................................483
15.1.5. pSELECT-neo-mcs-FCGR2A sh78m m ....................................................................................................................................................486
15.1.6. pJ201:CD55-GPI ..................................................................................................................................................................................................................................................489
15.1.7. pSELECT-neo-mcs-CD32/55 ...............................................................................................................................................................................................491
15.1.8. pLKO. 1 -puro-TRCN029574 ................................................................................................................................................................................................. 494
15.1.9. pLK0.1-puro-TRCN029575 ..................................................................................................................................................................................................
15.1.10. pLKO.l-puro-TRCN029576 ..........................................................................................................................................................................................  502
15.1.11. pLKO .l-puro-TRCN 029577 ........................................................................................................................................................................................... 506
15.1.12. pLK0.1-puro-TRCN029578 ............................................................................................................................................................................................510
15.2 Posterior Probability and Copy Number Assignm ent................................514
15.2.1. PCA-transformed D a ta ............................................................................................................................................................................................................... .......
15.2.2. LDF-transformed Data ....................................................................................................................................................................................................................522
15.3 ECCS/ERS Predicted Lung Function Values................................................. 530
15.3.1.Male s ................................................................................................................................................................................................................................. 53 q
15.3.2. Fem ales ......................................................................................................................................................................................................................................................  952
viii
11. M a t e r ia l s  a n d  M e t h o d s
11.1. Antibodies, Reagents and Culture Media
All chemical reagents were from Sigma Aldrich (Poole, Dorset, UK), unless 
otherwise stated. Human leukocyte elastase was from Elastin Products 
Company (Owensville, Missouri, USA) and dextran T-500 from Pharmacia / 
Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). Percoll™ and 
OptiPrep™ density media were from GE Healthcare (Chalfont St. Giles, Bucks, 
Buckinghamshire, UK) and Axis Shield/Sigma Aldrich (Uxbridge, Middlesex, 
UK), respectively. Purified LPS (E.coli 0111 :B 4) was from Sigma Aldrich and 
recombinant human TNF-a from R&D Systems (Abingdon, Oxfordshire, UK). 
Protease inhibitor cocktail reagents were from Roche Applied Science 
(Burgess Hill, West Sussex, UK) and Fluka / Sigma Aldrich (Buchs, 
Switzerland). Phosphatase inhibitors and the biotinylation reagent (EZ-Link™ 
Sulfo-NHS-LC-Biotin) were from Pierce / Thermo Fisher Scientific 
(Cramlington, Northumberland, UK). Protein G-Sepharose™ was from GE 
Healthcare. Ultrapure agarose was from Invitrogen (Renfrew, Paisley, 
Renfrewshire, UK) and low-melting point agarose was from Promega 
(Southampton, Hampshire, UK). Tris Borate EDTA (TBE) buffer was obtained 
from Invitrogen. FluorSave™ reagent was from Merck-Calbiochem (Beeston, 
Nottingham, UK). Fluorescein isothiocyanate- (FITC-), R-Phycoerythrin- (R- 
PE-) and allophycocyanin- (APC-) conjugated recombinant annexin V were 
obtained from Caltag, Invitrogen (Renfrew, Paisley, Renfrewshire, UK). TO- 
PRO®-3 nuclear stain, biotin-conjugated recombinant cholera toxin B subunit,
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Alexa Fluor™ 647-conjugated recombinant streptavidin, 
dihydrorhodamine-123 (DHR123), 5-chloromethylfluorescein diacetate 
(CMFDA; CellTracker™ Green) and 7-hydroxy-9H-(l,3-dichloro-9,9- 
dimethylacridin-2-one) succinimidyl ester (DDAO-SE)(CellTrace™ Far Red) 
were obtained from Molecular Probes, Invitrogen (Renfrew, Paisley, 
Renfrewshire, UK). Horseradish peroxidase (HRP)-conjugated recombinant 
streptavidin was from Dako Cytomation (Ely, Cambridgeshire, UK). Cholesterol 
and cholesteryl ester quantification kit was from Merck-Calbiochem. 
Cytometric bead array reagents (human inflammation kit) were from BD 
Biosciences (Oxford, Oxfordshire, UK).
Lipofectamine LTX™ and Lipofectamine PLUS™ transfection reagents were 
from Invitrogen and jetPEI™ reagent from PolyPlus™ Transfection (Autogen 
Bioclear, Caine, Wiltshire, UK). G418 (neomycin) was from Merck-Calbiochem 
or Invitrogen. Unless otherwise stated, all SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) reagents and buffers were from 
Invitrogen and Atto Corporation (Braintree, Essex, UK), with the exception of 
nitrocellulose protein transfer membrane, which was obtained from 
Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). Enhanced 
chemiluminescence (ECL™) and ECL Plus™ reagents were from Amersham/GE 
Healthcare (Chalfont St. Giles, Bucks, Buckinghamshire, UK). All PCR reagents 
were from Promega, with the exception of oligonucleotide primers, which 
were synthesised and purified by MWG Biotech -  Eurofins (Ebersberg, 
Germany) and the high fidelity Pfu Polymerase, which was obtained from
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Stratagene - Agilent Technologies UK (Stockport, Cheshire, UK). Reagents used 
for plasmid extraction (molecular biology- and cell transfection-grade), DNA 
extraction, nucleic acid purification, and qPCR were from Qiagen (Crawley, 
West Sussex, UK). Ligase and alkaline phosphatase enzymes were obtained 
from Roche Applied Science and restriction endonucleases were from 
Promega or Roche Applied Science.
The following mouse monoclonal anti-human CD32 antibodies were used in 
this study: IV.3 (IgG2b, or F(ab’) 2), AT-10 (IgGl, R-PE-conjugated, Abeam, 
Cambridge, Cambridgeshire, UK), or F(ab’) 2), 7.3 (F(ab ’) 2  from IgGl, Ancell 
Corp. Bayport, Minnesota, USA), and FLI8.26 (IgG2b, FITC-conjugated; BD 
Biosciences). Goat polyclonal anti-human CD32a (AF 1875) was obtained from 
R&D Systems. Corresponding isotype control antibodies were from Dako 
Cytomation, AbD Serotec (Kidlington, Oxfordshire, UK), or Sigma Aldrich and 
included: mouse monoclonal IgGl isotype control (MOPC-21, Sigma Aldrich), 
mouse monoclonal IgG2a isotype control (UPC-10, Sigma Aldrich), mouse 
monoclonal IgG2b isotype control (MOPC-141, Sigma Aldrich), FITC- or R-PE- 
conjugated mouse IgGl negative control (AbD Serotec). Mouse monoclonal 
anti-human caveolin-I (C060, IgM and 2297, IgGl), mouse monoclonal anti­
human flotillin-1 (clone 18/flotillin-l, IgGl), mouse monoclonal anti-human 
transferrin receptor/CD71 (clone 2, IgGl), and biotin-conjugated mouse 
monoclonal anti-phosphotyrosine (PY-20, IgG2b) were from BD Transduction 
Laboratories (BD Biosciences, Oxford, Oxfordshire, UK). FITC-conjugated 
mouse monoclonal anti-biotin (BN-34, IgGl), FITC-conjugated mouse
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monoclonal anti-human CD16 (3G8, IgGl), FITC-conjugated mouse 
monoclonal anti-human CD62L (FMC46, IgG2b), and agarose-conjugated goat 
polyclonal IgG anti-mouse immunoglobulin were from Sigma Aldrich. FITC- 
conjugated mouse monoclonal anti-human C D llb  (ICRF44, IgGl), mouse 
monoclonal anti-human CD16 (3G8, IgGl), and mouse monoclonal anti-human 
CD64 (10.1, IgGl) were from AbD Serotec. FITC-conjugated mouse monoclonal 
anti-human CD24 (SN3, IgGl), and FITC-conjugated mouse monoclonal anti­
human CD16 (3G8, IgGl) were from Caltag, Invitrogen and BD Pharmingen 
(Oxford, Oxfordshire, UK), respectively. R-PE-conjugated mouse monoclonal 
anti-human GPI-80 (3H9, IgGl) was obtained from MBL International 
(Woburn, Massachusetts, USA). CD16b allotype-specific mouse monoclonal 
antibodies were the following: for NA1: CLB-gran/11 (IgG2a), and for NA2: 
GRM-1 (IgG2a). HRP-conjugated goat polyclonal IgG anti-mouse 
immunoglobulin, HRP-conjugated rabbit polyclonal IgG anti-goat 
immunoglobulin, and FITC- or R-PE-conjugated goat polyclonal F(ab ’) 2  anti­
mouse immunoglobulin were from Dako Cytomation. FITC- or Alexa Fluor™ 
488-conjugated goat polyclonal F(ab ' ) 2  anti-mouse immunoglobulin were from 
Invitrogen. Further details about all the antibodies used in this study are 
presented in Table 11.1.
Cell culture media, buffers and other supplements and reagents, including L- 
glutamine, penicillin/streptomycin and trypsin/EDTA solutions were obtained 
from PAA Laboratories (Pasching, Austria), unless otherwise stated. Iscove's 
Modified Dulbecco's Medium (IMDM) and RPMI 1640 media were from PAA
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Laboratories or from Invitrogen. Dulbecco’s Modified Eagle Medium (DMEM): 
Ham's F-12 (DMEM:F12) medium and Opti-MEM® I Reduced growth medium 
were obtained from Invitrogen. Foetal bovine serum (heat-inactivated or not) 
was purchased from Biowest (Ringmer, West Sussex, UK). Terrific Broth (TB), 
bacterial selection antibiotics and other reagents used for bacterial cell culture 
were from Sigma Aldrich. Lysogeny Broth (LB) media were prepared in-house 
with reagents purchased from Sigma Aldrich, BDH (VWR International, 
Lutterworth, Leicestershire, UK) and Oxoid (Basingstoke, Hampshire, UK).
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Table 11.1: Monoclonal and Polyclonal Antibodies Used in this Study
Specificity Reactivity Host Clonality Isotype Clone Conjugation Supplier
C D llb Hu Mo Mono IgGl ICRF44 FITC (FL1) AbD Serotec
CD16 Hu Mo Mono IgGl 3G8 FITC (FL1) BD Pharmingen
Hu Mo Mono IgGl 3G8 - In house/Serotec
Hu Mo Mono IgGl 3G8 FITC Sigma
CD16b NA1 Hu Mo Mono lgG2a CLB-gran/11 - 1
CD16b NA2 Hu Mo Mono lgG2a GRM-1 - 1
CD24 Hu Mo Mono IgGl SN3 FITC(FLl) Invitrogen
CD32 Hu Mo Mono lgG2b FLI8.26 FITC(FLl) BD Pharmingen
Hu Mo Mono IgGl AT-10 R-PE (FL2) Abeam
Hu Mo Mono Ffab'h AT-10 - 2
Hu Mo Mono F(ab')2 7.3 - Ancell
CD32a Hu Mo Mono lgG2b IV.3 - In house
Hu Mo Mono F(ab'h IV.3 - In house
Hu Go Mono IgG - - R&D Systems
CD62L Hu Mo Mono lgG2b FMC46 FITC (FL1) Sigma
CD64 Hu Mo Mono IgGl 10.1 - AbD Serotec
CD71 Hu Mo Mono IgGl 2 - BD Transduction
Caveolin-I Hu, Ha Mo Mono IgGl 2297 - Laboratories
Hu, Ha Mo Mono IgM C060 -
Flotillin-1 Hu Mo Mono IgGl 18 -
GPI-80 Hu Mo Mono IgGl 3H9 R-PE (FL2) MBLIntl
Ig Mo Go Poly IgG - HRP Dako Cytomation
Go Ra Poly IgG - HRP Dako Cytomation
Mo Go Poly IgG - Agarose Sigma
Mo Go Poly F(ab')2 - R-PE (FL2) Dako Cytomation
Mo Go Poly F(ab')2 - FITC (FL1) Dako Cytomation
Mo Go Poly F(ab')2 - FITC (FL1) Invitrogen
Mo Go Poly F(ab')2 - AF488 (FL1) Invitrogen
Negative - Mo Mono lgG2a UPC-10 - Sigma
control - Mo Mono lgG2b MOPC-141 - Sigma
- Mo Mono IgGl MOPC-21 - In house
- Mo Mono IgGl 3 FITC(FLl) AbD Serotec
- Mo Mono IgGl 3 R-PE (FL2) AbD Serotec
P-tyrosine - Mo Mono lgG2b PY-20 Biotin BD Biosciences
Biotin - Mo Mono IgGl BN-34 FITC (FL1) Sigma
Notes: 1 . Provided from Ian Dransfield, University of Edinburgh; 2. Gift from Martin J. 
Glennie, University of Southampton.
Abbreviations: Ig: immunoglobulin; P: phospho; Hu: human; Ha: hamster; Mo: mouse; 
Go: goat; Ra: rabbit; Mono: monoclonal; Poly: polyclonal; FITC: Fluorescein 
isothiocyanate; R-PE: R-Phycoerythrin; HRP: horseradish peroxidase; AF: AlexaFluor™.
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11.2. Bacterial Strains
Bacterial strains used in this study were the following E.coli K12 derivatives: 
JM109 [endAl, recAl,gyrA96, thi, hsdR17 (nr, mk+), re/Al, supE44, A[lac- 
proAB), [ F  traD36, proAB, /aqdqZAM15]) obtained from Promega and DH5a (F' 
cp80/acZAM15 A(/acZYA-arpF)U169 deoR recAl endAl hsdR17 (rk~, mi<+] phoA 
supEAA thi-1 gyrA96 re/Al A") from Invitrogen.
Unless otherwise stated, bacterial cells were grown in the complex LB media 
(1%  w/v tryptone, 0.5%  w/v yeast extract, 85 mM NaCl; Sigma Aldrich). For 
long term storage, bacterial glycerol stocks (10%  v/v glycerol in Terrific Broth 
(TB, Sigma Aldrich; 1.2% tryptone, 2.4% yeast extract, 54 mM K2HPO4,16 mM 
KH2PO4, 0.4%  v/v glycerol) were prepared and stored at -80°C.
11.3. Plasmid Constructs
The following plasmids were used in this study:
pJ201:CD55-GPI: ampicillin resistant, pJ201 vector (DNA2.0 Inc., Menlo Park, 
California, USA) containing the GPI-modification consensus sequence flanked 
by Xhol and Blnl restriction sites at the 5' and 3' end, respectively. This 
construct contained no mammalian selection marker.
p-SELECT-neo-mcs-FCGR2A: kanamycin/neomycin resistant, p-SELECT-based 
vector (Invivogen, Autogen Bioclear, Caine, Wiltshire, UK) with the FCGR2A 
ORF cloned at the multiple cloning site (mcs). Protein was expressed under the 
control of a hEFl/HTLV mammalian promoter. This plasmid construct was
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used as the template for all site-directed mutagenesis reactions. The following 
derivatives of the p-SELECT-neo-mcs-FCGF2A were created in this study: (i) p- 
SELECT-neo-mcs-FCGF2A A224S, and (ii) p-SELECT-neo-mcs-FCGF2A C241A 
containing the A224S and C241A mutation within the FCGR2A ORF, (iii) p- 
SELECT-neo-mcs-FCGF2A sh78mm, containing the original protein sequence 
of CD32a, but with incorporated silent mutations within the shRNA- 
recognising sequence of clone TRCN029578 (recognising sequence 5'- 
GAAGAAACCAACAATGACTAT) to prevent targeting by the shRNA, (iv) p- 
SELECT-neo-mcs-FCG/?2A Xhol, engineered with an Xhol restriction site at the 
extracellular, membrane proximal region of CD32a (from the pSELECT-noe- 
mcs-FCGR2A sh78mm vector) used for the generation of CD32/CD55 
chimaeric protein, and (v) p-SELECT-neo-mcs-FCGF2A/CD55-GPI, expressing 
the chimaeric CD32a/CD55 protein (GPI-anchored CD32a) instead of CD32a.
Mission shRNA clones were obtained from Sigma Aldrich and were based on 
the pLKO.l-puro vector system, carrying ampicillin and puromycin resistance 
genes. shRNA-expressing sequences were constitutively under the control of 
human polymerase III (Pol III) U6 promoter. These shRNA clones were the 
following: TRCN029574 (target sequence on CD32a: 5'- 
GCCATCAGAAAGAGACAACTT, TRCN029575 (5'-GCACCTACTGACGATGATAAA), 
TRCN029576 (5'-CCAGAAATTCTCCCGTTTGGA), TRCN029577 (5’- 
CCATGTCAACAGTAATAACTA), TRCN029578 (5'-GAAGAAACCAACAATGACTAT). 
All the plasmid maps and sequences are presented in Section 15.1.
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11.4. Clinical Study Subjects
All subjects in the clinical study were of Caucasian origin and provided written 
informed consent. Ethical approval was obtained from the Lothian Research 
Ethics Committee (LREC/2002/4/65) and from the Lothian University 
Hospital -  National Health Service (NHS) trust (R&D department) (2002/R/ 
UO/22). Control patients (n=218) included healthy blood donors and patients 
admitted at the Respiratory Medicine Unit of the Royal Infirmary of Edinburgh 
with minor and non-chronic lung pathologies, without any evidence or history 
of lung fibrosis. The diagnosis of IPF was made based on the ATS/ERS 
international multidisciplinary consensus classification (ATS/ERS, 2002), 
according to the following criteria: (i) exclusion of all known causes or 
associations with lung fibrosis, including drug toxicities, connective tissue 
disease or exposure to environmental agents, (ii) presence of typical features 
on high resolution computed tomography scans, including bibasilar lung 
honeycombing with minimal ground glass opacities, (iii) abnormal pulmonary 
function with evidence of restriction (reduced FVC (forced expiratory vital 
capacity), often with an increased FEVi(forced expiratory volume in 1 
second)/VC (vital capacity) ratio) and/or reduced gas transfer measurements 
(decreased D L co  (diffusing capacity for carbon monoxide)), (iv) age >50 years 
and (v) duration of illness >3 months (Table 7.2). When bronchoalveolar 
lavage (BAL) or transbronchial lung biopsy was performed, no features were 
evident to support an alternative diagnosis. Surgical lung biopsy and/or BAL 
were performed in cases for which a confident diagnosis on clinical, functional
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and radiological grounds was not possible. A consensus diagnosis was made in 
each case following joint review by two respiratory clinicians and a radiologist 
(and a pathologist for cases in which biopsy was performed). In 39 of 142 
patients the diagnosis was confirmed by surgical biopsy, which revealed a 
histological profile typical of usual interstitial pneumonia. Pulmonary function 
measurements were recorded at baseline (first radiologic evidence for IPF; 
date of first HRCT scan) and included FEVi, FVC, TLC (total lung capacity) 
assessed by spirometry. In addition, the diffusing capacity for carbon 
monoxide ( D l c o )  and Kco (corrected D l c o  for alveolar volume) were measured 
by the single breath technique. FVC and D l c o  were monitored for at least 12 
months following disease diagnosis (baseline) to assess disease progression 
and prognosis in 121 IPF patients. For the remaining 21 patients, we were 
unable to obtain serial lung function measurements, as either contact with the 
patients was lost or they were unfit to participate in multiple pulmonary 
function tests.
11.5. Cell Isolation and Culture
11.5.1. Cell Lines and Culture
The following cell lines were used in this study: K562 cells (ATCC No.: 
CCL-243), a human erythromyeloid leukaemic cell line, CH0-K1 cell line 
(CCL-61), a derivative of the Chinese hamster ovary (CHO) cell line, with 
epithelial-like morphology, HL-60 cell line (CCL-240), a human promyelocytic 
cell line, mouse monoclonal (IV.3) antibody-producing hybridoma cells
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(HB-217) and Jurkat cells that were previously stably transfected to express 
human CD16 and or CD32 (described in Green eta l. (1997)). In brief, the 
sham-transfected Jurkat cell line was transfected with the empty pRc/ 
CMV:FLAG vector, CD32-expressing cells with the pRc/CMV:CD32a vector and 
CD16-expressing cells with the pCEP4:CD16b vector. CD16- and CD32- 
expressing Jurkat cells were co-transfected with both the pRc/CMV:CD32a and 
the pCEP4:CD16b vectors.
Unless otherwise stated, K562 and Jurkat cells were cultured in RPM I1640 
medium (PAA or Invitrogen) supplemented with 10%  foetal calf serum (FCS), 
L-glutamine (2 mM) and penicillin (100 U mb1)/streptomycin (100 pg ml'1). 
HL-60 cells were cultured in RPMI 1640 medium (PAA or Invitrogen) 
supplemented with 20%  foetal calf serum (FCS), L-glutamine (2 mM) and 
penicillin (100 U ml'1)/streptomycin (100 pg ml'1). K562, Jurkat and HL-60 
cells were maintained at a cell density of I x l 0 5-5 x l0 5 cells ml'1. Chinese 
Hamster Ovary (CH0-K1) cells were maintained in D-MEM:F-12 (1:1) (Gibco, 
Invitrogen) with GlutaMAX™, 10%  FCS and penicillin (100 U ml'1)/ 
streptomycin (100 pg ml'1). IV.3 hybridoma cells were cultured in IMDM 
supplemented with 10%  heat-inactivated FCS, 4 mM L-glutamine, 25 mM 
HEPES, penicillin (100 U ml'1) and streptomycin (100 pg ml'1) and maintained 




Ethical approval was obtained from the Lothian Local Research Ethics 
Committee (approval 1702/95/3111 and 08/S1103/38) and all human 
subjects provided oral or written informed consent, as required. Peripheral 
venous blood from healthy volunteers was drawn via a 19-gauge needle from 
an antecubital vein and collected into polypropylene tubes containing sodium 
citrate as an anticoagulant (12.9 mM final concentration). Citrated blood was 
then immediately processed for leukocyte isolation, based on previously 
described protocols (Bournazos etal., 2008; Dransfield e t a l ,  1994).
Briefly, following centrifugation of whole blood at 350$ for 20 min, platelet- 
rich plasma was removed and used for platelet isolation and the generation of 
autologous serum (see below). Erythrocytes were sedimented from the cell- 
enriched layer by dilution 1:1 with sterile saline pre-warmed to 37°C with the 
addition of dextran T-500 (Pharmacia, GE Healthcare) solution (prepared in 
sterile saline solution) at a final concentration of 0.6%  (w/v). The leukocyte- 
rich layer was then washed once with saline solution (350g; 6 min) and 
mononuclear leukocytes were fractionated from polymorphonuclear 
leukocytes by centrifugation at 720g  for 20 minutes using discontinuous 
isotonic Percoll™ gradients (final Percoll™ concentration: 50% , 61% , 73% ; GE 
Healthcare). Mononuclear cells were harvested from the 61% /50%  interface 
and polymorphonuclear cells from the 73% /61% . Harvested cells were 
washed twice with phosphate buffered saline (PBS) (Ca2+, Mg2+ free) and
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purity was routinely assessed by flow cytometry and/or microscopic 
examination of Diff-Quick-stained cytocentrifuge preparations.
Monocytes (CD14+) represented 8-25%  of total mononuclear cell population 
and neutrophils (CD16+) comprised >95%  of the polymorphonuclear cell 
fraction. Cell viability was routinely assessed by Trypan blue exclusion and 
cells were >99% viable. Unless otherwise stated, isolated cells were used 
immediately for subsequent experiments. Autologous serum was prepared by 
re-calcification of platelet-rich plasma (final CaCh concentration: 22 mM) and 
incubation in sterile glass tubes at 37°C for at least 1 h. Serum was stored for 
future use at 4°C.
11.5.3. Generation of Human Monocyte-Derived Macrophages
Freshly isolated mononuclear cells (described in Section 11.5.2) were re­
suspended in IMDM at 4 x l0 6 cells ml'1 and allowed to adhere to 48-well tissue 
culture plates (Corning-Costar, Fisher Scientific UK, Loughborough, 
Leicestershire, UK) for 1 h at 37°C (5%  CO2). Non-adherent lymphocytes were 
removed by extensive washing with Hanks' Balanced Salt Solution (HBSS) 
(containing Ca2+/Mg2+) and adherent monocytes were cultured for 6 days in 
IMDM containing 4 mM L-glutamine, penicillin (100 U ml-1)/streptomycin 
(100 pg ml'^(PAA Laboratories) and supplemented with 10%  autologous 
serum at 37°C (5% CO2). Culture medium was replaced every three days.
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Cells displaying macrophage-specific functional and phenotypic 
characteristics, as assessed by morphologic criteria and flow cytometric 
analysis represented >80%  of the total population. For immunolabelling and 
analysis by flow cytometry, macrophages were washed once with HBSS (Ca2+/ 
Mg2+ free) and incubated with pre-warmed HBSS containing 5 mM EDTA, 5 
mM sodium citrate and 0.5%  FCS for 15 min at 37°C, followed by 15 min on 
ice. Cells were then harvested from the tissue culture plate by forceful 
pipetting. For use for the phagocytosis assay, cells were detached following 
phagocytosis with PBS containing 0.05%  (w/v) Trypsin and 0.02%  EDTA to 
remove adherent, non-ingested apoptotic cells from the macrophage surface, 
as described Section 11.12.
11.6. Immunolabelling and Flow Cytometry
For the determination of cell surface molecule expression, cells were directly 
or indirectly immunolabelled and examined by flow cytometry. For direct 
immunolabelling, cells were washed once in PBS and re-suspended at a final 
concentration of 5 x l0 6 cells ml'1 in ice-cold PBS containing 1% FCS and the 
corresponding fluorochrome-conjugated antibody or isotype control antibody 
was added at saturating concentration (as determined by titration analysis). 
Cells were incubated on ice protected from light for 20 min and then, washed 
once with ice-cold PBS (1%  FCS), prior to flow cytometric analysis. For 
indirect immunolabelling, cells were incubated with the primary antibody (10 
pg ml'1, diluted with PBS containing 1% FCS) for 30 min on ice. Then, cells
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were washed twice with ice-cold PBS (1%  FCS) and incubated for 20 min on 
ice with the corresponding fluorochrome-conjugated secondary antibody (10 
pg ml'1) to detect primary antibody binding. Unless otherwise stated, 
secondary antibodies were F(ab ' ) 2  fragments to minimise cross-reactivity with 
Fey receptors. Following incubation with the secondary antibodies, cells were 
washed twice with ice-cold PBS (1%  FCS) and analysed immediately by flow 
cytometry. Flow cytometric analysis of the samples was performed using a BD 
FACS Calibur® or FACScan® cytometer (BD Biosciences). Data were analysed 
using BD CellQuest™ (BD Biosciences), BD FACS Diva® (BD Biosciences) or 
Flowjo™ (TreeStar™, Ashland, Oregon, USA) software and unless otherwise 
stated, results are presented as the geometric mean fluorescence intensity.
r>
11.7. IV.3 (anti-CD32a) Antibody Purification
IV.3 hybridoma cells (mouse IgG2b, k ) were cultured as described in Section
11.5.1 and cell-free supernatants were collected. Supernatants were filtered 
with 0.22 pm pore filters, pH was adjusted to 8.0 and stored at 4°C until used 
for antibody purification. An aliquot of the supernatant was used for indirect 
immunolabelling of CD32a-transfected CHO cells, to confirm the presence of 
functional antibody in the collected supernatant. Antibody was purified using 
a 4 ml Protein G-Sepharose™ (GE Healthcare) column and all procedures were 
performed at 4°C. The column was equilibrated with 50 ml of 0.1 M phosphate 
buffer (pH 8.0) at a rate of 5 ml min-1. Supernatants were then slowly applied 
to the column at a rate of 0.5 ml min-1. The column was then washed with 15
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ml of 0.1 M citrate buffer, pH 6.0, collecting 1 ml fractions and the protein 
content was estimated by UV spectrophotometry at 280 nm. Column was 
washed with 0.1 M citrate buffer, pH 6.0 until A280 was essentially zero. Bound 
antibody was eluted from the Protein G column, following wash with 0.1 M 
citrate buffer, pH 3.0. Fractions (1 ml) were collected and pH was immediately 
adjusted by the addition of 1 M Tris, pH 9.0. A280 was measured in the collected 
fractions and antibody-containing fractions identified by measurement of 
absorbance at 280 nm were pooled and concentrated using an Amicon® 
concentrator device (10,000 Da molecular weight cut-off filter, Amicon®, 
Millipore, Watford, Hertfordshire, UK) under helium pressure. Purified 
antibody was then dialysed against PBS (Ca2+/Mg2+-free), sodium azide (Sigma 
Aldrich) was added to a final concentration of 0.1% (w/v) and stored at 4°C. 
The specificity and binding of the purified antibody was assessed by indirect 
immunolabelling of CD32-expressing CHO cells and/or isolated neutrophils 
(protocol described in Section 11.6) and antibody titre determined.
Antibody purification from IV.3 hybridoma supernatants was also performed 
with slight modifications to the above-described protocol. In detail, cell-free 
supernatants (0.22 pm filtered and pH adjusted to 8.0) were used for 
ammonium sulfate precipitation, as previously described by Harlow and Lane 
(1988), to increase antibody concentration of the supernatant. Saturated 
ammonium sulfate solution (4.1 M, pH 7.5) was slowly added drop-wise to an 
equal volume to hybridoma supernatant, which was continuously and 
vigorously stirred to ensure adequate mixing. The mixture was incubated at
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4°C without stirring for 20 h to allow antibodies to precipitate and transferred 
to 50 ml polypropylene tubes. Precipitated material was then pelleted by 
centrifugation in a swinging-bucket rotor (3700$ for 30 min) and re­
suspended by slowly adding minimal volume of PBS (Ca2+/Mg2+ free), until 
completely dissolved. Solution was then dialysed against 0.1 M phosphate 
buffer (pH 8.0) and applied to the Protein G-Sepharose column, following the 
protocol described above.
11.8. Protein Biotinylation
Purified proteins were biotinylated using the EZ-Link™ Sulfo-NHS-LC-Biotin 
reagent (Pierce/ Thermo Fisher Scientific), according to manufacturer's 
instructions. Purified protein (BSA or IgG) was suspended in PBS, unless 
otherwise stated and incubated with freshly prepared biotinylation reagent for 
2 h at room temperature. EZ-Link™ Sulfo-NHS-LC-Biotin was added at a final 
molar ratio of 20:1 (biotin reagent:protein). Biotinylated protein was then 
dialysed against PBS (Ca2+/Mg2+ free) (4°C) using Slide-A-Lyzer® dialysis 
cassettes (Pierce/ Thermo Fisher Scientific) with 10,000 Da molecular weight- 
cut-off (MWCO) membranes, according to manufacturer’s recommendations.
11.9. CD32 Immunoprecipitation and Immunoblotting
Cells were re-suspended (2 x l0 7) in PBS (Ca2+/Mg2+ free) and surface- 
biotinylated by incubation with biotin (EZ-Link™ Sulfo-NHS-LC-Biotin; 1 mg 
mT1) for 60 min on ice. Then, cells were washed extensively with PBS (Ca2+/
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Mg2+ free] containing 20 mM Tris (pH 8.0) to remove non-reacted biotin. Cells 
were lysed at a density of 2 x l0 7 cells ml'1 with 1% (v/v) NP-40 (nonyl 
phenoxylpolyethoxylethanol) in TBS (Tris Buffered Saline, 50 mM Tris, 150 
mM NaCl; pH 7.5) containing protease inhibitors (Complete mini protease 
inhibitor tablets, Roche Applied Sciences). Following a 30-min incubation on 
ice, lysates were cleared by centrifugation (14,0005; 15 min, 4°C). Samples 
(250 pi) were then incubated with agarose-conjugated anti-CD32 antibody (50 
pi, clone IV.3) for 2 h at 4°C.
Agarose pellets were then extensively washed (12 times) using ice-cold lysis 
buffer and proteins were resolved by SDS-PAGE using 9%  or 5-20%  gradient 
Tris-glycine gels (ePAGEL, Atto Corporation). Proteins were electrophoretically 
transferred onto nitrocellulose membrane (Amersham Biosciences) for 40 min 
at 100 V in 25 mM Tris, 192 mM Glycine pH 8.3 containing 20%  methanol and 
blocked with 0.1% (v/v) Tween®-20. Blots were probed with HRP-conjugated 
streptavidin (1 :5000) and visualised using enhanced chemiluminescence 
(ECL™ reagent; Amersham Biosciences) and detection using ECL hyperfilm™ 
(Amersham Biosciences; GE Healthcare).
For CD32 immunoblotting, cells were washed twice with ice-cold PBS (Ca2+/ 
Mg2+ free) and incubated with 1 mM PMSF for 30 min on ice. Cells were then 
lysed with 1% (v/v) NP-40 in TBS containing protease inhibitors (Complete 
mini protease inhibitor tablets, Roche Applied Sciences) at a final density of
1 .5 x l0 7 cells ml'1 and incubated on ice for 30 min prior to centrifugation 
(14 ,0005 ,15  min, 4°C). Proteins were immediately resolved by SDS-PAGE
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using 9%  or 12%  Tris-glycine gels and electrophoretically transferred onto 
nitrocellulose membrane (Amersham Biosciences] as described above. 
Membranes were blocked with 5%  (w/v) fat-free milk, then probed with goat 
polyclonal anti-CD32 (1:500; R&D systems], followed by HRP-conjugated 
rabbit anti-goat Ig (1 :5000; Dako Cytomation] and visualised using enhanced 
chemiluminescence (ECL™ reagent; Amersham Biosciences] and detection 
using ECL hyperfilm™ (Amersham Biosciences; GE Healthcare].
11.10. Immune (IgG) Complex Binding Assay
11.10.1. Generation of Immune Complexes
Immune complexes were generated as previously described (Hart e t a l ,  
2004a]. Briefly, for biotin -  anti-biotin complexes (BxB], FITC-conjugated anti­
biotin (mouse IgGl, clone BN-34; 170 gg ml'1] was co-incubated with biotin- 
conjugated bovine serum albumin (500 gg ml'1] at 4°C for 30 min. For the 
generation of fetuin -  anti-fetuin complexes (Bob93] serum-free supernatants 
from anti-fetuin-producing hybridoma cells (clone Bob93, mouse IgGl] were 
co-incubated with FITC-conjugated purified fetuin (0.5 mg ml'1] at 4°C for 30 
min (Hart et a l, 2003]. Human IgG complexes (human heat-aggregated IgG; 
hHAIgG] were formed by incubating monomeric human IgG (10 mg ml'1] for 
20 min at 63°C and centrifuged at 14,000^ to remove protein precipitates. For 
human heat-aggregated IgG complexes, either FITC-conjugated or 
unconjugated IgG was used. In all cases, complexes were found to be stable 
when stored for at least one month at 4°C undiluted.
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11.10.2. Measurement of Immune Complex Binding
Immune (IgG) complex binding was assessed based on a previously described 
assay that measures binding of fluorochrome conjugated- IgG complexes to 
CD32 by flow cytometry [Hart et a l, 2004a; Hart et al., 2003). Cells were 
washed once in PBS (Ca2+/Mg2+ free) and re-suspended in ice-cold PBS 
containing 0.1%  (w/v) IgG-free BSA [Sigma Aldrich) at a final density of 106 
cells ml'1. Cells were incubated with varying concentrations of IgG complexes 
[diluted in PBS with 0.1%  [w/v) BSA) for 30 min on ice, then washed twice 
with PBS containing 0.1% [w/v) BSA and analysed immediately by flow 
cytometry. For blocking experiments, function blocking anti-CD32 antibodies 
[IV.3 or AT-10 F[ab’) 2 ; 10 pg m l1) or anti-CD16 [3G8 F[ab’) 2,- 10 gg ml'1) were 
added 10 min prior to the addition of IgG complexes. Flow cytometric analysis 
of the samples was performed using a BD FACS Calibur™ or FACScan™ 
cytometer [BD Biosciences). Data were analysed using BD CellQuest™ (BD 
Biosciences), BD FACS Diva™ (BD Biosciences) or Flowjo™ (TreeStar) software 
and all results are presented as the median fluorescence intensity.
11.11. Induction and Assessment of Neutrophil Apoptosis
Unless otherwise stated, freshly isolated neutrophils were cultured at 4 x 1 06 
cells ml'1 in IMDM containing 4 mM L-glutamine, penicillin (100 U ml'1)/ 
streptomycin (100 pg ml'^PAA Laboratories) and supplemented with 10%  
heat-inactivated foetal bovine serum (FBS) at 37°C for 20 h (5%  CO2), during 
which time a proportion of the cells underwent spontaneous apoptosis.
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Neutrophil apoptosis and secondary necrosis were assessed by annexin-V 
binding and propidium iodide staining, respectively. In brief, following 
overnight culture, neutrophils were re-suspended in annexin binding buffer 
(HBSS (Mg2+ free] containing 5 mM CaCh) at a final concentration of 4 x l0 6 
cells ml'1. APC-or FITC-conjugated recombinant annexin-V (Caltag, Invitrogen] 
was then added (diluted 1:50 in annexin binding buffer) to the cells and 
incubated for 10 min on ice. Propidium iodide (Sigma Aldrich) was added 
immediately prior to flow cytometry analysis at a final concentration of 1 pg 
ml'1. Cells were then analysed by flow cytometry using a BD FACS Calibur™ 
flow cytometer (BD Biosciences) and data were analysed using BD CellQuest™ 
(BD Biosciences), BD FACS Diva™ (BD Biosciences) or Flowjo™ (TreeStar) 
software.
11.12. Macrophage Phagocytosis Assay
11.12.1. Cell Labelling for Phagocytosis Assay
Cells were labelled with either one of the following cell-permeable, long-term 
dyes: 5-chloromethylfluorescein diacetate (CMFDA; CellTracker™ Green, 
Molecular Probes, Invitrogen), or 7-hydroxy-9H-(l,3-dichloro-9,9- 
dimethylacridin-2-one) succinimidyl ester (DDAO-SE)(CellTrace™ Far Red, 
Molecular Probes, Invitrogen), detected in FL-1 and FL-4 channels in flow 
cytometry, respectively. These reagents were prepared in dimethyl sulfoxide 
(DMSO) at a stock concentration of 10 mM, protected from light and the 
following protocol was used for cell labelling (Hart et a l, 2008). Freshly
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isolated neutrophils were suspended in IMDM, containing 4 mM L-glutamine, 
25 mM HEPES, penicillin (100 U ml'1) and streptomycin (100 pg ml'1) at a final 
density of 107 cells ml'1 and cells were incubated with cell labelling reagent 
(final concentration of 20 pM) at 37°C (5%  CO2) for 15 min. Cells were then 
washed once, re-suspended in IMDM (4 mM L-glutamine, 25 mM HEPES, 
penicillin (100 U ml'1) and streptomycin (100 pg ml'1)) supplemented with 
10%  FCS and cultured at 37°C (5%  CO2) for 20 h, as described in Section 11.11. 
The extent of neutrophil apoptosis was determined in unlabelled cells that 
were cultured in identical conditions.
11.12.2. Flow Cytometry-based Apoptotic Cell Phagocytosis Assay
Macrophage phagocytosis of apoptotic cells was assessed as previously 
described, using a method that measures macrophage-mediated 
internalisation of fluorescently labelled apoptotic cells by flow cytometry 
(Hart e t a l ,  2008; Jersmann e t a l ,  2003). Following labelling and in vitro 
culture of freshly isolated neutrophils for 20 h at 37°C (5%  C02)(described in 
Sections 11.11 and 11.12.1), cells were washed once in PBS (Ca2+/Mg2+ free) 
and were incubated (107 cells ml'1) for 20 min on ice with either PBS or heat- 
aggregated human IgG (100 pg ml'1)(prepared as described in Section 11.10.1). 
Cells were then washed once with PBS (Ca2+/Mg2+ free) and re-suspended at 
2 x l0 6 cells ml'1 in pre-warmed IMDM containing 25 mM HEPES and 4 mM L- 
glutamine without serum. Culture medium was removed and the macrophage 
monolayer washed once with pre-warmed medium (IMDM without serum) to 
remove non-adherent cells (contaminating lymphocytes and dead cells).
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For experiments involving the block of macrophage Fey receptors, 
macrophages were incubated with saturating concentrations of the relevant 
monoclonal antibody (10 pg ml'1), diluted in PBS containing 1% (v/v) of 
autologous serum) and incubated for 15 min at 37°C (Vivers etal., 2004). 
Medium was then aspirated and for each well of a 48-well culture plate, l x l  06 
"aged" neutrophils were added (2 x l0 6 cells ml'1) and incubated for 60 min at 
37°C (5%  CO2). For experiments involving the use of cell populations labelled 
with different dyes, cells were added at 1:1 ratio (CMFDA-labelled:DDAO-SE- 
labelled). Following incubation, medium was aspirated and cells were 
detached with 0.5 ml of PBS containing trypsin (0.05%  (w/v))/EDTA (0.02%  
(w/v)) solution. Cells were incubated with the detaching solution for 10 min at 
37°C, followed by 10 min at 4°C. Then, FBS was added to the cells at a final 
concentration of 0.5%  (v/v) to competitively inhibit trypsin activity and limit 
cell aggregation and detached cells were harvested by forceful pipetting. 
Samples were analysed by flow cytometry using a BD FACS Calibur™ flow 
cytometer (BD Biosciences) and at least 5,000 events in the macrophage gate 
were collected, Apoptotic cells and macrophages were identified based on 
their characteristic autofluorescence, forward and side scatter laser 
properties. In particular, when neutrophils were labelled with the far red dye 
DDAO-SE (detected in FL-4 channel), the macrophage population was 
identified on the basis of increased FL-1 autofluorescence and greater forward 
scatter laser properties compared with the other cell types (apoptotic 
neutrophils, contaminating lymphocytes and erythrocytes) present. The 
FL-4brisht and FL-4dim macrophages represented the phagocytic and non-
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phagocytic macrophage populations, respectively. Similarly, in phagocytosis 
assays using CMFDA-labelled apoptotic neutrophils, F L -lbright macrophages 
defined on the basis of forward and side scatter laser properties represented 
those with internalised apoptotic cells. Data were analysed using BD 
CellQuest™ (BD Biosciences), BD FACS Diva™ (BD Biosciences) or Flowjo™ 
(TreeStar) software and unless otherwise stated, results are presented as the 
percentage of F L -lbright or FL-4bright (depending on the fluorescent dye used) 
events in the macrophage gate from the total number of macrophages. For the 
determination of the flow cytometric phagocytic index, the percentage of 
phagocytic macrophages (FL-4bright or FL -lbright) was multiplied by the 
geometric mean fluorescence (either FL-4 or FL-1) of the phagocytic 
population.
11.12.3. Microscopy-based Apoptotic Cell Phagocytosis Assay
Microscopy-based assessment of phagocytosis was performed essentially the 
same as the flow cytometry-based assay, with the exception that apoptotic 
neutrophils were not labelled prior to use in the assay. Instead, 
myeloperoxidase (MPO) activity that is exclusively found in neutrophil 
granules was detected using a colourimetric method (Hart et a l, 2004a; Hart 
e t a l ,  2008). Macrophages and neutrophils were cultured and prepared for the 
phagocytosis assay as described for the flow cytometry-based phagocytosis 
assay. Following co-incubation of macrophages with apoptotic neutrophils (60 
min, 37°C, 5% CO2), macrophage cell monolayer was extensively washed with 
ice-cold HBSS (containing Ca2+/Mg2+) to remove non-ingested apoptotic
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neutrophils. To ensure complete removal of non-ingested apoptotic cells, 
macrophages were inspected by light microscopy. Cells were fixed with 3% 
(w/v) paraformaldehyde for 30 min at room temperature and cell monolayer 
was rinsed once prior to staining for MPO. Cells were incubated with 0.1 mg 
ml'1 3,3'-dimethoxybenzidine (Sigma Aldrich) containing 0.03%  (v/v) 
hydrogen peroxide for approximately 60 min or until ingested neutrophils 
developed a brown colour, while macrophages remained unstained. Cells were 
rinsed with PBS (Ca2+/Mg2+ free) and stored at 4°C in PBS containing 0.1%  (w/ 
v) sodium azide until further analysis. For the determination of macrophage 
phagocytosis, the proportion of macrophages (MPO negative) that had 
ingested one or more apoptotic neutrophils (MPO positive) was quantified (at 
least 300 cells per well) using an inverted microscope. In addition, the 
phagocytic index was determined as the number of ingested apoptotic 
neutrophils present in 100 macrophages. Unless otherwise stated, results are 
expressed as the mean (either percent phagocytosis or phagocytic index) for 
at least three experiments performed in duplicate wells.
11.13. Cytokine Measurement
Cell-free supernatants from LPS-treated (50 ng ml'1, 18 h, 37°C) macrophages 
were collected by centrifugation (14,000$, 2 min) and stored at -20°C until 
analysis. Cytokines IL-1(3, IL-6, IL-8, IL-10, IL-12p70 and TNF-a were 
measured in these samples using a fluorescent bead-based sandwich assay 
(cytometric bead array (CBA); human inflammation kit, BD Biosciences),
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according to manufacturer’s instructions. Briefly, 25 pi of cytokine standard or 
cell-free supernatant were co-incubated with 25 pi of capture beads (mixed at 
equal volumes for each cytokine) and 25 pi secondary PE-conjugated detection 
reagent for 3 h at room temperature protected from light. Beads were then 
washed with the CBA wash buffer (200$, 5 min) and bead pellet was carefully 
vortexed and re-suspended in CBA wash buffer. Analysis of the samples was 
performed using a BD FACS Array™ Bioanalysis System (BD Biosciences), using 
FL-2 and FL-3 detection channels, based on pre-installed settings for the 
Human Inflammation kit. Standard curves were calculated and data were 
analysed using BD CBA Software (BD Biosciences).
11.14. Measurement of NADPH Oxidase Activity
11.14.1. Measurement of Intracellular ROS levels
Intracellular ROS levels were determined in neutrophils using a fluorescent 
probe, dihydrorhodaminel23 (DHR123), which upon reacting with 
intracellular ROS (mainly superoxide and H2 O2), is oxidised to rhodamine 123 
that is excitable at 488 nm and is emitted at a wavelength of 515 nm. Freshly 
isolated neutrophils (control or protease-treated) were re-suspended at a final 
concentration of 2 .5 x l0 6 cells ml'1 in pre-warmed HBSS containing Ca2+/Mg2+. 
Cells were incubated for 5 min at 37°C with 1 pM DHR123 dye and then, 
human heat aggregated IgG complexes (0.1-100 pg ml'1) or fMLP (100 nM) 
were added and cells were further incubated for 60 min at 37°C. Cells were 
then immediately transferred on ice and analysed by flow cytometry using a
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BD FACS Calibur™ or BD FACScan™ (BD Biosciences) flow cytometer and 
fluorescence was detected using the FL-1 detection channel. Data were 
analysed using BD CellQuest™ (BD Biosciences), or Flowjo™ (TreeStar) 
software. Background fluorescence (baseline ROS levels) was subtracted from 
each corresponding sample and results are presented as the median 
fluorescence intensity of at least three independent experiments.
11.14.2. Superoxide Release Assay
The generation and release of superoxide from stimulated neutrophils was 
measured, essentially as previously described, based on cytochrome c 
reduction (Stocks etal., 1995). Briefly, neutrophils (5 x l0 5 cells mb1) were 
suspended in HBSS (with Ca2+/Mg2+) containing cytochrome c (1 mg mh1; 
Sigma Aldrich) in the presence of an agonist (PMA: 100 nM or human heat 
aggregated IgG: 0-200 pg ml-1). Samples were incubated at 37°C for 45 min 
and then cells were immediately transferred on ice. Supernatants were 
obtained by centrifugation (300$, 5 min) and absorbance was measured at 
550 nm using a BioTek™ microplate UV spectrophotometer (BioTek 
Instruments, Potton, Bedfordshire, UK). Spontaneous cytochrome c oxidation 
or background autofluorescence was subtracted from the non-cell sample and 
results are presented as the mean absorbance of three independent 
experiments performed in triplicates.
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11.15. Analysis of CD32 Tyrosine Phosphorylation
Following stimulation of CHO cells with IgG complexes (10 gg ml-1, 5 min, 
37°C), cells (3 x l0 7 cells ml'1] were washed extensively in ice-cold PBS and 
lysed with 2% Triton X-100 in Tris buffered saline (150 mM NaCl, 50 mM Tris, 
pH 7.5), in the presence of phosphatase and protease inhibitors (Halt™ 
Protease and Phosphatase Inhibitor Cocktail, Pierce/Thermo Scientific) for 15 
min on ice, based on manufacturer's recommendations. Lysates were then 
cleared of insoluble material by centrifugation (14,000$, 15 min, 4°C) and 
incubated with agarose-conjugated goat anti-mouse Ig (Sigma Aldrich) for 60 
min at 4°C to minimise non-specific protein interactions. Anti-CD32 antibody 
(IV.3; 1 gg per 0.25 ml sample) was then added to the pre-cleared lysates and 
incubated for 60 min at 4°C, followed by goat anti-mouse Ig agarose (25 pi) for 
90 min at 4°C shaking. Agarose pellets were then extensively washed (12 
times) using ice-cold lysis buffer and proteins were resolved by SDS-PAGE 
using 4-12%  Bis-Tris gels (NuPAGE, Invitrogen), according to manufacturer's 
instructions. Proteins were then electroblotted onto nitrocellulose membrane 
(Amersham), blocked with 0.1%  (v/v) Tween™-20 and probed with biotin- 
conjugated mouse anti-phosphotyrosine (1 :7000). Membranes were then 
incubated with HRP-conjugated streptavidin (1 :5000) and visualised using 
enhanced chemiluminescence (ECL™ reagent; Amersham Biosciences). To 
assess total CD32 content, membranes were stripped with 0.1 M glycine pH 2.5 
containing 0.1% (v/v) Tween™-20 (45 min at room for temperature) and then 
blocked with 5% w/v fat-free milk in PBS Tween™-20 (0.1%  v/v) for 60 min.
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Blots were then re-probed with goat polyclonal anti-human CD32a (1 :500), 
followed by HRP-conjugated rabbit anti-goat Ig (1 :5000).
11.16. Nucleic Acid Purification
11.16.1. Molecular Blology-grade Bacterial Plasmid DNA Extraction
Plasmid DNA extraction was performed using the Qiagen QIAprep™ Spin 
MiniPrep Kit (Qiagen), according to manufacturer's recommendations. Briefly, 
under aseptic conditions, a single E.coli colony was inoculated to pre-warmed 
(37°C) LB medium (10 ml) containing the corresponding selection antibiotic 
(kanamycin (50 pg ml'1) or carbenicillin (100 pg ml"1) and cultures were 
incubated overnight at 37°C shaking (250 rpm). Overnight cultures (10 ml) 
were then centrifuged (3700$, 10 min) and bacterial pellets were re­
suspended in Buffer P I (250 pi), containing LyseBlue™ reagent and RNase A 
(100 pg ml'1). Bacterial cells were lysed following the addition of Buffer P2 
(250 pi), mixed thoroughly by gentle inversion (4-6 times). Lysates were 
neutralised immediately by adding 350 pi of Buffer N3. Following careful and 
thorough mixing, lysates were cleared of protein precipitates by centrifugation 
(10 min, 14,000$) and supernatants were applied to the QIAprep™ spin 
column. The column was centrifuged (14,000$, 1 min) and washed by the 
addition of buffer PB (0.75 ml) and further centrifuged for 1 min (14,000$). 
Column flow-though was discarded and the QIAprep™ Spin column was again 
washed using Buffer PE (0.75 ml). After a 1-minute centrifugation at 14,000$, 
flow-through was discarded and the column was further centrifuged for an
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additional 1 min to completely remove residual wash buffer. Plasmid DNA was 
then eluted from the column by adding 50 pi Tris (10 mM), pH 8.5, incubated 
for 1 min at room temperature and centrifuged (14,000$, 1 min). Flow­
through containing the eluted plasmid was stored at -20°C. Plasmid 
concentration was determined by spectrophotometric analysis over a 230-300 
nm absorbance range using a NanoDrop™ 1000 spectrophotometer (Thermo 
Scientific, Wilmington, Delaware, USA) and absorbance 260 nm/280 nm 
(A260/280) ratio values between 1.8 and 2.0 were considered to be optimal and 
indicative of pure DNA preparations. The quality of the extracted plasmid DNA 
was also assessed by agarose (1%  w/v) gel electrophoresis.
11.16.2. Transfection-grade Bacterial Plasmid DNA Extraction
For the extraction and purification of plasmid DNA intended for cell 
transfection purposes, the Qiagen Plasmid Maxi kit was used essentially based 
on manufacturer’s guidelines. In detail, single E.coli colonies were inoculated 
to pre-warmed (37°C) LB medium (5 ml) containing the relevant plasmid 
selection antibiotic (kanamycin (50 gg ml"1) or carbenicillin (100 gg ml'1)). 
Following an 8-hour incubation period (37°C; 7-8 h, 250 rpm), starter cultures 
were diluted into selective LB medium (1 ml of the culture was added to 500 
ml LB medium) and further incubated for 16 h at 37°C (250 rpm). Bacterial 
cells were harvested by centrifugation (6,000$, 15 min, 4°C) and bacterial 
pellets were thoroughly re-suspended in 10 ml of ice-cold buffer PI, 
containing LyseBlue™ reagent and RNase A (100 pg ml"1). Lysis buffer (Buffer 
P2; 10 min) was then added to the re-suspended bacterial cells and mixed
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thoroughly by vigorous inversion (5 times]. Following a 5-minute incubation 
at room temperature, lysates were neutralised by the addition of ice-cold 
Buffer P3 (10 ml), incubated on ice for 20 min, and centrifuged for 30 min 
(6,000$, 4°C) to remove precipitated material (genomic DNA, proteins, cell 
debris). Supernatant was then transferred to polypropylene tubes and re­
centrifuged (3,400$, 15 min, 4°C) to remove any residual precipitated 
material. Supernatant was then applied to a QIAGEN-tip™ 500 column that was 
previously equilibrated by washing it with Buffer QBT (10 ml). Plasmid DNA 
was allowed to bind to the column, which was thoroughly washed by applying 
60 ml of wash buffer (Buffer QC). Plasmid DNA was then eluted from the 
column by the addition of 15 ml of Buffer QF (elution buffer) and then 10.5 ml 
of isopropanol immediately added to the eluate and mixed thoroughly to 
precipitate DNA. Isopropanol-precipitated DNA was centrifuged (4,000$, 30 
min, 4°C) and pelleted DNA was washed with 5 ml of room-temperature 
ethanol (70%  v/v). Following centrifugation for 10 min (4,000$, 4°C), 
supernatant was carefully decanted and DNA pellet was air-dried before gently 
re-dissolving it with nuclease- and DNA-free sterile water to a final 
concentration of 1-2 mg ml'1. Plasmid quantity and quality was assessed by UV 
spectrophotometry and agarose gel electrophoresis, as described in Section
11.16.1.
11.16.3. Purification of PCR Products
PCR products were purified using the QIAquick™ PCR Purification kit (Qiagen), 
according to the manufacturer's instructions. Following PCR amplification, 250
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gl of Buffer PB were added to the PCR sample (5 volumes buffer for 1 volume 
of PCR sample) and mixed thoroughly prior to application to a QIAquick™ 
column. Following centrifugation for 1 min at 14,000$, the column was then 
washed with 0.75 ml of Buffer PE and centrifuged for 1 min at 14,000$, 
followed by an additional centrifugation step (1 min at 14,000$) to remove 
residual wash buffer. DNA was then eluted from the column by adding 30 gl 10 
mM Tris, pH 8.5 at room temperature for 2 min and centrifugation at 14,000$ 
for 1 min to collect the eluted PCR products. DNA concentration of the samples 
was determined by UV spectrophotometric analysis over a 230-300  nm 
absorbance range and absorbance 260 nm/280 nm (A260/280) ratio values 
between 1.8 and 2.0 were considered to be optimal and indicative of pure DNA 
preparations. DNA samples were stored at -20°C for subsequent analysis.
11.16.4. Genomic DNA Extraction
Peripheral venous blood was obtained from consenting donors, collected into 
disodium EDTA (K2EDTA)-containing tubes (S-Monovette™, Sarstedt, Leicester, 
Leicestershire, UK) and stored at -20°C until processed for genomic DNA 
extraction. DNA was extracted using QIAamp™ Blood Midi Kit (Qiagen), based 
on manufacturer’s recommendations. In detail, 2 ml of anticoagulated blood 
was mixed with QIAGEN Protease suspension (200 gl), before the addition of 
lysis buffer (Buffer AL; 2.4 ml). Adequate cell lysis was ensured by vigorous 
agitation and vortexing of the mixture for at least 1 min. Lysed blood was 
incubated at 70°C for 10 min and 2 ml of molecular biology-grade ethanol 
(100%  v/v) was added, followed by vigorous shaking and vortexing of the
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samples to achieve even mixing and then applied onto the QIAamp™ Midi 
column and centrifuged for 3 min at 1,850g. The column was then washed 
using 2 ml of Buffer AW1 and centrifuged for 1 min at 3,700g. A second 
washing step included the addition of 2 ml of Buffer AW2, followed by 
centrifugation for 15 min at 3,700g, to ensure complete removal of the 
washing buffer. Genomic DNA was eluted from the column by adding Buffer AE 
(300 pi) to the centre of the column. Then, column was incubated for 5 min at 
room temperature prior to centrifugation for 2 min at 3,700g. Eluted material 
was then re-applied to the column and eluted as described above to increase 
the final concentration of the eluted DNA. Extracted genomic DNA 
concentration of the samples was then determined by spectrophotometric 
analysis over a 230-300 nm absorbance range using a NanoDrop™ 1000 UV 
spectrophotometer (Thermo Scientific) and absorbance 260 nm/280 nm 
(A260/280) ratio values between 1.8 and 2.0 were considered to be optimal and 
indicative of pure DNA preparations, without evidence of protein 
contamination. DNA samples were stored at -20°C for subsequent analysis.
11.17. Bacterial Transformation
E.coli JM109 or DH5a were transformed using a modification of the previously 
described calcium chloride protocol (Maniatis et ah, 1982). Under aseptic 
conditions, a single E.coli colony from a freshly streaked LB plate was 
inoculated to pre-warmed (37°C) LB medium (5 ml) and incubated overnight 
at 37°C shaking (250 rpm). Overnight cultures were then diluted at 1 :100  with
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fresh, pre-warmed LB medium (200 pi of overnight culture to 19.8 ml LB 
medium) and cultures were incubated at 37°C. Cell growth was monitored at 
40 min intervals by recording the OD595 absorbance and incubated until cells 
reached a mid-exponential growth (OD595=0.7). Then, 1 ml of culture was 
transferred to individual 1.5 ml microcentrifuge tubes and cells were pelleted 
by brief centrifugation (14,000^, 1 min). Bacterial cells were re-suspended in 
ice-cold, sterile 50 mM CaCh solution (0.5 ml) and incubated on ice for 10 min. 
Cells were centrifuged and pellets were again re-suspended in ice-cold CaCh 
solution (50 mM; 0.3 ml). Following a 30-minute incubation on ice, plasmid 
DNA, or sterile water, or ligation reaction products or site-directed 
mutagenesis products were added to the cells and mixed very gently. Cells 
were incubated for a further 30 min on ice and heat-shocked by a 2-min 
incubation in a 42°C water bath. Cells were immediately placed on ice and 
incubated for 10 min. LB medium (without any selection antibiotics) was then 
added (1 ml) and cells were incubated for 60 min at 37°C. Then, cells were 
centrifuged, re-suspended in LB medium (100 pi) and inoculated onto pre­
warmed, selective LB plates (50 pi of cell suspension per plate). Plates were 
incubated in a humidified incubator (37°C) for at least 20 h and any selected 
bacterial colonies were purified by culturing them into fresh selective plates 
prior to further plasmid analysis.
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11.18. Short Hairpin RNA (shRNA)-Mediated CD32 Expression Knock- 
Down
CD32a expression was downregulated using shRNA lentiviral vectors that 
were obtained from Sigma Aldrich (MISSION shRNA clones; for more 
information, see Section 11.3). All five shRNA plasmid clones supplied were 
validated for CD32 knockdown efficiency by transient transfection to CHO cells 
expressing wild type CD32a. One particular clone achieved >70% gene 
expression knock-down (clone TRCN029578; recognising sequence 5'- 
GAAGAAACCAACAATGACTAT) as evidenced by flow cytometric analysis of 
surface levels of CD32a expression. This clone was then stably transfected to 
wild type K562 cells as described in Section 11.21. Following selection and cell 
sorting, CD32a expression and IgG complex binding was assessed in shRNA 
expressing K562 cells.
11.19. Site-Directed Mutagenesis
11.19.1. Design of Mutagenic Primer Pairs
For the site-directed mutagenesis, primers were designed to incorporate the 
relevant mutations based on the following criteria: (i) GC content of at least 
55%  with either C or G at both 5' and 3’ primer ends, (ii) >90%  primer purity; 
primers were purified by HPLC (high performance liquid chromatography] 
(MWG Biotech), (iii) mismatched sequences were designed to be at the centre 
of the primer with at least 10 bp sequence flanking the mutation at each end
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and (iv) primer Tm of at least 70°C. For each mutation, a set of two primers was 
designed, each covering the sense and the anti-sense strand of the plasmid at 
the same sequence.
The following primer sequences were designed and used in this study:
For the A224S mutation: Forward: 5’-GGCTGTGGTCATTTCGACTGCTGTAGC-3’, 
Reverse: 5’-GCTACAGCAGTCGAAATGACCACAGCC-3’. For the C241A mutation: 
Forward: 5’-GTAGTGGCCTTGATCTACGCCAGGAAAAAGCGGATTTC-3', Reverse: 
5 ’-GAAATCCGCTTTTTCCTGGCGTAGATCAAGGCCACTAC-3’. For the introduction 
of the Xhol restriction site (see Section 11.20 for more details): Forward: 5 ’- 
CCAAGTGCCCAGCATGGGCTCGAGTTCACCAATGGGGATC-3', Reverse: 5'- 
GATCCCCATTGG TGAACTCGAGCCCATGCTGGGCACTTGG-3'. For the generation 
of silent mutations in the shRNA target sequence (see Section 11.18 for more 
details): Forward: 5'-GAAGAAACCAACAACGATTACGAAACAGCTGACGGCGG-3’, 
Reverse: 5'-CCGCCGTCAGCTGTTTCGTAATCGTTGTTGGTTTCTTC-3’. All primers 
were synthesised and obtained from MWG Biotech/Eurofins.
11.19.2. Site-Directed Mutagenesis
Full length human CD32a ORF sub-cloned into a pSELECT-neo-mcs vector was 
obtained from Invivogen and was used as the template for the site- 
mutagenesis reactions. Specific primers incorporating the desired mutations 
were designed and obtained from MWG Biotech - Eurofins (RP-HPLC purified, 
>90%  purity). For more information, see Section 11.19.1. Each site-directed 
mutagenesis reaction (50 pi) contained 100 ng plasmid DNA as template, 200
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pM dNTP (Promega), 125 ng of each primer pair and 2.5 U of P/uUltra™ High 
Fidelity DNA polymerase in the presence of the respective reaction buffer 
(Stratagene). Reactions were performed in a Touchgene™ gradient thermal 
cycler (Techne Corporation, Fisher Scientific UK, Loughborough, 
Leicestershire, UK) and cycling conditions were the following: 1 min 
denaturation at 94°C, 18 cycles of 1 min at 94°C, 1 min at 55°C, 9 min at 68°C, 
followed by an additional 30-minute extension step at 68°C. Each reaction was 
incubated for 3 h at 37°C with Dpnl (0.2 U pi'1; Promega) to digest the 
methylated wild-type plasmid and mutated plasmids were then transformed 
into CaCh-competent E.coli DH5a cells (see Section 11.17 for bacterial 
transformation). Mutated plasmid sequences were validated by direct 
sequencing and, where applicable by restriction endonuclease analysis.
11.19.3. Plasmid DNA sequencing
The efficiency and validity of the site-directed mutagenesis reactions was 
validated by the direct sequencing of the mutated plasmid sequences. DNA 
sequencing reactions were performed by the Sequencing Service (College of 
Life Sciences, University of Dundee, UK) using Applied Biosystems Big-Dye™
3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer (Applied Biosystems, Birchwood, Warrington, Cheshire, UK). For 
the sequencing, the following set of primer pairs were designed and used, so 
as to cover the entire plasmid sequence (4.5 kb): For the sense strand:
Forward 1: 5’- CCTGCTTGCTCAACTCTACG-3', Forward 2 5'- 
GAGCGACTCCATTCAGTGGT-3', Forward 3 5’-CAGCCAATTCCACTGATCCT-3’, For
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the anti-sense strand: Reverse 1 5'-CTGTCAATGGTTGAAGCAGC-3’, Reverse 2 
5'-ATGTGACCTTGACCAGAGGC-3', Reverse 3 5’- ACTGTTGACATGGTCGTTGG-3’. 
Plasmid DNA was sequenced at both the sense and the antisense strands 
(double-pass sequencing) and chromatograph files were viewed and analysed 
using the Sequence Scanner Software (vl.O) (Applied Biosystems) or the 
4Peaks™ Sequence Analysis Software (Mekentosj.com, Aalsmeer, The 
Netherlands).
11.20. Generation of GPI-anchored CD32
11.20.1. Design of the GPI-anchored CD32
The GPI modification site was predicted in the human CD55 gene based on 
Eisenhaber eta l. (1999) and using the big-PI Predictor Software (http: // 
mendel.imp.ac.at/gpi/gpi server.html). The chimaeric CD32/55 construct was 
designed to include the following: (i) the extracellular, IgG binding domains of 
CD32, consisting of the signal peptide, the two immunoglobulin domains and 
the extracellular, membrane proximal region and (ii) the GPI-anchored 
consensus sequence of CD55, comprising the co site and downstream 
consensus domains. Hydrophobicity and protein folding thermodynamic 
analyses were also performed on the designed protein sequences using the 
PreLink software (http://genomics.eu.org/prelink) based on Coeytaux and 
Poupon (2005), in order to minimise the possibility of protein misfolding of 
the engineered CD32/55 construct.
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11.20.2. Cloning of the CD32/55 Chimaeric Protein
The GPI-anchored CD32 (CD32/55 chimaeric protein) was designed as 
described in Section 11.20.1. CD55 GPI-consensus sequence was sub-cloned to 
a pJ201 vector and the Xho\ (Restriction site sequence) and Blnl (Avril) 
(restriction site) sites were engineered to flank the 5’ and 3 ’ end, respectively. 
The design and selection of the chosen restriction sites was based on the 
following criteria: (i) creation of cohesive ends (either in the form of 5' or 3' 
overhangs), (ii) absence of these restriction recognition sites in the sequence 
of the pJ201 vector and of the pSELECT-neo-mcs-FCGF2A plasmid, unless in 
designated or intentionally created sites, (iii) introduction of these restriction 
sites in the pSELECT-neo-mcs-FCGF2A plasmid by site-directed mutagenesis 
using the minimum number of nucleotide changes. The final construct was 
synthetically generated from DNA2.0.
An Xhol site was introduced at the end of the extracellular domain of the wild- 
type CD32a ORF (pSELECT-neo-mcs-FCGFZ4 plasmid) by site-directed 
mutagenesis (see Sections 11.19.1 and 11.19.2 for primer design and site- 
directed mutagenesis protocol). The Blnl (Avril) restriction site was present in 
the original pSELECT-neo-mcs-FCGF2A plasmid, within the CD32a ORF and 
downstream of the introduced Xhol recognition site. Cloning of the CD55 GPI- 
consensus sequence within the CD32 ORF (pSELECT-neo-mcs-FCGF2A plasmid 
comprising the Xhol site) was performed using the Rapid DNA dephos™ and 
ligation kit (Roche Applied Science), following manufacturer's 
recommendations.
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Initially, the purified pJ201:CD55-GPI plasmid was restricted with Xhol 
(Promega) and Blnl (Roche Applied Science) for 3 h at 37°C, according to 
product instructions, so as to excise the CD55 GPI-consensus insert from the 
pJ201 vector. Next, the restriction products were resolved by gel 
electrophoresis, using ultra pure, low melting point agarose (1%  w/v) without 
the addition of ethidium bromide. Following electrophoresis, gels were briefly 
incubated with ethidium bromide solution (0.2 pg ml'1; 5 min), following by 
wash in ultra pure water for 20 min. Gels were visualised under low-power UV 
light and the CD55-GPI insert was excised and purified from the gel, using the 
QIAquick™ Gel extraction kit (Qiagen), based on manufacturer’s instructions. 
Briefly, excised gel fragments were dissolved by the addition of Buffer QC (3 
volumes for 1 volume gel), following by incubation at 50°C for 10 min or until 
all agarose was dissolved. Then, isopropanol was added at equal volume to the 
gel and samples were vigorously agitated to ensure even mixing. Samples were 
then applied to a QIAquick™ column and centrifuged for 1 min (14,000$). The 
flow-through fraction was discarded and column was washed with Buffer QG 
(0.5 ml) and Buffer PE (0.75 ml). At each washing step, the column flow­
through was discarded from the collection tube and column was centrifuged 
for an additional 1 min at 14,000$ to completely remove residual wash buffer. 
DNA was then eluted by incubation for 1 min at room temperature with 30 pi 
10 mM Tris, pH 8.5 and centrifugation at 14,000$ for 1 min. The purified DNA 
fragment was quantified by UV spectrophotometry and stored at -20°C, until 
used for the ligation reaction.
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The pSELECT-neo-mcs-FCGlfi^A plasmid vector containing the Xhol restriction 
site was restricted with Xhol (Promega) and Blnl (Roche Applied Science) for 3 
h at 37°C. A small fraction of the restriction products (150 ng) was analysed by 
agarose gel (1%  w/v) electrophoresis to assess the efficiency and specificity of 
the reaction and the remaining of the restricted pSELECT-neo-mcs-FCGR2A 
plasmid vector was purified using the QIAquick™ PCR Purification Kit 
(Qiagen), so as to remove restriction enzymes that will interfere with the 
ligation reaction. The detailed protocol of the DNA purification using the 
QIAquick™ PCR Purification Kit (Qiagen) is described in Section 11.16.3. The 
purified and restricted pSELECT-neo-mcs-FCGR2A vector (500 ng) was then 
treated with alkaline phosphatase (1 U) for 45 min at 37°C using the Rapid 
DNA Dephos™ Kit (Roche Applied Science). Alkaline phosphatase was heat- 
inactivated (2 min; 75°C) and 50 ng of vector DNA from the dephosphorylation 
reaction mixture was used for the ligation reaction. Ligation was performed 
using the Roche DNA Ligation Kit (Roche Applied Science) and reaction 
mixtures were assembled as instructed by the manufacturer. Insert DNA 
(excised and purified CD55-GPI consensus fragment) was added to the ligation 
reaction at a final molar ratio of insert:vector of 3:1.
Ligation mixtures were incubated at room temperature for 90 min and ligation 
products (5 pi) were transformed into CaCh-competent DH5a cells and plated 
onto selective LB medium. Any positive (resistant) clones were purified, 
plasmids were extracted and their inserts were analysed by double Xhol-BInl 
restriction. Plasmids with the predicted insert size were selected and their
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sequences were validated by direct sequencing, as described in Section 11.19.3. 
CD32/55 expressing plasmid was then transfected in CH0-K1 and K562 cells 
(described in detail in Section 11.21) and the GPI modification of the chimaeric 
protein was confirmed by reduction in expression following treatm ent with 
phosphatidylinositol-specific phospholipase C (PI-PLC; 0.1 U ml'1) (Sigma 
Aldrich) for 20 min at 37°C.
11.21. Generation of Transgene-Expressing Cell Lines
11.21.1. Cell Transfection
CHO cells were transfected using either jetPEI™ Transfection reagent (PolyPlus 
Transfection) or Lipofectamine LTX™ (Invitrogen), according to 
manufacturer's instructions. For jetPEI™-based transfection, 24 h before 
transfection, 3 x l0 5 cells were plated in each well of a 6 well plate and cultured 
in DMEM:F-12 (1:1) supplemented with GlutaMAX™ and 10%  (v/v) FBS. 
Purified plasmid DNA (3 gg) was diluted in 150 mM NaCl to a final volume of 
100 gl. Similarly, 3.6 gl of jetPEI™ transfection reagent was diluted in NaCl 
(150 mM) to a final volume of 100 gl and following gentle vortexing it was 
added to the diluted DNA solution. The mixture was immediately vortexed and 
incubated at room temperature for 30 min. Then, 200 gl of the jetPEI™/DNA 
mixture was added drop-wise to the cells, which contained 2 ml of serum 
containing medium (DMEM:F-12 (1:1) supplemented with GlutaMAX™ and 
10%  (v/v) FBS) and the plate was gently shaken to ensure adequate mixing.
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Cells were incubated at 37°C (5%  CO2) and expression was assessed at least 24 
h following transfection.
For Lipofectamine-based transfection, the following protocol was used: CHO 
cells were plated at 2 x l0 5 cells per well in a 6-well plate 24 hours before 
transfection and cultured in DMEM:F-12 (1:1) supplemented with GlutaMAX™ 
and 10%  (v/v) FCS. Plasmid DNA (2.5 pg) was diluted in 500 pi Opti-MEM® I 
Reduced growth medium (Invitrogen) and 8.75 pi of Lipofectamine LTX™ 
reagent was added. Lipofectamine-DNA solution was gently mixed and 
incubated at room temperature for 25 min. In the meantime, culture medium 
from cells was replaced with 2 ml of complete growth medium, containing 
10%  (v/v) FCS, but without any antibiotics. DNA-Lipofectamine complexes 
(500 pi) were then added drop-wise to each well and mixed gently. Cells were 
then incubated at 37°C (5%  CO2) and expression was assessed 24 h following 
transfection by flow cytometry.
K562 cells were transfected using Lipofectamine LTX™ and Lipofectamine 
PLUS™ reagent (Invitrogen) based on the following protocol: 5 x l0 5 cells were 
plated into each well of a 6 well tissue culture plate containing 2 ml of RPMI 
1640 complete medium (2 mM L-glutamine + 10%  (v/v) FCS). Plasmid DNA 
(2.5 pg) was diluted in 500 pi Opti-MEM® I Reduced growth medium 
(Invitrogen) and 2.5 pi of PLUS™ reagent were added to the diluted DNA, 
followed by gentle mixing and incubation for 15 min at room temperature. 
Then, 10 pi of Lipofectamine LTX was added to the DNA/PLUS™ solution, 
mixed gently and incubated for 25 min at room temperature to allow
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formation of Lipofectamine/DNA complexes. This mixture (500 pi) was then 
added drop-wise to the plated cells, mixed gently and cells were incubated at 
37°C (5%  CO2). Transgene expression was assessed 24 h following transfection 
by flow cytometry as described in Section 11.6.
11.21.2. Cell Selection
For the generation of stable transfectants, 48 h following transfection cells 
were cultured with the corresponding selection antibiotic. CHO cells were 
cultured in DMEM:F12 (1:1) (GlutaMAX™ + 10%  (v/v) FCS) medium 
containing 1 mg m l1 G418 (Invitrogen) for about 14 days. K562 cells were 
maintained in RPM1 1640 medium supplemented with 2 mM L-glutamine and 
10%  (v/v) FCS and selected with either G418 (initially added at 1 mg ml'1 for 
the first 48 h and then at 500 pg ml'1) or puromycin (2 pg ml'1; Sigma Aldrich). 
Selection of positive clones was performed by cell sorting (see Section 11.21.3 
for more details). For CHO cells, single clone populations were established 
either by serial dilution culture or single cell sorting so as to maintain a stable 
transgene-expressing cell population.
11.21.3. Cell Sorting
Following direct immunolabelling of cells with FITC-conjugated anti-CD32 
antibodies (Clone FLI8.26, IgG2b, BD Biosciences)(for detailed protocol on 
immunolabelling see Section 11.6), cells were re-suspended in DMEM medium 
supplemented with 2 mM L-glutamine and 0.5% (v/v) FCS and processed
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immediately for fluorescence-activated cell sorting using a BD FACS Vantage™ 
SE/DiVA™ Cell sorter. Sorted cells were collected in either 5 ml polypropylene 
tubes (BD Biosciences) for K562 cells or in 96-well plates (Costar) for CHO 
cells, using single cell sorting so as to obtain single clone cell populations. Data 
were visualised and analysed using BD FACS Diva™ software (BD Biosciences).
11.22. Assessment of CD32-Lipid Raft Interactions
11.22.1. Detergent-Resistant Membrane Fractionation and Analysis
Detergent-resistant membrane (DRM) domain fractionation was performed 
essentially as previously described based on well-validated protocols (Rollet- 
Labelle e t a l ,  2004; Setiadi and McEver, 2008). All cell lysis procedures were 
carried out at 4°C and unless otherwise stated, all reagents were ice cold. 
Following stimulation of cells (CHO: 2 x l0 7 or K562: lx lO 7) with IgG 
complexes (hHAIgG, 10 gg ml'1), cells were washed twice with ice-cold PBS 
(Ca2+/Mg2+ free) and incubated for 10 min with TNE buffer (50 mM Tris, 150 
mM NaCl, 2 mM EDTA; pH 7.5) at 4°C. Cells were homogenised using a 25- 
gauge needle (passed 15-20 times) and incubated on ice for a further 5 min 
prior to the addition of Triton™ X-100 (0.25%  v/v final concentration).
Triton™ X-100 lysates were incubated for 30 min on ice before addition of 
OptiPrep™ (Axis-Shield; Sigma Aldrich) density gradient medium to a final 
concentration of 40%  (v/v). After gentle mixing, lysates (600 pi) were applied 
to the bottom of pre-chilled 2.2 ml ultracentrifuge, thin-walled, polypropylene
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tubes (Ultra-Clear™, 8x49 mm, Beckman Coulter, High Wycombe, 
Buckinghamshire, UK) and sequentially overlaid with 35%  (v/v) and 25%  (v/ 
v) OptiPrep™ solutions (600 pi in TNE buffer), followed by 200 pi of TNE 
buffer (0% ). Samples were then centrifuged at 54,000 rpm (194,000^avg) for 2 
h at 4°C in an Optima-MAX™ benchtop ultracentrifuge (Beckman Coulter) 
using a TLS-55 swinging bucket rotor (Beckman Coulter). Following 
centrifugation, fractions (200 pi) were carefully collected from the top to the 
bottom of the tube and stored at -20°C for subsequent analysis.
Fractions obtained after DRM isolation were resolved by SDS-PAGE using 
4-12%  Bis-Tris gradient gels (NuPAGE, Invitrogen) under non-reducing 
conditions, according to manufacturer’s instructions. Following the same 
recommendations, proteins were then electroblotted onto nitrocellulose 
membranes (Amersham Biosciences)(30 V, 60 min) and blocked with 5% w/v 
fat-free milk in PBS containing 0.05%  (v/v) Tween™-20. Membranes were 
probed for 60 min at room temperature with the corresponding primary 
antibodies: goat anti-human CD32a (1:500, R&D Systems), mouse anti-human 
caveolin-1 (1:500, BD Biosciences), mouse anti-human transferrin receptor 
(CD 71)(1:1000, BD Biosciences), mouse anti-human flotillin-1 (1:1000, BD 
Biosciences). Membranes were then incubated with HRP-conjugated 
secondary antibodies (either goat anti-mouse or rabbit anti-goat Ig; 1:5000, 
Dako Cytomation) for 40 min at room temperatures. All antibody dilutions 
were prepared in PBS containing Tween™-20 (0.05%  v/v) and after each 
incubation step with either primary or secondary antibody, membranes were
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thoroughly washed at least four times with PBS-Tween™-20 (0.05%  v/v). 
Bound antibodies were visualised using enhanced chemiluminescence (ECL™ 
or ECL Plus™ reagent; Amersham Biosciences) and Hyperfilm™ (Amersham 
Biosciences; GE Healthcare). For the quantification of gel band intensities, 
ImageJ (National Institutes of Health, Bethesda, Maryland, USA) software 
package was used.
11.22.2. Confocal Immunofluorescence Microscopy
CD32 and GM1 immunolabelling was performed using previously described 
protocols (Harder etal., 1998). Briefly, CHO cells were grown on sterile glass 
coverslips for 24 h (37°C; 5% CO2) prior to immunolabelling. Cells were 
washed twice with ice-cold medium (DMEM containing 2 mg m l1 BSA) and 
incubated with the mouse anti-human CD32 antibody (IV.3 clone; 20 pg ml'1) 
and biotin-conjugated cholera toxin B subunit (10 pg ml-1) at 12°C for 60 min 
under gentle rocking. Then, cells were washed with ice-cold PBS (Ca2+/Mgz+ 
free) and subsequently incubated with Alexa Fluor™ 647-labelled streptavidin 
(10 pg ml'1) and R-PE-conjugated goat F(ab ' )2  anti-mouse IgG (10 pg ml'1). 
Cells were fixed on ice for 4 min with 3.8% (w/v) formaldehyde in PBS (Ca2+/ 
Mg2+ free) followed by a 5-minute incubation in methanol (100% ) at -20°C. 
K562 immunolabelling was performed as described above with the exception 
that cells were labelled in suspension and were then attached to poly-L-lysine 
(Sigma Aldrich)-coated coverslips, according to manufacturer’s instructions 
prior to fixation. Coverslips were briefly washed in distilled water and then 
mounted using the FluorSave™ reagent (Merck-Calbiochem). Slides were
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visualised (lOOx oil-immersion objective) using Zeiss™ LSM510meta laser 
scanning confocal microscope (Carl Zeiss, Welwyn Garden City, Hertfordshire, 
UK) equipped with argon and helium/neon lasers and digital images were 
prepared using the LSM™ image browser (Carl Zeiss), Volocity™ (Improvision 
-  PerkinElmer, Waltham, Massachusetts, USA) and Adobe® Photoshop® CS4 
(Adobe Corporation, San Jose, California, USA). For the quantification of CD32- 
GM1 co-localisation, images (from at least 50 cells obtained from random 
fields) were analysed using the Zeiss® LSM™ 510 software package or 
Volocity™ and co-localisation expressed as the percentage of pixels from the 
CD32 channel co-localising with pixels from the GM1 channel.
11.23. Measurement of Cellular Cholesterol
Total cellular cholesterol was quantified in CHO and K562 cells, using the 
cholesterol/cholesteryl ester quantitation kit (Merck Calbiochem), according 
to manufacturer's instructions. Cells (5 x l0 6) were washed twice with ice-cold 
PBS (Ca2+/Mg2+-free) and pellets were air-dried to ensure complete removal of 
PBS. Then, cell pellets were re-suspended in 1ml chloroform:methanol (2:1) 
solution and homogenised using a 25-gauge needle and by sonication, until 
completely dissolved. Samples were then centrifuged for 10 min at 14,000# 
and the organic phase was transferred into a glass tube and vacuum-dried 
using a heated vacuum centrifuge (Eppendorf, Cambridge, Cambridgeshire, 
UK). Dried lipids were re-dissolved in 100 pi isopropanol containing 10%  (v/ 
v) Triton™ X-100 and stored at -20°C until further analysis. Samples (1 pi)
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were then diluted with the supplied Cholesterol Reaction Buffer (49 pi] and 
co-incubated for 60 min at 37°C with an equal volume of the reaction mix, 
containing the fluorescent cholesterol probe, cholesterol esterase and 
cholesterol oxidase. During this 60-minute incubation step, cholesteryl esters 
are hydrolysed by cholesterol esterases to yield cholesterol, which is then 
oxidised by cholesterol oxidase to produce hydrogen peroxide (H2O2). 
Hydrogen peroxide then reacts with the sensitive cholesterol probe resorufin, 
which becomes fluorescent. Sample fluorescence was quantified at an 
excitation wavelength of 535 nm and an emission wavelength of 590 nm, using 
a BioTek™ microplate fluorimeter -  spectrophotometer (BioTek Instruments). 
Standard curves were generated using predefined amounts of purified 
cholesterol (0-1 gg) and results are defined as the mean cholesterol amount of 
two independent experiments performed in triplicates.
11.24, SNP Genotyping
11.24.1. Allele-specific PCR Amplification
For the determination of FcyRIIIb NA1/2 and FcyRIIa R131H polymorphisms, 
PCR amplification reactions were performed using allele-specific PCR primers 
(Eurofins, MWG). Nucleotides in bold are allele-specific and those underlined 
indicate mismatched nucleotides to the original gene sequences to increase 
primer specificity. For the FCGR3B NA1 allele: forward: 5'- 
CAGTGGTTTCACAATGTGAA-3', reverse: 5'-ATGGACTTCTAGCTGCACCG-3’; For 
the FCGR3B NA2 allele: forward: 5'-CTCAATGGTACAGCGTGCTT-3’, reverse: 5’-
371
CTCAATGGTACAGCGTGCTT-3'. For the FCGR2A R131 allele: forward: 5'- 
AAATCCCAGAAATTCTCACG-3’, reverse: 5’-CACTCCTCTTTGCTCCAGTG-3’; For 
the FCGR2A H131 allele: forward: 5’-AAATCCCAGAAATTCTCACA-3', reverse: 5'- 
CACTCCTCTTTGCTCCAGTG-3'.
PCR amplification reactions were performed in a 50-pl volume, containing 200 
pM dNTP, 1.5 mM MgCh, 200 nM of each primer pair (forward and reverse),
2.5 U Taq DNA polymerase (GoTaq™ Flexi DNA Polymerase, Promega) in green 
GoTaq™ Flexi buffer (Promega) and 1 pi of extracted genomic DNA (200-500 
ng). Reactions were performed in a Touchgene™ gradient thermal cycler 
(Techne). All PCR amplification conditions included an initial denaturation 
step of 5 min at 94°C, and a final extension step of 5 min at 72°C and were as 
following: for FCGR2A R131 and H131: 30 cycles of 45 sec at 94°C, 45 sec at 
54°C and 45 sec at 72°C; for FCGR3B NA1:11 cycles of 1 min at 94°C, 1.5 min at 
60°C and 2.5 min at 72°C, followed by 25 cycles of 1 min at 95°C, 1 min at 57°C 
and 1 min at 72°C; for FCGR3B NA2: 36 cycles of 1 min at 95°C, 1 min 62°C and 
1 min at 72°C.
PCR products (10 pi) were analysed by agarose gel (2%  w/v; UltraPure™ 
Agarose, Invitrogen) electrophoresis in Tris Borate EDTA (TBE) buffer. Gels 
were stained with ethidium bromide (added to the gel at a final concentration 
of 1 pg ml'1) and visualised under UV illumination. The efficiency and 
specificity of the allele-specific PCR amplification was further validated by 
direct sequencing (see Section 11.24.2 for more details).
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11.24.2. DNA Sequencing of PCR Products
In order to validate the efficiency and specificity of the allele-specific PCR 
amplification, regions within the FCGR2A and FCGR3B genes containing the 
R131H and NA1/NA2 polymorphisms, respectively were PCR amplified in a 50 
pi reaction volume containing 200 pM dNTP, 1.5 mM MgCh, 200 nM of each 
primer pair (forward and reverse), 2.5 U Taq DNA polymerase [GoTaq™ Flexi 
DNA Polymerase, Promega) in colourless Go Taq™ Flexi buffer (Promega) and 1 
pi of extracted genomic DNA (200-500 ng). The following primer pairs were 
used: for FcyRIIa: Forward: 5'-TGAGACTGAAAAACCCTTGG-3', Reverse: 5’- 
CACTCCTCTTTGCTCCAGTG-3'; For FcyRlIIb: Forward: 5'- 
GTGTAGAGCCTGCTCCTCTCC-3', Reverse: 5’-AGTGGGACCACACATCATCTC-3’.
Reactions were performed in a Touchgene™ gradient thermal cycler (Techne). 
All PCR amplification conditions included an initial denaturation step of 5 min 
at 94°C, and a final extension step of 5 min at 72°C and were as following: for 
FCGR2A: 35 cycles of 45 sec at 94°C, 45 sec at 54°C and 45 sec at 72°C; for 
FCGR3B-. 35 cycles of 1 min at 94°C, 1 min at 60°C and 1 min at 72°C. In order 
to confirm successful amplification, an aliquot (10 pi) of the PCR products was 
analysed by agarose gel (2%  w/v; UltraPure™ Agarose, Invitrogen) 
electrophoresis and the remaining PCR samples were purified using the 
QIAquick™ PCR Purification kit (Qiagen)(see Section 11.16.3 for further 
details) prior to direct sequencing analysis.
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DNA sequencing reactions were performed by the Sequencing Service (College 
of Life Sciences, University of Dundee, UK) using Applied Biosystems Big-Dye™ 
3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. For the sequencing, the same set of primer pairs were used with 
those used for the PCR amplification (see above) and both the sense and the 
antisense strands of the PCR product were sequenced (double-pass 
sequencing). Chromatograph files were viewed and analysed using the 
Sequence Scanner Software (vl.O) (Applied Biosystems) or the 4Peaks™ 
Sequence Analysis Software (Mekentosj).
11.24.3. Allotype-specific Neutrophil Immunolabelling and Flow Cytometry
Neutrophil granulocytes were isolated by dextran sedimentation and 
discontinuous Percoll™ gradient centrifugation (described in Section 11.5.2; 
(Bournazos e t a l ,  2008; Dransfield etal., 1995)) from citrated peripheral 
venous blood drawn from subjects previously typed as NA1/NA1, NA1/NA2, 
and NA2/NA2. Eosinophils comprised <3% of the isolated polymorphonuclear 
cell fraction. Neutrophils were immunolabelled using either allotype-specific 
mouse monoclonal antibodies (10 gg ml-1) against human FcyRIIIb (NA1: CLB- 
gran/11, mouse IgG2a, NA2: GRM1, mouse IgG2a) or isotype negative control 
monoclonal antibody (UPC-10, mouse IgG2a; Sigma Aldrich). Briefly, freshly 
isolated cells were incubated with the corresponding monoclonal antibody (10 
gg m l1 diluted in PBS containing 0.1% w/v BSA) or the isotype control 
antibody for 30 min on ice at a final concentration of 105 cells ml'1. Cells were 
then washed twice with PBS containing 0.1% (w/v) BSA and incubated with
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Alexa Fluor™ 488-conjugated F(ab ' ]2  goat anti-mouse Ig (Invitrogen) for 20 
min on ice. Cells were again washed twice with PBS containing 0.1%  (w/v]
BSA and re-suspended in the same buffer at a final concentration of 2 x l0 5 cells 
ml'1, prior to flow cytometric analysis. Surface expression of FcyRIIIb (NA1 or 
NA2) was assessed by flow cytometry based on FL-1 intensity fluorescence 
using a BD FACScan™ flow cytometer (BD Biosciences] and data were analysed 
using BD CellQuest™ (BD Biosciences], BD FACS Diva™ (BD Biosciences] or 
Flowjo™ (TreeStar] software.
11.25. Measurement of FCGR3B Copy Number Variation
11.25.1. Quantification of FCGR3B Copy Number by Quantitative Real-Time PCR
(qPCR)
FCGR3B gene copy number was measured by quantitative real-time PCR, based 
on previously described protocols (Aitman et al., 2006; Fanciulli et al., 2007; 
Willcocks et al., 2008]. PCR amplification reactions were performed using 
QuantiFast® SYBR Green PCR Kit (Qiagen] in 25 gl volume, containing 12.5 gl 
of 2x QuantiFast® SYBR Green PCR Master Mix (Qiagen], 1 gM of each primer 
pair, and 2.5 ng of genomic DNA. The following primer pairs were used: for 
FCGR3B: Forward: 5’-CACCTTGAATCTCATCCCCAGGGTCTTG-3’; Reverse: 5’- 
CCATCTCTGTCACCTGCCAG-3’; For CD36 (used as a single copy control]: 
Forward: 5’-TAAGTTCAGGTTCCTGGAATGC-3'; Reverse: 5'- 
CAAATTATGGTATGGACTGTGC-3'.
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Reactions were performed in 96-well PCR plates (MicroAmp® Fast 96-well 
Reaction Plates, Applied Biosystems) using an Applied Biosystems 7500 Fast 
(Applied Biosystems) real-time cycler. Amplification conditions were the 
following: initial denaturation and polymerase activation step for 5 min at 
95°C followed by 40 cycles of 10 sec at 95°C and 30 sec at 60°C. Melting curve 
analysis of the PCR products was performed to verify their specificity and 
identity. Standard curves were generated by serial two-fold dilution of a single 
genomic DNA sample over the range of 25 ng to 0.78 ng per reaction. Unless 
otherwise stated, samples and standard curve reactions were run in 
quadruplicates. Amplification data were collected and analysed using the 
Sequence Detection System (SDS®) software (v l.4 ) (Applied Biosystems).
For the analysis of results, baseline amplification threshold and threshold 
cycle (Ct) values were automatically calculated by the SDS® software. Samples 
that displayed deviations from the expected melting curve analysis profile, 
suggesting non-specific amplification, were excluded from analysis. Based on 
the standard curve analysis, Ct values from each reaction were expressed as 
amount of DNA (ng). The reproducibility of the qPCR assay for each sample 
was assessed by calculating the coefficient of intra-sample variation 
(Coefficient of Variation (CV)%= 100x(standard deviation/mean)) and 
samples with >15% CV were treated as outliers and excluded from the dataset. 
The mean amount of DNA for each sample was calculated from quadruplicate 
reactions and the ratio of FCGR3B- to CD36-specific amplification was used to 
determine FCGR3B gene copy number for each sample.
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11.25.2. Bioinformatics Analysis of Array Comparative Genome Hybridization 
(aCGH) Data
In order to validate the results obtained from the determination of FCGR3B 
gene copy number variation using qPCR, we compared our results with those 
obtained from the Whole Genome TilePath (WGTP) project from the Sanger 
Institute (Redon etal., 2006). This project involved the genome-wide analysis 
of copy number variation in 270 HapMap individuals using array comparative 
genome hybridisation (aCGH) on the WGTP array. The aCGH data from the 
WGTP project were downloaded from the Sanger Institute website (http: // 
www.sanger.ac.uk/humgen/cnv/data/). Log2 intensity ratio values that were 
normalised to a single male reference (HapMap individual NA10851) were 
used for analysis. The probe (8H4), mapping to the Fey receptor locus (lq 2 3 ), 
which also contains the FCGR3B gene, has been identified based on the March 
2006  human genome assembly (NCBI Build 36.1) using the University of 
California, Santa Cruz genome browser (http://genome.ucsc.edu). Plotting of 
the log2 intensity ratios from the 270 HapMap individuals revealed distinct 
pattern of clustering, suggestive of groups with 0 ,1 , 2, 3 and >3 gene copies. 
Based on these results, two individuals were selected from each group and 
were the following: for 0 copies: NA18564 and NA19210; for 1 copy: NA18853 
and NA10839; for 2 copies: NA12248 and NA19005; for 3 copies: NA12234 
and NA10860; and for >3 copies: NA10846 and NA18603. DNA samples were 
obtained from the Coriell Institute (Camden, New jersey, USA) and used as 




Results from multiple experiments are presented as mean ± standard 
deviation (SD). One- or two-way analysis of variance (ANOVA) was used to test 
for differences in the mean values of quantitative variables, and where 
statistically significant effects were found, post-hoc analysis using Bonferroni 
t-test was performed. Unless otherwise stated, P values of <0.05 were 
considered to be statistically significant. Data were analysed with GraphPad™ 
Prism software (v5.Ob) (GraphPad Software, La Jolla, California, USA).
11.26.2. Pulmonary Function Data Analysis
The following pulmonary function measurements were obtained at baseline: 
FEVi, FVC, FEVi/VC, TLC, D L co  and K c o .  Baseline was defined as the date of the 
first radiologic evidence for IPF (date of first HRCT scan). FVC and D L co  were 
monitored for at least 12 months following disease diagnosis (baseline) to 
assess disease progression and prognosis. Predicted pulmonary function 
values were calculated for each patient based on the gender, age and height, 
according to the standardised criteria from the European Community for Coal 
and Steel (ECCS) and the European Respiratory Society (ERS) [Section 15.3). 
Unless otherwise stated, pulmonary function values are expressed as the 
percentage predicted for each patient. One-way analysis of variance (ANOVA) 
was used to test for differences in the mean values (actual or % predicted) of 
pulmonary function measurements among the three genotypes for each SNP
378
(FcyRIIa R131H or FcyRIIIb NA1/2) or among the FcyRIIIb copy number 
variants (<2, 2, >2).
Patients with <40% predicted D L co  at baseline are generally associated with a 
more severe disease phenotype (Bradley e t a l ,  2008; Latsi etal., 2003b]. 
Similarly, a drop of 10%  in FVC or 15%  in D L co  in the first 12 months following 
diagnosis is indicative of progressive disease (Bradley et a l, 2008; Flaherty et 
al., 2003; Hanson etal., 1995; Latsi etal., 2003b). Therefore, baseline and 
serial lung function measurements were used to determine disease severity 
and progression, and patients were categorised accordingly. Association of 
genotypes or copy number variants with disease severity (<40%  D L co  at 
presentation) or progression (-10%  FVC or -15%  D L co )  was assessed by 3x2 
contingency tables (x2 test with two degrees of freedom (d/)). Fisher's exact 
test (2x2 contingency table) was used to assess for differences in the allelic 
frequency among the disease severity or progression groups, x2 test was used 
to test for association of subject gender with genotypes or disease 
progression / severity groups. Unless otherwise stated, pulmonary function 
data are presented as mean ± SD with the exception of graphical 
representations of lung function measurements, where data are presented as 
mean ± 95%  confidence interval (Cl).
11.26.3. Genetic Analysis -  SNP
Hardy-Weinberg equilibrium was assessed by a x2 test with one degree of 
freedom (no of alleles -  1) to test for differences between the observed
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genotype frequency and the expected one. Expected genotype frequencies 
were calculated assuming that the genotypes were in Hardy-Weinberg 
equilibrium, based on the observed allele frequencies. Differences in the 
genotype frequencies between control and IPF patients were analysed by the 
X2 test with two degrees of freedom (df). Fisher's exact test was used to assess 
differences in allele frequencies between the two cohorts and to calculate the 
odds ratio that confers protection or susceptibility for a particular allele.
11.26.4. Genetic Analysis -  CNV
Association of FcyRIIlb copy number and IPF susceptibility was assessed by 
two main strategies: (i) direct comparison of FCGR3B-.CD36 ratio values 
between the two cohorts and (ii) assignment of copy number based on 
FCGR3B-.CD36 ratios.
Firstly, non-parametric tests (Mann-Whitney) were used to test for differences 
in the FCGR3B-.CD36 ratio values between control and IPF groups, since data 
were clustered in distinct copy number groups and were not following 
Gaussian distribution. Secondly, assignment of the FCGR3B:CD36 ratio to copy 
number classes was initially attempted by a priori binning of ratio values to 
predefined thresholds (<2: 0-0.75 (FCGR3B-.CD36]; 2: 0.75-1.25; >2: >1.25). 
However, in order to avoid biases in the copy number classification due to the 
presence of samples in the dataset with FCGR3B-.CD36 values near the 
threshold boundaries, a recently developed, likelihood ratio test was 
employed, which integrates copy number classification and case-control
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association testing (Barnes etal., 2008). The fitting code was obtained from 
http://cnv-tools.sourceforge.net/ and was available as an R package (http:// 
www.r-project.org/). Clustering and copy number assignment of the 
FCGR3B-.CD36 ratios were performed with two fitting models: principal 
components analysis (PCA) and linear discriminant function (LDF), as 
previously described. Posterior probability values for each classification 
component (PI, P2, P3 representing 1, 2 and 3 copies, respectively) of the 
samples are presented in Section 15.2. There was agreement in the copy 
number classification between PCA- and LDF-transformed data. Association 
between copy numbers and the case-control status was tested using the 
likelihood ratio approach, using the Gaussian or T mixture model and the 
results were distributed as x2 with one degree of freedom, as described by 
Barnes and co-workers (2008). Alternatively, copy number classification 
obtained from the PCA and LDF fitting models were used for analysis and 
differences in the copy numbers between control and IPF groups or between 
progressive and non-progressive groups were analysed by a 3x2 contingency 
table (x2 test with 2 degrees of freedom). Association of the >2 copy variant 
with disease susceptibility or progression was assessed by Fisher’s exact test 
and the odds ratios were calculated.
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1 4. L is t  o f  A b b r e v i a t i o n s
2-BP 2-bromopalmitate
aCGH array comparative genome hybridisation
AC PA anti-citrullinated protein/ peptide antibodies
ADAM a disintegrin and metalloproteinase
ADCC antibody-dependent cellular cytotoxicity
AF AlexaFluor™
AIP acute interstitial pneumonitis
Amp ampicillin
ANCA anti-neutrophil cytoplasmic antibody
ANOVA analysis of variance
APC allophycocyanin
APS anti-phospholipid syndrome
ATS American Thoracic Society




BPIP bactericidal permeability-increasing protein
BSA bovine serum albumin
BTK Bruton's tyrosine kinase






CAP-37 cationic antimicrobial protein 37
CBA cytometric bead array
CHL cholesterol
CHO Chinese Hamster Ovary




CIDP chronic inflammatory demyelinating polyneuropathy
CMFDA 5-chloromethylfluoresceln diacetate
CMV human cytomegalovirus
CNV copy number variation
COP cryptogenic organising pneumonia
cppt central polypurine tract
CR complement receptor
CRP C-reactive protein
CTD connective tissue disease
CXR chest X ray
Cyto D cytochalasin D
DAG diacylglycerol
DC dendritic cells
DDAO-SE 7-hydroxy-9FI-(l,3-dichloro-9,9-dimethylacridin-2-one) succinimidyl ester
d f degrees of freedom
DHR123 dlhydrorhodamlne 123
DIP desquamative interstitial pneumonia
D L co diffusing capacity of the lung for carbon monoxide
DMB 3,3'-dimethoxybenzldine
DMEM Dulbecco's Modified Eagle Medium
DMSO dimethyl sulfoxide
DPLD diffuse parenchymal lung disease
DRM detergent-resistant membranes




ERK extracellular signal-regulated kinase
ERS European Respiratory Society
F female
Fab fragment, antibody binding
FACS fluorescence-activated cell sorting
FAK focal adhesion kinase
FBS foetal bovine serum
Fc fragment crystallisable
FCS foetal calf serum
468
FcyR Fey receptor
FDC follicular dendritic cells





FSC forward scatter (flow cytometry)
FVC forced vital capacity
G-CSF granulocyte colony-stimulating factor
Gas-6 growth arrest-specific protein 6
GATA-4 GATA-bindlng factor 4
GBS Gulllaln-Barré syndrome
GDNF Glial cell-derived neurotrophic factor






HBSS Hanks' Balanced Salt Solution
Hck haemopoletic cell kinase
h EF-la human elongation factor l a
HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
hHAIgG human heat aggregated IgG
hi heat inactivated
HIT heparin-induced thrombocytopenia
HLA human leukocyte antigen
HNA human neutrophil antigen
HNE human neutrophil elastase
HOCI hypochlorous acid
hPGK human phosphoglycerate kinase (promoter)
HPLC high performance liquid chromatography
HRCT high resolution computed tomography
HRP Horseradish peroxidase




1 CAM-1 Intercellular adhesion molecule-1
IFN-y interferon- y
lg immunoglobulin
IIP idiopathic interstitial pneumonias
IL interleukin
ILD interstitial lung disease
IMDM Iscove's Modified Dulbecco's Medium
IP immunoprécipitation
IPs inositol triphosphate
IPF idiopathic pulmonary fibrosis
ITAM immunoreceptor tyrosine-based activation motif
ITIM immunoreceptor tyrosine-based inhibition motif
ITP idiopathic thrombocytopenia purpura
JNK c-Jun N-terminal kinase
Jurkat:32 CD32a-transfected Jurkat cells
Kan kanamycin
KCO DLco corrected for lung volume
KIR killer cell immunoglobulin-like receptor
LAM lymphangioleiomyomatosis
LB Lysogeny Broth
Lck lymphocyte cell-specific protein-tyrosine kinase
LDF linear discriminant function
LFA-1 lymphocyte function-associated antigen-1
LIP lymphocytic interstitial pneumonia
LOX-1 lectin-like oxidised LDL receptor
LPC lysophosphatidylcholine
LPS lipopolysaccharide





MCP-1 monocyte chemotactic protein-1
470
mcs multiple cloning site
MEK MAPK/ERK kinase
Mertk Mer tyrosine kinase
MFG-E8 milk fat globule EGF-factor 8
MG myasthenia gravis









NAPDH nicotinamide adenine dinucleotide phosphate
NF-kB nuclear factor-xB
NFAT nuclear factor of activated T-cells
NGAL neutrophil gelatinase-associated lipocalin
NHS National Heath Service
NK natural killer
NOS nitric oxide synthase
NRAMP1 natural resistance-associated macrophage protein 1
NS non significant





ORF open reading frame
Ori origin
P phospho
P(A-a)02 difference between alveolar and arterial pressure
PAMP pathogen-associated molecular pattern
pAn polyadenylation (signal)
Pac>2 arterial oxygen tension
PBS phosphate buffered saline
471
PCA principal components analysis
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PI propidium iodide
PI-PLC phosphatidylinositol-specific phospholipase C
PI3K phosphoinositide 3-kinase
plgR polymeric immunoglobulin receptor
PLCy phospholipase C y






PSGL-1 P-selectin glycoprotein ligand-1
Ptdlns(3,4,5)P3 phosphatidylinositol 3,4,5-triphosphate
Ptdlns(4/5)P2 phosphatidylinositol 4,5-biphosphate





RB-ILD respiratory bronchiolitis-associated interstitial lung disease
RF rheumatic fever
RGD arginine-glycine-aspartic acid (peptide motif)
ROI reactive oxygen intermediates
ROS reactive oxygen species
RP-HPLC reverse phase high performance liquid chromatography
RRE rev response element
SAP serum amyloid protein
SD standard deviation
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SHC Src homology-containing protein
SHIP SH2 domain-containing Inositol 5-phosphatase
SHP2 SH2 domain-containing phosphatase
shRNA short hairpin RNA
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SLE systemic lupus erythematosus
SNP single nucleotide polymorphism
SP surfactant protein
SRA scavenger receptor A
SSC side scatter (flow cytometry)
SV40 Simian virus 40
Syk spleen tyrosine kinase
TB Terrific Broth
TBE Tris Borate EDTA
TCR T-cell receptor
TGF-ß transforming growth factor-ß
Th T helper
TIM-4 T-cell Immunoglobulin and mucin domain-containing protein 4
TLC total lung capacity
TLR Toll-like receptors
TNF-a tumour necrosis factor-a
TSP thrombospondin




WGTP Whole Genome TilePath
WT wild type
YY-1 Yin-Yang 1
ZAP-70 <; chain protein kinase 70
a-CD a-cyclodextrin
a-SMA a-smooth muscle actin
ßz-GPI ß2-glycoprotein-l
ßGlo human ß globin gene
i[) sequence - RNA packaging signal
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15. A p pen d ic es
15.1 Plasmid Maps and Sequences
15.1.1. pSELECT-neo-mcs-FCGR2A
Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; n eo : 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; |3Glo pAn: human p-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5') of the human T-cell 
leukaemia virus (HTLV) type 1 long terminal repeat (LTR); FCGR2A: FCGR2A 
ORF; SV40 pAn: Simian virus 40 late polyadenylation signal.
474
1 TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAA 
6 1  ATCAGCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATC GTAAC TAACATACGC TC TCCATCAAAACAAAAC GAAACAAAACAAAC TAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S  I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGG 
S S K P V T I T V Q V P S M G S S S P M  
1 4 4 1  GGATCATTGTGGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGG 
G I  I V A V V I A T A V A A I V A A V V  
1 5 0 1  CCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTG 
A L I Y C R K K R I S A N S T D P V K A  
1 5 6 1  CCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA 
A Q F E P P G R Q M I A I R K R Q L E E  
1 6 2 1  CCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCTAGGGCACCTA 
T N N D Y E T A D G G Y M T L N P R A P  
1 6 8 1  CTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATA 
T D D D K N I Y L T L P P N D H V N S N  
1 7 4 1  ACTAAAGAGTAACGTTATGCCATGTGGTCAGCTAGCTGGCCAGACATGATAAGATACATT 
N *
1 8 0 1  GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATT 
1 8 6 1  TGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC 
1 9 2 1  AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAG 
1 9 8 1  TAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTC 
2 0 4 1  CAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGG 
2 1 0 1  CTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT 
2 1 6 1  A GTG TA TTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGAC 
2 2 2 1  CTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
475
2 2 8 1  AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCA 
2 3 4 1  GTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAG 
2 4 0 1  CGAGCTTCTAGCTTTAGAAGAACTCATCAAGAAGTCTGTAGAAGGCAATTCTCTGGGAGT
* F F E D L L R Y F A I R Q S D  
2 4 6 1  CAGGGGCTGCAATGCCATAGAGCACTAGGAACCTGTCTGCCCACTCTCCCCCTAGCTCTT 
P A A I G Y L V L F R D A W E G G L E E  
2 5 2 1  CTGCTATGTCCCTGGTTGCTAGGGCAATGTCCTGGTACCTGTCAGCCACTCCCAGCCTGC
3 0 6 1
3 1 2 1
3 2 4 1
3 3 0 1
3 3 6 1
3 4 2 1
3 4 8 1
3 5 4 1
3 6 0 1
3 6 6 1
3 7 2 1
3 7 8 1
3 8 4 1
3 9 0 1
3 9 6 1
4 0 2 1
4 0 8 1
4 1 4 1
4 2 0 1
4 2 6 1
4 3 2 1
4 3 8 1
4 4 4 1
4 5 0 1
A R D R D V R
2 5 8 1  CACAGTCTATGAAGCCAGAGAACCTTCCATTTTCAACCATGATGTTGGGAAGGCAGGCAT
R N V M N D
2 6 4 1  CCCCATGAGTCACCACTAGGTCCTCACCATCTGGCATGGATGCCTTGAGCCTGGCAAATA
H V V D E D M A K R A
2 7 0 1  GTTCAGCAGGGGCCAGGCCCTGGTGTTCTTCATCCAAGTCATCTTGGTCCACCAGGCCAG
E A H E E D D D V
2 7 6 1  CCTCCATCCTGGTTCTGGCCCTCTCTATCCTGTGCTTGGCCTGGTGGTCAAAGGGGCAGG
E M R R R E R  H K Q H D
2 8 2 1  TGGCTGGGTCAAGGGTGTGGAGTCTTCTCATGGCATCAGCCATGATTGACACTTTCTCAG
H R R M D A M V K E
2 8 8 1  CTGGAGCTAGGTGAGAGGAAAGGAGGTCCTGCCCAGGCACCTCACCTAGTAGGAGCCAGT
H D Q V E W
2 9 4 1  CCCTTCCAGCTTCTGTGACCACATCAAGGACAGCTGCACAGGGGACCCCAGTTGTTGCCA
R A E V V V V A L
3 0 0 1  ACCAGGAGAGTCTGGCAGCCTCATCCTGGAGCTCATTGAGAGCCCCACTGAGGTCTGTCT
W R  A A N K
TTACAAAAAGGACTGGCCTGCCTTGGGCTGAAAGTCTGAAAACTGCTGCATCAGAGCAAC
V V R G Q A S V A A
CAATGGTCTGCTGTGCCCAGTCATAGCCAAACAGTCTCTCAACCCAGGCAGCTGGAGAAC
Q Q W D R E V W




























Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; neo: 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; 0Glo pAn: human (B-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5') of the human T-cell 
leukaemia virus (HTLV) type 1 long terminal repeat (LTR); FCGR2A: ECGR2A 
ORF; SV40 pAn: Simian virus 40 late polyadenylation signal.
477
1 TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAA 
6 1  ATCAGCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S  I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S  I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCTÇGAGTTCACCAATGG 
S S K P V T I T V Q V P S M G S S S P M  
1 4 4 1  GGATCATTGTGGCTGTGGTCATTTCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGG 
G I  I V A V V I A T A V A A I V A A V V  
1 5 0 1  CCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTG 
A L I Y C R K K R I S A N S T D P V K A  
1 5 6 1  CCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA 
A Q F E P P G R Q M I A I R K R Q L E E  
1 6 2 1  CCAACAAÇGATTAÇGAAACAGCTGACGGCGGCTACATGACTCTGAACCCTAGGGCACCTA 
T N N D Y E T A D G G Y M T L N P R A P  
1 6 8 1  CTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATA 
T D D D K N I Y L T L P P N D H V N S N  
1 7 4 1  ACTAAAGAGTAACGTTATGCCATGTGGTCAGCTAGCTGGCCAGACATGATAAGATACATT 
N *
1 8 0 1  GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATT 
1 8 6 1  TGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC 
1 9 2 1  AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAG 
1 9 8 1  TAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTC 
2 0 4 1  CAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGG 
2 1 0 1  CTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT 
2 1 6 1  A GTG TA TTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGAC 
2 2 2 1  CTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
478
2 2 8 1  AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCA 
2 3 4 1  GTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAG 
2 4 0 1  CGAGCTTCTAGCTTTAGAAGAACTCATCAAGAAGTCTGTAGAAGGCAATTCTCTGGGAGT
* F F E D L L R Y F A I R Q S D  
2 4 6 1  CAGGGGCTGCAATGCCATAGAGCACTAGGAACCTGTCTGCCCACTCTCCCCCTAGCTCTT 
P A A I G Y L V L F R D A W E G G L E E  
2 5 2 1  CTGCTATGTCCCTGGTTGCTAGGGCAATGTCCTGGTACCTGTCAGCCACTCCCAGCCTGC 
A I D R T A L A I D Q Y R D A V G L R G  
2 5 8 1  CACAGTCTATGAAGCCAGAGAACCTTCCATTTTCAACCATGATGTTGGGAAGGCAGGCAT 
C D I F G S F R G N E V M I N P L C A D  
2 6 4 1  CCCCATGAGTCACCACTAGGTCCTCACCATCTGGCATGGATGCCTTGAGCCTGGCAAATA 
G H T V V L D E G D P M S A K L R A F L  
2 7 0 1  GTTCAGCAGGGGCCAGGCCCTGGTGTTCTTCATCCAAGTCATCTTGGTCCACCAGGCCAG 
E A P A L G Q H E E D L D D Q D V L G A  
2 7 6 1  CCTCCATCCTGGTTCTGGCCCTCTCTATCCTGTGCTTGGCCTGGTGGTCAAAGGGGCAGG 
E M R T R A R E I R H K A Q H D F P C T  
2 8 2 1  TGGCTGGGTCAAGGGTGTGGAGTCTTCTCATGGCATCAGCCATGATTGACACTTTCTCAG 
A P D L T H L R R M A D A M I  S V K E A  
2 8 8 1  CTGGAGCTAGGTGAGAGGAAAGGAGGTCCTGCCCAGGCACCTCACCTAGTAGGAGCCAGT 
P A L H S S L L D Q G P V E G L L L W D  
2 9 4 1  CCCTTCCAGCTTCTGTGACCACATCAAGGACAGCTGCACAGGGGACCCCAGTTGTTGCCA 
R G A E T V V D L V A A C P V G T T A L  
3 0 0 1  ACCAGGAGAGTCTGGCAGCCTCATCCTGGAGCTCATTGAGAGCCCCACTGAGGTCTGTCT 
W S L R A A E D Q L E N L A G S L D T K  
3 0 6 1  TTACAAAAAGGACTGGCCTGCCTTGGGCTGAAAGTCTGAAAACTGCTGCATCAGAGCAAC 
V F L V P R G Q A S L R F V A A D S C G  
3 1 2 1  CAATGGTCTGCTGTGCCCAGTCATAGCCAAACAGTCTCTCAACCCAGGCAGCTGGAGAAC 
I T Q Q A W D Y G F L R E V W A A P S G  
3 1 8 1  CTGCATGTAGGCCATCTTGTTCAATCATGATGGCCCTCCTATAGTGAGTCGTATTATACT 
A H L G D Q E I M  
3 2 4 1  ATGCCGATATACTATGCCGATGATTAATTGTCAAAACAGCGTGGATGGCGTCTCCAGCTT 
3 3 0 1  ATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCG 
3 3 6 1  CCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTACT 
3 4 2 1  AGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCA 
3 4 8 1  AACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATG 
3 5 4 1  ACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAA 
3 6 0 1  TGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATAC 
3 6 6 1  ACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGG 
3 7 2 1  AAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGG 
3 7 8 1  TCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAA 
3 8 4 1  TTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC 
3 9 0 1  TGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC 
3 9 6 1  AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC 
4 0 2 1  TCG TGCG CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT 
4 0 8 1  CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG 
4 1 4 1  TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT 
4 2 0 1  CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG 
4 2 6 1  CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT 
4 3 2 1  GGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGC 
4 3 8 1  CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA 
4 4 4 1  GCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAG 




Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; neo: 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; 0Glo pAn: human (3-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5') of the human T-cell 
leukaemia virus (HTLV) type 1 long terminal repeat (LTR); FCGR2A. FCGR2A 
ORF; SV40 pAn: Simian virus 40 late polyadenylation signal.
480
1 TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAA 
6 1  A TCA GCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S  I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGG 
S S K P V T I T V Q V P S M G S S S P M  
1 4 4 1  GGATCATTGTGGCTGTGGTCATTTCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGG 
G I  I  V A V V I  S e r  T A V A A I V A A V V  
1 5 0 1  CCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTG 
A L I Y C R K K R I S A N S T D P V K A  
1 5 6 1  CCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA 
A Q F E P P G R Q M I A I R K R Q L E E  
1 6 2 1  CCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCTAGGGCACCTA 
T N N D Y E T A D G G Y M T L N P R A P  
1 6 8 1  CTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATA 
T D D D K N I Y L T L P P N D H V N S N  
1 7 4 1  ACTAAAGAGTAACGTTATGCCATGTGGTCAGCTAGCTGGCCAGACATGATAAGATACATT 
N *
1 8 0 1  GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATT 
1 8 6 1  TGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC 
1 9 2 1  AATTGCA TTO ATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGC AAG 
1 9 8 1  TAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTC 
2 0 4 1  CAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGG 
2 1 0 1  CTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT 
2 1 6 1  AGTGTATTTTCCCA AGGTTTGA A CTA GCTCTTCA TTTCTTTATGTTTTA A ATGCA CTGA C 
2 2 2 1  CTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
481
2 2 8 1  AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCA 
2 3 4 1  GTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAG 
2 4 0 1  CGAGCTTCTAGCTTTAGAAGAACTCATCAAGAAGTCTGTAGAAGGCAATTCTCTGGGAGT
* F F E D L L R Y F A I R Q S D  
2 4 6 1  CAGGGGCTGCAATGCCATAGAGCACTAGGAACCTGTCTGCCCACTCTCCCCCTAGCTCTT 
P A A I G Y L V L F R D A W E G G L E E  
2 5 2 1  CTGCTATGTCCCTGGTTGCTAGGGCAATGTCCTGGTACCTGTCAGCCACTCCCAGCCTGC 
A I D R T A L A I D Q Y R D A V G L R G  
2 5 8 1  CACAGTCTATGAAGCCAGAGAACCTTCCATTTTCAACCATGATGTTGGGAAGGCAGGCAT 
C D I F G S F R G N E V M I N P L C A D  
2 6 4 1  CCCCATGAGTCACCACTAGGTCCTCACCATCTGGCATGGATGCCTTGAGCCTGGCAAATA 
G H T V V L D E G D P M S A K L R A F L  
2 7 0 1  GTTCAGCAGGGGCCAGGCCCTGGTGTTCTTCATCCAAGTCATCTTGGTCCACCAGGCCAG 
E A P A L G Q H E E D L D D Q D V L G A  
2 7 6 1  CCTCCATCCTGGTTCTGGCCCTCTCTATCCTGTGCTTGGCCTGGTGGTCAAAGGGGCAGG 
E M R T R A R E I R H K A Q H D F P C T  
2 8 2 1  TGGCTGGGTCAAGGGTGTGGAGTCTTCTCATGGCATCAGCCATGATTGACACTTTCTCAG 
A P D L T H L R R M A D A M I  S V K E A  
2 8 8 1  CTGGAGCTAGGTGAGAGGAAAGGAGGTCCTGCCCAGGCACCTCACCTAGTAGGAGCCAGT 
P A L H S S L L D Q G P V E G L L L W D  
2 9 4 1  CCCTTCCAGCTTCTGTGACCACATCAAGGACAGCTGCACAGGGGACCCCAGTTGTTGCCA 
R G A E T V V D L V A A C P V G T T A L  
3 0 0 1  ACCAGGAGAGTCTGGCAGCCTCATCCTGGAGCTCATTGAGAGCCCCACTGAGGTCTGTCT 
W S L R A A E D Q L E N L A G S L D T K  
3 0 6 1  TTACAAAAAGGACTGGCCTGCCTTGGGCTGAAAGTCTGAAAACTGCTGCATCAGAGCAAC 
V F L V P R G Q A S L R F V A A D S C G  
3 1 2 1  CAATGGTCTGCTGTGCCCAGTCATAGCCAAACAGTCTCTCAACCCAGGCAGCTGGAGAAC 
I T Q Q A W D Y G F L R E V W A A P S G  
3 1 8 1  CTGCATGTAGGCCATCTTGTTCAATCATGATGGCCCTCCTATAGTGAGTCGTATTATACT 
A H L G D Q E I M  
3 2 4 1  ATGCCGATATACTATGCCGATGATTAATTGTCAAAACAGCGTGGATGGCGTCTCCAGCTT 
3 3 0 1  ATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCG 
3 3 6 1  CCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTACT 
3 4 2 1  AGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCA 
3 4 8 1  AACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATG 
3 5 4 1  ACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAA 
3 6 0 1  TGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATAC 
3 6 6 1  ACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGG 
3 7 2 1  AAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGG 
3 7 8 1  TCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAA 
3 8 4 1  TTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC 
3 9 0 1  TGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC 
3 9 6 1  AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC 
4 0 2 1  TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT 
4 0 8 1  CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG 
4 1 4 1  TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT 
4 2 0 1  CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG 
4 2 6 1  CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT 
4 3 2 1  GGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGC 
4 3 8 1  CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA 
4 4 4 1  GCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAG 
4 5 0 1  A TCCTTTGATCTTTTCTACGGGGTCTGACGC
482
15.1.4. pSELECT-neo-mcs-FCGR2A C241A
Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; neo: 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; (5Glo pAn: human (3-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5’) of the human T-cell 
leukaemia virus (HTLV] type 1 long terminal repeat (LTR); FCGR2A: FCGR2A 
ORF; SV40 pAn: Simian virus 40 late polyadenylation signal.
483
1 TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAA 
6 1  A TCA GCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S  I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGG 
S S K P V T I T V Q V P S M G S S S P M  
1 4 4 1  GGATCATTGTGGCTGTGGTCATTTCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGG 
G I  I V A V V I A T A V A A I V A A V V  
1 5 0 1  CCTTGATCTACGÇCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTG 
A L I Y  Al a  R K K R I S A N S T D P V K A  
1 5 6 1  CCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA 
A Q F E P P G R Q M I A I R K R Q L E E  
1 6 2 1  CCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCTAGGGCACCTA 
T N N D Y E T A D G G Y M T L N P R A P  
1 6 8 1  CTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATA 
T D D D K N I Y L T L P P N D H V N S N  
1 7 4 1  ACTAAAGAGTAACGTTATGCCATGTGGTCAGCTAGCTGGCCAGACATGATAAGATACATT 
N *
1 8 0 1  GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATT 
1 8 6 1  TGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC 
1 9 2 1  AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAG 
1 9 8 1  TAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTC 
2 0 4 1  CAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGG 
2 1 0 1  CTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT 
2 1 6 1  AGTGTATTTTCCCA AGGTTTGA A CTA GCTCTTCA TTTCTTTATGTTTTA A ATGCA CTGA C 
2 2 2 1  CTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
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2 2 8 1  AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCA 
2 3 4 1  GTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAG 
2 4 0 1  CGAGCTTCTAGCTTTAGAAGAACTCATCAAGAAGTCTGTAGAAGGCAATTCTCTGGGAGT
* F F E D L L R Y F A I R Q S D  
2 4 6 1  CAGGGGCTGCAATGCCATAGAGCACTAGGAACCTGTCTGCCCACTCTCCCCCTAGCTCTT 
P A A I G Y L V L F R D A W E G G L E E  
2 5 2 1  CTGCTATGTCCCTGGTTGCTAGGGCAATGTCCTGGTACCTGTCAGCCACTCCCAGCCTGC 
A I D R T A L A I D Q Y R D A V G L R G  
2 5 8 1  CACAGTCTATGAAGCCAGAGAACCTTCCATTTTCAACCATGATGTTGGGAAGGCAGGCAT 
C D I F G S F R G N E V M I N P L C A D  
2 6 4 1  CCCCATGAGTCACCACTAGGTCCTCACCATCTGGCATGGATGCCTTGAGCCTGGCAAATA 
G H T V V L D E G D P M S A K L R A F L  
2 7 0 1  GTTCAGCAGGGGCCAGGCCCTGGTGTTCTTCATCCAAGTCATCTTGGTCCACCAGGCCAG 
E A P A L G Q H E E D L D D Q D V L G A  
2 7 6 1  CCTCCATCCTGGTTCTGGCCCTCTCTATCCTGTGCTTGGCCTGGTGGTCAAAGGGGCAGG 
E M R T R A R E I R H K A Q H D F P C T  
2 8 2 1  TGGCTGGGTCAAGGGTGTGGAGTCTTCTCATGGCATCAGCCATGATTGACACTTTCTCAG 
A P D L T H L R R M A D A M I  S V K E A  
2 8 8 1  CTGGAGCTAGGTGAGAGGAAAGGAGGTCCTGCCCAGGCACCTCACCTAGTAGGAGCCAGT 
P A L H S S L L D Q G P V E G L L L W D  
2 9 4 1  CCCTTCCAGCTTCTGTGACCACATCAAGGACAGCTGCACAGGGGACCCCAGTTGTTGCCA 
R G A E T V V D L V A A C P V G T T A L  
3 0 0 1  ACCAGGAGAGTCTGGCAGCCTCATCCTGGAGCTCATTGAGAGCCCCACTGAGGTCTGTCT 
W S L R A A E D Q L E N L A G S L D T K  
3 0 6 1  TTACAAAAAGGACTGGCCTGCCTTGGGCTGAAAGTCTGAAAACTGCTGCATCAGAGCAAC 
V F L V P R G Q A S L R F V A A D S C G  
3 1 2 1  CAATGGTCTGCTGTGCCCAGTCATAGCCAAACAGTCTCTCAACCCAGGCAGCTGGAGAAC 
I T Q Q A W D Y G F L R E V W A A P S G  
3 1 8 1  CTGCATGTAGGCCATCTTGTTCAATCATGATGGCCCTCCTATAGTGAGTCGTATTATACT 
A H L G D Q E I M  
3 2 4 1  ATGCCGATATACTATGCCGATGATTAATTGTCAAAACAGCGTGGATGGCGTCTCCAGCTT 
3 3 0 1  ATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCG 
3 3 6 1  CCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTACT 
3 4 2 1  AGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCA 
3 4 8 1  AACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATG 
3 5 4 1  ACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAA 
3 6 0 1  TGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATAC 
3 6 6 1  ACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGG 
3 7 2 1  AAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGG 
3 7 8 1  TCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAA 
3 8 4 1  TTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC 
3 9 0 1  TGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC 
3 9 6 1  AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC 
4 0 2 1  TCG TGCG CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT 
4 0 8 1  CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG 
4 1 4 1  TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT 
4 2 0 1  CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG 
4 2 6 1  CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT 
4 3 2 1  GGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGC 
4 3 8 1  CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA 
4 4 4 1  GCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAG 




Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; neo\ 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; pGlo pAn: human p-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5') of the human T-cell 
leukaemia virus (HTLV) type 1 long terminal repeat (LTR); FCGR2A-. FCGR2A 
ORF; SV40 pAn: Simian virus 40 late polyadenylation signal.
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1 TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAA 
6 1  A TCA GCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S  I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGG 
S S K P V T I T V Q V P S M G S S S P M  
1 4 4 1  GGATCATTGTGGCTGTGGTCATTTCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGG 
G I  I V A V V I A T A V A A I V A A V V  
1 5 0 1  CCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTG 
A L I Y C R K K R I S A N S T D P V K A  
1 5 6 1  CCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA
a q f e p p g r q m i a i r k r q l e e
1 6 2 1  CCAACAAÇGATTAÇGAAACAGCTGACGGCGGCTACATGACTCTGAACCCTAGGGCACCTA 
T N N D Y E T A D G G Y M T L N P R A P  
1 6 8 1  CTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATA 
T D D D K N I Y L T L P P N D H V N S N  
1 7 4 1  ACTAAAGAGTAACGTTATGCCATGTGGTCAGCTAGCTGGCCAGACATGATAAGATACATT 
N *
1 8 0 1  GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATT 
1 8 6 1  TGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC 
1 9 2 1  AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAG 
1 9 8 1  TAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTC 
2 0 4 1  CAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGG 
2 1 0 1  CTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT 
2 1 6 1  AGTGTATTTTCCCA AGGTTTGA A CTA GCTCTTCA TTTCTTTATGTTTTA A ATGCA CTGA C 
2 2 2 1  CTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
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2 2 8 1  AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCA 
2 3 4 1  GTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAG 
2 4 0 1  CGAGCTTCTAGCTTTAGAAGAACTCATCAAGAAGTCTGTAGAAGGCAATTCTCTGGGAGT
* F F E D L L R Y F A I R Q S D  
2 4 6 1  CAGGGGCTGCAATGCCATAGAGCACTAGGAACCTGTCTGCCCACTCTCCCCCTAGCTCTT 
P A A I G Y L V L F R D A W E G G L E E  
2 5 2 1  CTGCTATGTCCCTGGTTGCTAGGGCAATGTCCTGGTACCTGTCAGCCACTCCCAGCCTGC 
A I D R T A L A I D Q Y R D A V G L R G  
2 5 8 1  CACAGTCTATGAAGCCAGAGAACCTTCCATTTTCAACCATGATGTTGGGAAGGCAGGCAT 
C D I F G S F R G N E V M I N P L C A D  
2 6 4 1  CCCCATGAGTCACCACTAGGTCCTCACCATCTGGCATGGATGCCTTGAGCCTGGCAAATA 
G H T V V L D E G D P M S A K L R A F L  
2 7 0 1  GTTCAGCAGGGGCCAGGCCCTGGTGTTCTTCATCCAAGTCATCTTGGTCCACCAGGCCAG 
E A P A L G Q H E E D L D D Q D V L G A  
2 7 6 1  CCTCCATCCTGGTTCTGGCCCTCTCTATCCTGTGCTTGGCCTGGTGGTCAAAGGGGCAGG 
E M R T R A R E  I R H K A Q H D F P C T  
2 8 2 1  TGGCTGGGTCAAGGGTGTGGAGTCTTCTCATGGCATCAGCCATGATTGACACTTTCTCAG 
A P D L T H L R R M A D A M I  S V K E A  
2 8 8 1  CTGGAGCTAGGTGAGAGGAAAGGAGGTCCTGCCCAGGCACCTCACCTAGTAGGAGCCAGT 
P A L H S S L L D Q G P V E G L L L W D  
2 9 4 1  CCCTTCCAGCTTCTGTGACCACATCAAGGACAGCTGCACAGGGGACCCCAGTTGTTGCCA 
R G A E T V V D L V A A C P V G T T A L  
3 0 0 1  ACCAGGAGAGTCTGGCAGCCTCATCCTGGAGCTCATTGAGAGCCCCACTGAGGTCTGTCT 
W S L R A A E D Q L E N L A G S L D T K  
3 0 6 1  TTACAAAAAGGACTGGCCTGCCTTGGGCTGAAAGTCTGAAAACTGCTGCATCAGAGCAAC 
V F L V P R G Q A S L R F V A A D S C G  
3 1 2 1  CAATGGTCTGCTGTGCCCAGTCATAGCCAAACAGTCTCTCAACCCAGGCAGCTGGAGAAC 
I T Q Q A W D Y G F L R E V W A A P S G  
3 1 8 1  CTGCATGTAGGCCATCTTGTTCAATCATGATGGCCCTCCTATAGTGAGTCGTATTATACT 
A H L G D Q E I M  
3 2 4 1  ATGCCGATATACTATGCCGATGATTAATTGTCAAAACAGCGTGGATGGCGTCTCCAGCTT 
3 3 0 1  ATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCG 
3 3 6 1  CCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTACT 
3 4 2 1  AGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCA 
3 4 8 1  AACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATG 
3 5 4 1  ACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAA 
3 6 0 1  TGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATAC 
3 6 6 1  ACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGG 
3 7 2 1  AAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGG 
3 7 8 1  TCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAA 
3 8 4 1  TTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC 
3 9 0 1  TGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC 
3 9 6 1  AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC 
4 0 2 1  TCG TGCG CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT 
4 0 8 1  CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG 
4 1 4 1  TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT 
4 2 0 1  CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG 
4 2 6 1  CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT 
4 3 2 1  GGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGC 
4 3 8 1  CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA 
4 4 4 1  GCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAG 
4 5 0 1  A TCCTTTGATCTTTTCTACGGGGTCTGACGC
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15.1.6. pJ201:CD55-GPI
pUCori: E.coli origin of replication from a pUC vector; KanR: kanamycin 
resistance gene; CD55 insert: GPI-consensus sequence from the human CD55 
gene; Txn: bacterial transcription terminator sequences.
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1 TAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTT 
71  GAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTA 
1 4 1  TCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTA 
2 1 1  TCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCC 
2 8 1  AGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCAT 
3 5 1  TCGTGATTGCGCCTGAGCGAGGCGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAG 
4 2 1  TGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATA 
4 9 1  CCTGGAACGCTGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATG 
5 6 1  CTTGATGGTCGGAAGTGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTG 
6 3 1  GCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAAGCGATAGATTG 
7 0 1  TCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATT 
7 7 1  TAATCGCGGCCTCGACGTTTCCCGTTGAATATGGCTCATATTCTTCCTTTTTCAATATTATTGAAGCATT 
8 4 1  TATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTCA 
9 1 1  GTGTTACAACCAATTAACCAATTCTGAACATTATCGCGAGCCCATTTATACCTGAATATGGCTCATAACA 
9 8 1  CCCCTTGTTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACG 
1 0 5 1  CCGTAGCGCCGATGGTAGTGTGGGGACTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACG 
1 1 2 1  AAAGGCTCAGTCGAAAGACTGGGCCTTTCGCCCGGGCTAATTAGGGGGTGTCGCCCTTTGAACCCTCGAG 
1 1 9 1  TGGTACTACCCGTCTTCTATCTGGGCACACGTGTTTCACGTTGACAGGTTTGCTTGGGACGCTAGTAACC 
1 2 6 1  ATGGGCTTGCTGACTTAGCCTAGGGGCGTCAAAGGGCGACACAAAATTTATTCTAAATGCATAATAAATA 
1 3 3 1  CTGATAACATCTTATAGTTTGTATTATATTTTGTATTATCGTTGACATGTATAATTTTGATATCAAAAAC 
1 4 0 1  TGATTTTCCCTTTATTATTTTCGAGATTTATTTTCTTAATTCTCTTTAACAAACTAGAAATATTGTATAT 
1 4 7 1  ACAAAAAATCATAAATAATAGATGAATAGTTTAATTATAGGTGTTCATCAATCGAAAAAGCAACGTATCT 
1 5 4 1  TATTTAAAGTGCGTTGCTTTTTTCTCATTTATAAGGTTAAATAATTCTCATATATCAAGCAAAGTGACAG 
1 6 1 1  GCGCCCTTAAATATTCTGACAAATGCTCTTTCCCTAAACTCCCCCCATAAAAAAACCCGCCGAAGCGGGT 
1 6 8 1  TTTTACGTTATTTGCGGATTAACGATTACTCGTTATCAGAACCGCCCAGGGGGCCCGAGCTTAAGACTGG 
1 7 5 1  CCGTCGTTTTACAACACAGAAAGAGTTTGTAGAAACGCAAAAAGGCCATCCGTCAGGGGCCTTCTGCTTA 
1 8 2 1  GTTTGATGCCTGGCAGTTCCCTACTCTCGCCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGT 
1 8 9 1  TCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAAC 
1 9 6 1  GCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGT 
2 0 3 1  TTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCC 
2 1 0 1  GACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTG 
2 1 7 1  CCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTA 
2 2 4 1  GGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGA 
2 3 1 1  CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCA 
2 3 8 1  GCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGG 
2 4 5 1  CTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAA 
2 5 2 1  AAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG 
2 5 9 1  CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGT 
2 6 6 1  GGAACGACGCGCGCGTAACTCACGTTAAGGGATTTTGGTCATGAGCTTGCGCCGTCCCGTCAAGTCAGCG 
2 7 3 1  TAATGCTCTGCTTT
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15.1.7. pSELECT-neo-mcs-CD32/55
Ori: E.coli origin of replication; CMV: human cytomegalovirus immediate-early 
gene 1 promoter enhancer; EM7: bacterial E.coli constitutive promoter; n eo : 
neo gene conferring resistance to kanamycin in E.coli and to G418 in 
mammalian cells; pGlo pAn: human (3-globin 3'UTR and polyadenylation 
sequence; h E F-la : human elongation factor l a  (E F-la) core promoter; HTLV: 
the R segment and part of the U5 sequence (R-U5') of the human T-cell 
leukaemia virus (HTLV) type 1 long terminal repeat (LTR); C D 32/55: CD32 




6 1  A TCA GCG GCCG CA ATA A AA TATCTTTATTTTCA TTACATCTGTGTG TTGG TTTTTTG TGT 
1 2 1  GAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAA 
1 8 1  TAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGAT 
2 4 1  CGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG 
3 0 1  GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT 
3 6 1  GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCA 
4 2 1  GTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTT 
4 8 1  CGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGC 
5 4 1  CGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC 
6 0 1  TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTA 
6 6 1  CCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTT 
7 2 1  GTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGAT 
7 8 1  CACCGGTCATCATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGT 
M T M E T Q M S Q N V C P R N L  
8 4 1  GGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAG 
W L L Q P L T V L L L L A S A D S Q A A  
9 0 1  CTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACT 
A P P K A V L K L E P P W I N V L Q E D  
9 6 1  CTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCC 
S V T L T C Q G A R S P E S D S  I Q W F  
1 0 2 1  ACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACA 
H N G N L I P T H T Q P S Y R F K A N N  
1 0 8 1  ATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATC 
N D S G E Y T C Q T G Q T S L S D P V H  
1 1 4 1  TGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG 
L T V L S E W L V L Q T P H L E F Q E G  
1 2 0 1  AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCT 
E T I M L R C H S W K D K P L V K V T F  
1 2 6 1  TCCAGAATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAG 
F Q N G K S Q K F S R L D P T F S I P Q  
1 3 2 1  CAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCT 
A N H S H S G D Y H C T G N I G Y T L F  
1 3 8 1  CATCCAAGCCTGTGACCATCACTGTCCAAGTGCCCAGCATGGGCTCGAGTGGTACTAGGC 
S S K P V T I T V Q V P S M G S S G T T  
1 4 4 1  GTCTTCTATCTGGGCACACGTGTTTCACGTTGACAGGTTTGCTTGGGACGCTAGTAACCA 
R L L S G H T C F T L T G L L G T L V T  
1 5 0 1  TGGGCTTGCTGACTTAGCCTAGGGCACCTACTGACGATGATAAAAACATCTACCTGACTC 
M G L  L  T *
1 5 6 1  TTCCTCCCAACGACCATGTCAACAGTAATAACTAAAGAGTAACGTTATGCCATGTGGTCA 
1 6 2 1  GCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATG 
1 6 8 1  CAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATT 
1 7 4 1  ATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAG 
1 8 0 1  GGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTC 
1 8 6 1  TAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCT 
1 9 2 1  GAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAG 
1 9 8 1  CCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTC 
2 0 4 1  TTCA TTTCTTTATG TTTTA A ATG CA CTG ACCTCCCA CA TTCCCTTTTTA GTA A AA TA TTC 
2 1 0 1  AGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCA 
2 1 6 1  GATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGA 
2 2 2 1  ACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTTAGAAGAACTCATCAA
*  F  F  E D L
2 2 8 1  GAAGTCTGTAGAAGGCAATTCTCTGGGAGTCAGGGGCTGCAATGCCATAGAGCACTAGGA 
L R Y F A I R Q S D P A A I G Y L V L F  
2 3 4 1  ACCTGTCTGCCCACTCTCCCCCTAGCTCTTCTGCTATGTCCCTGGTTGCTAGGGCAATGT
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R D A W E G G L E E A I D R T A L A I D  
2 4 0 1  CCTGGTACCTGTCAGCCACTCCCAGCCTGCCACAGTCTATGAAGCCAGAGAACCTTCCAT 
Q Y R D A V G L R G C D I F G S F R G N  
2 4 6 1  TTTCAACCATGATGTTGGGAAGGCAGGCATCCCCATGAGTCACCACTAGGTCCTCACCAT 
E V M I N P L C A D G H T V V L D E G D  
2 5 2 1  CTGGCATGGATGCCTTGAGCCTGGCAAATAGTTCAGCAGGGGCCAGGCCCTGGTGTTCTT 
P M S A K L R A F L E A P A L G Q H E E  
2 5 8 1  CATCCAAGTCATCTTGGTCCACCAGGCCAGCCTCCATCCTGGTTCTGGCCCTCTCTATCC 
D L D D Q D V L G A E M R T R A R E I R  
2 6 4 1  TGTGCTTGGCCTGGTGGTCAAAGGGGCAGGTGGCTGGGTCAAGGGTGTGGAGTCTTCTCA 
H K A Q H D F P C T A P D L T H L R R M  
2 7 0 1  TGGCATCAGCCATGATTGACACTTTCTCAGCTGGAGCTAGGTGAGAGGAAAGGAGGTCCT 
A D A M I S V K E A P A L H S S L L D Q  
2 7 6 1  GCCCAGGCACCTCACCTAGTAGGAGCCAGTCCCTTCCAGCTTCTGTGACCACATCAAGGA 
G P V E G L L L W D R G A E T V V D L V  
2 8 2 1  CAGCTGCACAGGGGACCCCAGTTGTTGCCAACCAGGAGAGTCTGGCAGCCTCATCCTGGA 
A A C P V G T T A L W S L R A A E D Q L  
2 8 8 1  GCTCATTGAGAGCCCCACTGAGGTCTGTCTTTACAAAAAGGACTGGCCTGCCTTGGGCTG 
E N L A G S L D T K V F L V P R G Q A S  
2 9 4 1  AAAGTCTGAAAACTGCTGCATCAGAGCAACCAATGGTCTGCTGTGCCCAGTCATAGCCAA 
L R F V A A D S C G I T Q Q A W D Y G F  
3 0 0 1  ACAGTCTCTCAACCCAGGCAGCTGGAGAACCTGCATGTAGGCCATCTTGTTCAATCATGA 
L R E V W A A P S G A H L G D Q E  I M  
3 0 6 1  TGGCCCTCCTATAGTGAGTCGTATTATACTATGCCGATATACTATGCCGATGATTAATTG 
3 1 2 1  TCAAAACAGCGTGGATGGCGTCTCCAGCTTATCTGACGGTTCACTAAACGAGCTCTGCTT 
3 1 8 1  ATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTA 
3 2 4 1  CGACATTTTGGAAAGTCCCGTTGATTTACTAGTCAAAACAAACTCCCATTGACGTCAATG 
3 3 0 1  GGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGC 
3 3 6 1  CAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGA 
3 4 2 1  AAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACG 
3 4 8 1  TCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTAC 
3 5 4 1  CGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACA 
3 6 0 1  TACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTT 
3 6 6 1  ACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAA 
3 7 2 1  AGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTG 
3 7 8 1  ACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAA 
3 8 4 1  GATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGC 
3 9 0 1  TTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCAC 
3 9 6 1  GCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAAC 
4 0 2 1  CCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGG 
4 0 8 1  TAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGT 
4 1 4 1  ATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAA 
4 2 0 1  CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCT 
4 2 6 1  CTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGA 
4 3 2 1  TTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACG 





U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: central 
polypurine tract; hPGK: human phosphoglycerate kinase eukaryotic promoter; 
Puro: puromycin resistance gene for mammalian selection; 3 ’ LTR: 3' self 
inactivating long terminal repeat; f l  ori: E.coli f l  origin of replication; AmpR 
Prom : bacterial constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; pUC ori: pUC-based 
E.coli origin of replication; 5' LTR: L' long terminal repeat; i|j : ij; sequence - 
RNA packaging signal; RRE: Rev response element.
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1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
6 1  CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
1 2 1  CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
1 8 1  CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
2 4 1  GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC
M A A R
3 0 1  CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
R P R W A V A N S G C S A G R A E S S G  
3 6 1  CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
R E G A V R E A G C G A V V W A L F L P  
4 2 1  GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
A R C S A F C K P P E R T S A V G S L V  
4 8 1  GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
D R I T D L S P Q G D P P E L T M T E Y  
5 4 1  AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
K P T V R L A T R D D V P R A V R T L A  
6 0 1  GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
A A F A D Y P A T R H T V D P D R H I E  
6 6 1  CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
R V T E L Q E L F L T R V G L D I G K V  
7 2 1  TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
W V A D D G A A V A V W T T P E  S V E A  
7 8 1  GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
G A V F A E I G P R M A E L S G S R L A  
8 4 1  GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
A Q Q Q M E G L L A P H R P K E P A W F  
9 0 1  CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
L A T V G V S P D H Q G K G L G S A V V  
9 6 1  CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
L P G V E A A E R A G V P A F L E T S A  
1 0 2 1  CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
P R N L P F Y E R L G F T V T A D V E V  
1 0 8 1  CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
P E G P R T W C M T R K P G A *
1 1 4 1  GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
1 2 0 1  ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
1 2 6 1  GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
1 3 2 1  TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
1 3 8 1  CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
1 4 4 1  AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
1 5 0 1  TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
1 5 6 1  AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
1 6 2 1  A ATA AAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
1 6 8 1  TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
1 7 4 1  CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
1 8 0 1  AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
1 8 6 1  GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
1 9 2 1  ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
1 9 8 1  CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
2 0 4 1  GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
2 1 0 1  GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
2 1 6 1  TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
2 2 2 1  GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
2 2 8 1  GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT



















































































































5 7 6 1  CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
5 8 2 1  TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
5 8 8 1  TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
5 9 4 1  TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
6 0 0 1  GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
6 0 6 1  CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
6 1 2 1  TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
6 1 8 1  CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
6 2 4 1  AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
6 3 0 1  TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
6 3 6 1  TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
6 4 2 1  CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
6 4 8 1  AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
6 5 4 1  ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
6 6 0 1  TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
6 6 6 1  AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
6 7 2 1  TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
6 7 8 1  TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCCATCAGAAAGAGACAACT 
6 8 4 1  TCTCGAGAAGTTGTCTCTTTCTGA TGGCTTTTTAA TCTG TCA GCA TCTG GG TCA TTCATA  
6 9 0 1  ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
6 9 6 1  AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
7 0 2 1  AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 
7 0 8 1  AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCCGCGGCTCGAGGGGG
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15.1.9. pLK0.1-puro-TRCN029575
U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: central 
polypurine tract; hPGK: human phosphoglycerate kinase eukaryotic promoter; 
Puro: puromycin resistance gene for mammalian selection; 3 ’ LTR: 3 ’ self 
inactivating long terminal repeat; f l  ori: E.coli f l  origin of replication; AmpR 
Prom : bacterial constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; pUC ori: pUC-based 
E.coli origin of replication; 5' LTR: L’ long terminal repeat; i| j: iJj sequence - 
RNA packaging signal; RRE: Rev response element.
498
1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
6 1  CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
1 2 1  CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
1 8 1  CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
2 4 1  GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC
M A A R
3 0 1  CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
R P R W A V A N S G C S A G R A E S S G  
3 6 1  CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
R E G A V R E A G C G A V V W A L F L P  
4 2 1  GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
A R C S A F C K P P E R T S A V G S L V  
4 8 1  GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
D R I T D L S P Q G D P P E L T M T E Y  
5 4 1  AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
K P T V R L A T R D D V P R A V R T L A  
6 0 1  GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
A A F A D Y P A T R H T V D P D R H I E  
6 6 1  CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
R V T E L Q E L F L T R V G L D I G K V  
7 2 1  TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
W V A D D G A A V A V W T T P E  S V E A  
7 8 1  GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
G A V F A E I G P R M A E L S G S R L A  
8 4 1  GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
A Q Q Q M E G L L A P H R P K E P A W F  
9 0 1  CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
L A T V G V S P D H Q G K G L G S A V V  
9 6 1  CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
L P G V E A A E R A G V P A F L E T S A  
1 0 2 1  CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
P R N L P F Y E R L G F T V T A D V E V  
1 0 8 1  CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
P E G P R T W C M T R K P G A *
1 1 4 1  GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
1 2 0 1  ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
1 2 6 1  GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
1 3 2 1  TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
1 3 8 1  CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
1 4 4 1  AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
1 5 0 1  TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
1 5 6 1  AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
1 6 2 1  AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
1 6 8 1  TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
1 7 4 1  CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
1 8 0 1  AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
1 8 6 1  GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
1 9 2 1  ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
1 9 8 1  CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
2 0 4 1  GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
2 1 0 1  GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
2 1 6 1  TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
2 2 2 1  GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
2 2 8 1  GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT
2 3 4 1  g g a g t c c a c g t t c t t t a a t a g t g g a c t c t t g t t c c a a a c t g g a a c a a c a c t c a a c c c t a t
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2 4 0 1  CTCGG TCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
2 4 6 1  TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
2 5 2 1  GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
2 5 8 1  TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
2 6 4 1  A GGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
2 7 0 1  TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
2 7 6 1  TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
2 8 2 1  TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
2 8 8 1  GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
2 9 4 1  AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
3 0 0 1  AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
3 0 6 1  ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
3 1 2 1  ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
3 1 8 1  ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
3 2 4 1  ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
3 3 0 1  CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
3 3 6 1  CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
3 4 2 1  GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
3 4 8 1  ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
3 5 4 1  TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
3 6 0 1  AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
3 6 6 1  GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
3 7 2 1  ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
3 7 8 1  TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
3 8 4 1  CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
3 9 0 1  ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
3 9 6 1  AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
4 0 2 1  CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
4 0 8 1  AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
4 1 4 1  ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
4 2 0 1  GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
4 2 6 1  CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
4 3 2 1  GCTCACATGTTCTTTCCTGCGTTA TCCCCTGA TTCTGTGGA TA ACCGTA TTA CCGCCTTT 
4 3 8 1  GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
4 4 4 1  GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
4 5 0 1  TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
4 5 6 1  GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
4 6 2 1  TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
4 6 8 1  GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
4 7 4 1  AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
4 8 0 1  TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
4 8 6 1  CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
4 9 2 1  ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
4 9 8 1  ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
5 0 4 1  AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
5 1 0 1  AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
5 1 6 1  GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
5 2 2 1  AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
5 2 8 1  CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
5 3 4 1  ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
5 4 0 1  TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
5 4 6 1  ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
5 5 2 1  AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
5 5 8 1  GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
5 6 4 1  CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
5 7 0 1  GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA
500
5 7 6 1  CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
5 8 2 1  TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
5 8 8 1  TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
5 9 4 1  TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
6 0 0 1  GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
6 0 6 1  CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
6 1 2 1  TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
6 1 8 1  CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
6 2 4 1  AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
6 3 0 1  TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
6 3 6 1  TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
6 4 2 1  CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
6 4 8 1  AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
6 5 4 1  ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
6 6 0 1  TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
6 6 6 1  AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
6 7 2 1  TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
6 7 8 1  TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCACCTACTGACGATGATAA 
6 8 4 1  ACTCGAGTTTATCATCGTCAGTAGGTGCTTTTTAA TCTG TCA GCA TCTG GG TCA TTCATA  
6 9 0 1  ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
6 9 6 1  AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
7 0 2 1  AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 
7 0 8 1  AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCCGCGGCTCGAGGGGG
501
15.1.10. pLK0.1-puro-TRCN029576
U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: central 
polypurine tract; hPGK: human phosphoglycerate kinase eukaryotic promoter; 
Puro: puromycin resistance gene for mammalian selection; 3 ' LTR: 3' self 
inactivating long terminal repeat; f l  ori: E.coli f l  origin of replication; AmpR 
Prom : bacterial constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; pUC ori: pUC-based 
E.coli origin of replication; 5 ' LTR: L' long terminal repeat; ij/: ij; sequence - 
RNA packaging signal; RRE: Rev response element.
502
1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
6 1  CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
1 2 1  CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
1 8 1  CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
2 4 1  GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC
M A A R
3 0 1  CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
R P R W A V A N S G C S A G R A E S S G  
3 6 1  CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
R E G A V R E A G C G A V V W A L F L P  
4 2 1  GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
A R C S A F C K P P E R T S A V G S L V  
4 8 1  GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
D R I T D L S P Q G D P P E L T M T E Y  
5 4 1  AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
K P T V R L A T R D D V P R A V R T L A  
6 0 1  GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
A A F A D Y P A T R H T V D P D R H  I E  
6 6 1  CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
R V T E L Q E L F L T R V G L D I G K V  
7 2 1  TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
W V A D D G A A V A V W T T P E  S V E A  
7 8 1  GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
G A V F A E I G P R M A E L S G S R L A  
8 4 1  GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
A Q Q Q M E G L L A P H R P K E P A W F  
9 0 1  CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
L A T V G V S P D H Q G K G L G S A V V  
9 6 1  CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
L P G V E A A E R A G V P A F L E T S A  
1 0 2 1  CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
P R N L P F Y E R L G F T V T A D V E V  
1 0 8 1  CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
P E G P R T W C M T R K P G A *
1 1 4 1  GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
1 2 0 1  ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
1 2 6 1  GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
1 3 2 1  TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
1 3 8 1  CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
1 4 4 1  AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
1 5 0 1  TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
1 5 6 1  AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
1 6 2 1  A ATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
1 6 8 1  TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
1 7 4 1  CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
1 8 0 1  AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
1 8 6 1  GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
1 9 2 1  ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
1 9 8 1  CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
2 0 4 1  GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
2 1 0 1  GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
2 1 6 1  TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
2 2 2 1  GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
2 2 8 1  GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 



















































































































5 7 6 1  CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
5 8 2 1  TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
5 8 8 1  TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
5 9 4 1  TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
6 0 0 1  GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
6 0 6 1  CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
6 1 2 1  TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
6 1 8 1  CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
6 2 4 1  AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
6 3 0 1  TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
6 3 6 1  TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
6 4 2 1  CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
6 4 8 1  AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
6 5 4 1  ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
6 6 0 1  TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
6 6 6 1  AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
6 7 2 1  TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
6 7 8 1  TGTTGGGTTTATATATCTTGTGGAAAGGACGAAACACCGGCCAGAAATTCTCCCGTTTGG 
6 8 4 1  ACTCGAGTCCAAACGGGAGAATTTCTGGTTTTTAA TCTG TCA GCA TCTG GG TCA TTCATA  
6 9 0 1  ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
6 9 6 1  AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
7 0 2 1  AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 
7 0 8 1  AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCCGCGGCTCGAGGGGG
505
15.1.11. pLKO.l-puro-TRCN029577
U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: central 
polypurine tract; hPGK: human phosphoglycerate kinase eukaryotic promoter; 
Puro: puromycin resistance gene for mammalian selection; 3 ' LTR: 3' self 
inactivating long terminal repeat; f l  ori: E.coli f l  origin of replication; AmpR 
Prom : bacterial constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; pUC ori: pUC-based 
E.coli origin of replication; 5 ' LTR: L' long terminal repeat; i| j: vj; sequence - 
RNA packaging signal; RRE: Rev response element.
506
1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
6 1  CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
1 2 1  CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
1 8 1  CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
2 4 1  GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC
M A A R
3 0 1  CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
R P R W A V A N S G C S A G R A E S S G  
3 6 1  CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
R E G A V R E A G C G A V V W A L F L P  
4 2 1  GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
A R C S A F C K P P E R T S A V G S L V  
4 8 1  GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
D R I T D L S P Q G D P P E L T M T E Y  
5 4 1  AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
K P T V R L A T R D D V P R A V R T L A  
6 0 1  GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
A A F A D Y P A T R H T V D P D R H I E  
6 6 1  CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
R V T E L Q E L F L T R V G L D I G K V  
7 2 1  TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
W V A D D G A A V A V W T T P E  S V E A  
7 8 1  GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
G A V F A E I G P R M A E L S G S R L A  
8 4 1  GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
A Q Q Q M E G L L A P H R P K E P A W F  
9 0 1  CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
L A T V G V S P D H Q G K G L G S A V V  
9 6 1  CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
L P G V E A A E R A G V P A F L E T S A  
1 0 2 1  CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
P R N L P F Y E R L G F T V T A D V E V  
1 0 8 1  CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
P E G P R T W C M T R K P G A *
1 1 4 1  GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
1 2 0 1  ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
1 2 6 1  GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
1 3 2 1  TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
1 3 8 1  CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
1 4 4 1  AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
1 5 0 1  TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
1 5 6 1  AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
1 6 2 1  AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
1 6 8 1  TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
1 7 4 1  CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
1 8 0 1  AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
1 8 6 1  GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
1 9 2 1  ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
1 9 8 1  CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
2 0 4 1  GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
2 1 0 1  GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
2 1 6 1  TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
2 2 2 1  GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
2 2 8 1  GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 



















































































































5 7 6 1  CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
5 8 2 1  TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
5 8 8 1  TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
5 9 4 1  TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
6 0 0 1  GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
6 0 6 1  CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
6 1 2 1  TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
6 1 8 1  CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
6 2 4 1  AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
6 3 0 1  TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
6 3 6 1  TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
6 4 2 1  CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
6 4 8 1  AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
6 5 4 1  ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
6 6 0 1  TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
6 6 6 1  AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
6 7 2 1  TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
6 7 8 1  TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCCATGTCAACAGTAATAACT 
6 8 4 1  ACTCGAGTAGTTATTACTGTTGACATGGTTTTTAA TCTG TCA GCA TCTG GG TCA TTCATA  
6 9 0 1  ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
6 9 6 1  AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
7 0 2 1  AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 





U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: central 
polypurine tract; hPGK: human phosphoglycerate kinase eukaryotic promoter; 
Puro: puromycin resistance gene for mammalian selection; 3' LTR: 3' self 
inactivating long terminal repeat; f l  ori: E.coli f l  origin of replication; AmpR 
Prom : bacterial constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; pUC ori: pUC-based 
E.coli origin of replication; 5' LTR: L' long terminal repeat; iJj: ij; sequence - 
RNA packaging signal; RRE: Rev response element.
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1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
6 1  CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
1 2 1  CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
1 8 1  CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
2 4 1  GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC
M A A R
3 0 1  CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
R P R W A V A N S G C S A G R A E S S G  
3 6 1  CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
R E G A V R E A G C G A V V W A L F L P  
4 2 1  GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
A R C S A F C K P P E R T S A V G S L V  
4 8 1  GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
D R I T D L S P Q G D P P E L T M T E Y  
5 4 1  AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
K P T V R L A T R D D V P R A V R T L A  
6 0 1  GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
A A F A D Y P A T R H T V D P D R H I E  
6 6 1  CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
R V T E L Q E L F L T R V G L D I G K V  
7 2 1  TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
W V A D D G A A V A V W T T P E  S V E A  
7 8 1  GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
G A V F A E I G P R M A E L S G S R L A  
8 4 1  GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
A Q Q Q M E G L L A P H R P K E P A W F  
9 0 1  CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
L A T V G V S P D H Q G K G L G S A V V  
9 6 1  CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
L P G V E A A E R A G V P A F L E  T S A  
1 0 2 1  CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
P R N L P F Y E R L G F T V T A D V E V  
1 0 8 1  CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
P E G P R T W C M T R K P G A *
1 1 4 1  GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
1 2 0 1  ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
1 2 6 1  GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
1 3 2 1  TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
1 3 8 1  CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
1 4 4 1  AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
1 5 0 1  TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
1 5 6 1  AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
1 6 2 1  AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
1 6 8 1  TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
1 7 4 1  CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
1 8 0 1  AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
1 8 6 1  GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
1 9 2 1  ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
1 9 8 1  CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
2 0 4 1  GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
2 1 0 1  GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
2 1 6 1  TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
2 2 2 1  GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
2 2 8 1  GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 



















































































































5 7 6 1  CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
5 8 2 1  TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
5 8 8 1  TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
5 9 4 1  TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
6 0 0 1  GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
6 0 6 1  CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
6 1 2 1  TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
6 1 8 1  CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
6 2 4 1  AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
6 3 0 1  TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
6 3 6 1  TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
6 4 2 1  CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
6 4 8 1  AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
6 5 4 1  ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
6 6 0 1  TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
6 6 6 1  AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
6 7 2 1  TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
6 7 8 1  TGTTGGGTTTATATATCTTGTGGAAAGGACGAAACACCGGGAAGAAACCAACAATGACTA 
6 8 4 1  TCTCGAGA TA G TCA TTG TTG G TTTCTTCTTTTTAA TCTG TCA GCA TCTG GG TCA TTCATA  
6 9 0 1  ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
6 9 6 1  AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
7 0 2 1  AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 
7 0 8 1  AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCCGCGGCTCGAGGGGG
513
15.2 Posterior Probability and Copy Number Assignment




Raw Ratio P I P2 P3
Copy
Number
Control 0.9675 0.000 0.995 0.005 2
Control 1.1136 0.000 0.978 0.022 2
Control 1.0466 0.000 0.990 0.010 2
Control 1.1669 0.000 0.954 0.046 2
Control 1.1915 0.000 0.932 0.068 2
Control 1.1216 0.000 0.976 0.024 2
Control 1.1840 0.000 0.940 0.060 2
Control 0.4641 1.000 0.000 0.000 1
Control 1.0596 0.000 0.989 0.011 2
Control 1.0641 0.000 0.988 0.012 2
Control 0.9536 0.000 0.996 0.004 2
Control 1.4091 0.000 0.134 0.866 3
Control 1.2356 0.000 0.865 0.135 2
Control 1.5345 0.000 0.005 0.995 3
Control 1.1130 0.000 0.978 0.022 2
Control 1.2173 0.000 0.899 0.101 2
Control 1.0863 0.000 0.985 0.015 2
Control 1.0292 0.000 0.992 0.008 2
Control 1.6498 0.000 0.000 1.000 3
Control 1.1051 0.000 0.980 0.020 2
Control 1.4383 0.000 0.069 0.931 3
Control 1.1612 0.000 0.957 0.043 2
Control 2.0798 0.000 0.000 1.000 3
Control 1.0612 0.000 0.989 0.011 2
Control 1.2316 0.000 0.874 0.126 2
Control 1.1481 0.000 0.965 0.035 2
Control 1.6086 0.000 0.001 0.999 3
Control 0.5232 0.999 0.001 0.000 1
Control 1.5153 0.000 0.009 0.991 3
Control 1.0976 0.000 0.982 0.018 2
Control 1.2431 0.000 0.848 0.152 2
Control 0.6179 0.970 0.030 0.000 1
Control 0.8911 0.000 0.997 0.003 2
Control 1.8126 0.000 0.000 1.000 3
Control 1.0479 0.000 0.990 0.010 2
Control 1.6222 0.000 0.000 1.000 3
Control 1.0837 0.000 0.985 0.015 2
Control 0.5555 0.997 0.003 0.000 1
Control 0.7793 0.008 0.990 0.002 2
Control 1.0002 0.000 0.994 0.006 2
514
FCGR3B:CD36 Copy
Trait Raw Ratio P I P2 P3 Number
Control 0.9995 0.000 0.994 0.006 2
Control 0.8326 0.000 0.997 0.002 2
Control 1.0619 0.000 0.988 0.012 2
Control 1.0054 0.000 0.994 0.006 2
Control 0.9738 0.000 0.995 0.005 2
Control 1.0524 0.000 0.990 0.010 2
Control 1.0869 0.000 0.984 0.016 2
Control 1.0464 0.000 0.990 0.010 2
Control 1.3716 0.000 0.276 0.724 3
Control 0.9999 0.000 0.994 0.006 2
Control 0.9464 0.000 0.996 0.004 2
Control 1.1635 0.000 0.956 0.044 2
Control 2.0339 0.000 0.000 1.000 3
Control 1.4495 0.000 0.052 0.948 3
Control 1.0779 0.000 0.986 0.014 2
Control 1.0276 0.000 0.992 0.008 2
Control 1.5403 0.000 0.004 0.996 3
Control 0.9003 0.000 0.997 0.003 2
Control 1.0512 0.000 0.990 0.010 2
Control 1.0740 0.000 0.987 0.013 2
Control 1.4166 0.000 0.113 0.887 3
Control 1.1193 0.000 0.976 0.024 2
Control 0.6000 0.986 0.014 0.000 1
Control 1.5125 0.000 0.010 0.990 3
Control 1.2728 0.000 0.761 0.239 2
Control 1.0324 0.000 0.992 0.008 2
Control 1.0751 0.000 0.987 0.013 2
Control 0.7693 0.015 0.983 0.002 2
Control 1.6080 0.000 0.001 0.999 3
Control 0.6287 0.953 0.047 0.000 1
Control 0.8811 0.000 0.997 0.003 2
Control 0.9627 0.000 0.996 0.004 2
Control 1.0664 0.000 0.988 0.012 2
Control 1.0255 0.000 0.992 0.008 2
Control 0.9619 0.000 0.996 0.004 2
Control 0.4475 1.000 0.000 0.000 1
Control 0.9297 0.000 0.996 0.004 2
Control 0.5917 0.990 0.010 0.000 1
Control 1.4929 0.000 0.017 0.983 3
Control 0.3965 1.000 0.000 0.000 1
Control 1.1582 0.000 0.959 0.041 2
Control 0.7965 0.003 0.995 0.002 2
Control 1.0518 0.000 0.990 0.010 2
Control 0.9570 0.000 0.996 0.004 2
Control 0.9766 0.000 0.995 0.005 2
Control 0.8970 0.000 0.997 0.003 2
Control 1.0066 0.000 0.994 0.006 2
Control 1.0621 0.000 0.988 0.012 2




Raw Ratio PI P2 P3
Copy
Number
Control 0.9574 0.000 0.996 0.004 2
Control 0.4569 1.000 0.000 0.000 1
Control 1.1141 0.000 0.978 0.022 2
Control 0.9340 0.000 0.996 0.004 2
Control 0.4811 1.000 0.000 0.000 1
Control 1.7737 0.000 0.000 1.000 3
Control 1.6154 0.000 0.000 1.000 3
Control 1.0987 0.000 0.982 0.018 2
Control 1.1100 0.000 0.979 0.021 2
Control 0.9499 0.000 0.996 0.004 2
Control 1.1003 0.000 0.982 0.018 2
Control 1.0909 0.000 0.984 0.016 2
Control 1.1700 0.000 0.951 0.049 2
Control 0.4865 1.000 0.000 0.000 1
Control 0.9442 0.000 0.996 0.004 2
Control 1.0979 0.000 0.982 0.018 2
Control 0.1143 1.000 0.000 0.000 1
Control 1.0216 0.000 0.992 0.008 2
Control 1.0014 0.000 0.994 0.006 2
Control 0.4864 1.000 0.000 0.000 1
Control 1.0851 0.000 0.985 0.015 2
Control 1.1107 0.000 0.979 0.021 2
Control 0.5483 0.998 0.002 0.000 1
Control 1.0926 0.000 0.983 0.017 2
Control 0.4371 1.000 0.000 0.000 1
Control 1.0294 0.000 0.992 0.008 2
Control 1.5431 0.000 0.004 0.996 3
Control 0.8870 0.000 0.997 0.003 2
Control 1.5951 0.000 0.001 0.999 3
Control 1.6733 0.000 0.000 1.000 3
Control 1.1494 0.000 0.964 0.036 2
Control 1.1069 0.000 0.980 0.020 2
Control 2.1450 0.000 0.000 1.000 3
Control 1.0820 0.000 0.985 0.015 2
Control 1.5047 0.000 0.012 0.988 3
Control 0.5723 0.995 0.005 0.000 1
Control 1.1392 0.000 0.969 0.031 2
Control 1.0351 0.000 0.991 0.009 2
Control 1.6399 0.000 0.000 1.000 3
Control 1.1629 0.000 0.956 0.044 2
Control 1.1713 0.000 0.950 0.050 2
Control 1.5265 0.000 0.006 0.994 3
Control 1.0155 0.000 0.993 0.007 2
Control 1.2106 0.000 0.909 0.091 2
Control 1.1235 0.000 0.975 0.025 2
Control 1.1898 0.000 0.934 0.066 2
Control 2.1985 0.000 0.000 1.000 3
Control 1.1649 0.000 0.955 0.045 2




Raw Ratio P I P2 P3
Copy
Number
Control 1.2374 0.000 0.861 0.139 2
Control 0.8664 0.000 0.997 0.002 2
Control 1.6999 0.000 0.000 1.000 3
Control 0.9503 0.000 0.996 0.004 2
Control 1.1712 0.000 0.950 0.050 2
Control 1.1835 0.000 0.940 0.060 2
Control 1.1094 0.000 0.979 0.021 2
Control 1.6298 0.000 0.000 1.000 3
Control 0.9602 0.000 0.996 0.004 2
Control 1.1193 0.000 0.976 0.024 2
Control 1.1977 0.000 0.926 0.074 2
Control 1.2232 0.000 0.889 0.111 2
Control 0.7059 0.332 0.666 0.001 2
Control 0.6585 0.838 0.162 0.000 1
Control 1.1769 0.000 0.946 0.054 2
Control 1.1293 0.000 0.973 0.027 2
Control 1.0575 0.000 0.989 0.011 2
Control 1.1321 0.000 0.972 0.028 2
Control 0.8824 0.000 0.997 0.003 2
Control 1.1446 0.000 0.966 0.034 2
Control 1.0170 0.000 0.993 0.007 2
Control 1.1387 0.000 0.969 0.031 2
Control 1.0670 0.000 0.988 0.012 2
Control 1.6784 0.000 0.000 1.000 3
Control 1.1555 0.000 0.961 0.039 2
Control 0.9733 0.000 0.995 0.005 2
Control 0.8573 0.000 0.998 0.002 2
Control 1.0854 0.000 0.985 0.015 2
Control 1.0535 0.000 0.989 0.011 2
Control 0.4852 1.000 0.000 0.000 1
Control 0.9983 0.000 0.994 0.006 2
Control 1.1105 0.000 0.979 0.021 2
Control 1.5186 0.000 0.008 0.992 3
Control 0.6881 0.552 0.447 0.001 1
Control 0.9880 0.000 0.995 0.005 2
Control 1.0191 0.000 0.993 0.007 2
Control 0.9526 0.000 0.996 0.004 2
Control 1.0391 0.000 0.991 0.009 2
Control 1.6512 0.000 0.000 1.000 3
Control 1.0940 0.000 0.983 0.017 2
Control 1.4911 0.000 0.017 0.983 3
Control 1.0378 0.000 0.991 0.009 2
Control 1.0900 0.000 0.984 0.016 2
Control 1.0064 0.000 0.994 0.006 2
Control 0.7814 0.007 0.991 0.002 2
Control 1.1613 0.000 0.957 0.043 2
Control 0.5986 0.986 0.014 0.000 1
Control 0.5771 0.994 0.006 0.000 1




Raw Ratio P I P2 P3
Copy
Number
Control 1.3258 0.000 0.516 0.484 2
Control 1.1159 0.000 0.977 0.023 2
Control 1.0780 0.000 0.986 0.014 2
Control 1.1872 0.000 0.937 0.063 2
Control 1.0300 0.000 0.992 0.008 2
Control 1.2041 0.000 0.918 0.082 2
Control 0.9998 0.000 0.994 0.006 2
Control 1.0108 0.000 0.993 0.007 2
Control 1.5874 0.000 0.001 0.999 3
Control 1.6637 0.000 0.000 1.000 3
Control 1.5504 0.000 0.003 0.997 3
Control 0.6416 0.919 0.081 0.000 1
Control 1.4019 0.000 0.155 0.845 3
Control 1.1238 0.000 0.975 0.025 2
Control 1.0823 0.000 0.985 0.015 2
Control 1.1489 0.000 0.964 0.036 2
Control 1.3652 0.000 0.306 0.694 3
Control 1.1848 0.000 0.939 0.061 2
Control 1.4974 0.000 0.015 0.985 3
Control 1.3872 0.000 0.209 0.791 3
Control 1.1671 0.000 0.953 0.047 2
Control 1.1276 0.000 0.974 0.026 2
Control 1.3251 0.000 0.520 0.480 2
Control 0.8300 0.000 0.997 0.002 2
Control 1.0681 0.000 0.988 0.012 2
Control 1.1477 0.000 0.965 0.035 2
Control 1.1917 0.000 0.932 0.068 2
Control 0.4220 1.000 0.000 0.000 1
Control 1.1296 0.000 0.973 0.027 2
Control 1.3845 0.000 0.219 0.781 3
Control 1.1249 0.000 0.974 0.026 2
Control 0.9329 0.000 0.996 0.004 2
Control 1.0084 0.000 0.993 0.007 2
Control 1.9476 0.000 0.000 1.000 3
Abbreviations: PI: probability for 1 copy; P2: probability for 2 copies; 






Raw Ratio P I P2 P3
Copy
Numbe
IPF 2.1711 0.000 0.000 1.000 3
IPF 1.3968 0.000 0.270 0.730 3
IPF 1.5450 0.000 0.006 0.994 3
IPF 2.2060 0.000 0.000 1.000 3
IPF 1.3214 0.000 0.684 0.316 2
IPF 1.3132 0.000 0.721 0.279 2
IPF 1.0129 0.000 0.997 0.003 2
IPF 1.0491 0.000 0.995 0.005 2
IPF 1.4637 0.000 0.061 0.939 3
IPF 0.5581 0.998 0.002 0.000 1
IPF 0.9792 0.000 0.998 0.002 2
IPF 0.9894 0.000 0.998 0.002 2
IPF 1.0467 0.000 0.995 0.005 2
IPF 2.0241 0.000 0.000 1.000 3
IPF 1.0578 0.000 0.995 0.005 2
IPF 1.4725 0.000 0.048 0.952 3
IPF 0.9557 0.000 0.998 0.002 2
IPF 1.2121 0.000 0.950 0.050 2
IPF 1.1685 0.000 0.976 0.024 2
IPF 1.1085 0.000 0.990 0.010 2
IPF 1.1416 0.000 0.984 0.016 2
IPF 1.2312 0.000 0.931 0.069 2
IPF 1.1632 0.000 0.978 0.022 2
IPF 1.4978 0.000 0.024 0.976 3
IPF 1.6640 0.000 0.000 1.000 3
IPF 0.6410 0.978 0.022 0.000 1
IPF 1.0767 0.000 0.993 0.007 2
IPF 1.1404 0.000 0.984 0.016 2
IPF 1.5634 0.000 0.003 0.997 3
IPF 1.5628 0.000 0.004 0.996 3
IPF 1.9961 0.000 0.000 1.000 3
IPF 1.1181 0.000 0.989 0.011 2
IPF 1.0472 0.000 0.995 0.005 2
IPF 1.5478 0.000 0.006 0.994 3
IPF 0.9940 0.000 0.997 0.003 2
IPF 0.9601 0.000 0.998 0.002 2
IPF 1.1311 0.000 0.986 0.014 2
IPF 1.1434 0.000 0.984 0.016 2
IPF 1.0228 0.000 0.997 0.003 2
IPF 0.9838 0.000 0.998 0.002 2
IPF 1.0479 0.000 0.995 0.005 2
IPF 1.4858 0.000 0.034 0.966 3
IPF 0.9478 0.000 0.998 0.002 2
IPF 1.1501 0.000 0.982 0.018 2
IPF 1.7194 0.000 0.000 1.000 3
IPF 1.0355 0.000 0.996 0.004 2
IPF 1.0132 0.000 0.997 0.003 2
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FCGR3B-.CD36 Copy
Trait Raw Ratio P I P2 P3 Number
IPF 1.6713 0.000 0.000 1.000 3
IPF 1.0989 0.000 0.991 0.009 2
IPF 0.9766 0.000 0.998 0.002 2
IPF 0.6159 0.990 0.010 0.000 1
IPF 1.1049 0.000 0.991 0.009 2
IPF 0.5693 0.998 0.002 0.000 1
IPF 1.4920 0.000 0.028 0.972 3
IPF 1.1201 0.000 0.988 0.012 2
IPF 1.5012 0.000 0.022 0.978 3
IPF 1.0456 0.000 0.996 0.004 2
IPF 1.2888 0.000 0.813 0.187 2
IPF 1.1924 0.000 0.964 0.036 2
IPF 1.1254 0.000 0.987 0.013 2
IPF 1.2433 0.000 0.915 0.085 2
IPF 1.4252 0.000 0.152 0.848 3
IPF 1.4739 0.000 0.046 0.954 3
IPF 1.6892 0.000 0.000 1.000 3
IPF 0.9269 0.000 0.998 0.001 2
IPF 1.6696 0.000 0.000 1.000 3
IPF 1.3881 0.000 0.314 0.686 3
IPF 0.9839 0.000 0.998 0.002 2
IPF 1.0226 0.000 0.997 0.003 2
IPF 1.4307 0.000 0.135 0.865 3
IPF 0.9503 0.000 0.998 0.002 2
IPF 1.1615 0.000 0.978 0.022 2
IPF 1.0718 0.000 0.994 0.006 2
IPF 1.2479 0.000 0.908 0.092 2
IPF 2.2557 0.000 0.000 1.000 3
1PF 1.1806 0.000 0.971 0.029 2
IPF 0.9777 0.000 0.998 0.002 2
IPF 0.9538 0.000 0.998 0.002 2
IPF 1.2072 0.000 0.954 0.046 2
IPF 1.2011 0.000 0.959 0.041 2
IPF 0.9289 0.000 0.998 0.002 2
IPF 1.2107 0.000 0.952 0.048 2
IPF 0.9603 0.000 0.998 0.002 2
IPF 1.6115 0.000 0.001 0.999 3
IPF 1.5406 0.000 0.007 0.993 3
IPF 0.5789 0.997 0.003 0.000 1
IPF 1.0380 0.000 0.996 0.004 2
IPF 1.1796 0.000 0.971 0.029 2
IPF 0.9389 0.000 0.998 0.002 2
IPF 1.5209 0.000 0.012 0.988 3
IPF 1.1170 0.000 0.989 0.011 2
IPF 0.9712 0.000 0.998 0.002 2
IPF 2.0041 0.000 0.000 1.000 3
1PF 1.7512 0.000 0.000 1.000 3
IPF 1.0100 0.000 0.997 0.003 2




Raw Ratio P I P2 P3
Copy
Number
IPF 1.9305 0.000 0.000 1.000 3
IPF 1.8685 0.000 0.000 1.000 3
IPF 1.1660 0.000 0.977 0.023 2
IPF 1.0130 0.000 0.997 0.003 2
IPF 1.1913 0.000 0.965 0.035 2
IPF 1.0190 0.000 0.997 0.003 2
IPF 0.9373 0.000 0.998 0.002 2
IPF 0.9853 0.000 0.998 0.002 2
IPF 0.9768 0.000 0.998 0.002 2
IPF 1.2139 0.000 0.949 0.051 2
IPF 1.0266 0.000 0.996 0.004 2
IPF 0.8827 0.000 0.998 0.001 2
IPF 0.8623 0.001 0.997 0.001 2
IPF 1.6398 0.000 0.000 1.000 3
IPF 1.0795 0.000 0.993 0.007 2
IPF 0.8379 0.006 0.993 0.001 2
IPF 1.0144 0.000 0.997 0.003 2
IPF 1.0486 0.000 0.995 0.005 2
IPF 1.0802 0.000 0.993 0.007 2
IPF 1.0940 0.000 0.992 0.008 2
IPF 1.6231 0.000 0.001 0.999 3
IPF 0.5368 0.999 0.001 0.000 1
IPF 0.9170 0.000 0.999 0.001 2
IPF 1.5121 0.000 0.016 0.984 3
IPF 1.6658 0.000 0.000 1.000 3
IPF 1.1283 0.000 0.987 0.013 2
IPF 1.0327 0.000 0.996 0.004 2
IPF 1.1235 0.000 0.988 0.012 2
IPF 1.3897 0.000 0.306 0.694 3
IPF 0.5941 0.995 0.005 0.000 1
IPF 1.6574 0.000 0.000 1.000 3
IPF 1.4870 0.000 0.033 0.967 3
IPF 0.9118 0.000 0.999 0.001 2
IPF 1.1953 0.000 0.963 0.037 2
IPF 1.0183 0.000 0.997 0.003 2
IPF 1.5652 0.000 0.003 0.997 3
IPF 1.3776 0.000 0.372 0.628 3
IPF 1.9446 0.000 0.000 1.000 3
IPF 1.0464 0.000 0.995 0.005 2
IPF 1.6262 0.000 0.000 1.000 3
IPF 1.0214 0.000 0.997 0.003 2
IPF 1.1909 0.000 0.965 0.035 2
IPF 1.1341 0.000 0.986 0.014 2
IPF 1.4634 0.000 0.061 0.939 3
IPF 0.9401 0.000 0.998 0.002 2
IPF 1.1008 0.000 0.991 0.009 2
Abbreviations: PI: probability for 1 copy; P2: probability for 2 copies; 







Ratio PI P2 P3
Copy
Numbe
Control 2.8819 0.000 0.995 0.005 2
Control 3.3171 0.000 0.978 0.022 2
Control 3.1176 0.000 0.990 0.010 2
Control 3.4758 0.000 0.954 0.046 2
Control 3.5491 0.000 0.932 0.068 2
Control 3.3410 0.000 0.976 0.024 2
Control 3.5268 0.000 0.940 0.060 2
Control 1.3823 1.000 0.000 0.000 1
Control 3.1562 0.000 0.989 0.011 2
Control 3.1697 0.000 0.988 0.012 2
Control 2.8405 0.000 0.996 0.004 2
Control 4.1972 0.000 0.134 0.866 3
Control 3.6806 0.000 0.865 0.135 2
Control 4.5709 0.000 0.005 0.995 3
Control 3.3154 0.000 0.978 0.022 2
Control 3.6261 0.000 0.899 0.101 2
Control 3.2359 0.000 0.985 0.015 2
Control 3.0658 0.000 0.992 0.008 2
Control 4.9142 0.000 0.000 1.000 3
Control 3.2917 0.000 0.980 0.020 2
Control 4.2843 0.000 0.069 0.931 3
Control 3.4588 0.000 0.957 0.043 2
Control 6.1952 0.000 0.000 1.000 3
Control 3.1608 0.000 0.989 0.011 2
Control 3.6685 0.000 0.874 0.126 2
Control 3.4199 0.000 0.965 0.035 2
Control 4.7914 0.000 0.001 0.999 3
Control 1.5584 0.999 0.001 0.000 1
Control 4.5137 0.000 0.009 0.991 3
Control 3.2694 0.000 0.982 0.018 2
Control 3.7029 0.000 0.848 0.152 2
Control 1.8406 0.970 0.030 0.000 1
Control 2.6542 0.000 0.997 0.003 2
Control 5.3990 0.000 0.000 1.000 3
Control 3.1215 0.000 0.990 0.010 2
Control 4.8320 0.000 0.000 1.000 3
Control 3.2279 0.000 0.985 0.015 2
Control 1.6548 0.997 0.003 0.000 1
Control 2.3212 0.008 0.990 0.002 2
Control 2.9793 0.000 0.994 0.006 2
Control 2.9772 0.000 0.994 0.006 2
Control 2.4799 0.000 0.997 0.002 2
Control 3.1630 0.000 0.988 0.012 2




Ratio PI P2 P3
Copy
Number
Control 2.9006 0.000 0.995 0.005 2
Control 3.1348 0.000 0.990 0.010 2
Control 3.2375 0.000 0.984 0.016 2
Control 3.1169 0.000 0.990 0.010 2
Control 4.0856 0.000 0.276 0.724 3
Control 2.9785 0.000 0.994 0.006 2
Control 2.8191 0.000 0.996 0.004 2
Control 3.4657 0.000 0.956 0.044 2
Control 6.0584 0.000 0.000 1.000 3
Control 4.3177 0.000 0.052 0.948 3
Control 3.2108 0.000 0.986 0.014 2
Control 3.0608 0.000 0.992 0.008 2
Control 4.5880 0.000 0.004 0.996 3
Control 2.6818 0.000 0.997 0.003 2
Control 3.1313 0.000 0.990 0.010 2
Control 3.1991 0.000 0.987 0.013 2
Control 4.2197 0.000 0.113 0.887 3
Control 3.3340 0.000 0.976 0.024 2
Control 1.7871 0.986 0.014 0.000 1
Control 4.5054 0.000 0.010 0.990 3
Control 3.7912 0.000 0.761 0.239 2
Control 3.0752 0.000 0.992 0.008 2
Control 3.2024 0.000 0.987 0.013 2
Control 2.2914 0.015 0.983 0.002 2
Control 4.7898 0.000 0.001 0.999 3
Control 1.8728 0.953 0.047 0.000 1
Control 2.6245 0.000 0.997 0.003 2
Control 2.8675 0.000 0.996 0.004 2
Control 3.1766 0.000 0.988 0.012 2
Control 3.0547 0.000 0.992 0.008 2
Control 2.8652 0.000 0.996 0.004 2
Control 1.3330 1.000 0.000 0.000 1
Control 2.7692 0.000 0.996 0.004 2
Control 1.7624 0.990 0.010 0.000 1
Control 4.4470 0.000 0.017 0.983 3
Control 1.1812 1.000 0.000 0.000 1
Control 3.4498 0.000 0.959 0.041 2
Control 2.3725 0.003 0.995 0.002 2
Control 3.1328 0.000 0.990 0.010 2
Control 2.8506 0.000 0.996 0.004 2
Control 2.9091 0.000 0.995 0.005 2
Control 2.6719 0.000 0.997 0.003 2
Control 2.9984 0.000 0.994 0.006 2
Control 3.1635 0.000 0.988 0.012 2
Control 3.0775 0.000 0.992 0.008 2
Control 2.8518 0.000 0.996 0.004 2
Control 1.3610 1.000 0.000 0.000 1
Control 3.3187 0.000 0.978 0.022 2
Control 2.7820 0.000 0.996 0.004 2
523
FCGR3B:CD36 Raw Copy
Trait Ratio P I P2 P3 Number
Control 1.4331 1.000 0.000 0.000 1
Control 5.2834 0.000 0.000 1.000 3
Control 4.8119 0.000 0.000 1.000 3
Control 3.2728 0.000 0.982 0.018 2
Control 3.3065 0.000 0.979 0.021 2
Control 2.8296 0.000 0.996 0.004 2
Control 3.2776 0.000 0.982 0.018 2
Control 3.2496 0.000 0.984 0.016 2
Control 3.4852 0.000 0.951 0.049 2
Control 1.4491 1.000 0.000 0.000 1
Control 2.8124 0.000 0.996 0.004 2
Control 3.2703 0.000 0.982 0.018 2
Control 0.3406 1.000 0.000 0.000 1
Control 3.0431 0.000 0.992 0.008 2
Control 2.9829 0.000 0.994 0.006 2
Control 1.4488 1.000 0.000 0.000 1
Control 3.2322 0.000 0.985 0.015 2
Control 3.3083 0.000 0.979 0.021 2
Control 1.6333 0.998 0.002 0.000 1
Control 3.2546 0.000 0.983 0.017 2
Control 1.3021 1.000 0.000 0.000 1
Control 3.0663 0.000 0.992 0.008 2
Control 4.5965 0.000 0.004 0.996 3
Control 2.6422 0.000 0.997 0.003 2
Control 4.7513 0.000 0.001 0.999 3
Control 4.9841 0.000 0.000 1.000 3
Control 3.4236 0.000 0.964 0.036 2
Control 3.2972 0.000 0.980 0.020 2
Control 6.3894 0.000 0.000 1.000 3
Control 3.2230 0.000 0.985 0.015 2
Control 4.4820 0.000 0.012 0.988 3
Control 1.7046 0.995 0.005 0.000 1
Control 3.3932 0.000 0.969 0.031 2
Control 3.0832 0.000 0.991 0.009 2
Control 4.8846 0.000 0.000 1.000 3
Control 3.4638 0.000 0.956 0.044 2
Control 3.4889 0.000 0.950 0.050 2
Control 4.5470 0.000 0.006 0.994 3
Control 3.0247 0.000 0.993 0.007 2
Control 3.6061 0.000 0.909 0.091 2
Control 3.3465 0.000 0.975 0.025 2
Control 3.5441 0.000 0.934 0.066 2
Control 6.5487 0.000 0.000 1.000 3
Control 3.4699 0.000 0.955 0.045 2
Control 2.3554 0.004 0.994 0.002 2
Control 3.6859 0.000 0.861 0.139 2
Control 2.5806 0.000 0.997 0.002 2
Control 5.0634 0.000 0.000 1.000 3




Ratio PI P2 P3
Copy
Number
Control 3.4885 0.000 0.950 0.050 2
Control 3.5253 0.000 0.940 0.060 2
Control 3.3045 0.000 0.979 0.021 2
Control 4.8548 0.000 0.000 1.000 3
Control 2.8601 0.000 0.996 0.004 2
Control 3.3342 0.000 0.976 0.024 2
Control 3.5676 0.000 0.926 0.074 2
Control 3.6434 0.000 0.889 0.111 2
Control 2.1026 0.332 0.666 0.001 2
Control 1.9616 0.838 0.162 0.000 1
Control 3.5057 0.000 0.946 0.054 2
Control 3.3638 0.000 0.973 0.027 2
Control 3.1499 0.000 0.989 0.011 2
Control 3.3721 0.000 0.972 0.028 2
Control 2.6285 0.000 0.997 0.003 2
Control 3.4095 0.000 0.966 0.034 2
Control 3.0294 0.000 0.993 0.007 2
Control 3.3918 0.000 0.969 0.031 2
Control 3.1784 0.000 0.988 0.012 2
Control 4.9993 0.000 0.000 1.000 3
Control 3.4419 0.000 0.961 0.039 2
Control 2.8991 0.000 0.995 0.005 2
Control 2.5535 0.000 0.998 0.002 2
Control 3.2330 0.000 0.985 0.015 2
Control 3.1381 0.000 0.989 0.011 2
Control 1.4451 1.000 0.000 0.000 1
Control 2.9735 0.000 0.994 0.006 2
Control 3.3078 0.000 0.979 0.021 2
Control 4.5235 0.000 0.008 0.992 3
Control 2.0498 0.552 0.447 0.001 1
Control 2.9429 0.000 0.995 0.005 2
Control 3.0355 0.000 0.993 0.007 2
Control 2.8376 0.000 0.996 0.004 2
Control 3.0951 0.000 0.991 0.009 2
Control 4.9184 0.000 0.000 1.000 3
Control 3.2587 0.000 0.983 0.017 2
Control 4.4415 0.000 0.017 0.983 3
Control 3.0913 0.000 0.991 0.009 2
Control 3.2469 0.000 0.984 0.016 2
Control 2.9977 0.000 0.994 0.006 2
Control 2.3277 0.007 0.991 0.002 2
Control 3.4593 0.000 0.957 0.043 2
Control 1.7831 0.986 0.014 0.000 1
Control 1.7189 0.994 0.006 0.000 1
Control 3.5200 0.000 0.942 0.058 2
Control 3.9491 0.000 0.516 0.484 2
Control 3.3239 0.000 0.977 0.023 2
Control 3.2109 0.000 0.986 0.014 2




Ratio PI P2 P3
Copy
Number
Control 3.0680 0.000 0.992 0.008 2
Control 3.5868 0.000 0.918 0.082 2
Control 2.9781 0.000 0.994 0.006 2
Control 3.0108 0.000 0.993 0.007 2
Control 4.7284 0.000 0.001 0.999 3
Control 4.9556 0.000 0.000 1.000 3
Control 4.6183 0.000 0.003 0.997 3
Control 1.9112 0.919 0.081 0.000 1
Control 4.1759 0.000 0.155 0.845 3
Control 3.3474 0.000 0.975 0.025 2
Control 3.2237 0.000 0.985 0.015 2
Control 3.4223 0.000 0.964 0.036 2
Control 4.0665 0.000 0.306 0.694 3
Control 3.5292 0.000 0.939 0.061 2
Control 4.4604 0.000 0.015 0.985 3
Control 4.1319 0.000 0.209 0.791 3
Control 3.4763 0.000 0.953 0.047 2
Control 3.3588 0.000 0.974 0.026 2
Control 3.9471 0.000 0.520 0.480 2
Control 2.4723 0.000 0.997 0.002 2
Control 3.1815 0.000 0.988 0.012 2
Control 3.4186 0.000 0.965 0.035 2
Control 3.5498 0.000 0.932 0.068 2
Control 1.2570 1.000 0.000 0.000 1
Control 3.3646 0.000 0.973 0.027 2
Control 4.1239 0.000 0.219 0.781 3
Control 3.3507 0.000 0.974 0.026 2
Control 2.7789 0.000 0.996 0.004 2
Control 3.0037 0.000 0.993 0.007 2
Control 5.8014 0.000 0.000 1.000 3
Abbreviations: PI: probability for 1 copy; P2: probability for 2 copies; P3: 






Ratio PI P2 P3
Copy
Numbe
IPF 6.4669 0.000 0.000 1.000 3
IPF 4.1606 0.000 0.270 0.730 3
IPF 4.6020 0.000 0.006 0.994 3
IPF 6.5709 0.000 0.000 1.000 3
IPF 3.9362 0.000 0.684 0.316 2
IPF 3.9117 0.000 0.721 0.279 2
IPF 3.0170 0.000 0.997 0.003 2
IPF 3.1250 0.000 0.995 0.005 2
IPF 4.3598 0.000 0.061 0.939 3
IPF 1.6623 0.998 0.002 0.000 1
IPF 2.9167 0.000 0.998 0.002 2
IPF 2.9471 0.000 0.998 0.002 2
IPF 3.1177 0.000 0.995 0.005 2
IPF 6.0290 0.000 0.000 1.000 3
IPF 3.1509 0.000 0.995 0.005 2
IPF 4.3861 0.000 0.048 0.952 3
IPF 2.8466 0.000 0.998 0.002 2
IPF 3.6106 0.000 0.950 0.050 2
IPF 3.4807 0.000 0.976 0.024 2
IPF 3.3018 0.000 0.990 0.010 2
IPF 3.4005 0.000 0.984 0.016 2
IPF 3.6675 0.000 0.931 0.069 2
IPF 3.4649 0.000 0.978 0.022 2
IPF 4.4616 0.000 0.024 0.976 3
IPF 4.9566 0.000 0.000 1.000 3
IPF 1.9092 0.978 0.022 0.000 1
IPF 3.2071 0.000 0.993 0.007 2
IPF 3.3970 0.000 0.984 0.016 2
IPF 4.6570 0.000 0.003 0.997 3
IPF 4.6550 0.000 0.004 0.996 3
IPF 5.9458 0.000 0.000 1.000 3
IPF 3.3303 0.000 0.989 0.011 2
IPF 3.1194 0.000 0.995 0.005 2
IPF 4.6104 0.000 0.006 0.994 3
IPF 2.9609 0.000 0.997 0.003 2
IPF 2.8598 0.000 0.998 0.002 2
IPF 3.3692 0.000 0.986 0.014 2
IPF 3.4058 0.000 0.984 0.016 2
IPF 3.0466 0.000 0.997 0.003 2
1PF 2.9305 0.000 0.998 0.002 2
IPF 3.1212 0.000 0.995 0.005 2
IPF 4.4256 0.000 0.034 0.966 3
IPF 2.8232 0.000 0.998 0.002 2
IPF 3.4258 0.000 0.982 0.018 2
IPF 5.1216 0.000 0.000 1.000 3
IPF 3.0843 0.000 0.996 0.004 2
IPF 3.0180 0.000 0.997 0.003 2
527
FCGR3B-.CD36 Raw Copy
Trait________ R a t io _________ P i P2 P3 Number
IPF 4.9781 0.000 0.000 1.000 3
IPF 3.2731 0.000 0.991 0.009 2
1PF 2.9090 0.000 0.998 0.002 2
IPF 1.8345 0.990 0.010 0.000 1
IPF 3.2913 0.000 0.991 0.009 2
IPF 1.6957 0.998 0.002 0.000 1
IPF 4.4441 0.000 0.028 0.972 3
IPF 3.3364 0.000 0.988 0.012 2
IPF 4.4716 0.000 0.022 0.978 3
IPF 3.1144 0.000 0.996 0.004 2
IPF 3.8389 0.000 0.813 0.187 2
IPF 3.5518 0.000 0.964 0.036 2
IPF 3.3522 0.000 0.987 0.013 2
IPF 3.7035 0.000 0.915 0.085 2
IPF 4.2452 0.000 0.152 0.848 3
IPF 4.3904 0.000 0.046 0.954 3
IPF 5.0315 0.000 0.000 1.000 3
IPF 2.7608 0.000 0.998 0.001 2
IPF 4.9731 0.000 0.000 1.000 3
IPF 4.1347 0.000 0.314 0.686 3
IPF 2.9308 0.000 0.998 0.002 2
IPF 3.0460 0.000 0.997 0.003 2
IPF 4.2616 0.000 0.135 0.865 3
IPF 2.8307 0.000 0.998 0.002 2
IPF 3.4596 0.000 0.978 0.022 2
IPF 3.1925 0.000 0.994 0.006 2
IPF 3.7171 0.000 0.908 0.092 2
IPF 6.7189 0.000 0.000 1.000 3
IPF 3.5167 0.000 0.971 0.029 2
IPF 2.9122 0.000 0.998 0.002 2
IPF 2.8412 0.000 0.998 0.002 2
IPF 3.5959 0.000 0.954 0.046 2
IPF 3.5776 0.000 0.959 0.041 2
IPF 2.7668 0.000 0.998 0.002 2
IPF 3.6064 0.000 0.952 0.048 2
IPF 2.8605 0.000 0.998 0.002 2
IPF 4.8001 0.000 0.001 0.999 3
IPF 4.5891 0.000 0.007 0.993 3
IPF 1.7245 0.997 0.003 0.000 1
IPF 3.0920 0.000 0.996 0.004 2
IPF 3.5138 0.000 0.971 0.029 2
IPF 2.7966 0.000 0.998 0.002 2
IPF 4.5303 0.000 0.012 0.988 3
IPF 3.3272 0.000 0.989 0.011 2
IPF 2.8928 0.000 0.998 0.002 2
IPF 5.9696 0.000 0.000 1.000 3
IPF 5.2164 0.000 0.000 1.000 3
IPF 3.0085 0.000 0.997 0.003 2




Ratio PI P2 P3
Copy
Number
IPF 5.7503 0.000 0.000 1.000 3
IPF 5.5657 0.000 0.000 1.000 3
IPF 3.4731 0.000 0.977 0.023 2
IPF 3.0174 0.000 0.997 0.003 2
IPF 3.5484 0.000 0.965 0.035 2
IPF 3.0353 0.000 0.997 0.003 2
IPF 2.7918 0.000 0.998 0.002 2
IPF 2.9348 0.000 0.998 0.002 2
IPF 2.9096 0.000 0.998 0.002 2
IPF 3.6159 0.000 0.949 0.051 2
IPF 3.0578 0.000 0.996 0.004 2
IPF 2.6293 0.000 0.998 0.001 2
IPF 2.5685 0.001 0.997 0.001 2
IPF 4.8846 0.000 0.000 1.000 3
IPF 3.2156 0.000 0.993 0.007 2
IPF 2.4958 0.006 0.993 0.001 2
IPF 3.0217 0.000 0.997 0.003 2
IPF 3.1234 0.000 0.995 0.005 2
IPF 3.2177 0.000 0.993 0.007 2
IPF 3.2587 0.000 0.992 0.008 2
IPF 4.8348 0.000 0.001 0.999 3
IPF 1.5991 0.999 0.001 0.000 1
IPF 2.7314 0.000 0.999 0.001 2
IPF 4.5042 0.000 0.016 0.984 3
IPF 4.9619 0.000 0.000 1.000 3
IPF 3.3610 0.000 0.987 0.013 2
IPF 3.0760 0.000 0.996 0.004 2
IPF 3.3466 0.000 0.988 0.012 2
IPF 4.1394 0.000 0.306 0.694 3
IPF 1.7697 0.995 0.005 0.000 1
IPF 4.9370 0.000 0.000 1.000 3
IPF 4.4292 0.000 0.033 0.967 3
IPF 2.7159 0.000 0.999 0.001 2
IPF 3.5605 0.000 0.963 0.037 2
IPF 3.0331 0.000 0.997 0.003 2
IPF 4.6621 0.000 0.003 0.997 3
IPF 4.1033 0.000 0.372 0.628 3
IPF 5.7924 0.000 0.000 1.000 3
IPF 3.1168 0.000 0.995 0.005 2
IPF 4.8439 0.000 0.000 1.000 3
IPF 3.0424 0.000 0.997 0.003 2
IPF 3.5472 0.000 0.965 0.035 2
IPF 3.3780 0.000 0.986 0.014 2
IPF 4.3590 0.000 0.061 0.939 3
IPF 2.8002 0.000 0.998 0.002 2
IPF 3.2791 0.000 0.991 0.009 2
Abbreviations: PI: probability for 1 copy; P2: probability for 2 copies; P3: 
probability for 3 copies; FCGR3B\CD36 ratio: ratio of FCGR3B- to CD36- 
specific qPCR amplification.
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Figure 15.1.: Predicted FEVi (L -forced expiratory volume in 1 sec) values for 
males aged 50-80 based on the European Community for Coal and Steel and the 
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Figure 15.2. : Predicted FVC (L -  forced vital capacity) values for males aged 50-80 
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Figure 15.3.: Predicted FEVi/VC Ratio (%) values for males aged 50-80 based on 
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Figure 15.4.: Predicted TLC (L - total lung capacity) values for males aged 50-80 
based on the European Community for Coal and Steel and the European 
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Figure 15.5.: Predicted D lCo  (ml min^mmHg1 - diffusing capacity for carbon 
monoxide) values for males aged 50-80 based on the European Community for 



















Figure 15.6.: Predicted K Co (ml min^mmHg1! 1 - DLco corrected for alveolar 
volume) values for males aged 50-80 based on the European Community for Coal 














(ml min 1 mmHg1)
Kco
(ml min'1 mm
1.50 2.51 3.00 78.2 4.91 7.34 1.50
1.51 2.55 3.06 78.2 4.98 7.45 1.49
1.52 2.60 3.12 78.2 5.06 7.56 1.49
1.53 2.64 3.17 78.2 5.14 7.67 1.49
1.54 2.68 3.23 78.2 5.22 7.78 1.49
1.55 2.73 3.29 78.2 5.30 7.89 1.49
1.56 2.77 3.35 78.2 5.38 8.00 1.49
1.57 2.81 3.40 78.2 5.46 8.11 1.48
1.58 2.85 3.46 78.2 5.54 8.22 1.48
1.59 2.90 3.52 78.2 5.62 8.33 1.48
1.60 2.94 3.58 78.2 5.70 8.45 1.48
1.61 2.98 3.63 78.2 5.78 8.56 1.48
1.62 3.03 3.69 78.2 5.86 8.67 1.48
1.63 3.07 3.75 78.2 5.94 8.78 1.48
1.64 3.11 3.81 78.2 6.02 8.89 1.48
1.65 3.16 3.86 78.2 6.10 9.00 1.47
1.66 3.20 3.92 78.2 6.18 9.11 1.47
1.67 3.24 3.98 78.2 6.26 9.22 1.47
1.68 3.28 4.04 78.2 6.34 9.33 1.47
1.69 3.33 4.09 78.2 6.42 9.45 1.47
1.70 3.37 4.15 78.2 6.50 9.56 1.47
1.71 3.41 4.21 78.2 6.58 9.67 1.47
1.72 3.46 4.27 78.2 6.66 9.78 1.47
1.73 3.50 4.32 78.2 6.74 9.89 1.47
1.74 3.54 4.38 78.2 6.82 10.00 1.47
1.75 3.59 4.44 78.2 6.90 10.11 1.47
1.76 3.63 4.50 78.2 6.98 10.22 1.46
1.77 3.67 4.56 78.2 7.06 10.33 1.46
1.78 3.71 4.61 78.2 7.14 10.45 1.46
1.79 3.76 4.67 78.2 7.22 10.56 1.46
1.80 3.80 4.73 78.2 7.30 10.67 1.46
1.81 3.84 4.79 78.2 7.38 10.78 1.46
1.82 3.89 4.84 78.2 7.46 10.89 1.46
1.83 3.93 4.90 78.2 7.54 11.00 1.46
1.84 3.97 4.96 78.2 7.62 11.11 1.46
1.85 4.02 5.02 78.2 7.70 11.22 1.46
1.86 4.06 5.07 78.2 7.78 11.33 1.46
1.87 4.10 5.13 78.2 7.86 11.45 1.46
1.88 4.14 5.19 78.2 7.94 11.56 1.46
1.89 4.19 5.25 78.2 8.02 11.67 1.45
1.90 4.23 5.30 78.2 8.10 11.78 1.45
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Age= 52
Height FEVi FVC Ratio TLC DLco Kco
(m) (L) (L) (%) (1) (ml min 1 mmHg'1) (ml mirr1 mm
1.50 2.45 2.95 77.9 4.91 7.20 1.47
1.51 2.50 3.01 77.9 4.98 7.31 1.47
1.52 2.54 3.06 77.9 5.06 7.43 1.47
1.53 2.58 3.12 77.9 5.14 7.54 1.46
1.54 2.62 3.18 77.9 5.22 7.65 1.46
1.55 2.67 3.24 77.9 5.30 7.76 1.46
1.56 2.71 3.29 77.9 5.38 7.87 1.46
1.57 2.75 3.35 77.9 5.46 7.98 1.46
1.58 2.80 3.41 77.9 5.54 8.09 1.46
1.59 2.84 3.47 77.9 5.62 8.20 1.46
1.60 2.88 3.52 77.9 5.70 8.31 1.46
1.61 2.93 3.58 77.9 5.78 8.43 1.46
1.62 2.97 3.64 77.9 5.86 8.54 1.46
1.63 3.01 3.70 77.9 5.94 8.65 1.45
1.64 3.05 3.75 77.9 6.02 8.76 1.45
1.65 3.10 3.81 77.9 6.10 8.87 1.45
1.66 3.14 3.87 77.9 6.18 8.98 1.45
1.67 3.18 3.93 77.9 6.26 9.09 1.45
1.68 3.23 3.98 77.9 6.34 9.20 1.45
1.69 3.27 4.04 77.9 6.42 9.31 1.45
1.70 3.31 4.10 77.9 6.50 9.43 1.45
1.71 3.36 4.16 77.9 6.58 9.54 1.45
1.72 3.40 4.22 77.9 6.66 9.65 1.45
1.73 3.44 4.27 77.9 6.74 9.76 1.45
1.74 3.48 4.33 77.9 6.82 9.87 1.45
1.75 3.53 4.39 77.9 6.90 9.98 1.45
1.76 3.57 4.45 77.9 6.98 10.09 1.45
1.77 3.61 4.50 77.9 7.06 10.20 1.44
1.78 3.66 4.56 77.9 7.14 10.31 1.44
1.79 3.70 4.62 77.9 7.22 10.42 1.44
1.80 3.74 4.68 77.9 7.30 10.54 1.44
1.81 3.79 4.73 77.9 7.38 10.65 1.44
1.82 3.83 4.79 77.9 7.46 10.76 1.44
1.83 3.87 4.85 77.9 7.54 10.87 1.44
1.84 3.91 4.91 77.9 7.62 10.98 1.44
1.85 3.96 4.96 77.9 7.70 11.09 1.44
1.86 4.00 5.02 77.9 7.78 11.20 1.44
1.87 4.04 5.08 77.9 7.86 11.31 1.44
1.88 4.09 5.14 77.9 7.94 11.42 1.44
1.89 4.13 5.19 77.9 8.02 11.54 1.44














(ml min 1 mmHg1)
Kco
(ml min'1 mm
1.50 2.39 2.90 77.5 4.91 7.07 1.44
1.51 2.44 2.95 77.5 4.98 7.18 1.44
1.52 2.48 3.01 77.5 5.06 7.29 1.44
1.53 2.52 3.07 77.5 5.14 7.40 1.44
1.54 2.57 3.13 77.5 5.22 7.52 1.44
1.55 2.61 3.18 77.5 5.30 7.63 1.44
1.56 2.65 3.24 77.5 5.38 7.74 1.44
1.57 2.70 3.30 77.5 5.46 7.85 1.44
1.58 2.74 3.36 77.5 5.54 7.96 1.44
1.59 2.78 3.41 77.5 5.62 8.07 1.44
1.60 2.82 3.47 77.5 5.70 8.18 1.43
1.61 2.87 3.53 77.5 5.78 8.29 1.43
1.62 2.91 3.59 77.5 5.86 8.40 1.43
1.63 2.95 3.64 77.5 5.94 8.52 1.43
1.64 3.00 3.70 77.5 6.02 8.63 1.43
1.65 3.04 3.76 77.5 6.10 8.74 1.43
1.66 3.08 3.82 77.5 6.18 8.85 1.43
1.67 3.13 3.88 77.5 6.26 8.96 1.43
1.68 3.17 3.93 77.5 6.34 9.07 1.43
1.69 3.21 3.99 77.5 6.42 9.18 1.43
1.70 3.25 4.05 77.5 6.50 9.29 1.43
1.71 3.30 4.11 77.5 6.58 9.40 1.43
1.72 3.34 4.16 77.5 6.66 9.52 1.43
1.73 3.38 4.22 77.5 6.74 9.63 1.43
1.74 3.43 4.28 77.5 6.82 9.74 1.43
1.75 3.47 4.34 77.5 6.90 9.85 1.43
1.76 3.51 4.39 77.5 6.98 9.96 1.43
1.77 3.56 4.45 77.5 7.06 10.07 1.43
1.78 3.60 4.51 77.5 7.14 10.18 1.43
1.79 3.64 4.57 77.5 7.22 10.29 1.43
1.80 3.68 4.62 77.5 7.30 10.40 1.42
1.81 3.73 4.68 77.5 7.38 10.52 1.42
1.82 3.77 4.74 77.5 7.46 10.63 1.42
1.83 3.81 4.80 77.5 7.54 10.74 1.42
1.84 3.86 4.85 77.5 7.62 10.85 1.42
1.85 3.90 4.91 77.5 7.70 10.96 1.42
1.86 3.94 4.97 77.5 7.78 11.07 1.42
1.87 3.99 5.03 77.5 7.86 11.18 1.42
1.88 4.03 5.08 77.5 7.94 11.29 1.42
1.89 4.07 5.14 77.5 8.02 11.40 1.42
1.90 4.11 5.20 77.5 8.10 11.52 1.42
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Age=56
Height FEVi FVC Ratio TLC DLco Kco
(m)______ (i)______ (1)______ (%)______ (¿.) (ml mirv1 mmHg'1) (ml mirr1 mmHg^Lx)
1.50 2.34 2.84 77.1 4.91 6.94 1.41
1.51 2.38 2.90 77.1 4.98 7.05 1.41
1.52 2.42 2.96 77.1 5.06 7.16 1.41
1.53 2.47 3.02 77.1 5.14 7.27 1.41
1.54 2.51 3.07 77.1 5.22 7.38 1.41
1.55 2.55 3.13 77.1 5.30 7.49 1.41
1.56 2.59 3.19 77.1 5.38 7.61 1.41
1.57 2.64 3.25 77.1 5.46 7.72 1.41
1.58 2.68 3.30 77.1 5.54 7.83 1.41
1.59 2.72 3.36 77.1 5.62 7.94 1.41
1.60 2.77 3.42 77.1 5.70 8.05 1.41
1.61 2.81 3.48 77.1 5.78 8.16 1.41
1.62 2.85 3.54 77.1 5.86 8.27 1.41
1.63 2.90 3.59 77.1 5.94 8.38 1.41
1.64 2.94 3.65 77.1 6.02 8.49 1.41
1.65 2.98 3.71 77.1 6.10 8.61 1.41
1.66 3.02 3.77 77.1 6.18 8.72 1.41
1.67 3.07 3.82 77.1 6.26 8.83 1.41
1.68 3.11 3.88 77.1 6.34 8.94 1.41
1.69 3.15 3.94 77.1 6.42 9.05 1.41
1.70 3.20 4.00 77.1 6.50 9.16 1.41
1.71 3.24 4.05 77.1 6.58 9.27 1.41
1.72 3.28 4.11 77.1 6.66 9.38 1.41
1.73 3.33 4.17 77.1 6.74 9.49 1.41
1.74 3.37 4.23 77.1 6.82 9.61 1.41
1.75 3.41 4.28 77.1 6.90 9.72 1.41
1.76 3.45 4.34 77.1 6.98 9.83 1.41
1.77 3.50 4.40 77.1 7.06 9.94 1.41
1.78 3.54 4.46 77.1 7.14 10.05 1.41
1.79 3.58 4.51 77.1 7.22 10.16 1.41
1.80 3.63 4.57 77.1 7.30 10.27 1.41
1.81 3.67 4.63 77.1 7.38 10.38 1.41
1.82 3.71 4.69 77.1 7.46 10.49 1.41
1.83 3.76 4.74 77.1 7.54 10.61 1.41
1.84 3.80 4.80 77.1 7.62 10.72 1.41
1.85 3.84 4.86 77.1 7.70 10.83 1.41
1.86 3.88 4.92 77.1 7.78 10.94 1.41
1.87 3.93 4.98 77.1 7.86 11.05 1.41
1.88 3.97 5.03 77.1 7.94 11.16 1.41
1.89 4.01 5.09 77.1 8.02 11.27 1.41

















1.50 2.28 2.79 76.8 4.91 6.81 1.39
1.51 2.32 2.85 76.8 4.98 6.92 1.39
1.52 2.36 2.91 76.8 5.06 7.03 1.39
1.53 2.41 2.96 76.8 5.14 7.14 1.39
1.54 2.45 3.02 76.8 5.22 7.25 1.39
1.55 2.49 3.08 76.8 5.30 7.36 1.39
1.56 2.54 3.14 76.8 5.38 7.47 1.39
1.57 2.58 3.20 76.8 5.46 7.58 1.39
1.58 2.62 3.25 76.8 5.54 7.70 1.39
1.59 2.67 3.31 76.8 5.62 7.81 1.39
1.60 2.71 3.37 76.8 5.70 7.92 1.39
1.61 2.75 3.43 76.8 5.78 8.03 1.39
1.62 2.79 3.48 76.8 5.86 8.14 1.39
1.63 2.84 3.54 76.8 5.94 8.25 1.39
1.64 2.88 3.60 76.8 6.02 8.36 1.39
1.65 2.92 3.66 76.8 6.10 8.47 1.39
1.66 2.97 3.71 76.8 6.18 8.58 1.39
1.67 3.01 3.77 76.8 6.26 8.70 1.39
1.68 3.05 3.83 76.8 6.34 8.81 1.39
1.69 3.10 3.89 76.8 6.42 8.92 1.39
1.70 3.14 3.94 76.8 6.50 9.03 1.39
1.71 3.18 4.00 76.8 6.58 9.14 1.39
1.72 3.22 4.06 76.8 6.66 9.25 1.39
1.73 3.27 4.12 76.8 6.74 9.36 1.39
1.74 3.31 4.17 76.8 6.82 9.47 1.39
1.75 3.35 4.23 76.8 6.90 9.58 1.39
1.76 3.40 4.29 76.8 6.98 9.70 1.39
1.77 3.44 4.35 76.8 7.06 9.81 1.39
1.78 3.48 4.40 76.8 7.14 9.92 1.39
1.79 3.53 4.46 76.8 7.22 10.03 1.39
1.80 3.57 4.52 76.8 7.30 10.14 1.39
1.81 3.61 4.58 76.8 7.38 10.25 1.39
1.82 3.65 4.64 76.8 7.46 10.36 1.39
1.83 3.70 4.69 76.8 7.54 10.47 1.39
1.84 3.74 4.75 76.8 7.62 10.58 1.39
1.85 3.78 4.81 76.8 7.70 10.70 1.39
1.86 3.83 4.87 76.8 7.78 10.81 1.39
1.87 3.87 4.92 76.8 7.86 10.92 1.39
1.88 3.91 4.98 76.8 7.94 11.03 1.39
1.89 3.96 5.04 76.8 8.02 11.14 1.39














(ml min 1 mmHg'1)
Kco
(ml min’1 mm
1.50 2.22 2.74 76.4 4.91 6.68 1.36
1.51 2.26 2.80 76.4 4.98 6.79 1.36
1.52 2.31 2.86 76.4 5.06 6.90 1.36
1.53 2.35 2.91 76.4 5.14 7.01 1.36
1.54 2.39 2.97 76.4 5.22 7.12 1.36
1.55 2.44 3.03 76.4 5.30 7.23 1.36
1.56 2.48 3.09 76.4 5.38 7.34 1.36
1.57 2.52 3.14 76.4 5.46 7.45 1.36
1.58 2.56 3.20 76.4 5.54 7.56 1.36
1.59 2.61 3.26 76.4 5.62 7.67 1.36
1.60 2.65 3.32 76.4 5.70 7.79 1.37
1.61 2.69 3.37 76.4 5.78 7.90 1.37
1.62 2.74 3.43 76.4 5.86 8.01 1.37
1.63 2.78 3.49 76.4 5.94 8.12 1.37
1.64 2.82 3.55 76.4 6.02 8.23 1.37
1.65 2.87 3.60 76.4 6.10 8.34 1.37
1.66 2.91 3.66 76.4 6.18 8.45 1.37
1.67 2.95 3.72 76.4 6.26 8.56 1.37
1.68 2.99 3.78 76.4 6.34 8.67 1.37
1.69 3.04 3.83 76.4 6.42 8.79 1.37
1.70 3.08 3.89 76.4 6.50 8.90 1.37
1.71 3.12 3.95 76.4 6.58 9.01 1.37
1.72 3.17 4.01 76.4 6.66 9.12 1.37
1.73 3.21 4.06 76.4 6.74 9.23 1.37
1.74 3.25 4.12 76.4 6.82 9.34 1.37
1.75 3.30 4.18 76.4 6.90 9.45 1.37
1.76 3.34 4.24 76.4 6.98 9.56 1.37
1.77 3.38 4.30 76.4 7.06 9.67 1.37
1.78 3.42 4.35 76.4 7.14 9.79 1.37
1.79 3.47 4.41 76.4 7.22 9.90 1.37
1.80 3.51 4.47 76.4 7.30 10.01 1.37
1.81 3.55 4.53 76.4 7.38 10.12 1.37
1.82 3.60 4.58 76.4 7.46 10.23 1.37
1.83 3.64 4.64 76.4 7.54 10.34 1.37
1.84 3.68 4.70 76.4 7.62 10.45 1.37
1.85 3.73 4.76 76.4 7.70 10.56 1.37
1.86 3.77 4.81 76.4 7.78 10.67 1.37
1.87 3.81 4.87 76.4 7.86 10.79 1.37
1.88 3.85 4.93 76.4 7.94 10.90 1.37
1.89 3.90 4.99 76.4 8.02 11.01 1.37

















1.50 2.16 2.69 76.1 4.91 6.54 1.33
1.51 2.21 2.75 76.1 4.98 6.65 1.33
1.52 2.25 2.80 76.1 5.06 6.77 1.34
1.53 2.29 2.86 76.1 5.14 6.88 1.34
1.54 2.33 2.92 76.1 5.22 6.99 1.34
1.55 2.38 2.98 76.1 5.30 7.10 1.34
1.56 2.42 3.03 76.1 5.38 7.21 1.34
1.57 2.46 3.09 76.1 5.46 7.32 1.34
1.58 2.51 3.15 76.1 5.54 7.43 1.34
1.59 2.55 3.21 76.1 5.62 7.54 1.34
1.60 2.59 3.26 76.1 5.70 7.65 1.34
1.61 2.64 3.32 76.1 5.78 7.77 1.34
1.62 2.68 3.38 76.1 5.86 7.88 1.34
1.63 2.72 3.44 76.1 5.94 7.99 1.34
1.64 2.76 3.49 76.1 6.02 8.10 1.34
1.65 2.81 3.55 76.1 6.10 8.21 1.35
1.66 2.85 3.61 76.1 6.18 8.32 1.35
1.67 2.89 3.67 76.1 6.26 8.43 1.35
1.68 2.94 3.72 76.1 6.34 8.54 1.35
1.69 2.98 3.78 76.1 6.42 8.65 1.35
1.70 3.02 3.84 76.1 6.50 8.77 1.35
1.71 3.07 3.90 76.1 6.58 8.88 1.35
1.72 3.11 3.96 76.1 6.66 8.99 1.35
1.73 3.15 4.01 76.1 6.74 9.10 1.35
1.74 3.19 4.07 76.1 6.82 9.21 1.35
1.75 3.24 4.13 76.1 6.90 9.32 1.35
1.76 3.28 4.19 76.1 6.98 9.43 1.35
1.77 3.32 4.24 76.1 7.06 9.54 1.35
1.78 3.37 4.30 76.1 7.14 9.65 1.35
1.79 3.41 4.36 76.1 7.22 9.76 1.35
1.80 3.45 4.42 76.1 7.30 9.88 1.35
1.81 3.50 4.47 76.1 7.38 9.99 1.35
1.82 3.54 4.53 76.1 7.46 10.10 1.35
1.83 3.58 4.59 76.1 7.54 10.21 1.35
1.84 3.62 4.65 76.1 7.62 10.32 1.35
1.85 3.67 4.70 76.1 7.70 10.43 1.35
1.86 3.71 4.76 76.1 7.78 10.54 1.35
1.87 3.75 4.82 76.1 7.86 10.65 1.36
1.88 3.80 4.88 76.1 7.94 10.76 1.36
1.89 3.84 4.93 76.1 8.02 10.88 1.36














(ml mln 1 mmHg'1)
Kco
(ml mirr1 mml
1.50 2.10 2.64 75.7 4.91 6.41 1.31
1.51 2.15 2.69 75.7 4.98 6.52 1.31
1.52 2.19 2.75 75.7 5.06 6.63 1.31
1.53 2.23 2.81 75.7 5.14 6.74 1.31
1.54 2.28 2.87 75.7 5.22 6.86 1.31
1.55 2.32 2.92 75.7 5.30 6.97 1.31
1.56 2.36 2.98 75.7 5.38 7.08 1.31
1.57 2.41 3.04 75.7 5.46 7.19 1.32
1.58 2.45 3.10 75.7 5.54 7.30 1.32
1.59 2.49 3.15 75.7 5.62 7.41 1.32
1.60 2.53 3.21 75.7 5.70 7.52 1.32
1.61 2.58 3.27 75.7 5.78 7.63 1.32
1.62 2.62 3.33 75.7 5.86 7.74 1.32
1.63 2.66 3.38 75.7 5.94 7.86 1.32
1.64 2.71 3.44 75.7 6.02 7.97 1.32
1.65 2.75 3.50 75.7 6.10 8.08 1.32
1.66 2.79 3.56 75.7 6.18 8.19 1.32
1.67 2.84 3.62 75.7 6.26 8.30 1.33
1.68 2.88 3.67 75.7 6.34 8.41 1.33
1.69 2.92 3.73 75.7 6.42 8.52 1.33
1.70 2.96 3.79 75.7 6.50 8.63 1.33
1.71 3.01 3.85 75.7 6.58 8.74 1.33
1.72 3.05 3.90 75.7 6.66 8.86 1.33
1.73 3.09 3.96 75.7 6.74 8.97 1.33
1.74 3.14 4.02 75.7 6.82 9.08 1.33
1.75 3.18 4.08 75.7 6.90 9.19 1.33
1.76 3.22 4.13 75.7 6.98 9.30 1.33
1.77 3.27 4.19 75.7 7.06 9.41 1.33
1.78 3.31 4.25 75.7 7.14 9.52 1.33
1.79 3.35 4.31 75.7 7.22 9.63 1.33
1.80 3.39 4.36 75.7 7.30 9.74 1.33
1.81 3.44 4.42 75.7 7.38 9.86 1.34
1.82 3.48 4.48 75.7 7.46 9.97 1.34
1.83 3.52 4.54 75.7 7.54 10.08 1.34
1.84 3.57 4.59 75.7 7.62 10.19 1.34
1.85 3.61 4.65 75.7 7.70 10.30 1.34
1.86 3.65 4.71 75.7 7.78 10.41 1.34
1.87 3.70 4.77 75.7 7.86 10.52 1.34
1.88 3.74 4.82 75.7 7.94 10.63 1.34
1.89 3.78 4.88 75.7 8.02 10.74 1.34
1.90 3.82 4.94 75.7 8.10 10.86 1.34
543
Age= 66
Height FEVi FVC Ratio TLC DLco Kco
(m) (L) (L) (%)_______(L) (ml min'1 mmHg'1) (ml min'1 mmHg^L-1)
1.50 2.05 2.58 75.3 4.91 6.28 1.28
1.51 2.09 2.64 75.3 4.98 6.39 1.28
1.52 2.13 2.70 75.3 5.06 6.50 1.28
1.53 2.18 2.76 75.3 5.14 6.61 1.29
1.54 2.22 2.81 75.3 5.22 6.72 1.29
1.55 2.26 2.87 75.3 5.30 6.83 1.29
1.56 2.30 2.93 75.3 5.38 6.95 1.29
1.57 2.35 2.99 75.3 5.46 7.06 1.29
1.58 2.39 3.04 75.3 5.54 7.17 1.29
1.59 2.43 3.10 75.3 5.62 7.28 1.29
1.60 2.48 3.16 75.3 5.70 7.39 1.30
1.61 2.52 3.22 75.3 5.78 7.50 1.30
1.62 2.56 3.28 75.3 5.86 7.61 1.30
1.63 2.61 3.33 75.3 5.94 7.72 1.30
1.64 2.65 3.39 75.3 6.02 7.83 1.30
1.65 2.69 3.45 75.3 6.10 7.95 1.30
1.66 2.73 3.51 75.3 6.18 8.06 1.30
1.67 2.78 3.56 75.3 6.26 8.17 1.30
1.68 2.82 3.62 75.3 6.34 8.28 1.31
1.69 2.86 3.68 75.3 6.42 8.39 1.31
1.70 2.91 3.74 75.3 6.50 8.50 1.31
1.71 2.95 3.79 75.3 6.58 8.61 1.31
1.72 2.99 3.85 75.3 6.66 8.72 1.31
1.73 3.04 3.91 75.3 6.74 8.83 1.31
1.74 3.08 3.97 75.3 6.82 8.95 1.31
1.75 3.12 4.02 75.3 6.90 9.06 1.31
1.76 3.16 4.08 75.3 6.98 9.17 1.31
1.77 3.21 4.14 75.3 7.06 9.28 1.31
1.78 3.25 4.20 75.3 7.14 9.39 1.31
1.79 3.29 4.25 75.3 7.22 9.50 1.32
1.80 3.34 4.31 75.3 7.30 9.61 1.32
1.81 3.38 4.37 75.3 7.38 9.72 1.32
1.82 3.42 4.43 75.3 7.46 9.83 1.32
1.83 3.47 4.48 75.3 7.54 9.95 1.32
1.84 3.51 4.54 75.3 7.62 10.06 1.32
1.85 3.55 4.60 75.3 7.70 10.17 1.32
1.86 3.59 4.66 75.3 7.78 10.28 1.32
1.87 3.64 4.72 75.3 7.86 10.39 1.32
1.88 3.68 4.77 75.3 7.94 10.50 1.32
1.89 3.72 4.83 75.3 8.02 10.61 1.32














(ml min 1 mmHg'1)
Kco
(ml min-1 mm
1.50 1.99 2.53 75.0 4.91 6.15 1.25
1.51 2.03 2.59 75.0 4.98 6.26 1.26
1.52 2.07 2.65 75.0 5.06 6.37 1.26
1.53 2.12 2.70 75.0 5.14 6.48 1.26
1.54 2.16 2.76 75.0 5.22 6.59 1.26
1.55 2.20 2.82 75.0 5.30 6.70 1.26
1.56 2.25 2.88 75.0 5.38 6.81 1.27
1.57 2.29 2.94 75.0 5.46 6.92 1.27
1.58 2.33 2.99 75.0 5.54 7.04 1.27
1.59 2.38 3.05 75.0 5.62 7.15 1.27
1.60 2.42 3.11 75.0 5.70 7.26 1.27
1.61 2.46 3.17 75.0 5.78 7.37 1.27
1.62 2.50 3.22 75.0 5.86 7.48 1.28
1.63 2.55 3.28 75.0 5.94 7.59 1.28
1.64 2.59 3.34 75.0 6.02 7.70 1.28
1.65 2.63 3.40 75.0 6.10 7.81 1.28
1.66 2.68 3.45 75.0 6.18 7.92 1.28
1.67 2.72 3.51 75.0 6.26 8.04 1.28
1.68 2.76 3.57 75.0 6.34 8.15 1.28
1.69 2.81 3.63 75.0 6.42 8.26 1.29
1.70 2.85 3.68 75.0 6.50 8.37 1.29
1.71 2.89 3.74 75.0 6.58 8.48 1.29
1.72 2.93 3.80 75.0 6.66 8.59 1.29
1.73 2.98 3.86 75.0 6.74 8.70 1.29
1.74 3.02 3.91 75.0 6.82 8.81 1.29
1.75 3.06 3.97 75.0 6.90 8.92 1.29
1.76 3.11 4.03 75.0 6.98 9.04 1.29
1.77 3.15 4.09 75.0 7.06 9.15 1.30
1.78 3.19 4.14 75.0 7.14 9.26 1.30
1.79 3.24 4.20 75.0 7.22 9.37 1.30
1.80 3.28 4.26 75.0 7.30 9.48 1.30
1.81 3.32 4.32 75.0 7.38 9.59 1.30
1.82 3.36 4.38 75.0 7.46 9.70 1.30
1.83 3.41 4.43 75.0 7.54 9.81 1.30
1.84 3.45 4.49 75.0 7.62 9.92 1.30
1.85 3.49 4.55 75.0 7.70 10.04 1.30
1.86 3.54 4.61 75.0 7.78 10.15 1.30
1.87 3.58 4.66 75.0 7.86 10.26 1.30
1.88 3.62 4.72 75.0 7.94 10.37 1.31
1.89 3.67 4.78 75.0 8.02 10.48 1.31

















1.50 1.93 2.48 74.6 4.91 6.02 1.23
1.51 1.97 2.54 74.6 4.98 6.13 1.23
1.52 2.02 2.60 74.6 5.06 6.24 1.23
1.53 2.06 2.65 74.6 5.14 6.35 1.23
1.54 2.10 2.71 74.6 5.22 6.46 1.24
1.55 2.15 2.77 74.6 5.30 6.57 1.24
1.56 2.19 2.83 74.6 5.38 6.68 1.24
1.57 2.23 2.88 74.6 5.46 6.79 1.24
1.58 2.27 2.94 74.6 5.54 6.90 1.25
1.59 2.32 3.00 74.6 5.62 7.01 1.25
1.60 2.36 3.06 74.6 5.70 7.13 1.25
1.61 2.40 3.11 74.6 5.78 7.24 1.25
1.62 2.45 3.17 74.6 5.86 7.35 1.25
1.63 2.49 3.23 74.6 5.94 7.46 1.25
1.64 2.53 3.29 74.6 6.02 7.57 1.26
1.65 2.58 3.34 74.6 6.10 7.68 1.26
1.66 2.62 3.40 74.6 6.18 7.79 1.26
1.67 2.66 3.46 74.6 6.26 7.90 1.26
1.68 2.70 3.52 74.6 6.34 8.01 1.26
1.69 2.75 3.57 74.6 6.42 8.13 1.27
1.70 2.79 3.63 74.6 6.50 8.24 1.27
1.71 2.83 3.69 74.6 6.58 8.35 1.27
1.72 2.88 3.75 74.6 6.66 8.46 1.27
1.73 2.92 3.80 74.6 6.74 8.57 1.27
1.74 2.96 3.86 74.6 6.82 8.68 1.27
1.75 3.01 3.92 74.6 6.90 8.79 1.27
1.76 3.05 3.98 74.6 6.98 8.90 1.28
1.77 3.09 4.04 74.6 7.06 9.01 1.28
1.78 3.13 4.09 74.6 7.14 9.13 1.28
1.79 3.18 4.15 74.6 7.22 9.24 1.28
1.80 3.22 4.21 74.6 7.30 9.35 1.28
1.81 3.26 4.27 74.6 7.38 9.46 1.28
1.82 3.31 4.32 74.6 7.46 9.57 1.28
1.83 3.35 4.38 74.6 7.54 9.68 1.28
1.84 3.39 4.44 74.6 7.62 9.79 1.28
1.85 3.44 4.50 74.6 7.70 9.90 1.29
1.86 3.48 4.55 74.6 7.78 10.01 1.29
1.87 3.52 4.61 74.6 7.86 10.13 1.29
1.88 3.56 4.67 74.6 7.94 10.24 1.29
1.89 3.61 4.73 74.6 8.02 10.35 1.29

















1.50 1.87 2.43 74.3 4.91 5.88 1.20
1.51 1.92 2.49 74.3 4.98 5.99 1.20
1.52 1.96 2.54 74.3 5.06 6.11 1.21
1.53 2.00 2.60 74.3 5.14 6.22 1.21
1.54 2.04 2.66 74.3 5.22 6.33 1.21
1.55 2.09 2.72 74.3 5.30 6.44 1.21
1.56 2.13 2.77 74.3 5.38 6.55 1.22
1.57 2.17 2.83 74.3 5.46 6.66 1.22
1.58 2.22 2.89 74.3 5.54 6.77 1.22
1.59 2.26 2.95 74.3 5.62 6.88 1.22
1.60 2.30 3.00 74.3 5.70 6.99 1.23
1.61 2.35 3.06 74.3 5.78 7.11 1.23
1.62 2.39 3.12 74.3 5.86 7.22 1.23
1.63 2.43 3.18 74.3 5.94 7.33 1.23
1.64 2.47 3.23 74.3 6.02 7.44 1.23
1.65 2.52 3.29 74.3 6.10 7.55 1.24
1.66 2.56 3.35 74.3 6.18 7.66 1.24
1.67 2.60 3.41 74.3 6.26 7.77 1.24
1.68 2.65 3.46 74.3 6.34 7.88 1.24
1.69 2.69 3.52 74.3 6.42 7.99 1.24
1.70 2.73 3.58 74.3 6.50 8.11 1.25
1.71 2.78 3.64 74.3 6.58 8.22 1.25
1.72 2.82 3.70 74.3 6.66 8.33 1.25
1.73 2.86 3.75 74.3 6.74 8.44 1.25
1.74 2.90 3.81 74.3 6.82 8.55 1.25
1.75 2.95 3.87 74.3 6.90 8.66 1.25
1.76 2.99 3.93 74.3 6.98 8.77 1.26
1.77 3.03 3.98 74.3 7.06 8.88 1.26
1.78 3.08 4.04 74.3 7.14 8.99 1.26
1.79 3.12 4.10 74.3 7.22 9.10 1.26
1.80 3.16 4.16 74.3 7.30 9.22 1.26
1.81 3.21 4.21 74.3 7.38 9.33 1.26
1.82 3.25 4.27 74.3 7.46 9.44 1.26
1.83 3.29 4.33 74.3 7.54 9.55 1.27
1.84 3.33 4.39 74.3 7.62 9.66 1.27
1.85 3.38 4.44 74.3 7.70 9.77 1.27
1.86 3.42 4.50 74.3 7.78 9.88 1.27
1.87 3.46 4.56 74.3 7.86 9.99 1.27
1.88 3.51 4.62 74.3 7.94 10.10 1.27
1.89 3.55 4.67 74.3 8.02 10.22 1.27

















1.50 1.81 2.38 73.9 4.91 5.75 1.17
1.51 1.86 2.43 73.9 4.98 5.86 1.18
1.52 1.90 2.49 73.9 5.06 5.97 1.18
1.53 1.94 2.55 73.9 5.14 6.08 1.18
1.54 1.99 2.61 73.9 5.22 6.20 1.19
1.55 2.03 2.66 73.9 5.30 6.31 1.19
1.56 2.07 2.72 73.9 5.38 6.42 1.19
1.57 2.12 2.78 73.9 5.46 6.53 1.19
1.58 2.16 2.84 73.9 5.54 6.64 1.20
1.59 2.20 2.89 73.9 5.62 6.75 1.20
1.60 2.24 2.95 73.9 5.70 6.86 1.20
1.61 2.29 3.01 73.9 5.78 6.97 1.21
1.62 2.33 3.07 73.9 5.86 7.08 1.21
1.63 2.37 3.12 73.9 5.94 7.20 1.21
1.64 2.42 3.18 73.9 6.02 7.31 1.21
1.65 2.46 3.24 73.9 6.10 7.42 1.22
1.66 2.50 3.30 73.9 6.18 7.53 1.22
1.67 2.55 3.36 73.9 6.26 7.64 1.22
1.68 2.59 3.41 73.9 6.34 7.75 1.22
1.69 2.63 3.47 73.9 6.42 7.86 1.22
1.70 2.67 3.53 73.9 6.50 7.97 1.23
1.71 2.72 3.59 73.9 6.58 8.08 1.23
1.72 2.76 3.64 73.9 6.66 8.20 1.23
1.73 2.80 3.70 73.9 6.74 8.31 1.23
1.74 2.85 3.76 73.9 6.82 8.42 1.23
1.75 2.89 3.82 73.9 6.90 8.53 1.24
1.76 2.93 3.87 73.9 6.98 8.64 1.24
1.77 2.98 3.93 73.9 7.06 8.75 1.24
1.78 3.02 3.99 73.9 7.14 8.86 1.24
1.79 3.06 4.05 73.9 7.22 8.97 1.24
1.80 3.10 4.10 73.9 7.30 9.08 1.24
1.81 3.15 4.16 73.9 7.38 9.20 1.25
1.82 3.19 4.22 73.9 7.46 9.31 1.25
1.83 3.23 4.28 73.9 7.54 9.42 1.25
1.84 3.28 4.33 73.9 7.62 9.53 1.25
1.85 3.32 4.39 73.9 7.70 9.64 1.25
1.86 3.36 4.45 73.9 7.78 9.75 1.25
1.87 3.41 4.51 73.9 7.86 9.86 1.25
1.88 3.45 4.56 73.9 7.94 9.97 1.26
1.89 3.49 4.62 73.9 8.02 10.08 1.26

















1.50 1.76 2.32 73.5 4.91 5.62 1.15
1.51 1.80 2.38 73.5 4.98 5.73 1.15
1.52 1.84 2.44 73.5 5.06 5.84 1.15
1.53 1.89 2.50 73.5 5.14 5.95 1.16
1.54 1.93 2.55 73.5 5.22 6.06 1.16
1.55 1.97 2.61 73.5 5.30 6.17 1.16
1.56 2.01 2.67 73.5 5.38 6.29 1.17
1.57 2.06 2.73 73.5 5.46 6.40 1.17
1.58 2.10 2.78 73.5 5.54 6.51 1.17
1.59 2.14 2.84 73.5 5.62 6.62 1.18
1.60 2.19 2.90 73.5 5.70 6.73 1.18
1.61 2.23 2.96 73.5 5.78 6.84 1.18
1.62 2.27 3.02 73.5 5.86 6.95 1.19
1.63 2.32 3.07 73.5 5.94 7.06 1.19
1.64 2.36 3.13 73.5 6.02 7.17 1.19
1.65 2.40 3.19 73.5 6.10 7.29 1.19
1.66 2.44 3.25 73.5 6.18 7.40 1.20
1.67 2.49 3.30 73.5 6.26 7.51 1.20
1.68 2.53 3.36 73.5 6.34 7.62 1.20
1.69 2.57 3.42 73.5 6.42 7.73 1.20
1.70 2.62 3.48 73.5 6.50 7.84 1.21
1.71 2.66 3.53 73.5 6.58 7.95 1.21
1.72 2.70 3.59 73.5 6.66 8.06 1.21
1.73 2.75 3.65 73.5 6.74 8.17 1.21
1.74 2.79 3.71 73.5 6.82 8.29 1.21
1.75 2.83 3.76 73.5 6.90 8.40 1.22
1.76 2.87 3.82 73.5 6.98 8.51 1.22
1.77 2.92 3.88 73.5 7.06 8.62 1.22
1.78 2.96 3.94 73.5 7.14 8.73 1.22
1.79 3.00 3.99 73.5 7.22 8.84 1.22
1.80 3.05 4.05 73.5 7.30 8.95 1.23
1.81 3.09 4.11 73.5 7.38 9.06 1.23
1.82 3.13 4.17 73.5 7.46 9.17 1.23
1.83 3.18 4.22 73.5 7.54 9.29 1.23
1.84 3.22 4.28 73.5 7.62 9.40 1.23
1.85 3.26 4.34 73.5 7.70 9.51 1.23
1.86 3.30 4.40 73.5 7.78 9.62 1.24
1.87 3.35 4.46 73.5 7.86 9.73 1.24
1.88 3.39 4.51 73.5 7.94 9.84 1.24
1.89 3.43 4.57 73.5 8.02 9.95 1.24
1.90 3.48 4.63 73.5 8.10 10.06 1.24
549
Age= 78
Height FEVi FVC Ratio TLC DLco Kco
(m) (L) (L) (%) (L) (ml mirr1 mmHg'1) (ml mirr1 mmHg^L'1)
1.50 1.70 2.27 73.2 4.91 5.49 1.12
1.51 1.74 2.33 73.2 4.98 5.60 1.12
1.52 1.78 2.39 73.2 5.06 5.71 1.13
1.53 1.83 2.44 73.2 5.14 5.82 1.13
1.54 1.87 2.50 73.2 5.22 5.93 1.14
1.55 1.91 2.56 73.2 5.30 6.04 1.14
1.56 1.96 2.62 73.2 5.38 6.15 1.14
1.57 2.00 2.68 73.2 5.46 6.26 1.15
1.58 2.04 2.73 73.2 5.54 6.38 1.15
1.59 2.09 2.79 73.2 5.62 6.49 1.15
1.60 2.13 2.85 73.2 5.70 6.60 1.16
1.61 2.17 2.91 73.2 5.78 6.71 1.16
1.62 2.21 2.96 73.2 5.86 6.82 1.16
1.63 2.26 3.02 73.2 5.94 6.93 1.17
1.64 2.30 3.08 73.2 6.02 7.04 1.17
1.65 2.34 3.14 73.2 6.10 7.15 1.17
1.66 2.39 3.19 73.2 6.18 7.26 1.17
1.67 2.43 3.25 73.2 6.26 7.38 1.18
1.68 2.47 3.31 73.2 6.34 7.49 1.18
1.69 2.52 3.37 73.2 6.42 7.60 1.18
1.70 2.56 3.42 73.2 6.50 7.71 1.19
1.71 2.60 3.48 73.2 6.58 7.82 1.19
1.72 2.64 3.54 73.2 6.66 7.93 1.19
1.73 2.69 3.60 73.2 6.74 8.04 1.19
1.74 2.73 3.65 73.2 6.82 8.15 1.20
1.75 2.77 3.71 73.2 6.90 8.26 1.20
1.76 2.82 3.77 73.2 6.98 8.38 1.20
1.77 2.86 3.83 73.2 7.06 8.49 1.20
1.78 2.90 3.88 73.2 7.14 8.60 1.20
1.79 2.95 3.94 73.2 7.22 8.71 1.21
1.80 2.99 4.00 73.2 7.30 8.82 1.21
1.81 3.03 4.06 73.2 7.38 8.93 1.21
1.82 3.07 4.12 73.2 7.46 9.04 1.21
1.83 3.12 4.17 73.2 7.54 9.15 1.21
1.84 3.16 4.23 73.2 7.62 9.26 1.22
1.85 3.20 4.29 73.2 7.70 9.38 1.22
1.86 3.25 4.35 73.2 7.78 9.49 1.22
1.87 3.29 4.40 73.2 7.86 9.60 1.22
1.88 3.33 4.46 73.2 7.94 9.71 1.22
1.89 3.38 4.52 73.2 8.02 9.82 1.22

















1.50 1.64 2.22 72.8 4.91 5.36 1.09
1.51 1.68 2.28 72.8 4.98 5.47 1.10
1.52 1.73 2.34 72.8 5.06 5.58 1.10
1.53 1.77 2.39 72.8 5.14 5.69 1.11
1.54 1.81 2.45 72.8 5.22 5.80 1.11
1.55 1.86 2.51 72.8 5.30 5.91 1.11
1.56 1.90 2.57 72.8 5.38 6.02 1.12
1.57 1.94 2.62 72.8 5.46 6.13 1.12
1.58 1.98 2.68 72.8 5.54 6.24 1.13
1.59 2.03 2.74 72.8 5.62 6.35 1.13
1.60 2.07 2.80 72.8 5.70 6.47 1.13
1.61 2.11 2.85 72.8 5.78 6.58 1.14
1.62 2.16 2.91 72.8 5.86 6.69 1.14
1.63 2.20 2.97 72.8 5.94 6.80 1.14
1.64 2.24 3.03 72.8 6.02 6.91 1.15
1.65 2.29 3.08 72.8 6.10 7.02 1.15
1.66 2.33 3.14 72.8 6.18 7.13 1.15
1.67 2.37 3.20 72.8 6.26 7.24 1.16
1.68 2.41 3.26 72.8 6.34 7.35 1.16
1.69 2.46 3.31 72.8 6.42 7.47 1.16
1.70 2.50 3.37 72.8 6.50 7.58 1.17
1.71 2.54 3.43 72.8 6.58 7.69 1.17
1.72 2.59 3.49 72.8 6.66 7.80 1.17
1.73 2.63 3.54 72.8 6.74 7.91 1.17
1.74 2.67 3.60 72.8 6.82 8.02 1.18
1.75 2.72 3.66 72.8 6.90 8.13 1.18
1.76 2.76 3.72 72.8 6.98 8.24 1.18
1.77 2.80 3.78 72.8 7.06 8.35 1.18
1.78 2.84 3.83 72.8 7.14 8.47 1.19
1.79 2.89 3.89 72.8 7.22 8.58 1.19
1.80 2.93 3.95 72.8 7.30 8.69 1.19
1.81 2.97 4.01 72.8 7.38 8.80 1.19
1.82 3.02 4.06 72.8 7.46 8.91 1.19
1.83 3.06 4.12 72.8 7.54 9.02 1.20
1.84 3.10 4.18 72.8 7.62 9.13 1.20
1.85 3.15 4.24 72.8 7.70 9.24 1.20
1.86 3.19 4.29 72.8 7.78 9.35 1.20
1.87 3.23 4.35 72.8 7.86 9.47 1.20
1.88 3.27 4.41 72.8 7.94 9.58 1.21
1.89 3.32 4.47 72.8 8.02 9.69 1.21




















Figure 15.7.: Predicted FEVi (L -forced expiratory volume in 1 sec) values for 
females aged 50-80 based on the European Community for Coal and Steel and the 
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Figure 15.8.: Predicted FVC (L -forced vital capacity) values for females aged 




Figure 15.9.: Predicted FEVi/VC Ratio (%) values for females aged 50-80 based on 
the European Community for Coal and Steel and the European Respiratory Society 
guidelines.
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Figure 15.10.: Predicted TLC (L - total lung capacity) values for females aged 50-80 
based on the European Community for Coal and Steel and the European 
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Figure 15.11. : Predicted D lCo  (ml min^mmHg1 - diffusing capacity for carbon 
monoxide) values for females aged 50-80 based on the European Community for 
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Figure 15.12.: Predicted K Co (ml min^mmHg^L1 - D Lco corrected for alveolar 
volume) values for females aged 50-80 based on the European Community for 














(ml min 1 mmHg’1)
Kco
(ml min'1 mml
1.50 2.08 2.46 80.5 4.11 7.08 1.72
1.51 2.11 2.50 80.5 4.18 7.16 1.71
1.52 2.15 2.54 80.5 4.24 7.24 1.71
1.53 2.19 2.59 80.5 4.31 7.33 1.70
1.54 2.23 2.63 80.5 4.37 7.41 1.69
1.55 2.27 2.68 80.5 4.44 7.49 1.69
1.56 2.31 2.72 80.5 4.51 7.57 1.68
1.57 2.35 2.77 80.5 4.57 7.65 1.67
1.58 2.39 2.81 80.5 4.64 7.73 1.67
1.59 2.43 2.85 80.5 4.70 7.82 1.66
1.60 2.47 2.90 80.5 4.77 7.90 1.66
1.61 2.51 2.94 80.5 4.84 7.98 1.65
1.62 2.55 2.99 80.5 4.90 8.06 1.64
1.63 2.59 3.03 80.5 4.97 8.14 1.64
1.64 2.63 3.08 80.5 5.03 8.23 1.63
1.65 2.67 3.12 80.5 5.10 8.31 1.63
1.66 2.71 3.16 80.5 5.17 8.39 1.62
1.67 2.75 3.21 80.5 5.23 8.47 1.62
1.68 2.79 3.25 80.5 5.30 8.55 1.61
1.69 2.83 3.30 80.5 5.36 8.63 1.61
1.70 2.87 3.34 80.5 5.43 8.72 1.61
1.71 2.90 3.39 80.5 5.50 8.80 1.60
1.72 2.94 3.43 80.5 5.56 8.88 1.60
1.73 2.98 3.47 80.5 5.63 8.96 1.59
1.74 3.02 3.52 80.5 5.69 9.04 1.59
1.75 3.06 3.56 80.5 5.76 9.13 1.58
1.76 3.10 3.61 80.5 5.83 9.21 1.58
1.77 3.14 3.65 80.5 5.89 9.29 1.58
1.78 3.18 3.70 80.5 5.96 9.37 1.57
1.79 3.22 3.74 80.5 6.02 9.45 1.57
1.80 3.26 3.78 80.5 6.09 9.53 1.57
1.81 3.30 3.83 80.5 6.16 9.62 1.56
1.82 3.34 3.87 80.5 6.22 9.70 1.56
1.83 3.38 3.92 80.5 6.29 9.78 1.56
1.84 3.42 3.96 80.5 6.35 9.86 1.55
1.85 3.46 4.01 80.5 6.42 9.94 1.55
1.86 3.50 4.05 80.5 6.49 10.02 1.55
1.87 3.54 4.09 80.5 6.55 10.11 1.54
1.88 3.58 4.14 80.5 6.62 10.19 1.54
1.89 3.62 4.18 80.5 6.68 10.27 1.54

















1.50 2.03 2.40 80.1 4.11 6.98 1.70
1.51 2.06 2.45 80.1 4.18 7.06 1.69
1.52 2.10 2.49 80.1 4.24 7.15 1.68
1.53 2.14 2.54 80.1 4.31 7.23 1.68
1.54 2.18 2.58 80.1 4.37 7.31 1.67
1.55 2.22 2.62 80.1 4.44 7.39 1.66
1.56 2.26 2.67 80.1 4.51 7.47 1.66
1.57 2.30 2.71 80.1 4.57 7.55 1.65
1.58 2.34 2.76 80.1 4.64 7.64 1.65
1.59 2.38 2.80 80.1 4.70 7.72 1.64
1.60 2.42 2.85 80.1 4.77 7.80 1.64
1.61 2.46 2.89 80.1 4.84 7.88 1.63
1.62 2.50 2.93 80.1 4.90 7.96 1.62
1.63 2.54 2.98 80.1 4.97 8.05 1.62
1.64 2.58 3.02 80.1 5.03 8.13 1.61
1.65 2.62 3.07 80.1 5.10 8.21 1.61
1.66 2.66 3.11 80.1 5.17 8.29 1.60
1.67 2.70 3.16 80.1 5.23 8.37 1.60
1.68 2.74 3.20 80.1 5.30 8.45 1.60
1.69 2.78 3.24 80.1 5.36 8.54 1.59
1.70 2.82 3.29 80.1 5.43 8.62 1.59
1.71 2.85 3.33 80.1 5.50 8.70 1.58
1.72 2.89 3.38 80.1 5.56 8.78 1.58
1.73 2.93 3.42 80.1 5.63 8.86 1.57
1.74 2.97 3.47 80.1 5.69 8.95 1.57
1.75 3.01 3.51 80.1 5.76 9.03 1.57
1.76 3.05 3.55 80.1 5.83 9.11 1.56
1.77 3.09 3.60 80.1 5.89 9.19 1.56
1.78 3.13 3.64 80.1 5.96 9.27 1.56
1.79 3.17 3.69 80.1 6.02 9.35 1.55
1.80 3.21 3.73 80.1 6.09 9.44 1.55
1.81 3.25 3.78 80.1 6.16 9.52 1.55
1.82 3.29 3.82 80.1 6.22 9.60 1.54
1.83 3.33 3.86 80.1 6.29 9.68 1.54
1.84 3.37 3.91 80.1 6.35 9.76 1.54
1.85 3.41 3.95 80.1 6.42 9.85 1.53
1.86 3.45 4.00 80.1 6.49 9.93 1.53
1.87 3.49 4.04 80.1 6.55 10.01 1.53
1.88 3.53 4.09 80.1 6.62 10.09 1.52
1.89 3.57 4.13 80.1 6.68 10.17 1.52














(ml min 1 mmHg'1)
Kco
(ml mln'1 mm
1.50 1.98 2.35 79.7 4.11 6.88 1.67
1.51 2.01 2.40 79.7 4.18 6.97 1.67
1.52 2.05 2.44 79.7 4.24 7.05 1.66
1.53 2.09 2.48 79.7 4.31 7.13 1.65
1.54 2.13 2.53 79.7 4.37 7.21 1.65
1.55 2.17 2.57 79.7 4.44 7.29 1.64
1.56 2.21 2.62 79.7 4.51 7.37 1.64
1.57 2.25 2.66 79.7 4.57 7.46 1.63
1.58 2.29 2.71 79.7 4.64 7.54 1.63
1.59 2.33 2.75 79.7 4.70 7.62 1.62
1.60 2.37 2.79 79.7 4.77 7.70 1.61
1.61 2.41 2.84 79.7 4.84 7.78 1.61
1.62 2.45 2.88 79.7 4.90 7.87 1.60
1.63 2.49 2.93 79.7 4.97 7.95 1.60
1.64 2.53 2.97 79.7 5.03 8.03 1.59
1.65 2.57 3.02 79.7 5.10 8.11 1.59
1.66 2.61 3.06 79.7 5.17 8.19 1.59
1.67 2.65 3.10 79.7 5.23 8.27 1.58
1.68 2.69 3.15 79.7 5.30 8.36 1.58
1.69 2.73 3.19 79.7 5.36 8.44 1.57
1.70 2.77 3.24 79.7 5.43 8.52 1.57
1.71 2.80 3.28 79.7 5.50 8.60 1.57
1.72 2.84 3.33 79.7 5.56 8.68 1.56
1.73 2.88 3.37 79.7 5.63 8.77 1.56
1.74 2.92 3.41 79.7 5.69 8.85 1.55
1.75 2.96 3.46 79.7 5.76 8.93 1.55
1.76 3.00 3.50 79.7 5.83 9.01 1.55
1.77 3.04 3.55 79.7 5.89 9.09 1.54
1.78 3.08 3.59 79.7 5.96 9.17 1.54
1.79 3.12 3.64 79.7 6.02 9.26 1.54
1.80 3.16 3.68 79.7 6.09 9.34 1.53
1.81 3.20 3.72 79.7 6.16 9.42 1.53
1.82 3.24 3.77 79.7 6.22 9.50 1.53
1.83 3.28 3.81 79.7 6.29 9.58 1.52
1.84 3.32 3.86 79.7 6.35 9.67 1.52
1.85 3.36 3.90 79.7 6.42 9.75 1.52
1.86 3.40 3.95 79.7 6.49 9.83 1.52
1.87 3.44 3.99 79.7 6.55 9.91 1.51
1.88 3.48 4.03 79.7 6.62 9.99 1.51
1.89 3.52 4.08 79.7 6.68 10.07 1.51
















(ml min 1 mm
1.50 1.93 2.30 79.3 4.11 6.79 1.65
1.51 1.96 2.34 79.3 4.18 6.87 1.64
1.52 2.00 2.39 79.3 4.24 6.95 1.64
1.53 2.04 2.43 79.3 4.31 7.03 1.63
1.54 2.08 2.48 79.3 4.37 7.11 1.63
1.55 2.12 2.52 79.3 4.44 7.20 1.62
1.56 2.16 2.56 79.3 4.51 7.28 1.61
1.57 2.20 2.61 79.3 4.57 7.36 1.61
1.58 2.24 2.65 79.3 4.64 7.44 1.60
1.59 2.28 2.70 79.3 4.70 7.52 1.60
1.60 2.32 2.74 79.3 4.77 7.60 1.59
1.61 2.36 2.79 79.3 4.84 7.69 1.59
1.62 2.40 2.83 79.3 4.90 7.77 1.58
1.63 2.44 2.87 79.3 4.97 7.85 1.58
1.64 2.48 2.92 79.3 5.03 7.93 1.58
1.65 2.52 2.96 79.3 5.10 8.01 1.57
1.66 2.56 3.01 79.3 5.17 8.09 1.57
1.67 2.60 3.05 79.3 5.23 8.18 1.56
1.68 2.64 3.10 79.3 5.30 8.26 1.56
1.69 2.68 3.14 79.3 5.36 8.34 1.55
1.70 2.72 3.19 79.3 5.43 8.42 1.55
1.71 2.75 3.23 79.3 5.50 8.50 1.55
1.72 2.79 3.27 79.3 5.56 8.59 1.54
1.73 2.83 3.32 79.3 5.63 8.67 1.54
1.74 2.87 3.36 79.3 5.69 8.75 1.54
1.75 2.91 3.41 79.3 5.76 8.83 1.53
1.76 2.95 3.45 79.3 5.83 8.91 1.53
1.77 2.99 3.50 79.3 5.89 8.99 1.53
1.78 3.03 3.54 79.3 5.96 9.08 1.52
1.79 3.07 3.58 79.3 6.02 9.16 1.52
1.80 3.11 3.63 79.3 6.09 9.24 1.52
1.81 3.15 3.67 79.3 6.16 9.32 1.51
1.82 3.19 3.72 79.3 6.22 9.40 1.51
1.83 3.23 3.76 79.3 6.29 9.49 1.51
1.84 3.27 3.81 79.3 6.35 9.57 1.51
1.85 3.31 3.85 79.3 6.42 9.65 1.50
1.86 3.35 3.89 79.3 6.49 9.73 1.50
1.87 3.39 3.94 79.3 6.55 9.81 1.50
1.88 3.43 3.98 79.3 6.62 9.89 1.50
1.89 3.47 4.03 79.3 6.68 9.98 1.49

















1.50 1.88 2.25 78.9 4.11 6.69 1.63
1.51 1.91 2.29 78.9 4.18 6.77 1.62
1.52 1.95 2.34 78.9 4.24 6.85 1.62
1.53 1.99 2.38 78.9 4.31 6.93 1.61
1.54 2.03 2.42 78.9 4.37 7.02 1.60
1.55 2.07 2.47 78.9 4.44 7.10 1.60
1.56 2.11 2.51 78.9 4.51 7.18 1.59
1.57 2.15 2.56 78.9 4.57 7.26 1.59
1.58 2.19 2.60 78.9 4.64 7.34 1.58
1.59 2.23 2.65 78.9 4.70 7.42 1.58
1.60 2.27 2.69 78.9 4.77 7.51 1.57
1.61 2.31 2.73 78.9 4.84 7.59 1.57
1.62 2.35 2.78 78.9 4.90 7.67 1.56
1.63 2.39 2.82 78.9 4.97 7.75 1.56
1.64 2.43 2.87 78.9 5.03 7.83 1.56
1.65 2.47 2.91 78.9 5.10 7.92 1.55
1.66 2.51 2.96 78.9 5.17 8.00 1.55
1.67 2.55 3.00 78.9 5.23 8.08 1.54
1.68 2.59 3.04 78.9 5.30 8.16 1.54
1.69 2.63 3.09 78.9 5.36 8.24 1.54
1.70 2.67 3.13 78.9 5.43 8.32 1.53
1.71 2.70 3.18 78.9 5.50 8.41 1.53
1.72 2.74 3.22 78.9 5.56 8.49 1.53
1.73 2.78 3.27 78.9 5.63 8.57 1.52
1.74 2.82 3.31 78.9 5.69 8.65 1.52
1.75 2.86 3.35 78.9 5.76 8.73 1.52
1.76 2.90 3.40 78.9 5.83 8.81 1.51
1.77 2.94 3.44 78.9 5.89 8.90 1.51
1.78 2.98 3.49 78.9 5.96 8.98 1.51
1.79 3.02 3.53 78.9 6.02 9.06 1.50
1.80 3.06 3.58 78.9 6.09 9.14 1.50
1.81 3.10 3.62 78.9 6.16 9.22 1.50
1.82 3.14 3.66 78.9 6.22 9.31 1.50
1.83 3.18 3.71 78.9 6.29 9.39 1.49
1.84 3.22 3.75 78.9 6.35 9.47 1.49
1.85 3.26 3.80 78.9 6.42 9.55 1.49
1.86 3.30 3.84 78.9 6.49 9.63 1.49
1.87 3.34 3.89 78.9 6.55 9.71 1.48
1.88 3.38 3.93 78.9 6.62 9.80 1.48
1.89 3.42 3.97 78.9 6.68 9.88 1.48

















1.50 1.83 2.20 78.6 4.11 6.59 1.60
1.51 1.86 2.24 78.6 4.18 6.67 1.60
1.52 1.90 2.28 78.6 4.24 6.75 1.59
1.53 1.94 2.33 78.6 4.31 6.84 1.59
1.54 1.98 2.37 78.6 4.37 6.92 1.58
1.55 2.02 2.42 78.6 4.44 7.00 1.58
1.56 2.06 2.46 78.6 4.51 7.08 1.57
1.57 2.10 2.51 78.6 4.57 7.16 1.57
1.58 2.14 2.55 78.6 4.64 7.24 1.56
1.59 2.18 2.59 78.6 4.70 7.33 1.56
1.60 2.22 2.64 78.6 4.77 7.41 1.55
1.61 2.26 2.68 78.6 4.84 7.49 1.55
1.62 2.30 2.73 78.6 4.90 7.57 1.54
1.63 2.34 2.77 78.6 4.97 7.65 1.54
1.64 2.38 2.82 78.6 5.03 7.74 1.54
1.65 2.42 2.86 78.6 5.10 7.82 1.53
1.66 2.46 2.90 78.6 5.17 7.90 1.53
1.67 2.50 2.95 78.6 5.23 7.98 1.53
1.68 2.54 2.99 78.6 5.30 8.06 1.52
1.69 2.58 3.04 78.6 5.36 8.14 1.52
1.70 2.62 3.08 78.6 5.43 8.23 1.51
1.71 2.65 3.13 78.6 5.50 8.31 1.51
1.72 2.69 3.17 78.6 5.56 8.39 1.51
1.73 2.73 3.21 78.6 5.63 8.47 1.51
1.74 2.77 3.26 78.6 5.69 8.55 1.50
1.75 2.81 3.30 78.6 5.76 8.64 1.50
1.76 2.85 3.35 78.6 5.83 8.72 1.50
1.77 2.89 3.39 78.6 5.89 8.80 1.49
1.78 2.93 3.44 78.6 5.96 8.88 1.49
1.79 2.97 3.48 78.6 6.02 8.96 1.49
1.80 3.01 3.52 78.6 6.09 9.04 1.49
1.81 3.05 3.57 78.6 6.16 9.13 1.48
1.82 3.09 3.61 78.6 6.22 9.21 1.48
1.83 3.13 3.66 78.6 6.29 9.29 1.48
1.84 3.17 3.70 78.6 6.35 9.37 1.47
1.85 3.21 3.75 78.6 6.42 9.45 1.47
1.86 3.25 3.79 78.6 6.49 9.53 1.47
1.87 3.29 3.83 78.6 6.55 9.62 1.47
1.88 3.33 3.88 78.6 6.62 9.70 1.47
1.89 3.37 3.92 78.6 6.68 9.78 1.46
1.90 3.41 3.97 78.6 6.75 9.86 1.46
563
Age= 62
Height FEVi FVC Ratio TLC DLco Kco
(m) (L) (L) (%) (1) (ml mirr1 mmHg'1) (ml mirr1 mm
1.50 1.78 2.14 78.2 4.11 6.49 1.58
1.51 1.81 2.19 78.2 4.18 6.57 1.57
1.52 1.85 2.23 78.2 4.24 6.66 1.57
1.53 1.89 2.28 78.2 4.31 6.74 1.56
1.54 1.93 2.32 78.2 4.37 6.82 1.56
1.55 1.97 2.36 78.2 4.44 6.90 1.55
1.56 2.01 2.41 78.2 4.51 6.98 1.55
1.57 2.05 2.45 78.2 4.57 7.06 1.55
1.58 2.09 2.50 78.2 4.64 7.15 1.54
1.59 2.13 2.54 78.2 4.70 7.23 1.54
1.60 2.17 2.59 78.2 4.77 7.31 1.53
1.61 2.21 2.63 78.2 4.84 7.39 1.53
1.62 2.25 2.67 78.2 4.90 7.47 1.52
1.63 2.29 2.72 78.2 4.97 7.56 1.52
1.64 2.33 2.76 78.2 5.03 7.64 1.52
1.65 2.37 2.81 78.2 5.10 7.72 1.51
1.66 2.41 2.85 78.2 5.17 7.80 1.51
1.67 2.45 2.90 78.2 5.23 7.88 1.51
1.68 2.49 2.94 78.2 5.30 7.96 1.50
1.69 2.53 2.98 78.2 5.36 8.05 1.50
1.70 2.57 3.03 78.2 5.43 8.13 1.50
1.71 2.60 3.07 78.2 5.50 8.21 1.49
1.72 2.64 3.12 78.2 5.56 8.29 1.49
1.73 2.68 3.16 78.2 5.63 8.37 1.49
1.74 2.72 3.21 78.2 5.69 8.46 1.48
1.75 2.76 3.25 78.2 5.76 8.54 1.48
1.76 2.80 3.29 78.2 5.83 8.62 1.48
1.77 2.84 3.34 78.2 5.89 8.70 1.48
1.78 2.88 3.38 78.2 5.96 8.78 1.47
1.79 2.92 3.43 78.2 6.02 8.86 1.47
1.80 2.96 3.47 78.2 6.09 8.95 1.47
1.81 3.00 3.52 78.2 6.16 9.03 1.47
1.82 3.04 3.56 78.2 6.22 9.11 1.46
1.83 3.08 3.60 78.2 6.29 9.19 1.46
1.84 3.12 3.65 78.2 6.35 9.27 1.46
1.85 3.16 3.69 78.2 6.42 9.36 1.46
1.86 3.20 3.74 78.2 6.49 9.44 1.45
1.87 3.24 3.78 78.2 6.55 9.52 1.45
1.88 3.28 3.83 78.2 6.62 9.60 1.45
1.89 3.32 3.87 78.2 6.68 9.68 1.45
1.90 3.36 3.92 78.2 6.75 9.76 1.45
564
Age- 64
Height FEVi FVC Ratio TLC DLco Kco
(m) (L ) ( L )  [ % )  (L ) (ml min '1 m m Hg"1) (ml m in 1 m m H g^L'1)
1.50 1.73 2.09 77.8 4.11 6.39 1.56
1.51 1.76 2.14 77.8 4.18 6.48 1.55
1.52 1.80 2.18 77.8 4.24 6.56 1.55
1.53 1.84 2.22 77.8 4.31 6.64 1.54
1.54 1.88 2.27 77.8 4.37 6.72 1.54
1.55 1.92 2.31 77.8 4.44 6.80 1.53
1.56 1.96 2.36 77.8 4.51 6.88 1.53
1.57 2.00 2.40 77.8 4.57 6.97 1.52
1.58 2.04 2.45 77.8 4.64 7.05 1.52
1.59 2.08 2.49 77.8 4.70 7.13 1.52
1.60 2.12 2.53 77.8 4.77 7.21 1.51
1.61 2.16 2.58 77.8 4.84 7.29 1.51
1.62 2.20 2.62 77.8 4.90 7.38 1.50
1.63 2.24 2.67 77.8 4.97 7.46 1.50
1.64 2.28 2.71 77.8 5.03 7.54 1.50
1.65 2.32 2.76 77.8 5.10 7.62 1.49
1.66 2.36 2.80 77.8 5.17 7.70 1.49
1.67 2.40 2.84 77.8 5.23 7.78 1.49
1.68 2.44 2.89 77.8 5.30 7.87 1.48
1.69 2.48 2.93 77.8 5.36 7.95 1.48
1.70 2.52 2.98 77.8 5.43 8.03 1.48
1.71 2.55 3.02 77.8 5.50 8.11 1.48
1.72 2.59 3.07 77.8 5.56 8.19 1.47
1.73 2.63 3.11 77.8 5.63 8.28 1.47
1.74 2.67 3.15 77.8 5.69 8.36 1.47
1.75 2.71 3.20 77.8 5.76 8.44 1.47
1.76 2.75 3.24 77.8 5.83 8.52 1.46
1.77 2.79 3.29 77.8 5.89 8.60 1.46
1.78 2.83 3.33 77.8 5.96 8.68 1.46
1.79 2.87 3.38 77.8 6.02 8.77 1.46
1.80 2.91 3.42 77.8 6.09 8.85 1.45
1.81 2.95 3.46 77.8 6.16 8.93 1.45
1.82 2.99 3.51 77.8 6.22 9.01 1.45
1.83 3.03 3.55 77.8 6.29 9.09 1.45
1.84 3.07 3.60 77.8 6.35 9.18 1.44
1.85 3.11 3.64 77.8 6.42 9.26 1.44
1.86 3.15 3.69 77.8 6.49 9.34 1.44
1.87 3.19 3.73 77.8 6.55 9.42 1.44
1.88 3.23 3.77 77.8 6.62 9.50 1.44
1.89 3.27 3.82 77.8 6.68 9.58 1.43
1.90 3.31 3.86 77.8 6.75 9.67 1.43
565
Age= 66
Height FEVi FVC Ratio TLC DLco Kco
(m) (J.)________ (L)________ (%)________ (L) (ml min '1 mmHg-1) (ml miry1 m m Hg-1 L 1)
1.50 1.68 2.04 77.4 4.11 6.30 1.53
1.51 1.71 2.08 77.4 4.18 6.38 1.53
1.52 1.75 2.13 77.4 4.24 6.46 1.52
1.53 1.79 2.17 77.4 4.31 6.54 1.52
1.54 1.83 2.22 77.4 4.37 6.62 1.51
1.55 1.87 2.26 77.4 4.44 6.71 1.51
1.56 1.91 2.30 77.4 4.51 6.79 1.51
1.57 1.95 2.35 77.4 4.57 6.87 1.50
1.58 1.99 2.39 77.4 4.64 6.95 1.50
1.59 2.03 2.44 77.4 4.70 7.03 1.49
1.60 2.07 2.48 77.4 4.77 7.11 1.49
1.61 2.11 2.53 77.4 4.84 7.20 1.49
1.62 2.15 2.57 77.4 4.90 7.28 1.48
1.63 2.19 2.61 77.4 4.97 7.36 1.48
1.64 2.23 2.66 77.4 5.03 7.44 1.48
1.65 2.27 2.70 77.4 5.10 7.52 1.48
1.66 2.31 2.75 77.4 5.17 7.60 1.47
1.67 2.35 2.79 77.4 5.23 7.69 1.47
1.68 2.39 2.84 77.4 5.30 7.77 1.47
1.69 2.43 2.88 77.4 5.36 7.85 1.46
1.70 2.47 2.93 77.4 5.43 7.93 1.46
1.71 2.50 2.97 77.4 5.50 8.01 1.46
1.72 2.54 3.01 77.4 5.56 8.10 1.46
1.73 2.58 3.06 77.4 5.63 8.18 1.45
1.74 2.62 3.10 77.4 5.69 8.26 1.45
1.75 2.66 3.15 77.4 5.76 8.34 1.45
1.76 2.70 3.19 77.4 5.83 8.42 1.45
1.77 2.74 3.24 77.4 5.89 8.50 1.44
1.78 2.78 3.28 77.4 5.96 8.59 1.44
1.79 2.82 3.32 77.4 6.02 8.67 1.44
1.80 2.86 3.37 77.4 6.09 8.75 1.44
1.81 2.90 3.41 77.4 6.16 8.83 1.43
1.82 2.94 3.46 77.4 6.22 8.91 1.43
1.83 2.98 3.50 77.4 6.29 9.00 1.43
1.84 3.02 3.55 77.4 6.35 9.08 1.43
1.85 3.06 3.59 77.4 6.42 9.16 1.43
1.86 3.10 3.63 77.4 6.49 9.24 1.42
1.87 3.14 3.68 77.4 6.55 9.32 1.42
1.88 3.18 3.72 77.4 6.62 9.40 1.42
1.89 3.22 3.77 77.4 6.68 9.49 1.42

















1.50 1.63 1.99 77.0 4.11 6.20 1.51
1.51 1.66 2.03 77.0 4.18 6.28 1.50
1.52 1.70 2.08 77.0 4.24 6.36 1.50
1.53 1.74 2.12 77.0 4.31 6.44 1.50
1.54 1.78 2.16 77.0 4.37 6.53 1.49
1.55 1.82 2.21 77.0 4.44 6.61 1.49
1.56 1.86 2.25 77.0 4.51 6.69 1.48
1.57 1.90 2.30 77.0 4.57 6.77 1.48
1.58 1.94 2.34 77.0 4.64 6.85 1.48
1.59 1.98 2.39 77.0 4.70 6.93 1.47
1.60 2.02 2.43 77.0 4.77 7.02 1.47
1.61 2.06 2.47 77.0 4.84 7.10 1.47
1.62 2.10 2.52 77.0 4.90 7.18 1.46
1.63 2.14 2.56 77.0 4.97 7.26 1.46
1.64 2.18 2.61 77.0 5.03 7.34 1.46
1.65 2.22 2.65 77.0 5.10 7.43 1.46
1.66 2.26 2.70 77.0 5.17 7.51 1.45
1.67 2.30 2.74 77.0 5.23 7.59 1.45
1.68 2.34 2.78 77.0 5.30 7.67 1.45
1.69 2.38 2.83 77.0 5.36 7.75 1.45
1.70 2.42 2.87 77.0 5.43 7.83 1.44
1.71 2.45 2.92 77.0 5.50 7.92 1.44
1.72 2.49 2.96 77.0 5.56 8.00 1.44
1.73 2.53 3.01 77.0 5.63 8.08 1.44
1.74 2.57 3.05 77.0 5.69 8.16 1.43
1.75 2.61 3.09 77.0 5.76 8.24 1.43
1.76 2.65 3.14 77.0 5.83 8.32 1.43
1.77 2.69 3.18 77.0 5.89 8.41 1.43
1.78 2.73 3.23 77.0 5.96 8.49 1.42
1.79 2.77 3.27 77.0 6.02 8.57 1.42
1.80 2.81 3.32 77.0 6.09 8.65 1.42
1.81 2.85 3.36 77.0 6.16 8.73 1.42
1.82 2.89 3.40 77.0 6.22 8.82 1.42
1.83 2.93 3.45 77.0 6.29 8.90 1.41
1.84 2.97 3.49 77.0 6.35 8.98 1.41
1.85 3.01 3.54 77.0 6.42 9.06 1.41
1.86 3.05 3.58 77.0 6.49 9.14 1.41
1.87 3.09 3.63 77.0 6.55 9.22 1.41
1.88 3.13 3.67 77.0 6.62 9.31 1.41
1.89 3.17 3.71 77.0 6.68 9.39 1.40

















1.50 1.58 1.94 76.7 4.11 6.10 1.48
1.51 1.61 1.98 76.7 4.18 6.18 1.48
1.52 1.65 2.02 76.7 4.24 6.26 1.48
1.53 1.69 2.07 76.7 4.31 6.35 1.47
1.54 1.73 2.11 76.7 4.37 6.43 1.47
1.55 1.77 2.16 76.7 4.44 6.51 1.47
1.56 1.81 2.20 76.7 4.51 6.59 1.46
1.57 1.85 2.25 76.7 4.57 6.67 1.46
1.58 1.89 2.29 76.7 4.64 6.75 1.46
1.59 1.93 2.33 76.7 4.70 6.84 1.45
1.60 1.97 2.38 76.7 4.77 6.92 1.45
1.61 2.01 2.42 76.7 4.84 7.00 1.45
1.62 2.05 2.47 76.7 4.90 7.08 1.44
1.63 2.09 2.51 76.7 4.97 7.16 1.44
1.64 2.13 2.56 76.7 5.03 7.25 1.44
1.65 2.17 2.60 76.7 5.10 7.33 1.44
1.66 2.21 2.64 76.7 5.17 7.41 1.43
1.67 2.25 2.69 76.7 5.23 7.49 1.43
1.68 2.29 2.73 76.7 5.30 7.57 1.43
1.69 2.33 2.78 76.7 5.36 7.65 1.43
1.70 2.37 2.82 76.7 5.43 7.74 1.42
1.71 2.40 2.87 76.7 5.50 7.82 1.42
1.72 2.44 2.91 76.7 5.56 7.90 1.42
1.73 2.48 2.95 76.7 5.63 7.98 1.42
1.74 2.52 3.00 76.7 5.69 8.06 1.42
1.75 2.56 3.04 76.7 5.76 8.15 1.41
1.76 2.60 3.09 76.7 5.83 8.23 1.41
1.77 2.64 3.13 76.7 5.89 8.31 1.41
1.78 2.68 3.18 76.7 5.96 8.39 1.41
1.79 2.72 3.22 76.7 6.02 8.47 1.41
1.80 2.76 3.26 76.7 6.09 8.55 1.40
1.81 2.80 3.31 76.7 6.16 8.64 1.40
1.82 2.84 3.35 76.7 6.22 8.72 1.40
1.83 2.88 3.40 76.7 6.29 8.80 1.40
1.84 2.92 3.44 76.7 6.35 8.88 1.40
1.85 2.96 3.49 76.7 6.42 8.96 1.40
1.86 3.00 3.53 76.7 6.49 9.04 1.39
1.87 3.04 3.57 76.7 6.55 9.13 1.39
1.88 3.08 3.62 76.7 6.62 9.21 1.39
1.89 3.12 3.66 76.7 6.68 9.29 1.39
1.90 3.16 3.71 76.7 6.75 9.37 1.39
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Age= 72
Height FEVi FVC Ratio TLC DLco Kco
(m) (L) [L) (%) (L) (ml min'1 mmHg"1) (ml mirr1 mmHg'1!/1)
1.50 1.53 1.88 76.3 4.11 6.00 1.46
1.51 1.56 1.93 76.3 4.18 6.08 1.46
1.52 1.60 1.97 76.3 4.24 6.17 1.45
1.53 1.64 2.02 76.3 4.31 6.25 1.45
1.54 1.68 2.06 76.3 4.37 6.33 1.45
1.55 1.72 2.10 76.3 4.44 6.41 1.44
1.56 1.76 2.15 76.3 4.51 6.49 1.44
1.57 1.80 2.19 76.3 4.57 6.57 1.44
1.58 1.84 2.24 76.3 4.64 6.66 1.44
1.59 1.88 2.28 76.3 4.70 6.74 1.43
1.60 1.92 2.33 76.3 4.77 6.82 1.43
1.61 1.96 2.37 76.3 4.84 6.90 1.43
1.62 2.00 2.41 76.3 4.90 6.98 1.42
1.63 2.04 2.46 76.3 4.97 7.07 1.42
1.64 2.08 2.50 76.3 5.03 7.15 1.42
1.65 2.12 2.55 76.3 5.10 7.23 1.42
1.66 2.16 2.59 76.3 5.17 7.31 1.42
1.67 2.20 2.64 76.3 5.23 7.39 1.41
1.68 2.24 2.68 76.3 5.30 7.47 1.41
1.69 2.28 2.72 76.3 5.36 7.56 1.41
1.70 2.32 2.77 76.3 5.43 7.64 1.41
1.71 2.35 2.81 76.3 5.50 7.72 1.40
1.72 2.39 2.86 76.3 5.56 7.80 1.40
1.73 2.43 2.90 76.3 5.63 7.88 1.40
1.74 2.47 2.95 76.3 5.69 7.97 1.40
1.75 2.51 2.99 76.3 5.76 8.05 1.40
1.76 2.55 3.03 76.3 5.83 8.13 1.40
1.77 2.59 3.08 76.3 5.89 8.21 1.39
1.78 2.63 3.12 76.3 5.96 8.29 1.39
1.79 2.67 3.17 76.3 6.02 8.37 1.39
1.80 2.71 3.21 76.3 6.09 8.46 1.39
1.81 2.75 3.26 76.3 6.16 8.54 1.39
1.82 2.79 3.30 76.3 6.22 8.62 1.39
1.83 2.83 3.34 76.3 6.29 8.70 1.38
1.84 2.87 3.39 76.3 6.35 8.78 1.38
1.85 2.91 3.43 76.3 6.42 8.87 1.38
1.86 2.95 3.48 76.3 6.49 8.95 1.38
1.87 2.99 3.52 76.3 6.55 9.03 1.38
1.88 3.03 3.57 76.3 6.62 9.11 1.38
1.89 3.07 3.61 76.3 6.68 9.19 1.38














(ml min 1 mmHg'1)
Kco
(ml min1 mm
1.50 1.48 1.83 75.9 4.11 5.90 1.44
1.51 1.51 1.88 75.9 4.18 5.99 1.43
1.52 1.55 1.92 75.9 4.24 6.07 1.43
1.53 1.59 1.96 75.9 4.31 6.15 1.43
1.54 1.63 2.01 75.9 4.37 6.23 1.42
1.55 1.67 2.05 75.9 4.44 6.31 1.42
1.56 1.71 2.10 75.9 4.51 6.39 1.42
1.57 1.75 2.14 75.9 4.57 6.48 1.42
1.58 1.79 2.19 75.9 4.64 6.56 1.41
1.59 1.83 2.23 75.9 4.70 6.64 1.41
1.60 1.87 2.27 75.9 4.77 6.72 1.41
1.61 1.91 2.32 75.9 4.84 6.80 1.41
1.62 1.95 2.36 75.9 4.90 6.89 1.40
1.63 1.99 2.41 75.9 4.97 6.97 1.40
1.64 2.03 2.45 75.9 5.03 7.05 1.40
1.65 2.07 2.50 75.9 5.10 7.13 1.40
1.66 2.11 2.54 75.9 5.17 7.21 1.40
1.67 2.15 2.58 75.9 5.23 7.29 1.39
1.68 2.19 2.63 75.9 5.30 7.38 1.39
1.69 2.23 2.67 75.9 5.36 7.46 1.39
1.70 2.27 2.72 75.9 5.43 7.54 1.39
1.71 2.30 2.76 75.9 5.50 7.62 1.39
1.72 2.34 2.81 75.9 5.56 7.70 1.39
1.73 2.38 2.85 75.9 5.63 7.79 1.38
1.74 2.42 2.89 75.9 5.69 7.87 1.38
1.75 2.46 2.94 75.9 5.76 7.95 1.38
1.76 2.50 2.98 75.9 5.83 8.03 1.38
1.77 2.54 3.03 75.9 5.89 8.11 1.38
1.78 2.58 3.07 75.9 5.96 8.19 1.38
1.79 2.62 3.12 75.9 6.02 8.28 1.37
1.80 2.66 3.16 75.9 6.09 8.36 1.37
1.81 2.70 3.20 75.9 6.16 8.44 1.37
1.82 2.74 3.25 75.9 6.22 8.52 1.37
1.83 2.78 3.29 75.9 6.29 8.60 1.37
1.84 2.82 3.34 75.9 6.35 8.69 1.37
1.85 2.86 3.38 75.9 6.42 8.77 1.37
1.86 2.90 3.43 75.9 6.49 8.85 1.36
1.87 2.94 3.47 75.9 6.55 8.93 1.36
1.88 2.98 3.51 75.9 6.62 9.01 1.36
1.89 3.02 3.56 75.9 6.68 9.09 1.36

















1.50 1.43 1.78 75.5 4.11 5.81 1.41
1.51 1.46 1.82 75.5 4.18 5.89 1.41
1.52 1.50 1.87 75.5 4.24 5.97 1.41
1.53 1.54 1.91 75.5 4.31 6.05 1.40
1.54 1.58 1.96 75.5 4.37 6.13 1.40
1.55 1.62 2.00 75.5 4.44 6.22 1.40
1.56 1.66 2.04 75.5 4.51 6.30 1.40
1.57 1.70 2.09 75.5 4.57 6.38 1.40
1.58 1.74 2.13 75.5 4.64 6.46 1.39
1.59 1.78 2.18 75.5 4.70 6.54 1.39
1.60 1.82 2.22 75.5 4.77 6.62 1.39
1.61 1.86 2.27 75.5 4.84 6.71 1.39
1.62 1.90 2.31 75.5 4.90 6.79 1.38
1.63 1.94 2.35 75.5 4.97 6.87 1.38
1.64 1.98 2.40 75.5 5.03 6.95 1.38
1.65 2.02 2.44 75.5 5.10 7.03 1.38
1.66 2.06 2.49 75.5 5.17 7.11 1.38
1.67 2.10 2.53 75.5 5.23 7.20 1.38
1.68 2.14 2.58 75.5 5.30 7.28 1.37
1.69 2.18 2.62 75.5 5.36 7.36 1.37
1.70 2.22 2.67 75.5 5.43 7.44 1.37
1.71 2.25 2.71 75.5 5.50 7.52 1.37
1.72 2.29 2.75 75.5 5.56 7.61 1.37
1.73 2.33 2.80 75.5 5.63 7.69 1.37
1.74 2.37 2.84 75.5 5.69 7.77 1.36
1.75 2.41 2.89 75.5 5.76 7.85 1.36
1.76 2.45 2.93 75.5 5.83 7.93 1.36
1.77 2.49 2.98 75.5 5.89 8.01 1.36
1.78 2.53 3.02 75.5 5.96 8.10 1.36
1.79 2.57 3.06 75.5 6.02 8.18 1.36
1.80 2.61 3.11 75.5 6.09 8.26 1.36
1.81 2.65 3.15 75.5 6.16 8.34 1.36
1.82 2.69 3.20 75.5 6.22 8.42 1.35
1.83 2.73 3.24 75.5 6.29 8.51 1.35
1.84 2.77 3.29 75.5 6.35 8.59 1.35
1.85 2.81 3.33 75.5 6.42 8.67 1.35
1.86 2.85 3.37 75.5 6.49 8.75 1.35
1.87 2.89 3.42 75.5 6.55 8.83 1.35
1.88 2.93 3.46 75.5 6.62 8.91 1.35
1.89 2.97 3.51 75.5 6.68 9.00 1.35

















1.50 1.38 1.73 75.1 4.11 5.71 1.39
1.51 1.41 1.77 75.1 4.18 5.79 1.39
1.52 1.45 1.82 75.1 4.24 5.87 1.38
1.53 1.49 1.86 75.1 4.31 5.95 1.38
1.54 1.53 1.90 75.1 4.37 6.04 1.38
1.55 1.57 1.95 75.1 4.44 6.12 1.38
1.56 1.61 1.99 75.1 4.51 6.20 1.38
1.57 1.65 2.04 75.1 4.57 6.28 1.37
1.58 1.69 2.08 75.1 4.64 6.36 1.37
1.59 1.73 2.13 75.1 4.70 6.44 1.37
1.60 1.77 2.17 75.1 4.77 6.53 1.37
1.61 1.81 2.21 75.1 4.84 6.61 1.37
1.62 1.85 2.26 75.1 4.90 6.69 1.36
1.63 1.89 2.30 75.1 4.97 6.77 1.36
1.64 1.93 2.35 75.1 5.03 6.85 1.36
1.65 1.97 2.39 75.1 5.10 6.94 1.36
1.66 2.01 2.44 75.1 5.17 7.02 1.36
1.67 2.05 2.48 75.1 5.23 7.10 1.36
1.68 2.09 2.52 75.1 5.30 7.18 1.36
1.69 2.13 2.57 75.1 5.36 7.26 1.35
1.70 2.17 2.61 75.1 5.43 7.34 1.35
1.71 2.20 2.66 75.1 5.50 7.43 1.35
1.72 2.24 2.70 75.1 5.56 7.51 1.35
1.73 2.28 2.75 75.1 5.63 7.59 1.35
1.74 2.32 2.79 75.1 5.69 7.67 1.35
1.75 2.36 2.83 75.1 5.76 7.75 1.35
1.76 2.40 2.88 75.1 5.83 7.83 1.34
1.77 2.44 2.92 75.1 5.89 7.92 1.34
1.78 2.48 2.97 75.1 5.96 8.00 1.34
1.79 2.52 3.01 75.1 6.02 8.08 1.34
1.80 2.56 3.06 75.1 6.09 8.16 1.34
1.81 2.60 3.10 75.1 6.16 8.24 1.34
1.82 2.64 3.14 75.1 6.22 8.33 1.34
1.83 2.68 3.19 75.1 6.29 8.41 1.34
1.84 2.72 3.23 75.1 6.35 8.49 1.34
1.85 2.76 3.28 75.1 6.42 8.57 1.34
1.86 2.80 3.32 75.1 6.49 8.65 1.33
1.87 2.84 3.37 75.1 6.55 8.73 1.33
1.88 2.88 3.41 75.1 6.62 8.82 1.33
1.89 2.92 3.45 75.1 6.68 8.90 1.33

















1.50 1.33 1.68 74.8 4.11 5.61 1.36
1.51 1.36 1.72 74.8 4.18 5.69 1.36
1.52 1.40 1.76 74.8 4.24 5.77 1.36
1.53 1.44 1.81 74.8 4.31 5.86 1.36
1.54 1.48 1.85 74.8 4.37 5.94 1.36
1.55 1.52 1.90 74.8 4.44 6.02 1.36
1.56 1.56 1.94 74.8 4.51 6.10 1.35
1.57 1.60 1.99 74.8 4.57 6.18 1.35
1.58 1.64 2.03 74.8 4.64 6.26 1.35
1.59 1.68 2.07 74.8 4.70 6.35 1.35
1.60 1.72 2.12 74.8 4.77 6.43 1.35
1.61 1.76 2.16 74.8 4.84 6.51 1.35
1.62 1.80 2.21 74.8 4.90 6.59 1.34
1.63 1.84 2.25 74.8 4.97 6.67 1.34
1.64 1.88 2.30 74.8 5.03 6.76 1.34
1.65 1.92 2.34 74.8 5.10 6.84 1.34
1.66 1.96 2.38 74.8 5.17 6.92 1.34
1.67 2.00 2.43 74.8 5.23 7.00 1.34
1.68 2.04 2.47 74.8 5.30 7.08 1.34
1.69 2.08 2.52 74.8 5.36 7.16 1.34
1.70 2.12 2.56 74.8 5.43 7.25 1.33
1.71 2.15 2.61 74.8 5.50 7.33 1.33
1.72 2.19 2.65 74.8 5.56 7.41 1.33
1.73 2.23 2.69 74.8 5.63 7.49 1.33
1.74 2.27 2.74 74.8 5.69 7.57 1.33
1.75 2.31 2.78 74.8 5.76 7.66 1.33
1.76 2.35 2.83 74.8 5.83 7.74 1.33
1.77 2.39 2.87 74.8 5.89 7.82 1.33
1.78 2.43 2.92 74.8 5.96 7.90 1.33
1.79 2.47 2.96 74.8 6.02 7.98 1.33
1.80 2.51 3.00 74.8 6.09 8.06 1.32
1.81 2.55 3.05 74.8 6.16 8.15 1.32
1.82 2.59 3.09 74.8 6.22 8.23 1.32
1.83 2.63 3.14 74.8 6.29 8.31 1.32
1.84 2.67 3.18 74.8 6.35 8.39 1.32
1.85 2.71 3.23 74.8 6.42 8.47 1.32
1.86 2.75 3.27 74.8 6.49 8.55 1.32
1.87 2.79 3.31 74.8 6.55 8.64 1.32
1.88 2.83 3.36 74.8 6.62 8.72 1.32
1.89 2.87 3.40 74.8 6.68 8.80 1.32
1.90 2.91 3.45 74.8 6.75 8.88 1.32
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Letter to the Editor
Choice of Anticoagulant Critically Affects Measurement of 
Circulating Platelet-Leukocyte Complexes
Stylianos Bournazos, Jillian Rennie, Simon P. Hart, Ian Dransfield
In circulation, platelets adhere to leukocytes forming rela­tively stable com plexes that have been reported to be 
elevated in cases o f unstable angina, myocardial infarction, 
coronary artery disease, and postangioplasty restenosis.1-10 
For this reason, measurement o f circulating platelet-leukocyte 
complexes has been proposed as an early and accurate marker 
of in vivo platelet activation and myocardial injury after 
infarction.9-10 Increased levels o f such com plexes have also 
been noted in a range o f chronic inflammatory diseases, 
including rheumatoid arthritis, end-stage renal failure, type I 
diabetes, and system ic lupus erythematosus.11-13
In the m ajority o f published studies that have examined 
platelet-monocyte or platelet-polymorphonuclear (PM N ) leu­
kocyte com plexes in human peripheral venous blood, sodium 
citrate (0 .3 2  to 0 .3 8 % ), a calcium-depleting agent, has been 
used as the blood anticoagulant. Because platelet adhesion to 
leukocytes is predominantly mediated by calcium-dependent 
interactions between platelet P-selectin and its leukocyte 
counter-receptor, P-selectin glycoprotein ligand-1 (P SG L- 
l) ,14 we aimed to determine whether calcium  depletion by 
sodium citrate could affect p latelet-leukocyte com plex 
formation.
For this reason, platelet-m onocyte and -PM N  leukocyte 
complexes in citrated blood (0 .38%  wt/vol final concentra­
tion) were measured using 2-color flow cytometry (described 
in3) and compared with those observed in blood anticoagu­
lated by hirudin (2 0 0  U m L~'; lepirudin), heparin (10  U 
mL_l), or PPA C K  (D-phenylalanyl-L-propyl-L-arginine chlo- 
romethylketone; 75 /xmol/L), which act independently of 
calcium chelation.
We observed significantly lower percentages o f platelet 
binding to m onocytes (defined as C D 42a+/CD14+ events) in 
blood anticoagulated with sodium citrate compared with 
hirudin-, heparin-, or PPACK-anticoagulated blood (Figure). 
No significant differences in PM N-platelet binding were 
evident using the different anticoagulants (13 .7%  ± 2 .3  for 
citrate, 18.8%  ± 5  for heparin, 16.8%  ± 4 .4  for hirudin, 19.3%  
±4 .3  for PPA C K ; n = 6 ) ,  an observation reflecting lower
Original received  A ugust 6 , 2 0 0 7 ; final version accepted O ctober 28 , 
2007.
From the U niversity  o f  Edinburgh/M edical R esearch  C ouncil (M R C ) 
Centre for In flam m ation  R esearch  (S .B ., J .R ., S .P .H ., I .D .)  and the 
Centre for C ard iovascular S c ie n c e  ( S .B .) ,  Q u een’s M ed ical R esearch  
Institute, Edinburgh, U K .
Correspondence to  Ian D ran sfield , T h e  U niversity o f  Edinburgh/M RC 
Centre for In flam m ation  R esearch , Q u een’s M edical R esearch  Institute, 
47 Little F ran ce C rescent, Edinburgh, E H 1 6  4 T J , U nited K ingdom . 
E-mail i.d ran sfie ld @ ed .ac .u k
(Arterioscler T hrom b Vase B iol. 2 0 0 8 ;2 8 :e 2 -e 3 .)
©  2007 American Heart Association, Inc.
Arterioscler Thromb Vase B iol  is available a t http ://atvb-ihajoum als.org
DOI: 10 .1161/A T V B A H A .107.153387
levels o f cation-dependent platelet adhesion that might be 
attributed to lower levels o f PSG L-1 expression on PMN 
leukocytes compared with m onocytes (data not shown).
Incubation o f blood with E D T A  (10  mmol/L) resulted in a 
substantial decrease (to approximately 15% ) in monocyte- 
platelet binding, an effect that was irrespective o f the antico­
agulant used (Figure). Because E D T A  and sodium citrate are 
both calcium chelators but E D T A  acts on other divalent 
cations as well, one interpretation could be the involvement 
o f other divalent cation-dependent interactions (eg, M g2+- 
dependent integrin-mediated interactions). However, use of 
E G TA , a selective chelator o f Ca2+, resulted in com parable 
m onocyte-platelet binding to that observed in E D T A  (14 .3%  
± 1 .6  for ED T A ; 14.1%  ± 1 .4  for E G T A ; n = 4 ) . W e therefore 
suggest that the higher percentage o f m onocytes binding to 
platelets observed in blood anticoagulated with citrate com ­
pared with ED TA  reflects the relative inefficiency o f sodium 
citrate as calcium  chelator.
W e conclude that in the presence o f sodium citrate, a 
substantial component o f the Ca2+-dependent interactions 
between platelets and monocytes is excluded, hence leading 
to underestimation o f the actual percentage o f monocyte- 
platelet binding in circulation. W hen compared with E D T A , 
sodium citrate has a limited capacity for calcium  depletion 
and as a consequence, residual Ca2+ ions could influence 
platelet adhesion to monocytes. The existence o f divalent 
cation-dependent and -independent mechanisms for platelet 
adhesion to monocytes is well established.3 W e suggest that 
previous studies describing an association o f platelet- 
monocyte binding with disease pathogenesis should be care­
fully reexamined because the contribution o f these com po­
nent interactions cannot be precisely determined when citrate 
was used as blood anticoagulant.
In summary, without necessarily  proposing the use o f 
one anticoagulant in p reference to another, our findings 
clearly indicate that the choice  o f blood anticoagulation is 
critically  important in studies o f  p latelet-leu kocyte inter­
actions. Particular caution is required when interpreting 
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Figure. Impact of different anticoagulation strategies on the per­
centage of platelet-monocyte complexes. Peripheral venous 
blood obtained from 6 healthy donors was anticoagulated with: 
sodium citrate (0.38% wt/vol), heparin (10 U mT1), hirudin (200 
U ml”1), or PPACK (75 /xmol/L) and incubated with □ or without 
E 10 mmol/L EDTA. Using 2-color flow cytometry, monocytes 
(CD14+) were identified and the percentage of platelet binding 
to them (defined as CD14+/CD42a+ events) was measured. A, In 
sodium citrate anticoagulated blood, significantly lower percent­
ages of platelet-monocyte complexes were observed compared 
with blood anticoagulated with heparin, hirudin, or PPACK. 
Incubation of blood with EDTA (10 mmol/L) resulted in all cases 
in a substantial decrease in platelet-monocyte complexes. 
Results are presented as mean±SD from 6 independent experi­
ments in which platelet-monocyte complexes were measured in 
different donors. *P<0.01; **P<0.05, compared with sodium 
citrate. B, Representative flow cytometry histograms of mono­
cytes (CD42a~) and platelet-monocyte complexes (CD42a+; M1 
region) in blood anticoagulated with sodium citrate, heparin, 
hirudin, or PPACK. Histograms are gated only on CD14+ cells.
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Monocyte Functional Responsiveness After 
PSGL-l-Mediated Platelet Adhesion Is Dependent on 
Platelet Activation Status
Stylianos Bournazos, Jillian Rennie, Simon P. Hart, Keith A.A. Fox, Ian Dransfield
Objective— A cute coronary diseases are characterized by elevated  levels o f  circu lating p latelet-leu kocyte com p lexes, 
raising the p ossib ility  that proinflam m atory processes m ight be initiated in leukocytes after platelet adhesion. H ere we 
exam ined the m echanism  o f  p latelet binding to polym orphonuclear leukocytes, m onocytes, and m on ocyte subsets and 
in v e s tig a te d  th e  p o te n tia l fu n c tio n a l c o n s e q u e n c e s  o f  m o n o c y te  b in d in g  to  m in im a lly  a c t iv a te d  o r 
throm bin-activated platelets.
Methods and Results— In this article , we describe key d ifferences in term s o f  stability  o f  P S G L -l-m e d ia te d  in teraction  o f  
platelets w ith m on ocytes and polym orphonuclear leukocytes and a sm all but s ignificant d ifference in p latelet binding 
to m onocyte subsets (C D 1 4 h'gh and C D 1 4 low/H LA -D Rh'gh). W e also report d ifferential e ffects  o f  p latelet binding on 
m onocyte functional responses betw een m inim ally and throm bin-activated platelets. In particular, m on ocyte C D  l i b  
expression and re lease  o f  proinflam m atory cytokines, lik e  interleukin 1 /3 and tum or necrosis fa c to r a, w ere s ignificantly  
upregulated on adhesion o f  stim ulated platelets, w hereas unstim ulated p latelets had no e ffect. M oreover, binding o f  
unstimulated, but not o f  throm bin-activated, platelets to m onocytes had no im pact on N F -k B  activ ity , m onocyte 
m igration, and induction o f  apoptosis in the absence o f  survival factors.
Conclusions— O ur data suggest that in the absence o f  overt activation , P S G L -l-P -se le c tin -d e p e n d e n t p latelet binding to 
m onocytes represents a norm al physiological process w ith little im pact on the potential o f  m onocytes to cause vascular 
injury. (Arterioscler Thromb Vase Biol. 2008;28 :1491-1498)
K e y  W o rd s : m onocyte ■ platelet □ adhesion b  selectin  ■ throm bin ■  proinflam m atory
A dhesion o f platelets and leukocytes to activated endo­thelium is an early event in the development o f athero­
sclerosis.1 Activated platelets deposit at the damaged arterial 
wall associated with unstable plaque rupture, precipitating or 
potentiating thrombus formation and coronary vascular ob­
struction. In addition, platelet and leukocyte interactions with 
endothelium play an important role in acute coronary syn­
dromes (A C S), myocardial infarction, and unstable angina. 
Whereas current strategies for treatment o f A CS are mainly 
targeted to lim it platelet aggregation via glycoprotein Ilb -IIIa  
antagonists or thienopyridines, there is evidence that alterna­
tive selectin-dependent adhesion pathways are also important 
in the development o f vascular injury.2
Binding o f platelets to leukocytes can be demonstrated in 
whole blood samples from healthy volunteers, and the pro­
portion o f platelet-bound leukocytes is elevated in cases o f 
unstable angina, myocardial infarction, coronary artery dis­
ease, and postangioplasty restenosis.3-5 Also, increased levels 
of platelet-m onocyte com plexes were noted in patients with 
type 2 diabetes,6’7 end stage renal disease,8 and rheumatoid
arthritis9 and in sm okers.10 W e have previously shown that 
platelets bind to monocytes predominantly via a divalent 
cation-dependent P-selectin-P-selectin  glycoprotein ligand-1 
(PSG L-1/C D 162) pathway. In addition, residual divalent 
cation-independent platelet-monocyte binding indicates that 
alternative molecular mechanisms for interaction also exist.5 
Antibody-m ediated cross-linking induces association o f 
PSG L-1 with cytoskeletal proteins including ezrin and also 
signaling cascades eg, Syk tyrosine kinases.11’12 Because 
P SG L-1 may be induced to redistribute after binding o f 
platelets to leukocytes, engagement o f P SG L-1 has the 
potential to influence leukocyte behavior through signaling 
pathways or via cytoskeletal regulation.
Based on the proinflammatory signaling cascades after 
P SG L-1 engagement, as well as the association o f platelet- 
m onocyte com plexes with A C S, increased platelet-m onocyte 
binding was suggested to represent a risk factor for develop­
ment o f atherosclerosis,13’14 possibly as a consequence o f 
altered leukocyte recruitment and activation status. However, 
there is little published evidence for priming and activation o f
Original received N ovem ber 2 1 , 2 0 0 7 ; final version accepted M ay 8, 2 0 0 8 .
From the U niversity  o f  Edinburgh/M edical R esearch  Council (M R C ) Centre for Inflam m ation R esearch  (S .B .,  J .R . ,  S .P .H ., I .D .) , Q u een ’s M edical 
Research Institute, Edinburgh, U K ; and the Centre for Cardiovascular S c ie n c e  (S .B .,  K .A .A .F .) , U niversity o f  Edinburgh, Q ueen s M ed ica l R esearch  
Institute, Edinburgh, U K .
Correspondence to Ian D ran sfield , T h e U niversity o f  Edinburgh/M RC Centre for Inflam m ation R esearch , Queen s M edical R esearch  Institu te, 4 7  L ittle  
France C rescent, Edinburgh, E H 1 6  4 T J , U K . E -m ail i.dransfie ld @ ed .ac .u k  
©  2008  A m erican  H eart A sso ciation , Inc.
Arterioscler Throm b Vase B io l  is av ailab le  a t h ttp ://a tv b .a h a jo u rn a ls .o rg  D O I: 1 0 .1 1 6 1 /A T V B A H A .1 0 8 .1 6 7 6 0 1
Downloaded from atvb.ahajouMflI.org by guest on July 2 4 ,2 0 0 8
1492 Arterioscler Thromb Vase Biol August 2008
£.6 0
B




"  /• A A
40 ! /  ̂ Il 1
i Í 1 II I
jo F > i V J  \ IX L102
CD 162




Control TNF-o LPS MCP-1
Figure 1. Differential binding of platelets to monocytes and 
PMN. Platelet binding to monocytes and PMN in whole blood 
(WB) or isolated cells. B, Expression of CD11a and CD162 In 
PMN and monocytes. C, Overlay histogram of CD162 
expression for PMN (unfilled) and monocytes (gray). D, Plate- 
let-PMN interactions after agonist treatment. Expression (E) 
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peripheral blood polymorphonuclear leukocytes (PM N ) or 
monocytes that would be consistent with a former platelet- 
bound population.15 Thus, although platelets can be demon­
strated to bind to leukocytes in whole blood, this binding may 
not necessarily influence leukocyte function in vitro.
Here, we examined the differences in the regulation o f 
platelet adhesion to PM N and monocytes and analyzed 
platelet binding to monocyte subsets (C D 14h‘sl' and C D 14l07  
HLA-DRh'Eh). W e also investigated the functional conse­
quences o f platelet binding to monocytes in terms o f cell 
surface receptor expression, cytokine production, cell migra­
tion, activation o f  proinflammatory transcription factors, and 
engagement o f apoptotic programs.
M ethods
For detailed descriptions o f  the M aterials and M ethods and Figure 
Legends, p lease see http://atvb.ahajoumals.org.
Immunolabeling and Flow Cytometry
Leukocyte-platelet interactions were determined using fluorochrom e 
conjugated an ti-C D 42a m Ab as described.5 F low  cytom etric analysis 
of the samples was perform ed using a B D  F A C SC alibu r or FA C Scan  
cytometer.
Cytokine Measurement
Monocytes (with or without platelets/agonists) were incubated at 
37°C for 5 hours, and cytokines (IL-1J3 and T N F -a ) were measured 
using a fluorescent bead-based sandw ich assay (B D  cytom etric bead 
array). A nalysis o f  the sam ples was perform ed using a B D  FA C S 
Array B ioan alysis System .
Transmigration Assay
Monocytes were preincubated with or without platelets, and trans­
well migration (1 to 6 hours; 37 °C ) in response to 6 .2 5  ng m l-1 
complement C 5a  was measured as described .16
Immunoblotting
Monocytes after treatm ent with agonists or platelets (30  minutes, 
37°C) were lysed, and proteins were resolved by S D S -P A G E . For
I x B a  detection, rabbit m onoclonal a n ti- I« B a  (1 :2 5 0 0 ; E l 30 , A b­
eam ) was used follow ed by H R P -con jugated  goat antirabbit IgG  
(1 :2 5 0 0 ; D ako C ytom ation).
Results
Preferential Binding of Platelets to Circulating 
Monocytes Over PMN Cells
The role o f P -selectin -PSG L -1 interaction in platelet binding 
to monocytes and PMN was determined using either function 
blocking antibodies against PSG L-1 (P L -1) or ED TA  to 
chelate divalent cations. For m onocytes, addition o f ED TA  
resulted in a substantial decrease in platelet adhesion, indi­
cating a divalent cation dependency (supplemental Figures I 
and II, available online at http://atvb.ahajournals.org). Con­
sistent with our previous data indicating a m ajor role for 
PSG L-1 in mediating platelet-m onocyte binding,5 function- 
blocking anti-PSG L-1 antibodies caused a sim ilar inhibition 
o f platelet binding to addition o f E D T A  (supplemental 
Figures I and II). Platelet adhesion to PM N  was also inhibited 
by divalent cation chelation or PSG L-1 inhibition, but to a 
lesser extent, an observation that might reflect the lower basal 
levels o f platelet adhesion (supplemental Figure II).
The importance o f P SG L -1-P -se lectin  interaction in medi­
ating platelet adhesion to leukocytes was further investigated 
by examining the effect o f platelet activators on the formation 
o f platelet-leukocyte com plexes. Platelet activation with ei­
ther thrombin (1 U m l-1) or T R A P  (20  pmol/L) significantly 
increased platelet binding to both m onocytes and PMN in a 
divalent cation-dependent manner (supplemental Figure III), 
an effect that was paralleled by increased expression o f 
platelet P-selectin (supplemental Figure IV ).
Although platelet adhesion to both monocytes and PMN 
has been shown to be mediated primarily through PSG L-1 - 
P-selectin interaction, we observed a profound difference in 
the extent o f platelet adhesion to these 2 leukocyte cell types
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in whole blood samples (supplemental Figure II). Notably, 
comparison o f the extent o f platelet binding either in unfrac­
tionated whole blood samples or after density gradient cell 
separation procedures revealed differences in the stability o f 
platelet adhesion to monocytes compared to PM N (Figure 
1A). There was no difference in the proportion o f monocytes 
that had bound platelets in whole blood and mononuclear cell 
fractions, and binding exhibited sim ilar divalent cation de­
pendency. In contrast, while platelet binding to PMN could 
be detected in whole blood, very low levels o f platelet 
binding were observed in isolated PMN cell preparations, 
despite follow ing sim ilar isolation procedures as in mono­
cytes. Interestingly, divalent cation-independent platelet 
binding to density gradient separated PMN cells was virtually 
abolished in the presence o f ED TA .
We examined a panel o f adhesion receptor molecules on 
monocytes and PM N from whole blood samples using flow 
cytometric analysis to determine whether the observed dif­
ferential stability o f platelet-PM N and platelet-monocyte 
binding reflected differences in the levels o f surface expres­
sion o f P SG L -1 . No significant differences in the expression 
of C D 62L or CD  l i b  were apparent between monocytes and 
PMN (Figure IB ) . In contrast, significantly lower levels o f 
C D lla  and P SG L-1 (CD  162) were found for PMN when 
compared to monocytes (Figure IB  and 1C). Based on our 
finding that platelet-leukocyte binding displays comparable 
sensitivity to E G T A  (a specific Ca2+ chelator) and E D T A 17 
and sensitivity to PSG L-1 blockade, one implication o f the 
above data are that the levels o f PSG L-1 expression might 
determine the extent o f  platelet-leukocyte interactions. How­
ever, additional experiments demonstrated that increased 
platelet binding to PM N occurred after exposure to T N F -a  or 
lipopolysaccharide (L P S) without affecting PMN expression 
of PSG L-1, suggesting that platelet binding could be regu­
lated independently o f receptor expression (Figure ID  and 
IE). W e therefore exam ined PSG L-1 localization in nonac­
tivated or T N F-a-activ ated  PM N (10  ng m f 1; 45  minutes, 
37°C) by imm unofluorescence microscopy. W hereas PSG L-1 
is evenly distributed throughout the entire surface o f nonac­
tivated PMN (Figure IF ) , it becom es localized in uropods o f 
TN F-a-activated PM N, suggesting that receptor localization 
might contribute to the regulation o f platelet binding.
As platelet-m onocyte binding was found to be more 
resistant to dissociation during cell isolation than platelet- 
PMN binding, we next examined the stability o f platelet 
adhesion on monocytes after brief (30  seconds) vortexing of 
samples in the presence or absence o f divalent cation chela­
tors (Figure 2A ). Repeated vortexing o f platelet-monocyte 
conjugates in the presence o f divalent cations had little 
impact on the proportion o f monocytes with bound platelets. 
In contrast, vortexing in the presence o f ED TA  readily 
reversed binding. S im ilar results were obtained when 
P-selectin-PSG L-1 interactions were disrupted with function- 
blocking antibodies (data not shown). Platelet binding was 
further examined using fluorescent labeled platelets isolated 
using minimal activation protocols and “platelet-free” mono­
cytes separated by immunomagnetic selection techniques in 
the presence o f E D TA . M axim al binding o f platelets to 
monocytes occurred within 15 minutes o f coincubation and
A
Number of vortex cycles
Figure 2. Effects of divalent cations on binding of platelets to 
monocytes. A, Platelet-monocyte complexes after vortexing 
with (■) or without (□) EDTA. Transmission (B) and scanning 
(C) electron microscopy analysis of platelet-monocyte com­
plexes In the presence of divalent cations. Binding of Intact 
platelets (CD42a:FITC) to monocytes (CD14:PE) with (D) and 
without divalent cations (E).
was dependent on the number o f platelets added back, 
suggesting that binding can occur relatively quickly (data not 
shown).
Examination o f platelet-monocyte interactions by trans­
mission and scanning electron m icroscopy in the presence o f 
divalent cations revealed that most platelet binding was to 
membrane projections (Figure 2B  and 2C ), although close 
apposition o f the platelet membrane to the monocyte surface 
was also observed in som e cases (data not shown). The 
possibility that in the absence o f divalent cations platelet 
microparticles rather than intact platelets were bound to 
m onocytes was excluded by exam ination o f p latelet- 
monocyte binding using scanning laser confocal microscopy 
(Figure 2D and 2E). Our analysis clearly showed that intact 
platelets bind to monocytes with little evidence o f micropar­
ticle binding.
Measurement of Platelet Adhesion to 
Monocyte Subsets
It is now well established that there are 2 distinct subpopu­
lations o f monocytes that can be defined in terms o f patterns 
o f expression o f C D 14, C D 16, and H L A -D R .18 Using 3-color 
flow cytometry, the patterns o f platelet binding to these 
different monocyte populations were defined in the presence 
or absence o f ED TA  (Figure 3A  and 3 B ). In paired analysis 
(n = 1 3 ), we found a small but significant difference in the
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Figure 3. Platelet binding to CD14hi9h and CD14l0W/HLA-DRhl9h monocyte subpopu­
lations. A-B, Laser scatter properties and R1 gate for CD14hi9h (R2 gate) and 
CD14low/HLA-DRhi9h (R3 gate) monocyte subpopulations to determine platelet bind­
ing (C). CD162 expression for monocyte subsets (D). *P<0.05.
extent o f platelet binding to the C D 14lowC D 16lowH LA -D Rhi8h 
subset when compared with the C D 14hlgh expressing mono­
cytes (Figure 3C ), even though PSG L-1 expression between 
these subsets was at sim ilar levels (Figure 3D ). In the 
presence o f E D TA , the levels o f binding o f platelets to both 
monocyte subsets were equivalent suggesting similar divalent 
cation sensitivity.
Functional Effects of Platelet Adhesion 
to Monocytes
Platelet adhesion to monocytes represents a more stable and 
long-lived interaction compared to PMN, and thus it is 
possible that these interactions could influence monocyte 
function. W e therefore wished to investigate the impact o f 
PSGL-1 engagement on monocyte functional activity after 
binding o f unstimulated and TRA P-activated platelets. W e 
measured the expression o f C D 62L  (rapidly shed on cell 
activation) and CD1 lb  (which is mobilized from intracellular 
stores) on the surface o f  monocytes with or without bound 
platelets as early markers o f m onocyte activation. Three-color 
flow cytometric analysis o f whole blood samples failed to 
reveal a significant effect o f platelet binding on surface 
expression o f either CD1 lb  or C D 62L  in the absence o f overt 
activation, with sim ilar levels o f receptor expression on 
CD42a positive (platelet-bound) and negative (platelet-free) 
monocytes (Figure 4A  through 4D ). Consistent with this 
observation, there were no significant differences in mono­
cyte transwell migration in response to C5a for monocytes 
with or without bound unstimulated platelets (supplemental 
Figure V). This observation suggests that binding o f unstimu­
lated platelets fail to influence monocyte adhesion and 
cytoskeletal reorganization, which is required for efficient
migration. Surprisingly, no significant change in the expres­
sion o f C D 62L  was noted for monocytes that had bound 
TRA P-activated platelets. In contrast, CD1 lb  expression was 
substantially increased for monocytes that had bound T R A P- 
activated platelets consistent with an effect o f adhesion o f 
activated (but not unstimulated) platelets on m onocyte func­
tional responses (Figure 4A  and 4C ).
W e next measured cytokine release from m onocytes coin­
cubated with unstimulated or thrombin-stimulated platelets 
(37°C , 5 hours). Interestingly, m onocyte expression and 
release o f I L - 1 /3 and T N F -a  was substantially upregulated for 
monocytes coincubated with thrombin-stimulated platelets 
(Figure 4 E  and 4F), but not in unstimulated platelets. Binding 
o f thrombin-activated platelets has been previously shown to 
activate N F -k B ,19 a critical regulator o f proinflammatory 
gene expression and a known survival factor for myeloid 
cells .20 W e therefore examined whether m onocytes with 
bound platelets displayed translocation o f N F-kB  to the 
nucleus, comparing the effects o f unstimulated and thrombin- 
stimulated platelets. W hereas monocytes with minimally 
activated platelets bound showed cytoplasm ic localization of 
N F-kB , monocytes with thrombin-activated platelets showed 
nuclear translocation o f N F-kB  (Figure 5A ). Ik B o  was 
detectable in the cytoplasm o f monocytes with unstimulated 
platelets (Figure 5 B ), but decreased cytoplasm ic expression 
was noted when thrombin-stimulated platelets were bound 
(Figure 5 B ), suggestive o f Ik B  degradation. Quantification of 
monocyte iK B a  expression by immunoblot analysis revealed 
that binding o f unstimulated platelets had no impact on Ik B o  
expression when compared with untreated m onocytes alone 
(Figure 5C).
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Figure 4. Lack of proinflammatory effects of platelet binding to monocytes. CD62L (A-B) and CD11b (C-D) expression for CD42a+ and 
CD42a~ monocytes in unstimulated or TRAP-stimulated whole blood samples. IL-1j3 (E) and TNF-a (F) release from monocytes colncu- 
bated with unstimulated (NA) or thrombin-stimulated platelets. *P<0.05.
Similarly, unstimulated platelet binding also failed to affect 
monocyte apoptotic programs again suggesting a lack o f 
effect on N F-kB  regulation. M onocyte apoptosis was exam ­
ined after culture in vitro in the absence o f 2 important 
survival factors: adherence and serum. As shown in Figure 
5D, monocytes cultured in suspension in the absence o f 
serum show a progressive decrease in the percentage o f 
viable cells over 72  hours. The decline in the number 
of viable cells was accompanied by an increase in the 
proportion o f cells that show evidence o f loss o f membrane 
permeability by failure to exclude propidium iodide (necro­
sis). Comparison o f  the proportion o f viable or necrotic cells 
revealed a minor antiapoptotic effect for binding o f unstimu­
lated platelets to monocytes. Interestingly, monocytes coin­
cubated with TRA P-activated platelets displayed decreased 
necrosis rate at all the time points analyzed compared to the 
corresponding control (monocytes incubated with T R A P but 
without platelets). Collectively, all these findings clearly 
indicate that in the absence o f overt stimulation, platelet 
adhesion on m onocytes had little impact on monocyte func­
tional responses and behavior.
Discussion
Platelet-leukocyte interactions have been reported to acceler­
ate restenosis21 and conversely, disruption o f such interac­
tions may be beneficial in animal models o f vascular injury .22 
However, whether platelet-m onocyte interactions contribute 
to the development o f cardiovascular disease is unknown. W e 
have measured platelet-leukocyte com plexes in peripheral 
blood from normal donors, providing the first analysis of 
platelet binding to the CD  14'°'7H LA-D Rhigh monocyte subset 
that is present at increased levels in the circulation during
inflammatory situations.23 Platelet binding to C D 14lo7 H L A - 
D R h'Eh and C D 14h'gh subsets shows sim ilar divalent cation 
dependency and susceptibility to blockade with P-selectin 
and PSG L-1 mAb. Although our data show that platelet 
binding to C D 14lcn7H L A -D R h,gh monocytes is statistically 
lower (P C 0 .0 1 ) than for the C D 14high m onocyte population, 
further studies would be required to define the biological 
significance o f the observed difference.
Comparison o f platelet binding to PM N and to monocyte 
subsets revealed that platelet adhesion to these cell types is 
predominantly mediated by P -selectin -P SG L -1  interactions. 
PSG L-1 blockade inhibits the m ajority o f platelet binding to 
monocytes in whole blood samples, indicating that P-selectin/ 
P SG L -l-m ed iated  adhesion occurs physiologically. Because 
a very low percentage ( < 1% ) o f circulating platelets express 
detectable levels o f P-selectin by flow cytom etry, monocytes 
may selectively bind the P -selectin-expressing platelets pres­
ent in the vasculature. Platelet-m onocyte binding appears to 
be more stable than platelet-PM N binding, being resistant to 
disruption by shear stress associated with repeated vortexing. 
Although the a Mj32 integrin has been reported to mediate 
platelet-leukocyte interactions,24 the sensitivity o f p latelet- 
monocyte interactions to the specific calcium  chelator 
E G T A 17 suggests that ¡8,  integrins are unlikely to contribute 
to platelet binding. W e observed higher levels o f expression 
o f P SG L-1, the leukocyte counter receptor for P-selectin 
(Figure IB )  on monocytes, and we speculate that this confers 
increased stability o f platelet binding to monocytes compared 
with PMN. Prolonged platelet-m onocyte interactions may 
differ from transient selectin-m ediated leukocyte-endothelial 
interactions during rolling adhesion and therefore have an 
impact on functional behavior. In particular, sustained inter-
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Figure 5. Effect of platelet binding on 
N F -kB  activation. Localization of monocyte 
N F -kB  (A) and IkB (B) on platelet binding 
(unstimulated or thrombin-stimulated). C, 
Immunoblot analysis of monocyte IkB 
expression (1) unstimulated; (2) TNF-a- 
treated; (3) unstimulated platelets; (4) 
thrombin-stimulated platelets; (5) thrombin 
alone; (6) platelets alone. D, Monocyte 
necrosis (AnxV+/PI+) and viability (AnxV-/ 
PI") after culture with or without platelets 
(unstimulated or TRAP-stimulated).
actions may have the potential to engage and cross-link 
PSGL-1 and initiate intracellular signaling pathways includ­
ing phosphorylation o f Syk and association o f ezrin with 
ITAM m otifs.12’25 
Several studies have investigated the functional conse­
quences o f interactions between thrombin-activated platelets 
and monocytes, demonstrating production o f chemokines and 
cytokines,25-27 tissue factor,28 and proteases.29 However, 
many o f these studies use prolonged coincubation times (18 
hours), during which time additional changes in platelet or 
monocyte activation states may occur, for example as a result 
of the formation o f large platelet-monocyte aggregates. Fur­
thermore, platelet-free monocyte preparations in which plate­
let binding via either selectin- or integrin-dependent path­
ways is disrupted by divalent cation chelation (ED TA  or 
citrate anticoagulation together with ED TA  washing) were 
used as controls for monocytes with bound platelets. These 
platelet-free monocytes fail to show activation o f monocyte 
production o f  chem okines, cytokines, proteases, or transcrip­
tion factors,26-29 implying that platelet binding to monocytes 
in the circulation fails to cause monocyte activation or 
alternatively that platelet-induced activation is readily re­
versed. M oreover, the use o f P-selectin immobilized on tissue 
culture plates as a surrogate for PSG L-1 ligation may be very 
different from P-selectin binding in the context o f an intact 
platelet. In support o f this suggestion, we have recently 
reported that presentation o f ligand on different sized latex 
microspheres may influence signaling pathways engaged
within leukocytes. Presentation o f J32 integrin ligands on
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particles considerably larger than a platelet ( > 3  gm  in 
diameter) was required for activation o f neutrophil effector 
functions.30 Finally, a recent elegant study suggests that both 
adhesion and cytokine signaling in com bination are required 
to induce expression o f C O X -2  mRNA production and 
stabilization in m onocytes,31 raising the possibility that ad­
hesive signals alone are insufficient to cause full activation o f 
monocyte transcriptional activity. Thus, the assumption that 
binding o f platelets to monocytes in the circulation is inevi­
tably associated with proinflammatory consequences may be 
incorrect.
Our flow cytometric analyses in whole blood samples fail 
to reveal a difference between monocytes with and without 
bound unstimulated platelets in terms o f monocyte surface 
expression o f the activation-regulated molecules C D 1 lb  and 
C D 62L , in contrast to findings reported by others.25 However, 
when platelet-free monocytes are isolated either via counter­
flow centrifugal élutriation in divalent cation-free condi­
tions32 or after platelet detachment with E D T A , a distinct 
population o f monocytes in terms o f C D l lb  or C D 62L  
expression corresponding to those having formerly bound 
platelets is not observed.
Engagement o f PSG L-1 after antibody cross-linking has 
the potential to influence integrin-mediated adhesion and 
subsequent transmigration. Somewhat contrary to our expec­
tations, we found that monocyte transmigration in response to 
the chemoattractant C 5a was sim ilar in the presence or 
absence o f bound unstimulated platelets. As an additional 
intracellular marker for cell activation, we examined whether
Bournazos et al Consequences of Platelet Adhesion on Monocytes 1497
unstimulated platelet binding influenced N F-kB  distribution 
and potentially the expression o f proinflammatory genes. In 
contrast to the observed translocation o f N F-kB  to the 
nucleus in monocytes after coincubation with thrombin-acti­
vated platelets, unstimulated platelets did not induce N F -kB  
redistribution. Sim ilarly, analysis o f I kB o: expression by both 
immunofluorescence m icroscopy and immunoblotting re­
vealed no differences in I kB  a  expression in monocytes with 
or without bound unstimulated platelets, whereas binding of 
thrombin-activated platelets caused rapid I kB o: degradation. 
Consistent with these findings, the expression o f N F kB -  
regulated proinflammatory cytokines, like IL-1/3 and T N F -a , 
was significantly upregulated in monocytes coincubated with 
thrombin-activated platelets, whereas no difference was ob­
served between monocytes with or without bound unstimu­
lated platelets. In this respect, binding o f unstimulated plate­
lets also failed to affect the induction o f monocyte apoptosis 
in response to serum deprivation and suspension culture. In 
contrast, addition o f TRA P-activated platelets had an antiapo- 
ptotic effect on monocytes, as evidenced by decreased num­
bers of apoptotic m onocytes at all time points examined over 
72 hours. Collectively, these findings clearly indicate that in 
the absence o f overt platelet activation, platelet binding to 
monocytes fails to influence N F -kB  activity.
In summary, we report that although platelet-m onocyte 
and platelet-PM N  interactions are mediated by PSG L-1 and 
P-selectin, more prolonged and stable binding to monocytes 
was observed. W e could find no m ajor difference in the 
binding o f platelets to monocyte subsets, and examination of 
a number o f different monocyte functional attributes sug­
gested that binding o f unstimulated platelets did not affect 
receptor expression, cytokine production, N F-kB  activation, 
chemotactic responses, or apoptosis. In contrast, binding of 
activated platelets does trigger proinflammatory responses in 
monocytes. One possibility is that high levels o f P-selectin on 
the surface o f activated platelets or binding o f multiple 
platelets per monocyte is required to trigger monocyte acti­
vation via P SG L -1 . In addition, release o f a range of 
proinflammatory cytokines, including IL-1/3, IL -6 , and IL -12  
after platelet activation (data not shown), might provide 
additional signals that lower the threshold for monocyte 
responsiveness. In this context, based on the reported increase 
in thrombin-mediated platelet activation in patients with 
ACS,33’34 it seems possible that under these conditions, 
monocyte-platelet interactions lead to enhanced proinflam­
matory responses which in turn exacerbate vascular inflam­
mation. In contrast, in the absence o f platelet activation, 
PSG L-1-m ediated platelet adhesion to circulating monocytes 
represent a physiological process with little impact on cell 
physiology, and the assumption that such interactions in 
peripheral blood have proinflammatory consequences should 
be carefully reconsidered.
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Apoptotic human cells inhibit migration 
of granulocytes via release of lactoferrin
Irini B o u rn a z o u ,1 Jo h n  D. P o u n d ,1 R o d g e r  D uffin ,1 S ty lia n o s  B o u rn a z o s ,1 L y n s e y  A. M elville ,1 
S im o n  B. B ro w n ,1 A d ria n o  G . R o s s i ,1 a n d  C h ris to p h e r  D. G r e g o r y 12
1The University of Edinburgh/Medical Research Council (MRC) Centre for Inflammation Research,
Queen’s Medical Research Institute, Edinburgh, United Kingdom. 2lmmunoSolv Ltd., Edinburgh, United Kingdom.
Apoptosis is a noninflammatory, programmed form o f cell death. One mechanism underlying the non-phlo- 
gistic nature o f  the apoptosis program is the swift phagocytosis o f the dying cells. How apoptotic cells attract 
mononuclear phagocytes and not granulocytes, the professional phagocytes that accumulate at sites o f  inflam­
mation, has not been determined. Here, we show that apoptotic human cell lines o f diverse lineages synthesize 
and secrete lactoferrin, a pleiotropic glycoprotein with known antiinflammatory properties. We further demon­
strated that lactoferrin selectively inhibited migration o f granulocytes but not mononuclear phagocytes, both in 
vitro and in vivo. Finally, we were able to attribute this antiinflammatory function of lactoferrin to its effects on 
granulocyte signaling pathways that regulate cell adhesion and motility. Together, our results identify lactofer­
rin as an antiinflammatory component o f  the apoptosis milieu and define what we believe to be a novel antiin­
flammatory property o f  lactoferrin: the ability to function as a negative regulator o f granulocyte migration.
Introduction
Apopcosis is a  p ro g ra m m e d , p h y sio lo g ica l fo r m  o f  ce ll d e a th  th a t, 
in in f la m m a to ry  te rm s , is  q u ie t : a p o p to tic  ce lls  a re  rap id ly  p h a g o - 
cytosed b y  th e ir  n e ig h b o rs  o r  b y  m o n o n u c le a r  p h a g o c y te s  th a t  are 
attracted  by  c h e m o ta c t ic  fa c to r s  s u c h  as ly so p h o sp h a tid y lch o lin e
(1) and fr a c ta lk in e  (2 ) re leased  b y  a p o p to tic  ce lls . T h e  ra p id  e n g u lf- 
raent o f  a p o p to tic  ce lls  m ilita te s  a g a in s t th e  p o te n t ia l  t is s u e -in ju r ­
ing an d  p r o in f la m m a to r y  fe a tu re s  o f  d e a d  ce lls  as ex e m p lifie d  by 
necrosis ( 3 - 6 ) .  In d eed , fa ile d  o r  d elayed c lea ra n ce  o f  a p o p to tic  cells 
can have d e tr im e n ta l  in f la m m a to r y  c o n s e q u e n c e s , in c lu d in g  th e  
developm ent o f  a u to im m u n e  p a th o lo g ie s  ( 7 - 9 ) .  T h e  m e c h a n ism s  
underlying th e  n o n -  o r  a n ti in f la m m a to r y  n a tu r e  o f  th e  a p o p to s is  
program  are  n o t  u n d e r s to o d  in  d e ta il. A n ti in f la m m a to r y  m e d ia ­
tors su ch  as T G F - p i  a n d  IL -1 0  are  k n o w n  to  be p ro d u c e d  a t  s ite s  
o f ap o p to sis , b o th  d ire c tly  by a p o p to tic  ce lls  th e m se lv e s  a n d  in d i­
rectly th r o u g h  in te r a c t io n  o f  a p o p to tic  ce lls  w ith  p h a g o cy te s  (1 0 , 
11). A p o p to tic  c e lls  se le c tiv e ly  a t t r a c t  m o n o n u c le a r  p h a g o c y te s  
(1 ,1 2 ), b u t ,  c u r io u s ly , th e  o th e r  c la ss  o f  p ro fe s s io n a l p h a g o c y te s , 
granu locy tes o r  p o ly m o r p h o n u c le a r  p h a g o c y te s , d o  n o t  m ig ra te  
toward a p o p to tic  ce lls  in  v itro  (1 2 )  a n d  d o  n o t  n o rm a lly  en g ag e  in  
apoptotic ce ll e n g u lfm e n t. T h e  a b se n ce  o f  g ra n u lo cy te s  f r o m  site s  
o f h o m e o s ta t ic  a n d  d e v e lo p m e n ta l a p o p to s is  su g g e sts  t h a t  a p o p ­
totic cells h ave th e  p o te n t ia l  to  se lectiv ely  re g u la te  th e  r e c r u itm e n t 
o f m o n o n u c le a r  leu k o cy tes .
In m ark e d  c o n tr a s t  to  s ite s  o f  a p o p to s is , s ite s  o f  a c u te  in fe c t io n  
are ch a ra cteriz e d  b y  th e  p re sen ce  o f  g ra n u lo cy tes , m o s t  c o m m o n ly  
n eu trop h ils, a s  a  m e a n s  to  p r o te c t  th e  h o s t  by  e n g u lf in g , k illin g , 
and d ig e s tin g  in v a d in g  in fe c t io u s  a g e n ts . N e u tr o p h ils ,  as a  f ir s t  
line o f  im m u n e  d e fe n se , a re  ra p id ly  re c r u ite d  to  th e  s ite  o f  in fe c ­
tion in  re s p o n s e  to  a  v a r ie ty  o f  in f la m m a to r y  s t im u li ,  in c lu d in g
C on flic t o f  i n t e r e s t :  C.D. Gregory and J.D. Pound are founders o f the company, 
ImmunoSolv Ltd., that supplied 2 o f  the monoclonal anti-laccoferrin antibodies used 
in Supplemental Figure 1.
N o n sta n d a rd  a b b r e v ia t io n s  u s e d : BL, Burkitt lymphoma; [Ca2’]j, intracellular calci­
um concentration; fMLP, formyl-methionyl-leucyl-phenylalanine; LTB.t, leukorriene B,. 
C itation  f o r  t h is  a r t i c le :  J. Clin. Invest. 119:20-32 (2009). doi:10.1172/JCI36226.
c h e m o k in e s , c y to k in e s , le u k o tr ie n e s , a n d  b a c te r ia l  c o m p o n e n ts  
s u c h  as L P S  a n d  A l-form ylated  p ep tid es  ( 1 3 ,1 4 ) .  C o m p a ra tiv e  s tu d ­
ies o n  th e  s lim e  m o ld  Dictyostelium discoideum h ave sh o w n  t h a t  in  
re sp o n se  to  c h e m o a ttr a c ta n ts ,  n e u tr o p h ils  o r ie n t  th e m se lv e s  a n d  
m ig ra te  in  a n  “a m e b o id  m o tio n ” b y  a n te r io r  p s e u d o p o d  e x te n s io n  
a c c o m p a n ie d  b y  s im u lta n e o u s  p o s te r io r  c o n t r a c t io n  a n d  re tr a c ­
tio n . S u c h  p o la r iz e d  m o r p h o lo g y  is  c h a r a c te r iz e d  b y  th e  fo r m a ­
t io n  o f  a  la m e llip o d iu m  a t  th e  le a d in g  ed g e a n d  a  u r o p o d  a t  th e  
tr a ilin g  ed ge o f  th e  n e u tro p h il  ( 1 5 - 1 8 ) .  T h is  p ro ce s s  is t ig h tly  c o n ­
tro lle d  n o t  o n ly  to  en su re  th e  e f f ic ie n t  m ig r a t io n  o f  n e u tro p h ils  to  
in f la m m a to r y  s ite s , b u t  a lso  to  p re v e n t th e ir  a b e r r a n t  in f i lt r a t io n  
a n d  c o n s e q u e n t t is su e -d a m a g in g  a c tiv it ie s . D e tr im e n ta l  e f fe c ts  o f  
n e u tro p h ils  — ca u se d , fo r  e x a m p le , b y  re le a se  o f  th e ir  p ro te o ly t ic  
en zy m es — c o n tr ib u te  to  m a n y  p a th o lo g ic a l  in f la m m a to r y  c o n d i­
t io n s , ra n g in g  fro m  v a s cu lit is  a n d  isc h e m ia / re p e rfu s io n  in ju r y  to  
g lo m e ru lo n e p h r itis , rh e u m a to id  a r th r it is ,  a n d  a c u te  g r a ft  re je c tio n  
(1 9 ) . T h e re fo r e , a t  in f la m m a to r y  s ite s , n e g a tiv e  s ig n a ls  e x is t  th a t  
p re v en t n e u tr o p h il  r e c r u itm e n t , d a m p e n  n e u tr o p h il  re s p o n s iv e ­
n ess , a n d  c o u n te rb a la n c e  o r  te rm in a te  th e  in f la m m a to r y  re sp o n se . 
T h is  a n t i in f la m m a to r y  p ro g ra m  is  c h a r a c te r iz e d  b y  c e s s a t io n  o f  
n e u tr o p h il  in f i l t r a t io n ,  as a r a c h id o n ic  a c id -d e r iv e d  p r o s ta g la n ­
d in s  a n d  le u k o tr ie n e s  are  sw itch e d  to  lip o x in s , re so lv in s , a n d  p ro - 
te c t in s  ( 2 0 ,2 1 ) .  R e s o lu tio n  o f  in f la m m a t io n  is  u lt im a te ly  ach iev ed  
th ro u g h  n e u tro p h il  a p o p to s is , a n d  a p o p to tic  n e u tro p h ils  a re  s u b ­
se q u e n tly  p h a g o c y to s e d  by  m a c r o p h a g e s , a  p ro c e s s  t h a t  lea d s to  
th e  release n o t  o n ly  o f  a n tiin f la m m a to r y  c y to k in e s  b u t  a lso  o f  su ch  
a n ti in f la m m a to r y  a n d  p ro re so lv in g  lip id  m e d ia to rs  as l ip o x in  A 4, 
re so lv in  E l ,  a n d  p r o te c t in  D 1  ( 2 2 - 2 5 ) .
G iv e n  (a ) th e  p r o d u c t io n  o f  n e g a t iv e  s ig n a l in g  m o le c u le s  a t  
in f la m m a t o r y  s ite s  to  l im i t  n e u t r o p h i l  r e c r u i tm e n t  a n d  f u n c ­
t io n  a n d  (b) fa ilu re  o f  n e u tr o p h il  m ig r a t io n  to  s ite s  o f  a p o p to s is , 
w e s o u g h t  to  d e te rm in e  w h e th e r  a p o p to t ic  ce lls  a c tiv e ly  p ro d u c e  
n eg ativ e  re g u la to rs  o f  n e u tr o p h il  c h e m o ta x is . W e p o s tu la te d  th a t  
th e  p r o d u c tio n  b y  a p o p to t ic  c e lls  o f  f a c to r s  t h a t  in h ib i t  n e u t r o ­
p h il  m ig r a t io n  c o n t r ib u t e  to  th e  n o n - p h lo g is t i c  n a tu r e  o f  th e  
a p o p to s is  p ro g ra m . H ere, w e p re s e n t ev id en ce  th a t  a p o p to t ic  ce lls  
a c tiv e ly  in h ib i t  n e u tr o p h il  m ig r a t io n  th r o u g h  th e  p r o d u c tio n  o f
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Figure 1
Apoptotlc cells release factor(s) that inhibit neutrophil migration. (A) Immunohistochemical analysis of neutrophils in BL (left) and spleen (positive 
control; right) sections. Inset images represent isotype control. (B) Representative images of stained Transwell filters. (C) Neutrophil chemotaxis 
toward increasing concentrations of BL cells was assessed in the presence of fMLP (100 nM). n  =  3 ; ' P <  0.05 vs. time 0. (D) BL cell-conditioned 
media obtained at the indicated time points were used to analyze fMLP-induced neutrophil chemotaxis. n  = 3; *P < 0.05 vs. fMLP. (E) Neutrophil 
chemotaxis toward fMLP was analyzed in the presence of control or Bcl-2-transfected BL2 cells obtained following a 0- and 5-hour incubation 
at 37°C. n  = 3; *P < 0.05 vs. BL2 0 h; NS vs. BL2/Bcl-2 0 h. Apoptosis levels were assessed by flow cytometry following staining with annexin V/ 
propidium iodide. Error bars indicate SEM. Original magnification; x400 (A; A, insets; B). hpf, high-power field.
la c to fe rr in , a n  8 0  k D a  a n t i in f la m m a to r y  g ly c o p r o te in  th a t  sp e ­
cifically  in h ib i ts  c h e m o ta x is  o f  n e u tr o p h ils  b u t  n o t  m o n o n u c le a r  
phagocytes. L a c to fe r r in  w as fo u n d  to  b e  sy n th e s iz e d  de n o v o  fo l­
low ing t r ig g e r in g  o f  a p o p to s is  a n d  re le a s e d  b y  a p o p t o t ic  ce lls  
o f  d iverse l in e a g e s . L a c t o f e r r in  im p a ire d  n e u t r o p h i l  a c t iv a t io n  
and p re v en ted  m o b il iz a t io n  o f  th e  ce lls  b y  in h ib i t in g  m ig ra to ry  
p o la riz a tio n  o f  th e  c e ll  b o d y . T h e s e  re su lts  d e m o n s tr a te  t h a t  th e  
n o n -p h lo g is t ic  c o n s t i t u t io n  o f  a p o p to t ic  c e lls  in c lu d e s  a n  a n t i ­
in f la m m a to ry  m o le c u le , la c to fe r r in ,  t h a t  we sh o w , fo r  th e  f i r s t  
time to  o u r  k n o w le d g e , h a s  p o te n t  n eg a tiv e  re g u la to ry  e ffe c ts  o n  
n eu tro p h il m ig r a t io n . T h e s e  f in d in g s  p ro v id e  a  r a t io n a le  fo r  th e  
absence o f  n e u tr o p h ils  f r o m  a p o p to t ic  s ite s  a n d  h ave im p o r ta n t  
im p lica tio n s f o r  u n d e r s ta n d in g  th e  m e c h a n is m s  in v o lv ed  in  th e  
reso lu tion  p h a se  o f  in f la m m a t io n .
Results
Apoptotic cells actively produce factor (s) that in hibit neutrophil chemotaxis. 
To a d d ress  w h e th e r  a p o p t o t ic  c e lls  in f lu e n c e  m ig r a to r y  a c t iv ­
ity o f  n e u tr o p h ils ,  w e c a rr ie d  o u t  a  series  o f  in  v itro  B o y d en -ty p e  
ch e m o ta x is  a ssa y s  to  in v e s t ig a te  n e u t r o p h i l  m ig r a t io n  to w a rd  
B u rkitt ly m p h o m a  (B L ) ce lls . W e in it ia lly  em p lo y ed  B L  as a  m o d el 
tissue as th e se  tu m o r  c e ll p o p u la t io n s  d isp la y  h ig h  levels o f  a p o p ­
tosis, a  p ro p e rty  th a t  is re ta in e d  c o n stitu tiv e ly  in  th e  tu m o r-d eriv ed  
cell lines. A s a t  a ll  s ite s  o f  a p o p to s is , th e re  is m a rk e d  in f i lt r a t io n  o f  
m acrophages th a t  e n g u lf  th e  a p o p to tic  cells , g iv in g  rise to  th e  ty p i­
cal “s tarry  sk y ” h is to lo g ic a l  a p p e a ra n ce  o f  th is  tu m o r. A s sh o w n  in  
Figure 1 A (le f t) , w h ile  m a cr o p h a g e s  w ere a b u n d a n t in  h is to lo g ic a l 
sections o f  B L , n e u tr o p h ils  w ere a b se n t. W e a ssessed  th e  e ffe c ts  o f  
BL cells o n  th e  m ig r a to r y  a c tiv ity  o f  n e u tr o p h ils  in  v itro  b y  a d d ­
ing n e u tro p h ils  to  th e  to p  c o m p a r tm e n t  o f  a  T ra n sw ell f i lte r  a n d  
inducing th e m  to  m ig ra te  to w ard  th e  low er c h a m b e r  c o n ta in in g  B L
ce lls  in  th e  p re se n ce  o f  th e  p o w e rfu l n e u tr o p h il  c h e m o a t tr a c t a n t  
fo r m y l-m e th io n y l- le u c y l-p h e n y la la n in e  ( fM L P ) (F ig u r e  I B ) .  As 
sh o w n  in  F ig u re  1C , n e u tro p h il  m ig ra t io n  w as s ig n if ic a n t ly  in h ib ­
ite d  in  B L  cells in  a  c o n c e n tr a tio n -d e p e n d e n t m a n n er . W e o b serv ed  
a  s im ila r  e ffe c t irresp ectiv e  o f  th e  c h e m o a t tr a c ta n t  u se d  ( in h ib it io n  
o f  n e u tro p h il  m ig ra t io n  in d u c e d  b y  C 5 a , IL -8 , a n d  le u k o tr ie n e  B 4 
[L T B 4]; d a ta  n o t  sh o w n , b u t  see b elo w ). W e ca rrie d  o u t  s u b s e q u e n t 
c h e m o ta x is  assays u s in g  B L -c o n d it io n e d  m e d iu m  o b ta in e d  o ver 
a  7 -h o u r  t im e  c o u rs e  a n d  fo u n d  t h a t  B L  c e lls  a c tiv e ly  re le a se d  a n  
in h ib ito r y  fa c to r (s )  (F ig u re  I D ) .  T h e  re le ase  o f  th e  in h ib ito r y  fa c ­
to r  a p p e a re d  to  b e  lin k e d  to  th e  lev els o f  a p o p to s is  in  th e  B L  ce ll 
p o p u la t io n s , s in ce  th e  in h ib ito r y  a c tiv ity  w as s ig n ific a n tly  lo w er in  
fu r th e r  c h e m o ta x is  assays u s in g  B L -c o n d it io n e d  m e d iu m  d erived  
fr o m  ce lls  o v e re x p re ss in g  th e  a p o p to s is  in h ib i to r  B c l-2 ,  a s  c o m ­
p a re d  w ith  th a t  o f  p a re n ta l ce lls  (F ig u re  IE ) .
Biochemical characterization o f  neutrophil migration-inhibitory 
factor(s). In  a n  a tte m p t to  g a in  fu r th e r  in s ig h t  in to  th e  b io c h e m i­
ca l n a tu re  o f  th e  fa c to r (s )  th a t  B L  ce lls  se c re te  in  o rd e r  to  ex c lu d e  
n e u tr o p h ils  f r o m  th e ir  e n v ir o n m e n t, w e in i t ia l ly  e s t im a te d  th e  
m o le c u la r  w e ig h t ran g e  o f  th e  in h ib ito r y  fa c to r (s )  b y  u s in g  f ilte rs  
w ith  m o le c u la r  w e ig h t c u t o f f  p o in ts  o f  a p p r o x im a te ly  3 , 1 0 , 3 0 ,  
5 0 ,  a n d  1 0 0  k D a . B L -c o n d it io n e d  m e d ia  o b ta in e d  a f t e r  2 4 -h o u r  
in c u b a tio n  w ere fr a c t io n a te d , a n d  e a c h  fr a c t io n  w as e x a m in e d  in  
v itro  u s in g  th e  n e u tro p h il  c h e m o ta x is  assay  d e scr ib e d  ab o v e . T h e  
re su lts  rev ealed  t h a t  fr a c t io n s  c o n t a in in g  m o le c u le s  o f  less  th a n  
5 0  k D a  fa iled  to  d isp lay  a n y  in h ib ito r y  e f fe c t  o n  n e u tr o p h il  m ig ra ­
t io n  (F ig u re  2A ). H ow ever, th e  u se o f  1 0 0  k D a  fi lte rs  revealed  th a t  
b o th  f r a c t io n s  (> 1 0 0  k D a  a n d  < 1 0 0  k D a ) d isp la y ed  a n  in h ib ito r y  
e f fe c t  o n  n e u tr o p h il  m ig r a t io n , in d ic a t in g  t h a t  a t  le a s t  1  f a c to r  
h a s  a  m o le c u la r  w e ig h t t h a t  r a n g e s  b e tw e e n  5 0  a n d  1 0 0  k D a . 
T h e  p re se n ce  o f  in h ib ito r y  a c tiv ity  in  th e  f i l t r a te  o f  th e  1 0 0  k D a
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Biochemical characterization of the inhibitory factor. Conditioned media from BL2 cells cultured for 24 hours were size fractionated using filters 
with 50 kDa (A) molecular weight cutoff sizes. Unfiltered medium was included as control. * P  < 0.001 compared with the corresponding positive 
control. Error bars indicate SEM. Ion exchange analysis included the use of Q Sepharose beads (positively charged) in order to distinguish posi­
tively and negatively charged molecules in the <100 kDa fraction (B) of the BL medium. Unbound molecules (Q1 fraction) were collected, where­
as bound molecules were eluted from the beads (Q2 fraction). Neutrophil migration toward these fractions in the presence of fMLP (100 nM) 
was assessed. Q1 and Q2 fractions (unbound and eluant fraction) of serum-free medium (no BL) were included as control, tP  < 0.05 compared 
with the corresponding control. Error bars indicate SEM. (C) Chemotaxis assay of neutrophils toward BL-conditioned medium that was heat 
inactivated (90°C for 10 minutes). (D) MALDI-TOF mass spectrum for the tryptic digest of the peptide band identified as lactoferrin.
c u to ff  m e m b ra n e  is  lik e ly  to  r e s u lt  f r o m  (a) im p re c ise  m o le c u la r  
w eight c u t o f f  o f  m o le c u le s  in  th e  5 0 - 1 0 0  k D a  ra n g e , (b ) c o m p le x  
fo rm atio n  th r o u g h  m u lt im e r iz a t io n  o f  th e  5 0 - 1 0 0  k D a  fa c to r  o r  
through in te r a c t io n  w ith  o th e r  m o le c u le s , o r  (c) th e  ex is te n ce  o f  a 
d istin ct in h ib i to r y  a c tiv ity  o f  g re a te r  th a n  1 0 0  k D a . I t  s h o u ld  be 
noted t h a t  th e  s e le c te d  is o la t io n  a p p r o a c h  is sk ew ed  in  fa v o r o f  
proteins a n d  t h a t  a d d it io n a l  lo w -m o le c u la r -w e ig h t (fo r  ex a m p le , 
lipid) m e d ia to rs  o f  n e u tr o p h il  m ig ra t io n  in h ib it io n  w o u ld  n o t  be 
identified b y  th e se  p ro c e d u re s .
To in v e stig a te  fu r th e r  th e  b io c h e m ic a l  p ro p e rt ie s  o f  th e  re te n - 
tate an d  f i l t r a te  o f  th e  1 0 0  k D a  c u t o f f  m e m b ra n e , we f i r s t  d e te r­
m ined th e  c h a r g e  (p i  v a lu e ) o f  th e  m ig r a t io n - in h ib ito r y  a c tiv ity  
by m ean s o f  a n  io n  e x c h a n g e  a n a ly s is  o f  B L -c o n d it io n e d  m ed ia . 
Using p o s itiv e ly  c h a r g e d  io n  e x c h a n g e  b ea d s (Q  S e p h a r o s e ) , th e  
100 k D a  m e m b ra n e  r e te n ta te  a n d  fi ltr a te  w ere sep ara te d  in to  p o s i­
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tively  ch a rg ed  (Q -s u p e rn a ta n t)  a n d  n eg a tiv e ly  ch a rg e d  (Q -e lu a n t)  
fr a c t io n s . A s sh o w n  in  F ig u re  2 B , th e  f i l tr a te  o f  th e  1 0 0  k D a  m e m ­
b ra n e  (< 1 0 0  k D a  f r a c t io n ) c o n ta in e d  m ig r a t io n -in h ib ito r y  activ ity  
in  b o th  th e  s u p e r n a ta n t  (p o s it iv e  c h a rg e ) a n d  th e  e lu a n t  (n e g a ­
tive ch a rg e ) o f  th e  Q  b ead s. B y  c o n tr a s t ,  a n a ly se s  o f  th e  r e te n ta te  
(> 1 0 0  k D a  fr a c t io n )  revealed  th a t  o n ly  th e  n eg a tiv e ly  c h a rg e d  e lu ­
a n t  d isp lay ed  s ig n if ic a n t  a c tiv ity  in  in h ib i t in g  n e u tr o p h il  m ig ra ­
tio n . T h e s e  re su lts  in d ica te  th a t  a t  le a s t  2  m o ie tie s  w ith  n e u tro p h il  
m ig r a t io n - in h ib ito r y  a c tiv ity  w ere p re se n t in  B L  c e l l -c o n d it io n e d  
m e d iu m : o n e  o f  5 0 - 1 0 0  k D a  w ith  p o s it iv e  p i  a n d  a  s e c o n d  o f  
1 0 0  k D a  o r  m o re  a n d  n eg ativ ely  ch a rg ed .
W e su b se q u e n tly  d e te rm in e d  w h e th e r  th e  n e u tro p h il  m ig r a t io n -  
in h ib i to r y  a c tiv ity  w as h e a t  la b ile . A s sh o w n  in  F ig u re  2 C , h e a t  
in a c t iv a tio n  c o m p le te ly  a b ro g a te d  a ll c h e m o ta x is  in h ib ito r y  a c tiv ­
ity  in  B L  c e l l -c o n d it io n e d  m e d iu m , s u g g e s t in g  th a t  th e  in h ib ito r y
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Figure 3
Lactoferrin specifically Inhibits neutrophil chemotaxls. Neutrophil chemotaxls in the presence of human anti-lactoferrin (anti-LTF) polyclonal 
antibody (gray) or Isotype control (black) using conditioned media from BL (A) and MCF7 (B) cells (A: n  =  3, *P < 0.05 vs. isotype control, NS vs. 
fMLP anti-lactoferrln control; B; n  =  3, tp < 0.001 vs. fMLP/lsotype; NS vs. fMLP/antl-LTF. (C) RT-PCR analysis to assess lactofernn expression 
in BL cells stably expressing LTF shRNA (LTF) cells and mock-transfected (mm) cells induced to become apoptotic (1 pM staurosporlne; 37°C). 
(D) Chemotaxis assay to determine neutrophil migration toward supernatants obtained from control, LTF shRNA, and mock-transfected BL 
cells (n = 5; §P < 0.05 compared with mm shRNA control; **P < 0.05 compared with fMLP; NS compared with fMLP control). (E) Dose-response 
analysis of purified human lactofernn. n = 3; up < 0.05 vs. 0 g/ml purified LTF + fMLP. Error bars indicate SEM.
factor(s) w ere m o s t  lik e ly  p ro te in  in  n a tu re . W e th e n  an a ly zed  th e  
proteins re le a se d  fr o m  B L  c e lls  in  v ia b le  a n d  a p o p to t ic  s ta te s  b y  
protein fin g e r p r in tin g . P o ly p ep tid e  b a n d s  o f  g re a te r  th a n  5 0  k D a  
were excised  fr o m  a  10%  S D S  p o ly a cry la m id e  gel. T ry p t ic  p ep tid es  
were gel e x tra c te d , a n d  m a tr ix -a s s is te d  la s e r  d e s o rp tio n / io n iz a - 
d o n -tim e o f  f l ig h t  (M A L D I-T O F ) m a ss sp e c tro m e tr ic  an a ly sis  w as 
carried o u t  (F ig u re  2 D ). A lso , g iv en  th e  c ru d e  b io c h e m ic a l  c h a r ­
acteristics d e scr ib e d  ab o v e , w e u n d e r to o k  a  c a n d id a te  a p p r o a ch  
based o n  th e  p ro te in s  re le a se d  f r o m  a p o p to tic  B L  ce lls . W e id e n ­
tified th e  f a c t o r  re le a se d  b y  B L  c e lls  t h a t  p re v e n te d  n e u tr o p h il  
chem otaxis as la c to fe r r in .
Lactoferrin specifically inhibits neutrophil chemotaxis toward a range 
of chemoattractants. L a c to fe r r in  is  a  g ly c o p r o te in  o f  a p p ro x im a te ly  
7 5 -8 0  k D a  t h a t  b e lo n g s  to  th e  tr a n s fe rr in  fa m ily  o f  p ro te in s  d u e 
to its iro n -b in d in g  p ro p e rtie s . I t  is a  w e ll-ch a ra cte riz ed  c o m p o n e n t 
o f n eu tro p h il se c o n d a ry  g ra n u les , la c r im a l flu id , c o lo s tru m , saliva, 
and m u co sa l s e c re tio n s , in  w h ich  i t  c o n fe r s  a n tib a c te r ia l  activ ity . 
We observed  t h a t  a d d itio n  o f  a n ti- la c to fe r r in  a n tib o d y  to  B L -c o n - 
d ition ed m e d iu m  n e u tr a l iz e d  i ts  n e u t r o p h i l  m ig r a t io n - in h ib i ­
tory a c tiv ity  u s in g  e i t h e r  p o ly c lo n a l  o r  m o n o c lo n a l  a n tib o d ie s  
(Figure 3A  a n d  S u p p le m e n ta l  F ig u re  1; s u p p le m e n ta l  m a te r ia l  
available o n lin e  w ith  th is  a r t ic le ;  d o i :1 0 .1 1 7 2 / J C I 3 6 2 2 6 D S l ) .  
Sim ilar re su lts  w ere o b serv ed  w ith  s u p e rn a ta n ts  o b ta in e d  fr o m  th e  
m am m ary c a r c in o m a  lin e  M C F -7 , in d ic a t in g  th a t  th e  n e u tro p h il  
m ig ra t io n -in h ib ito ry  a c tiv ity  is  n o t  re s tr ic te d  to  B L  c e ll-d e r iv e d  
lacto ferrin  (F ig u r e  3 B ) . F u r th e r m o r e ,  la c to fe r r in  p u r if ie d  f r o m  
hum an m ilk  d isp lay ed  d o se -d e p e n d e n t in h ib ito ry  activ ity  to w ard  
n eu tro p h il m ig r a t io n  in  re s p o n s e  to  fM L P  (F ig u re  3 E ) a n d  a lso  
inhibited  m ig r a t io n  to w a rd  C 5 a , IL - 8 , a n d  L T B 4  to  s im ila r  levels 
(Figure 4A ). T h e  n e u tr o p h il  m ig r a t io n - in h ib i t o r y  e f fe c t  w as a lso
d isp la y ed  b y  la c to fe r r in  p u r if ie d  f r o m  h u m a n  n e u tr o p h ils  (F ig ­
u re 4 D ). I t  s h o u ld  b e  n o te d  t h a t  b o th  ty p es o f  p u rif ie d  la c to fe r r in  
u se d  in  th is  s tu d y  w ere fre e  o f  e n d o to x in  c o n ta m in a t io n ,  a n d  th e  
o b serv ed  in h ib ito r y  e f fe c t  d id  n o t  a p p e a r to  b e  d u e to  a n y  la c to fe r -  
r in -a sso c ia te d  m o le c u le s  s u c h  as L P S . F u r th e r m o r e , in h ib it io n  o f  
la c to fe r r in  e x p re s s io n  b y  sh R N A  in  B L  ce lls  p ro v id e s  a d d it io n a l  
s u p p o r t  fo r  th e  s p e c i f i c i ty  o f  th e  o b s e r v e d  la c t o f e r r in  e f fe c t .  
T h u s , we fo u n d  th a t  n e u tr o p h il  c h e m o ta x is  to w a rd  s u p e r n a ta n ts  
o b ta in e d  fr o m  B L 2  ce lls  tr a n s fe c te d  w ith  sh R N A  v e c to rs  ta rg e te d  
a g a in s t  la c to fe r r in  w as h ig h e r  c o m p a re d  w ith  s u p e r n a ta n ts  fr o m  
B L  c o n t r o l  o r  m o c k -tr a n s fe c te d  c e lls  (F ig u re s  3 , C  a n d  D ). L a c ­
to f e r r in  e x e r te d  n o  to x ic  e f fe c ts  o n  n e u tr o p h i ls ,  as  a s s e s s e d  by  
a n n e x in  V / p ro p id iu m  io d id e  s ta in in g  o f  c o n t r o l  a n d  la c to fe r r in -  
tr e a te d  n e u tr o p h ils  (> 98%  ce ll v ia b ility ) . T h e s e  re s u lts  su g g e s te d  
t h a t  la c to fe r r in  b in d s  to  n e u tr o p h ils  a n d  in h ib i ts  th e ir  a b ility  to  
u n d e rg o  c h e m o ta x is . T o  e x c lu d e  th e  p o s s ib il ity  t h a t  th e  o b serv ed  
in h ib i to r y  a c tiv ity  o f  la c to fe r r in  w as d u e  in s te a d  to  its  a b ility  to  
b in d  a n d  fu n c t io n a lly  n e u tra liz e  th e  c h e m o a t tr a c ta n ts ,  a d d itio n a l 
c h e m o ta x is  assays w ere p e r fo rm e d  u s in g  c h e m o a t tr a c ta n ts  (fM L P , 
C 5 a , IL - 8 ) th a t  w ere p re a b so rb e d  w ith  la c to fe r r in . T o  ach iev e  th is , 
we p re in c u b a te d  c h e m o a ttr a c ta n ts  w ith  la c to fe r r in . S u b se q u e n tly , 
a n t i- la c to fe r r in  a n tib o d y  w as u se d  to  rem o v e th e  la c to fe r r in  w ith  
th e  a id  o f  m a g n e tic  b ea d s. A s s h o w n  in  F ig u re  4 B ,  n o  d if fe re n c e  
in  n e u tro p h il  c h e m o ta c t ic  a c tiv ity  w as o b serv ed  b e tw ee n  th e  c o n ­
tr o l a n d  la c to fe r r in -a b s o r b e d  c h e m o a t t r a c t a n t s ,  w h ic h  e x c lu d e s  
th e  p o s s ib il ity  t h a t  la c to fe r r in  b in d s  to , a n d  a lte rs  th e  a c tiv ity  o f, 
th e  c h e m o a t t r a c t a n t s .  F u r th e r  s u p p o r t in g  o u r  c o n c lu s io n  t h a t  
la c to fe r r in  e x e rts  its  in h ib ito r y  e ffe c ts  th r o u g h  b in d in g  to  n e u tr o ­
p h ils , we a lso  o b serv ed  th a t  p u rif ie d  la c to fe r r in  c a n  d ire c tly  a s s o c i­
a te  w ith  n e u tr o p h ils  (F ig u re  4 C ). In  a d d it io n , S c a tc h a r d  b in d in g
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Neutrophil chemotaxis toward lactoferrin is irrespective of the chemoattractant used and its iron saturation status. (A) Neutrophil chemotaxis 
toward different chemoattractants. n  =  3; *P < 0.05. (B) Neutrophil chemotaxis toward chemoattractants (control) or chemoattractants that were 
incubated with lactoferrin (10 pig/ml) followed by the addition of isotype or anti-lactoferrin monoclonal antibody (10 ng/ml). Antibodies were 
removed using magnetic IgG beads, n  =  3; *P < 0.05, NS compared with chemoattractant control. (C) Immunoblot analysis of lysates of neu­
trophils incubated with or without biotinylated lactoferrin (10 pg/ml) at 37°C for 1 hour. (D) Neutrophil chemotaxis toward lactoferrin (10 pg/ml) 
purified from human neutrophils or human milk. **P < 0.001 vs. fMLP. C5a-induced monocyte (E) or macrophage (F) chemotaxis. (G) Neutrophil 
migration in the presence of lactoferrin (10 pg/ml) in the top or bottom compartment of the Transweil insert (n  = 3; NS vs. corresponding +LTF 
controls). (H) Chemotaxis assay to determine neutrophil migration toward purified recombinant iron-depleted (Apo-), partially iron-saturated, and 
fully iron-saturated (Holo-) recombinant lactoferrin (10 pg/ml). Milk-purified lactoferrin and partially iron-saturated transferrin (TF; 10 gg/ml) were 
added as control, n  = 4; tp < 0.001 compared with fMLP control. Error bars indicate SEM.
analysis o f  12SI-la b e le d  a p o la c to fe rr in  in d ica te d , in  a cco rd a n ce  w ith  
earlier f in d in g s  ( 2 6 ,2 7 ) ,  th a t  la c to fe r r in  b o u n d  to  n e u tro p h ils  v ia  
2 classes o f  r e c e p to r  t h a t  d if fe r  in  a ff in ity  a n d  n u m b e r  o f  b in d in g  
sites p er ce ll. W e d e te r m in e d  th e  h ig h e r -a f f in ity  re c e p to rs  to  be 
expressed a t  a  d e n s ity  o f  9 ,1 0 0  ±  2 ,5 0 0  b in d in g  s ite s  p er ce ll, w ith  
an a ff in ity  o f  3 5 0  + 6 5  n M , a n d  th e  lo w e r-a ff in ity  re ce p to rs  to  be 
expressed a t  a  d e n s ity  o f  2 .5  x  1 0 6 ± 0 .7  x  1 0 6 p er ce ll, w ith  a n  a f f in ­
ity o f  2 0  ± 10  p M  (S u p p le m e n ta l F ig u re  2 ).
To d e te rm in e  w h e th e r  th e  m ig r a t io n -in h ib ito r y  e ffe c ts  o f  la c to ­
ferrin w ere s p e c if ic  to  n e u tro p h ils  a m o n g  p ro fe ss io n a l p h a g o cy te s , 
we an a ly zed  i ts  e f fe c ts  o n  m o n o c y te  a n d  m a c r o p h a g e  m ig r a t io n  
in vitro . A s s h o w n  in  F ig u re  4 , E  a n d  F , C 5 a -in d u ce d  c h e m o ta x is  
o f m o n o n u c le a r  p h a g o c y te s  w as u n im p a ire d  b y  la c to fe r r in . W e 
fu rth er a s se s se d  w h e th e r  la c to fe r r in  a c te d  by  in h ib i t in g  n e u tr o ­
phil m ig ra t io n  o r  p r o m o t in g  n e u tro p h il  re p u lsio n . In  ch e m o ta x is  
sssays, in  w h ich  w e ad d ed  la c to fe r r in  to  th e  u p p er c h a m b e r  a lo n g  
with n e u tro p h ils , w e o b se rv e d  in h ib it io n  o f  n e u tro p h il  m ig ra t io n
to w a rd  fM L P  a n d  c o n t r o l  m e d iu m  (F ig u r e  4 G ) ,  s u g g e s t in g  th a t  
la c to fe r r in  e x e rts  a  d ire c t e f fe c t  o n  n e u tr o p h ils  b y  in h ib i t in g  th e ir  
m ig ra to ry  a b ility  a n d  n o t  b y  fo r c in g  th e m  to  m ig ra te  in  a ll d ire c ­
t io n s  aw ay fr o m  th e  c h e m o a t tr a c ta n t .
Neutrophil migration-inhibitory effects o f  lactoferrin are not related 
to its iron-binding properties and are demonstrable in vitro and in vivo. 
I r o n  a n d  ir o n -a s s o c ia te d  m o le c u le s  h av e  b e e n  p re v io u s ly  sh o w n  
to  p lay  a n  im p o r ta n t  ro le  in  m a n y  im m u n o m o d u la to r y  fu n c t io n s . 
In d e e d , s u p p re s s io n  o f  IL -1  re le a se  b y  m o n o c y te s  is  o b se rv e d  by 
p u r ifie d  iro n -s a tu ra te d  la c to fe r r in , w h e re a s  a n  in h ib i t io n  o f  G M  
c o lo n y -s t im u la t in g  a c tiv ity  p r o d u c t io n  by  m o n o c y te s  a n d  m a c ­
ro p h a g e s  c o rre la te d  w ith  th e  iro n  s a tu r a t io n  s ta tu s  o f  la c to fe r r in  
( 2 8 - 3 0 ) .  T h e r e fo r e , w e f u r th e r  e x a m in e d  w h e th e r  d if fe r e n c e s  in  
th e  iro n  s a tu r a t io n  p ro f ile  o f  la c to fe r r in  a f fe c t  its  a b ility  to  in h ib i t  
n e u tr o p h il  m ig r a t io n . C h e m o ta x is  a ssa y s  to  d e te r m in e  n e u t r o ­
p h il  m ig r a t io n  to w a rd  ir o n -d e p le te d  (a p o - la c t o fe r r in ) ,  p a r t ia lly  
iro n -s a tu ra te d , o r  fu lly  i r o n -s a tu r a te d  (h o lo - la c to fe r r in )  la c to fe r -
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Figure 5
Lactoferrin inhibits neutrophil migration in 
vivo. Total cell (A) or neutrophil number (Gr-1+; 
B) obtained from peritoneal lavage. *P < 0.05 
vs. transferrin; tp  < 0.05 vs. thioglycollate 
(TG) control, **P < 0.01 vs. transferrin con­
trol. Error bars indicate SEM. (C ) Charac­
teristic cytospin images. Original magnifica­
tion, x400, top; x200, bottom.
Control LTF control
rin revealed  t h a t  th e  lev el o f  ir o n  s a tu r a t io n  w as n o t  re s p o n s ib le  
for th e  o b se rv e d  in h ib i t io n  in  n e u tr o p h il  m ig r a t io n  (F ig u re  4 H ). 
Also, as la c to fe r r in  b e lo n g s  to  th e  tr a n s fe r r in  fa m ily  o f  p ro te in s  
sh arin g  74%  s e q u e n c e  h o m o lo g y  w ith  tr a n s fe r r in  (b o th  o f  th e m  
are 8 0  k D a  c a t io n ic  i r o n - b in d in g  g ly c o p r o te in s ) ,  w e r e a s o n e d  
th at, i f  th e  u n d e r ly in g  n e u tr o p h il  m ig r a t io n - in h ib i t o r y  m e c h a ­
nism  o f  la c to fe r r in  w as ro o te d  in  its  a b ility  to  ch e la te  iro n , tr a n s ­
ferrin  m ig h t  s h o w  s im ila r  e f fe c ts  o n  n e u t r o p h i l  m ig r a t io n .  T o  
explore th is  p o ss ib ility , w e p e r fo rm e d  c h e m o ta x is  assays in  w h ich  
n e u tro p h ils  w ere  in d u c e d  to  m ig ra te  to w a rd  fM L P  in  th e  p r e s ­
ence o f  p a r t ia l ly  ir o n -s a t u r a t e d  tr a n s fe r r in . O u r  re s u lts  sh o w ed  
th at tr a n s fe r r in , u n lik e  la c to fe r r in ,  h a d  n o  e f fe c t  o n  n e u tr o p h il  
ch e m o tax is , fu r th e r  s u p p o r t in g  th e  c o n c lu s io n  th a t  th e  o b serv ed  
n eu tro p h il m ig r a t io n - in h ib i t o r y  e f fe c t  is  la c to fe r r in  s p e c if ic  a n d  
is u n lik ely  to  re q u ire  ir o n -c h e la t in g  a c tiv ity  (F ig u re  4 H ).
H aving e s ta b lish e d  th e  in h ib ito ry  e ffe c ts  o f  la c to fe rr in  o n  n e u tro ­
phil ch e m o ta x is  in  v itro , w e th e n  u sed  a  m u r in e  p e r ito n it is  m o d el 
to assess th e  e f fe c t  o f  la c to fe r r in  o n  le u k o cy te  r e c r u itm e n t in  vivo. 
L acto ferr in  a n d  tr a n s fe r r in  w ere te s te d  fo r  th e ir  a b ility  to  a f fe c t  
th io g ly c o lla te - in d u c e d  le u k o c y te  r e c r u i tm e n t  to  th e  p e r ito n e a l 
cavity. A s sh o w n  in  F ig u re  5 , A a n d  B , th io g ly c o lla te  c a u se d  rap id  
re cru itm en t o f  le u k o c y te s  c o m p a re d  w ith  v e h ic le  a lo n e , a n d  th e  
recruited le u k o cy te s  w ere p re d o m in a n tly  n e u tro p h ils  (88% ). In  th e  
presence o f  la c to fe r r in , th e  to ta l  n u m b e r  o f  n e u tro p h ils  re cru ite d  
to th e p e r ito n e a l ca v ity  w as re d u c e d  b y  5 2 %  c o m p a re d  w ith  c o n ­
trol, w h ereas tr a n s fe rr in  h a d  n o  e ffe c t. L a c to fe rr in  re d u ced  sp e c ifi­
cally th e  p ro p o r tio n  a n d  n u m b e r  o f  n e u tro p h ils  m ig ra tin g  in to  th e  
cavity b u t d id  n o t  a ffe c t  r e c r u itm e n t o f  o th e r  types o f  leu k o cy tes  in  
response to  th io g ly c o lla te  (F ig u re  5 C ). T h e s e  re su lts  d e m o n stra te  
that, s im ila r  to  its  e f fe c t  o n  n e u tr o p h il  c h e m o a t tr a c t io n  in  v itro , 
lactoferrin  is  a  p o te n t  in h ib i to r  o f  n e u tro p h il  m ig ra t io n  in  vivo.
Impairment o f neutrophil activation profile by lactoferrin. N e u tro p h il  
m ig ra tio n  in v o lv es  a c t iv a t io n ,  a d h e s io n , a n d  e x tra v a s a tio n  p r o ­
cesses th a t  a re  a c c o m p a n ie d  b y  g ro ss  c h a n g e s  in  c e ll m o rp h o lo g y : 
w h ereas  n o n a c tiv a te d  n e u tr o p h ils  are  ro u n d e d , a c tiv a te d  n e u t r o ­
p h ils  a c q u ire  a  p o la r iz e d  m o r p h o lo g y  w ith  sp r e a d in g  a n d  a d h e ­
s io n  to  th e  a v a ila b le  s u b s tr a tu m  (1 5 ) .  In  o rd e r  to  in it ia lly  asse ss  
th e  e f fe c ts  o f  la c to fe r r in  o n  n e u tr o p h il  a c t iv a t io n , w e p e r fo rm e d  
tim e -la p se  v id eo  m icr o s c o p y  o f  n e u tr o p h ils  a n d  re co rd e d  d ire c tly  
th e i r  a c t iv a t io n  m o r p h o lo g y , c e ll  s p r e a d in g , a n d  lo c o m o t io n .  
D u r in g  a  1 -h o u r  t im e  c o u r s e , la c to fe r r in -p r e tr e a te d  n e u tr o p h i l  
p o p u la t io n s  s t im u la te d  w ith  fM L P  d isp la y e d  a  g r e a te r  p r o p o r ­
t io n  o f  n o n a d h e r e n t  c e lls  as w ell as c e lls  p r e s e n t in g  a  r o u n d e d , 
n o n a c t iv a te d  m o r p h o lo g y  as c o m p a re d  w ith  n e u tr o p h i ls  tr e a te d  
w ith  fM L P  a lo n e  (F ig u re  6 , A a n d  B ). T h e s e  q u a n t i t a t iv e  d if fe r ­
e n c e s  b e tw e e n  la c t o f e r r in - t r e a t e d  a n d  u n t r e a t e d  n e u t r o p h i ls  
s t im u la t e d  w ith  fM L P  w ere r e f le c te d  in  th e  l o c o m o t io n  o f  th e  
c e lls  a r o u n d  th e  s u b s t r a t u m , w ith  la c to f e r r in - t r e a te d  c e lls  d is ­
p la y in g  m a rk e d ly  re d u c e d  m o v e m e n t.
C h a n g es in  ce ll m o rp h o lo g y  fo llo w in g  s t im u la t io n  w ith  fM L P  o r  
o th e r  n e u tro p h il  a g o n is ts  a re  c h a r a c te r iz e d  b y  a  ra p id  in c re a se  in  
in tr a c e llu la r  cy to p la s m ic  c a lc iu m  lev els th r o u g h  m o b il iz a t io n  o f  
c a lc iu m  fr o m  E R  s to re s  a n d  a c tiv a t io n  o f  c a lc iu m  in f lu x  c h a n n e ls  
o f  th e  p la s m a  m e m b ra n e , m e d ia te d  b y  th e  in o s ito l  tr ip h o s p h a te  
(IP 3) a n d  d iacylglycerol/PLC  (D A G /PLC ) p athw ays ( 3 1 - 3 3 ) .  In  o rd er 
to  d e te rm in e  w h eth e r  th e  o b serv ed  ce ll sh a p e  a lte ra tio n s  fo llo w in g  
la c to fe rr in  tre a tm e n t are re la ted  to  ch a n g e s  in  in tra c e llu la r  c a lc iu m  
c o n c e n tr a tio n s  ([C a2t]j), we m e a su re d  th e  lev els o f  [C a2+]i in  c o n tro l 
an d  la c to fe rr in -tre a te d  cells in  re sp o n se  to  fM L P  s t im u la t io n  (1 n M  
o r  10  n M ). N o  ch a n g e s w ere o b serv ed  in  th e  fM L P -m e d ia te d  [C a2*]j 
re sp o n se  betw een  c o n tr o l  a n d  la c to fe r r in -tr e a te d  n e u tro p h ils , su g ­
g e s tin g  t h a t  la c to fe r r in  a c ts  d o w n s tre a m  o r  in d e p e n d e n tly  o f  th e  
m e c h a n ism s  inv olved  in  in tra c e llu la r  c a lc iu m  flu x  (F ig u re  6 C ).
As la c to fe r r in  w as s h o w n  to  p re v e n t n e u tr o p h i l  m ig r a t io n ,  w e 
n e x t e x p lo re d  w h e th e r  i t  c o u ld  a lso  a f f e c t  th e  n e u tr o p h il  a c tiv a ­
t io n  s ta te . T o  th is  en d , w e c h o s e  to  m e a s u re  th e  e x p re s s io n  o f  2





Effect of lactoferrin on neutrophil polarization morphology and spreading. (A) Time-lapse video microscopy frames of control or lactoferrin-pre- 
treated neutrophils (10 pg/ml; 40 minutes at 37°C) stimulated with 1 pM fMLP over a 1 -hour incubation time course. Original magnification, x400. 
(B) Quantification of neutrophils (nonpolarized) counted from 5 different fields; *P < 0.05, **P < 0.01 vs. corresponding +LTF control. Error bars 
indicate SEM. (C) Representative plot (of 3 independent experiments) showing measurement of [Ca2+]i levels in neutrophils incubated in the 
presence or absence of lactoferrin (10 pg/ml; 30 minutes at 37°C) followed by stimulation with 10 nM fMLP.
known n e u tro p h il  a c t iv a t io n -a s s o c ia te d  m a rk e rs , C D 6 2 L  (L -selec- 
tin) a n d  C D  l i b ,  u s in g  2 -c o lo r  f lo w  cy to m e try . U p o n  a c tiv a t io n , 
C D 62L  is  c le a v e d  fr o m  th e  n e u tr o p h i l  s u r fa c e , w h erea s  C D l l b  
expression is u p re g u la te d  fo llo w in g  tr a n s lo c a t io n  f r o m  c y to p la s ­
mic g ra n u le s  to  th e  c e ll m e m b ra n e . F r e s h ly  is o la te d  n e u tro p h ils  
were p re tr e a te d  w ith  la c to fe r r in  a n d  th e n  e x p o s e d  to  th e  a c tiv a ­
tion s t im u li fM L P , T N F - a ,  a n d  P M A . As sh o w n  in  F ig u re  7 , A -D , 
we fo u n d  th a t ,  in  la c to fe r r in - tr e a te d  n e u tr o p h ils  c o m p a re d  w ith  
control ce lls , C D 6 2 L  e x p re ss io n  w as s ig n if ic a n t ly  h ig h e r , w h ereas 
C D l lb  lev els w ere lo w er. T h e s e  e f fe c ts  w ere c o m m o n  to  a ll  a c t i ­
vation s t im u li  u se d . T r a n s fe r r in - t r e a te d  n e u t r o p h i ls  w ere a lso  
includ ed b u t  sh o w e d  n o  s ig n i f i c a n t  d if fe r e n c e s  c o m p a r e d  w ith  
contro l ce lls . I t  is  n o te w o rth y  t h a t  th e  la c to fe r r in  e f fe c t  w as a lso  
evident w h e n  P M A , a  s p e c if ic  P K C  a c tiv a to r , w as u se d  as a n  a g o ­
nist, in d ic a t in g  th a t  la c to fe r r in  a c ts  d o w n s tre a m  o f  P K C  a n d  n o t  
on pathw ays in v o lv ed  in  P K C  a c tiv a t io n  a n d  C a 2J  re sp o n ses , su ch  
as the IP 3 a n d  D A G / P L C  p ath w ay s. T h is  f in d in g  p r o m p te d  u s to  
investigate p u ta tiv e  d o w n s tre a m  ta r g e ts  o f  P K C  in v o lv ed  in  th e  
late s ig n a lin g  c a sc a d e s  fo llo w in g  n e u tr o p h il  a c t iv a t io n  t h a t  a lso  
tegulate c e ll m o t i l i t y  a n d  a c t in  r e o r g a n iz a t io n .  S u c h  c a sca d e s  
involve th e  a c t iv a t io n  o f  M A P  fa m ily  k in a s e s  (3 4 ) ,  a n d  w e th e r e ­
fore ex a m in ed  th e  p h o s p h o r y la t io n  o f  p 4 4 / 4 2  (E R K 1  a n d  E R K 2 ) 
MAPKs. W h e re a s  in  u n tr e a te d  n e u tro p h ils , E R K 1  a n d  E R K 2  were 
ph osph orylated  fo llo w in g  fM L P  s t im u la t io n  (1 0 0  n M ), low er levels 
o f p h o sp h o ry la ted  E R K 1 / 2  w ere o b serv ed  in  n e u tro p h ils  th a t  h a d
b e e n  p re tre a te d  w ith  la c to fe r r in  p r io r  to  s t im u la t io n  w ith  fM L P  
(F ig u re  7 E ) . C o llec tiv e ly , th e s e  d a ta  s u g g e s t t h a t  la c to fe r r in  h a s  a  
c le a r  im p a c t  o n  n e u tr o p h il  a c t iv a t io n , in c lu d in g  im p a ir m e n t  o f  
n e u tro p h il  d e g ra n u la t io n , in h ib it io n  o f  e x p re ss io n  o f  (32  in te g r in s , 
a n d  re d u c tio n  o f  a c tiv a t io n  o f  in tra c e llu la r  k in a se s , w ith  p ro fo u n d  
e ffe c ts  o n  ce ll m ig ra t io n  a n d  m o tility .
Induction o f apoptosis upregulates lactoferrin expression and release 
in diverse cell types. P u r s u in g  o u r  in i t ia l  h y p o th e s is ,  w h ic h  w as 
s tre n g th e n e d  by  early  o b s e r v a tio n s  t h a t  in h ib i t io n  o f  n e u tr o p h il  
m ig ra t io n  b y  B L  ce lls  a p p e a re d  to  b e  c o rre la te d  w ith  B L  ce ll a p o p ­
to s is  (F ig u re  I E ) ,  w e a s s e s s e d  la c to fe r r in  e x p r e s s io n  fo l lo w in g  
in d u c t io n  o f  a p o p to s is  in  a  p a n e l o f  c e lls  o f  d iv erse  l in e a g e s . B y  
t r a n s c r ip t io n a l  a n a ly s is  u s in g  R T -P C R , w e fo u n d  t h a t  la c to f e r ­
r in  w as ex p re sse d , as re p o r te d  p re v io u s ly  (3 5 ) ,  by  M C F - 7  m a m ­
m a ry  e p ith e lia l ce lls  in  th e ir  v iab le  s ta te  b u t  n o t  by  Ju r k a t ,  B L 2 , o r  
A 5 4 9  ce lls . U p o n  a p o p to s is  in d u c tio n , la c to fe r r in  e x p re ss io n  w as 
u p re g u la te d  in  M C F -7  ce lls  a n d  e x p resse d  de n o v o  in  J u r k a t ,  B L 2 , 
a n d  A 5 4 9  ce lls  (F ig u re  8 ). M o re  sp e c if ic a lly , la c to fe r r in  w as t r a n ­
s c r ib e d  de n o v o  e a r ly  a f t e r  in d u c t io n  o f  a p o p to s is  in  A 5 4 9  ce lls  
b y  e ith e r  1 0 0  n M  e to p o s id e  o r  1 p M  s ta u r o s p o r in e  (F ig u re  8 B). 
L evels o f  la c to fe r r in  in d u c e d  b y  e to p o s id e  w ere re d u c e d  in  c e lls  
tr e a te d  in  th e  p re se n ce  o f  th e  b r o a d -s p e c t r u m  c a sp a se  in h ib i to r  
zV A D -fm k , w h ich  p re v en ted  a p o p to s is  in d u c tio n  (F ig u re  8 C ). T h e  
l in k  b e tw ee n  la c to fe r r in  e x p re s s io n  a n d  a p o p to s is  in d u c tio n  w as 
fu r th e r  su p p o r te d  by  th e  e f fe c ts  o f  th e  a p o p to s is  in h ib i to r  B c l-2 .








C = l-L T F
H i+ L T F
100 
«  80 
£ 60
700
_  600 
LL
500 
B  400 
^  300









Effect of lactoferrin on neutrophil activation status. The 
expression of CD62L (A and B) and CD11b (C and D) 
was assessed in fMLP- (100 nM), TN F-a- (1 ng ml), or 
PMA-stimulated (100 nM) neutrophils (30 minutes at 
37°C) that were preincubated (40 minutes at 37°C) in 
the presence or absence of lactoferrin (10 pg/ml). Rep­
resentative flow cytometry overlays of CD62L (A) and 
CD11b (C) expression in control (gray) and stimulated 
neutrophils (lactoferrin-treated: red; untreated: blue). 
n  = 3; *P < 0.05, **P < 0.01. Error bars indicate SEM. 
(E) Western blot analysis to determine levels of ERK1/2 
phosphorylation. Neutrophils were incubated with lacto­
ferrin (10 pg/ml; 40 minutes at 37°C), followed by stimu­
lation with fMLP (100 nM) for the indicated times. Mem­
brane was stripped and reprobed for total ERK2. Results 
are representative of 3 independent experiments.
fMLP
LTF -  -  -
(min) 0 3 5 7
42 kDa P -E R K 1 /2  
I 42 kDa ERK2
BL cells ex p re ss in g  e x o g e n o u s  B c l-2  th a t  p ro v id ed  p ro cecc io n  fro m  
ap op tosis e x p re sse d  lo w e r lev els o f  la c to fe r r in  u p o n  e x p o s u re  to  
s ta u ro sp o rin e  th a n  d id  th e ir  p a r e n ta l  c o u n te r p a r ts  (F ig u re  8 , A 
and D ). N o t o n ly  w as a p o p to s is -re la te d  la c to fe rr in  ex p ressio n  d e m ­
on strated  a t  th e  tr a n s c r ip t io n a l  level, la c to fe r r in  p ro te in  w as a lso  
recovered f r o m  s u p e rn a ta n ts  o f  ce lls  u n d e rg o in g  a p o p to s is  (F ig u re  
8D). T r e a tm e n t  o f  A 5 4 9  c e lls  w ith  b re fe ld in  A , w h ic h  in te r fe re s  
with in tra c e llu la r  tr a n s p o r t  o f  new ly sy n th esize d  p ro te in s , re su lte d  
in in h ib it io n  o f  a p o p to s is - in d u c e d  la c to fe r r in  re le a se , p ro v id in g  
further ev id en ce fo r  de n o v o  sy n th e s is  a n d  s e c re tio n  o f  la c to fe r r in  
by cells u n d e rg o in g  a p o p to s is  (F ig u re  8 E ) . A n  a n a lo g o u s  e f fe c t  w as 
also ev id en t f r o m  s u p e r n a ta n ts  o b ta in e d  fr o m  p r im a ry  ly m p h o ­
cytes in d u ced  to  b e c o m e  a p o p to tic  in  th e  p re sen ce  o f  1 p M  s ta u ro ­
sporine. F in a lly , im m u n o b lo t t in g  an a ly ses a n d  c h e m o ta x is  assays 
using s u p e r n a ta n ts  o f  B L  ce lls  u n d e rg o in g  p r im a ry  n e c ro s is  fu r­
ther revealed t h a t  th e  re lease  o f  la c to fe r r in  is  n o t  lin k e d  to  n e c ro s is  
but th a t la c to fe r r in  is  e x p resse d  a n d  activ e ly  re leased  fr o m  ce lls  as 
a co n seq u en ce  o f  a c t iv a t io n  o f  th e ir  a p o p to s is  p ro g ra m  (F ig u re  8 F  
and S u p p le m e n ta l F ig u re  3 ).
Discussion
A poptosis p lays a  k ey  ro le  in  re g u la t in g  ce ll p o p u la t io n s  th ro u g h  
p rog ram m ed  c e ll  d e a th , a n  in t r in s ic a l ly  n o n - p h lo g is t ic  p ro ce s s  
that c o n tra s ts  w ith  a c c id e n ta l ,  n e c r o t ic  ce ll d e a th , w h ich  h a s  p ro- 
in flam m ato ry  c o n s e q u e n c e s . D e f in in g  th e  p ro p e rtie s  o f  a p o p to tic  
cells th a t c o n tr ib u te  to  th e  n o n in f la m m a to r y  o r  a n t i in f la m m a to ­
ry n atu re o f  th e  a p o p to s is  p ro g ra m  is c r it ic a l  to  o u r  u n d e rs ta n d ­
ing o f  th is  fu n d a m e n ta l  b io lo g ic a l  p ro c e s s . W e h av e n o w  id e n t i­
fied la c to fe rr in  as a  c e l l -a u to n o m o u s  a n ti in f la m m a to r y  m e d ia to r
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th a t  is p ro d u c e d  b y  c e lls  o f  d iv erse lin e a g e s  u n d e rg o in g  a p o p to s is . 
F u r th e r m o r e , th e se  s tu d ie s  d e m o n s tr a te  a  h ith e r to  u n re co g n iz e d  
im m u n o m o d u la to r y  fu n c t io n  o f  la c to fe r r in :  to  in h ib i t  d ir e c tly  
th e  m ig ra t io n  o f  n e u tr o p h il  g ra n u lo cy te s . L a c to fe r r in  is th e re fo re  
a  c o n s t i tu t iv e  a n t i in f la m m a to r y  c o m p o n e n t  o f  a p o p t o t ic  c e lls  
th a t ,  in  a d d itio n  to  its  k n o w n  a n t i in f la m m a to r y  p ro p e r t ie s , m ili­
ta te s  a g a in s t  th e  p r o in f la m m a to r y  r e c r u i tm e n t  o f  g r a n u lo c y te s  
to  s ite s  o f  a p o p to s is .
F irs t d iscovered  in  m ilk  a lm o s t 7 0  years ag o , la c to fe rr in  is a  h ig h ly  
p le io tr o p ic  ir o n -b in d in g  g ly c o p r o te in  c lo s e ly  r e la te d  to  tr a n s fe r ­
rin  t h a t  is  a  w e ll-k n o w n  c o n s t i t u e n t  o f  e x o c r in e  s e c r e t io n s  a n d  
se co n d a ry  g ra n u le s  o f  n e u tro p h ils . I t  h a s  m a n y  a n t i in f la m m a to r y  
a n d  im m u n o r e g u la to ry  p ro p e rt ie s , a n d  th e  m a jo r ity  o f  th e s e  are 
n o t  re la ted  to  its  a b ility  to  c h e la te  iro n , a lth o u g h  so m e  o f  its  b a c te ­
r io s ta tic  fe a tu res  are d e p e n d e n t o n  iro n  b in d in g  ( 3 6 ,3 7 ) .  I ts  a b ility  
to  in h ib i t  n e u tro p h il  m ig ra t io n , as d e scr ib e d  h ere , is  a n  a d d itio n a l 
a n ti in f la m m a to r y  fe a tu r e  o f  th e  m o le c u le  t h a t  is  in d e p e n d e n t o f  
i ts  iro n -c h e la tin g  activ ity . In  a d d itio n  to  its  w e ll-e s ta b lish e d  a n t i ­
m ic r o b ia l  p r o p e r t ie s ,  la c to fe r r in  c a n  in h ib i t  p r o in f la m m a to r y  
re sp o n se s  n o t  o n ly  th ro u g h  its  a b ility  to  b in d  to  key  c o m p o n e n ts  
o f  b a c te r ia  a n d  v ir u s e s , b u t  a ls o  th r o u g h  its  d ir e c t  a c t iv ity  o n  
in n a te  im m u n e  ce lls  a n d  m o le cu le s  (3 6 , 3 7 ) .  T h u s , la c to fe r r in  ca n  
in h ib it  p ro d u c tio n  o f  p r o in fla m m a to r y  m e d ia to rs  su ch  as T N F - a  
a n d  IL -6  (3 8 , 3 9 )  a n d  c a n  p ro m o te  p r o d u c tio n  o f  a n t i in f la m m a ­
to ry  m e d ia to rs  in c lu d in g  IL -1 0 , IL -4 , a n d  T G F -(31  ( 4 0 ,4 1 ) .
T h e  id e n t if ic a t io n  o f  sp e c ia liz e d  h ig h - o r  lo w -a ff in ity  la c to fe r ­
rin  re ce p to rs  o n  h u m a n  n e u tro p h ils  p ro v id es  a n  in it ia l  m e c h a n is ­
t ic  in s ig h t  in to  h o w  la c to fe r r in  e x e rts  its  in h ib i to r y  e f fe c t  o n  th e  
n e u tr o p h il  m ig r a t io n  m a ch in e ry . T h is  is  in  a c c o r d a n c e  w ith  o u r
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Figure 8
Induction of apoptosis upregulates lactoferrin expression and release. (A) RT-PCR analysis In cell lines stimulated to undergo apoptosis (A) and 
unstimulated controls (V). MCF7 cells transfected with caspase-3 (25.4% apoptosis; 100 pM etoposide, 20 hours), Jurkat (18.4% apoptosis; 
1 pM staurosporine, 3 hours), BL2 (12.46% apoptosis), and BL2/Bcl-2 (7.42% apoptosis; 1 pM staurosporlne, 1 hour). The lanes were run on the 
same gel but, where indicated by the vertical lines, were noncontiguous. (B) Lactoferrin expression in A549 cells at defined time points (hours) fol­
lowing stimulation with 100 pM etoposide or 1 pM staurosporine. (C) Addition of pan-caspase inhibitor zVAD-fmk (100 pg/ml) for 12 hours In order 
to prevent etoposlde-lnduced apoptosis In A549 cells. (D) Immunoblot analysis of cell supernatants from: BL2 and primary lymphocytes in the 
presence (+) or absence (-) of staurosporine (1 pM) In serum-free conditions for 1 hour. A549 cells were stimulated with (+) or without (-) 100 pM 
etoposide for 5 hours. All samples were run on the same gel. Noncontiguous samples of A549 cells and lymphocytes (Lymph) are indicated 
by the vertical lines. (E) A549 cells were induced to become apoptotlc (100 pM etoposide; 20 hours) in the presence or absence of brefeldin A 
(1 pg/ml), a protein release inhibitor. (F) Immunoblot analysis of cell supernatants from control BL2 cells (1 x 106/ml) induced to undergo apop­
tosis (1 pM staurosporine, 1 hour) or primary necrosis (56°C, 1 hour) in serum-free conditions. St, staurosporine; con; control; Etop, etoposide.
results d e m o n s t r a t in g  t h a t  la c to fe r r in  b in d s  d ir e c tly  to  n e u t r o ­
phils a n d  im p in g e s  o n  in t r a c e l lu la r  s ig n a lin g  ev en ts  c o u p le d  to  
n eu trop h il a c t iv a t io n , r a th e r  th a n  in te r a c t in g  w ith  c h e m o a ttr a c -  
tants an d  m o d u la t in g  th e ir  activ ity . M o reo v er, th e  la tte r  p o ss ib ility  
was fu rth e r  e x c lu d ed  b y  th e  fa c t  th a t  th e  o b serv ed  in h ib ito ry  e ffe c t  
o f la c to fe rr in  w as (a) s p e c if ic  to  n e u tro p h il , n o t  m o n o c y te , m ig ra ­
tion, (b) o b se rv e d  w ith  a  d iv ersity  o f  c h e m o a ttr a c ta n ts ,  a n d  (c) n o t  
directly n e u tr a l iz e d  by  c h e m o a t tr a c t a n t s .  C o n s is te n t  w ith  o th e r  
studies (2 6 , 2 7 ) ,  o u r  re s u lts  d e m o n s tr a te d  2  c la sses  o f  la c to fe r r in  
receptor o n  th e  s u r fa c e  o f  h u m a n  n e u tro p h ils . O u r  re su lts  in d ica te  
that a  re la tiv ely  h ig h -a f f in ity  re c e p to r  is  exp ressed  a t  re la tiv ely  lo w  
density a n d  t h a t  a  re la tiv e ly  lo w -a ff in ity  r e c e p to r  is  ex p resse d  a t  
relatively h ig h  d e n sity . H ow ever, th e  d e ta ile d  c h a r a c te r iz a t io n  o f  
the la c to fe rr in  re ce p to r(s ) a n d  d isse c t io n  o f  d o w n stre a m  s ig n a lin g  
pathways r e m a in  a  s ig n if ic a n t  c h a lle n g e , as la c to fe r r in  h a s  b e e n  
extensively r e p o r te d  to  in t e r a c t  w ith  a  ra n g e  o f  m o le c u le s  a n d  
receptors in  a  c e ll-s p e c if ic  m a n n e r  a n d  th e re fo re  h as  th e  p o te n t ia l  
to elicit d if fe re n t  s ig n a lin g  ca sca d es  in  d if fe re n t ce ll ty p es. In d eed , 
many re s e a rc h e rs  o v e r  m a n y  y e a rs  h av e  a t te m p te d  th e  d e ta ile d  
ch a ra cte riz a tio n  o f  la c to fe r r in  re c e p to rs  f r o m  v a r io u s  c e ll ty p es 
with on ly  p a r t ia l  su cce ss , a n d  m a n y  c a n d id a te  re ce p to rs  have b een  
proposed fo r  d i f fe r e n t  c e ll  ty p es. Im p o r ta n tly , as h a s  b e e n  s u g ­
gested e lsew h ere  (4 2 ) ,  c r i t ic a l  d if f ic u lt ie s  in  th e  id e n t if ic a t io n  o f  
specific la c to fe r r in  re ce p to rs  s te m  fr o m  th e  c a t io n ic  n a tu r e  o f  th e  
lactoferrin  p ro te in , a llo w in g  i t  to  b in d  to  a n io n ic  m o le cu le s  fo u n d  
in v irtually  a ll c e ll ty p es.
Here, we have o b se rv e d  sev era l e f fe c ts  o f  la c to fe r r in  o n  ce ll a c t i ­
vation w ith  c le a r  im p lic a t io n s  fo r  m ig ra t io n , a d h e s io n , a n d  m o ti l ­
ity o f  n e u tro p h ils . T h e  in i t ia l  p h a se  o f  n e u tr o p h il  a c tiv a t io n  fo l ­
lowing a g o n is t  s t im u la t io n  is c h a r a c te r iz e d  by  a  ra p id  in cre a se  in  
[C a2* ] i,  w h ic h  in  tu r n  tr ig g e r s  th e  a c t iv a t io n  o f  P K C  as w ell as a 
range o f  c a lc iu m -d e p e n d e n t  s ig n a lin g  p a th w ay s th a t  c o n tr o l  key 
neutrophil e f fe c to r  fu n c t io n s ,  in c lu d in g  d e g ra n u la t io n , cy to sk e l- 
etal re a r r a n g e m e n ts , a n d  c e l l  m ig r a t io n  (3 2 ,  4 3 - 4 5 ) .  O u r  d a ta
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c le a rly  s u g g e s t  th a t  th e  o b se rv e d  la c to fe r r in -m e d ia te d  in h ib ito r y  
e f fe c ts  o n  n e u tr o p h il  c h e m o ta x is  c o u ld  b e  a t t r ib u te d  to  m o d u la ­
t io n  o f  m o le c u le s  o th e r  th a n  th o s e  in v o lv ed  in  th e  C a 2*j re sp o n s e  
fo llo w in g  a g o n is t  s t im u la t io n . In  a d d itio n , a n a ly sis  o f  th e  e x p res­
s io n  o f  early  a c t iv a t io n  m a rk e rs  s u c h  as C D 6 2 L  a n d  C D l l b  fo l ­
lo w in g  s t im u la t io n  w ith  d iv erse  n e u tr o p h il  a g o n is ts ,  in c lu d in g  
P M A , a  s p e c if ic  s y n th e t ic  in t r a c e l lu la r  a c t iv a to r  o f  P K C , fu r th e r  
su g g e sts  th a t  la c to fe r r in  a c ts  d o w n s tre a m  o r  in d e p e n d e n tly  o f  th e  
P K C  p athw ay, a ffe c t in g  s ig n a lin g  ca sca d e  c o m p o n e n ts  o f  th e  la te r  
p h a ses  o f  n e u tro p h il  a c tiv a t io n . T h is  n o t io n  w as s tr e n g th e n e d  by 
o u r  o b s e r v a tio n  t h a t  la c to fe r r in  in h ib i te d  th e  p h o s p h o r y la t io n  
o f  p 4 4 / 4 2  (E R K 1  a n d  E R K 2 )  M A P K s, in d ic a t in g  t h a t  i t s  a c t io n  
is  m e d ia te d , a t  le a s t  in  p a rt , v ia  th e  M A P K  p a th w a y , a  k e y  p a t h ­
w ay d o w n s tre a m  o f  P K C  w ith  a  c r u c ia l  ro le  in  th e  r e g u la t io n  o f  
cy to s k e le ta l re a rra n g e m e n t a n d  c e ll a d h e s io n  ( 4 6 - 4 8 ) .  T h e  p re v i­
o u sly  re p o rte d  sp e c ific  in te r a c t io n  o f  la c to fe r r in  w ith  th e  c a lc iu m - 
c a lm o d u lin  co m p le x  (C a2+/ C aM ) p ro v id es  fu r th e r  in s ig h t  in to  th e  
p o te n t ia l  in t r a c e l lu la r  s ig n a lin g  ta r g e ts  o f  la c to fe r r in  (4 9 ) .  T h e  
C a 2y C a M  co m p le x  is fo rm e d  fo llo w in g  th e  in c re a se  in  [C a2*]j an d  
P K C  a c tiv a t io n  a n d  re g u la te s  th e  a c tiv ity  o f  a  n u m b e r  o f  p ath w ay s 
in v o lv ed  in  c e ll a d h e s io n  a n d  m ig r a t io n ,  in c lu d in g  th e  E R K 1 / 2  
k in a se s  (5 0 ) . In d e e d , th e  u se  o f  s p e c if ic  in h ib i to r s  o f  c a lm o d u lin  
a c tiv ity  h a s  b e e n  d e m o n s tr a te d  to  m im ic  th e  e f fe c t  o f  la c to fe r r in  
— in h ib it io n  o f  n e u tro p h il  m ig ra t io n  — re p o r te d  h ere  ( 5 1 - 5 3 ) .
L a c to fe r r in  h a s  b e e n  sh o w n  p re v io u sly  to  b in d  to  r e c e p to rs  o n  
m o n o n u c le a r  p h ag o cy tes a n d  to  in h ib it  p ro in fla m m a to ry  resp o n ses  
v ia  N F - k B  (3 9 ,  5 4 ,  5 5 ) .  T a k e n  to g e th e r  w ith  th e  e v id e n c e  t h a t  
a p o p to tic  cells c a n  su p p ress  p r o in fla m m a to r y  re sp o n se s  o f  m o n o ­
n u c le a r  p h a g o c y te s  a n d  ca n  e lic it  a n t i in f la m m a to r y  re sp o n s e s  by 
th e se  ce lls  ( 1 0 ,1 1 ) ,  o u r  re su lts  in d ica te  th a t  i t  is n o w  re a so n a b le  to  
s u s p e c t th a t  th e se  e ffe c ts  a re  m e d ia te d , a t  le a s t  in  p a rt , by  la c to fe r ­
r in  p ro d u ce d  by  a p o p to tic  ce lls . H ow ever, th e  in v o lv e m e n t o f  th e  
N F -k B  p a th w a y  in  th e  in h ib i t io n  o f  n e u tr o p h il  m ig r a t io n  see m s 
u n lik e ly , s in ce  la c to fe r r in -m e d ia te d  in h ib i t io n  o f  c h e m o ta x is  o f
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n eu trop h ils  tr e a te d  w ith  g lio to x in , a  s p e c if ic  N F -k B  in h ib ito r ,  w as 
found to  b e  id e n t ic a l  to  th a t  o f  u n tr e a te d  ce lls  (d a ta  n o t  sh o w n ). 
In a d d itio n , n o  c h a n g e s  in  th e  levels o f  Ik B, a n  in h ib i to r  o f  N F -k B  
th at is d e g ra d e d  fo l lo w in g  N F - k B  a c t iv a t io n ,  w ere o b s e r v e d  in  
W estern b lo t  a n a ly sis  o f  fM L P -s tim u la te d  n e u tro p h ils  tre a te d  w ith  
or w ith o u t la c to fe r r in  (d a ta  n o t  sh o w n ).
In  g e n e ra l te r m s , in  p ro fe s s io n a l  p h a g o c y te s , s e n s in g  m e c h a ­
nism s t h a t  a re  n o t  y e t w ell d e fin e d  a llo w  th e se  ce lls  to  n a v ig a te  
to a p o p to tic  ce lls  th r o u g h  c h e m o ta c t ic  p ro c e s se s  in v o lv in g  lip id  
sign aling  m o le c u le s  a n d  c la s s ic a l c h e m o k in e  m e c h a n is m s  (1 , 2 ). 
It is n o te w o r th y  t h a t  o f  th e  2  c a te g o r ie s  o f  p ro fe s s io n a l  p h a g o ­
cytes — m o n o n u c le a r  (m o n o cy te s  an d  m a cro p h a g e s) a n d  p o ly m o r­
p h o n u clear (g ra n u lo c y te s ) — a p o p to tic  ce lls  a t t r a c t  m o n o n u c le a r  
p h ag o cy tes se le c t iv e ly  (1 2 ) .  In d e e d , th e  la c k  o f  r e c r u i tm e n t  o f  
granu locytes to  a p o p to tic  z o n e s  is a  h a llm a rk  o f  th e  n o n -p h lo g is -  
tic a p o p to s is  p ro g ra m , d is t in g u is h in g  n o r m a l a re a s  o f  c e ll d e a th  
from site s  o f  a c c id e n ta l o r  p a th o lo g ic a l tissu e  d a m a g e  o r  in fe c tio n . 
Recent e v id e n ce  su g g e s ts  t h a t  c e r ta in  r e c o m b in a n t  p re p a ra t io n s  
o f la c to fe rr in  h ave th e  p o te n t ia l  to  c h e m o a t tr a c t  m o n o c y te s  (5 6 ) . 
A lthough w e fa ile d  to  o b serv e  m o n o c y te  a t t r a c t io n  to  la c to fe r r in  
in o u r s tu d ie s  w ith  m ilk -d e r iv e d  la c to fe r r in ,  th e s e  r e s u lts  in d i­
cate th a t  la c to fe r r in  h a s  th e  p o te n t ia l  to  fu n c t io n  in  th e  se lec tiv e  
a ttra c tio n  o f  m o n o c y te s  b u t  e x c lu s io n  o f  g r a n u lo cy te s  f r o m  site s  
o f a p o p to s is . O u r  o b s e r v a tio n  t h a t  la c to fe r r in , re le a se d  in t o  th e  
su p e rn a ta n ts  o f  a p o p t o t ic  c e lls , is  a b le  to  in h ib i t  th e  m ig r a t io n  
o f n e u tro p h ils , d e m o n s tra te s  n o t  o n ly  th a t  p h y s io lo g ic a l c o n c e n ­
tration s o f la c t o f e r r in  are  fu n c t io n a l  in  m e d ia t in g  th is  e f fe c t  b u t  
also th a t  a p o p to t ic  c e lls  a re  a c tiv e  in  p ro d u c in g  a  fa c to r  t h a t  ca n  
p otently  su p p re s s  m ig r a t io n  o f  n e u tr o p h ils ,  th e  m a jo r  su b s e t  o f  
p ro fession al p h a g o c y te s  a m o n g  c ir c u la t in g  le u k o cy te s , to  s ite s  o f  
apoptosis. A lth o u g h  i t  is c le a r  th a t  th e  s e c re to ry  ev en ts  in h ib ite d  
by b re fe ld in  A  t r e a tm e n t  ( t r a n s p o r t  f r o m  th e  E R  a n d  G o lg i n e t ­
work) a re  im p o r ta n t  fo r  th e  re le ase  o f la c t o f e r r in  f r o m  a p o p to tic  
cells, fu r th e r  w o rk  w ill b e  re q u ire d  to  e lu c id a te  th e  d e ta ils  o f  th is  
secretory p ro c e s s  — in c lu d in g  w h e th e r  la c to fe r r in  is  tr a n s p o r te d  
directly f r o m  G o lg i m e m b ra n e s  fo r  re lease fr o m  th e  c e ll su rfa ce .
W hile n e u tr o p h i ls  m a y  la c k  th e  s e n s in g  m e c h a n is m s  to  g u id e  
them  to  s ite s  o f  a p o p to s is ,  th e  c o n s t i tu t iv e  p r o d u c t io n  o f  a  fa c ­
tor th a t  b lo c k s  n e u tr o p h i l  m ig r a t io n  to  s u c h  s ite s  is  lik e ly  to  be 
im p o rta n t w h e n  th e  a p o p to s is  p ro g ra m  is a c tiv a te d  in  th e  p re s ­
ence o f  s ig n a ls  t h a t  p r o m o t e  n e u t r o p h i l  r e c r u i tm e n t  d u r in g  
in f la m m a to ry  re s p o n s e s . In  th is  c o n t e x t ,  i t  is  n o te w o r th y  t h a t  
lacto ferrin  is  a c tiv e  in  in h ib i t in g  IL -8  p r o d u c tio n  b y  e n d o th e lia l  
cells (5 7 ) . F u r th e r m o r e , la c to fe r r in ’s a b ility  to  in h ib i t  n e u tr o p h il  
m ig ra tio n  is  l ik e ly  to  b e  im p o r ta n t  in  th e  r e s o lu t io n  o f  a c u te  
in f la m m a tio n . T h u s ,  o u r  re s u lts  s u g g e s t t h a t  la c to fe r r in  a r is in g  
from th e  s e c o n d a ry  g ra n u le s  o f  n e u tr o p h ils  a n d  fr o m  a p o p to tic  
cells c o n s t i tu t e s  a  n e g a tiv e  fe e d b a c k  c o m p o n e n t  t h a t  l im its  th e  
influx o f  n e u tr o p h ils  to  in f la m m a to r y  s ite s . W e w o u ld  sp e cu la te  
that n e u tr o p h ils  u n d e rg o in g  a p o p to s is  e n  ro u te  to  r e s o lu tio n  o f  
in fla m m a tio n  w o u ld  re lease  la c to fe r r in  as d o  o th e r  a p o p to tic  ce lls  
but w ou ld  b e  u n lik e ly  to  b e  re q u ire d  to  s y n th e s iz e  th e  p r o te in  de 
novo. T h e  n eg a tiv e  re g u la to ry  a c tiv ity  o f la c to fe r r in  d e scr ib ed  h ere 
places i t  as o n e  o f  th e  few  m o le c u le s , a lo n g s id e  l ip o x in s , n e tr in -1 , 
and a n n e x in -1 ,  t h a t  n e g a t iv e ly  re g u la te  n e u t r o p h i l  m ig r a t io n  
(21, 5 8 , 5 9 ) .  M o r e  im p o r ta n t ly , b a se d  o n  th e  h ig h  s p e c if ic i ty  o f  
its m ig r a t io n - in h ib ito r y  p ro p e r t ie s  to  n e u tr o p h ils ,  la c to fe r r in  is 
id entified  h e re  as a  p r o m is in g  th e r a p e u t ic  ta r g e t  fo r  a  ra n g e  o f  
chronic in f la m m a to r y  c o n d itio n s , in c lu d in g  v a scu litis , p u lm o n a ry  
fibrosis, a n d  isch e m ia / re p e rfu s io n  in ju ry , th a t  are ch a ra cte riz e d  by
excessiv e  n e u tr o p h il  in f i l t r a t io n  le a d in g  to  n e u tr o p h il-m e d ia te d  
h o s t  tissu e  d a m a g e  a n d  re m o d e lin g  (1 9 ) .
S in c e  th e  p ro p e rt ie s  o f la c t o f e r r in  e x te n d  w ell b e y o n d  its  a b ility  
to  re g u la te  in fe c t io n ,  im m u n e  re s p o n s e s , a n d  in f la m m a t io n ,  th e  
l in k  e s ta b lis h e d  h e re  b e tw e e n  la c to fe r r in  p r o d u c t io n  a n d  a p o p ­
to s is  h as m a n y  a d d itio n a l im p lic a t io n s . F ir s t ,  la c to fe r r in ’s a b ility  
to  a c t  as a  g ro w th  fa c to r  (6 0 ,  6 1 )  e x te n d s  ev id e n ce  c o u p lin g  th e  
a p o p to s is  p ro g ra m  w ith  tis s u e  re p a ir  re sp o n s e s  (6 2 , 6 3 ) . S e c o n d , 
a d d itio n a l re ce n t ev id en ce  s u g g e s ts  t h a t  its  p ro te a se  a c tiv ity  m ay 
b e  in s tr u m e n ta l  in  a c t iv a t in g  th e  c a s p a s e  c a sc a d e . In  p a r t ic u la r ,  
e n d o g e n o u s  la c to fe r r in  h a s  b e e n  r e p o r te d  b y  2  g r o u p s  to  in d u c e  
a p o p to s is  th r o u g h  a c tiv a t io n  o f  c a s p a se -3  (6 4 ,  6 5 ) .  I t  is te m p tin g  
to  s p e cu la te  th a t  th e  d e n o v o  s y n th e s is  o f la c t o f e r r in  b y  ce lls  tr ig ­
g e red  to  u n d e rg o  a p o p to s is  in  o u r  s tu d ie s  is  l in k e d  to  th e  in i t ia ­
t io n  o f  th e  a p o p to s is  p ro g ra m  as w ell as to  i t s  a n t i in f la m m a to r y  
fe a tu re s . T h e r e fo r e , la c to fe r r in  m a y  h av e  m u lt ip le  p r o p e r t ie s  in  
a p o p to s is : (a) re g u la t in g  th e  in i t ia t io n  o f  th e  p ro g ra m , (b ) in f lu ­
e n c in g  re p a ir  in  th e  tis s u e  m ic r o e n v ir o n m e n t, a n d  (c) p r o m o t in g  
th e  n o n -p h lo g is t ic  n a tu r e  o f  th e  p ro cess .
L a c t o f e r r in ’s f u n c t io n s  in  r e la t io n  to  tu m o r  b io lo g y  a re  c u r ­
r e n tly  u n c le a r . P ro te o ly z e d  fo r m s  o f  e x o g e n o u s  la c to fe r r in  h ave 
b e e n  re p o r te d  to  h ave p r o a p o p to t ic  a n d  a n t i tu m o r  a c tiv it ie s . In  
a d d itio n , la c to fe r r in  ap p e a rs  to  p ro m o te  a n t itu m o r  h o s t  im m u n e  
re s p o n s e s  (3 7 ) ,  a n d  a c t iv a t io n  o f  a n t ig e n -p r e s e n t in g  c e lls  h a s  
re ce n tly  b een  re p o rte d  u s in g  h ig h  d o se s  o f  re c o m b in a n t  la c to fe rr in  
p ro d u c e d  in  Aspergillus (5 6 ) . I t s  o b serv ed  e ffe c ts  o n  ce ll g ro w th  are 
in c o n s is te n t ,  a n d  b o th  g r o w th -p r o m o tin g  a n d  g r o w th -in h ib it in g  
e ffe c ts  have b een  re p o rte d  (6 0 , 6 1 , 6 6 ,  6 7 ) ,  s u g g e s t in g  th e  p o ss ib le  
im p o rta n c e  o f  tissu e  c o n te x t .  S in c e  la c to fe r r in  h a s  p o te n t  a b ility  
to  in h ib i t  n e u tr o p h il  m ig r a t io n , i t  se e m s lik e ly  t h a t  in  tu m o r s  in  
w h ich  n e u tro p h ils  p lay  a  su p p o rtiv e  ro le , l im ita t io n  o f  n e u tro p h il  
in f i l t r a t io n  th r o u g h  la c to fe r r in  a d m in is t r a t io n  c o u ld  b e  th e r a ­
p e u tica lly  b e n e fic ia l. H ow ever, in  tu m o r s  in  w h ich  n e u tro p h ils  are 
a b se n t, w e p ro p o se  th a t, g iv en  th e  k n o w n  a n t itu m o r  e ffe c ts  o f  n e u ­
tro p h ils  (6 8 - 7 1 ) ,  e n c o u ra g e m e n t o f  n e u tro p h il  in f ilt r a t io n  th ro u g h  
in h ib it io n  o f la c to fe r r in  m a y  e f fe c t  tu m o r  d e s tr u c tio n . O u r  re su lts  
m ig h t p re d ic t th a t  tu m o rs  in  w h ich  a p o p to s is  is  p r o m in e n t  w o u ld  
p ro d u ce  la c to fe r r in  in  s itu . W h ile  th is  s u g g e s t io n  re q u ire s  p ro p e r  
in v e stig a tio n , a t  le a s t  in  o n e  ca teg o ry , B L , a  h ig h -g ra d e  m a lig n a n c y  
in  w h ich  h ig h -ra te  a p o p to s is  o c cu rs , in  s itu  p ro d u c tio n  o f la c to fe r ­
rin  p ro te in  h as  b een  k n o w n  fo r  m a n y  y ears (7 2 ) .
In  c o n c lu s io n , w e d e scr ib e  a  n o v el h o m e o s ta t ic  fu n c t io n  fo r  th e  
h ig h ly  p le io tr o p ic  im m u n o m o d u la to r y  g ly c o p r o te in  la c to fe r r in . 
W e d e m o n s tra te  th a t  la c to fe r r in  p r o d u c tio n  is  c lo s e ly  c o u p le d  to  
th e  fu n d a m e n ta l  ce ll d e a th  p ro g ra m , a p o p to s is .  In  th is  re sp e c t, 
la c to fe r r in  is  m u c h  m o re  g e n e ra lly  ex p resse d  th a n  p re v io u sly  rea l­
ized . O u r  re su lts  sh o w  th a t  la c to fe r r in  en d o w s a p o p to tic  ce lls  w ith  
a n t i in f la m m a to r y  p r o p e r t ie s ,  in c lu d in g  th e  c a p a c ity  to  in h ib i t  
n e u tr o p h il  m ig ra t io n . G iv e n  th e  m u lt i f u n c t io n a l  a b ilit ie s  o f l a c ­
to fe r r in , th e se  re s u lts  h ave b ro a d  im p lic a t io n s  fo r  th e  in f lu e n c e  
o f  a p o p to tic  ce lls  o n  m u lt ip le  p h y s io lo g ic a l  p ro c e s se s , in c lu d in g  
c e ll  g r o w th , d i f f e r e n t ia t io n ,  a n d  in n a t e  a n d  a d a p tiv e  im m u n e  
re sp o n s e s , as w ell as th e  p a th o lo g ic a l  p ro c e s se s  o f  in f la m m a to r y  
a n d  m a lig n a n t d iseases.
Methods
Antibodies and reagents. T h e  fo llo w in g  a n tib o d ie s  an d  reag en ts w ere used  in 
th is  study: ra b b it p o lyclo n al a n t i-h u m a n  la c to fe rr in  Ig G  a n tib o d y  (S ig m a- 
A ld rich ), m o u se  m o n o c lo n a l a n t i-h u m a n  la c to fe r r in  a n tib o d ie s  (L F -2 B 8 , 
A bD  Sero tec ; im a b 7 5  an d  im a b 7 7 , Im m u n o S o lv ), ra b b it p o lyclo n al im m u -
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noglobulin  (Ig G ) n eg ativ e  c o n tro l (D a k o ), Ig G l  iso ty p e co n tro l (S ig m a- 
Aldrich), a l lo p h y c o c y a n in -c o n ju g a te d  (A P C -c o n ju g a te d ) a n t i - C D l l b  
(m lgG l; B D ), F IT C -c o n ju g a te d  a n ti-C D 6 2 L  (m lg G l ;  A b D  S ero tec), p u r i­
fied h u m an  la c to fe rr in  fro m  m ilk  (S ig m a-A ld rich ), p u rified  h u m an  lacto - 
ferrin fro m  n e u tro p h ils  (A th en s R esearch  an d  T ech n o lo g y ), re co m b in a n t 
human la c to fe r r in  (S ig m a-A ld rich ), h u m a n  re co m b in a n t ap o lacto ferrin /  
h o lo lacto ferrin  (P ro S p e c ), p u r ifie d  h u m a n  tra n s fe rr in  (S ig m a -A ld rich ), 
reco m bin an t h u m a n  T N F - a  (R & D  B io s c ie n c e ) , PM A  (S ig m a -A ld ric h ), 
fMLP (S ig m a-A ld rich ), C 5 a  (S ig m a -A ld rich ), IL -8  (S ig m a-A ld rich ), L T B 4 
(S ig m a-A ld rich ), b r e fe ld in  A (S ig m a -A ld r ic h ), s ta u r o s p o r in e  (S ig m a - 
Aldrich), a n d  g lio to x in  (S ig m a -A ld rich ). F o r  la c to fe rr in  a b s o rp tio n  ch e- 
m oatrractants, each  ch e m o a ttr a c ta n t w as in cu b a ted  w ith  p u rified  h u m an  
milk la c to ferrin  (1 0  pg/m l), an d  a  m o u se  m o n o c lo n a l a n ti-h u m a n  la c to ­
ferrin an tib o d y  (L F -2 B 8 ; 10  pg/m l) o r  isoty p e co n tro l was added. A n tib o d ­
ies were co m p le te ly  rem ov ed  by B io M a g  g o a t a n t i-m o u s e  Ig G  (Q IA G E N ) 
magnetic b ead s, an d  th e  e ffic ie n cy  o f  a n tib o d y  rem ov al w as assessed  by 
analysis o f  th e  p reab so rb ed  c h e m o a ttr a c ta n ts  by  a n t i-m o u s e  Ig G  EL ISA  
(data n o t sh o w n ). F u r th e rm o re , th e  d ep leted  a n tib o d y  w as readily  recov ­
ered fro m  th e  bead s (d a ta  n o t  sh ow n ).
Cell isolation. F re sh  h u m a n  v en o u s b lo o d  w as co llec te d  fro m  v o lu n teers 
according to  th e  R o yal In firm a ry  o f  E d in b u rg h  (S co tla n d ) R esearch  E th ­
ics C o m m ittee  (ap p rov al 1702/ 95/ 3/ 11), a n d  m o n o n u cle a r  and  p o lym o r­
phonuclear (P M N ) leu k o cy te s  w ere iso la te d  as p rev iou sly  d escrib ed  (73). 
N eutrophils rep resen ted  m o re  th a n  95%  o f  iso la ted  P M N  cells. M o n ocy tes 
(>90% C D 1 4 + ce lls) w ere p o sitiv e ly  s e le c te d  fro m  iso la te d  m o n o n u c le a r  
leukocytes u s in g  C D 1 4  m a g n e tic  bead s (M ilten y i B io tec ). H u m an  m o n o ­
cyte-derived m acro p h ag es  were o b ta in e d  fo llo w in g  cu ltu re  o f  m on o cy tes 
for 6 days in  Isco v e ’s m o d ifie d  D u lb e c c o ’s m ed iu m  (IM D M ) c o n ta in in g  
10% au to lo g o u s serum .
Chemotaxis assay. In  v itro  leu k o cy te  ch e m o ta x is  was m easu red  fo llow in g  
a w ell-established  tr a n s f ilte r  cell m ig ra tio n  assay, as p reviou sly  d escribed  
(12) u sin g  p olyvinyl u n co a te d  T ran sw ell in se r ts  (5  p m  p o re size; C o star, 
Corning). T im e  o f  in c u b a t io n  ( 3 7 ° C ; 5%  C O z) v aried  fo r  ce ll type (n eu ­
trophils: 6 0  m in u te s ; m o n o c y te s : 9 0  m in u te s ; m a cro p h a g e s : 4  h o u rs). 
Unless o th e rw ise  s ta te d , la c to fe r r in  w as u sed  a t  10 pg/m l. C h e m o ta c tic  
agents in clu d ed  fM L P  (1 0 0  n M ; S ig m a  A ld rich ), C 5 a  (6 .2 5  ng/m l; S ig m a  
Aldrich), IL -8  (5 0  n M ; R & D  Sy stem s), an d  L T B 4 (1 0 0  n M ; S ig m a  A ld rich). 
For n eu tra liza tio n  ex p erim en ts , ra b b it p o ly c lo n al a n ti-h u m a n  lacto ferrin  
antibody (S ig m a A ld rich ) o r  negative co n tro l (D ak o) were used. F ilters  were 
observed u sin g  an  in v erted  m icro sco p e  (Z eiss A xiovert 2 5 ) , an d  relative cell 
m igration w as d e term in ed  by en u m e ra tin g  th e  n u m b e r o f  m ig ra ted  cells 
in 10 ran d o m  h ig h -p o w er (x 4 0 0 )  field s.
shRNA lentiviral transduction ofBL cells. L acto ferrin  exp ression  was dow nreg- 
ulated u sin g  sh R N A  len tiv ira l vectors (M IS S IO N ; Sig m a-A ld rich ). Briefly , 
lactoferrin-targeted sh R N A  len tiv iral p lasm ids (p L K O .l-p u ro ) were co tran s­
fected w ith  V iraPow er L en tiv ira l p ack ag in g  m ix  (p L P l, pL P 2, pLP-V SV-G ; 
Invitrogen) r o 2 9 3 F T  cells u sin g  L ip o fec tam in e  L T X  (In vitrogen ). B L 2  cells 
were transd uced  w ith  th e  sh R N A -exp ressin g  len tiv iru s, an d  stab le  cell lines 
were generated by se le ctio n  w ith  pu rom y cin  (2 pg/inl; S igm a-A ldrich).
RT-PCR analysis. T o ta l R N A  w as e x tra cte d  (R N easy  k it ; Q IA G E N ) and  
reverse tra n sc rib e d  (2 pg) u s in g  S u p e rs c r ip t  III  R T  (In v itro g en ). R e su lt­
ing cD N As w ere used  as te m p la te  in  P C R  ex p erim en ts a t  a  co n ce n tra tio n  
of 1 ng/50 p i o f  P C R  m ix tu re . T h e  p rim ers used were: forw ard lacto ferrin  
(5 '-T G T C T T C C T C G T C C T G C T G T T C C T C G -3 ')  an d  reverse la c to fe rr in  
(5 '-C TG C C TC G TA TA TG A A A C C A C C A TC A A -3’), forw ard G A PD H  prim er 
(5'-CG A C A G TC A G C C G C A TC TTC m TG C G TC G -3') and reverse G A PD H  
primer (5 '-G G A C T G T G G T C A T G A G T C C T T C C A C G A T A C -3'). Cycle param ­
eters (lactoferrin : 4 0  cycles; G A PD H : 2 8  cycles) were: d en atu ration  9 4 ° C  for 
1 minute, prim er an n ealin g  a t 6 7 °  C (lactoferrin) o r 5 0 ° C  (G A PD H ) for 1 m in- 
ute, and ex ten sio n  a t 7 2  °C  fo r  4 5  secon d s, w ith  a f irs t d e n atu ratio n  step at
9 4 ° C f o r 7 m in u te s a n d a f in a le x te n s io n a t7 2 ° C fo r 5  m in u tes. Pu rified  PC R  
p rod u cts (Q IA qu ick  gel ex tractio n  k it; Q IA G E N ) were sequen ced  to  co n firm  
validity  by th e  Seq u e n c in g  Service o f  th e  S ch o o l o f  L ife S cien ces, U niversity  
o f  D u n d ee, u sin g  A pplied B io system s B igD ye 3 .1  ch e m istry  o n  an  A pplied 
B iosystem s m od el 3 7 3 0  au to m ated  cap illary  D N A  seq u en ce analyzer.
Peritonitis model. A ll a n im a l p ro ce d u re s  w ere ca rrie d  o u t  u n d e r  a  U K  
H om e O ffice  A n im als (S c ie n tific  P rocedu res) A ct 1 9 8 6  p ro je c t licence. M ice 
(8 - to  12-w eek-old  fem ale  C 57B L / 6 m ice ; n = 7  p er g ro u p ) were in je c te d  i.p. 
w ith  p u rified  h u m a n  la c to fe rr in  o r  tra n sfe rrin  (5 0 0  n g  in  saline/0.1% ; B SA  
S ig m a  A ld rich ) o r  salin e/ 0.1%  B SA  a lo n e  fo llo w ed  by  a  s e c o n d  i.p . in je c ­
t io n  w ith  1% th io g ly co lla te  (5 0 0  pi) o r  saline/ 0.1%  B SA  a fte r  2 0  m in u te s . 
R ecru ited  leu k ocy tes w ere h arvested  a fte r  4  h o u rs  by p e rito n e a l lavage w ith  
ice -co ld  salin e co n ta in in g  2 m M  E D T A . H arvested  cells w ere co u n te d  u sin g  
a  N u c le o C o u n te r  (C h e m o M e te c ), w h ich  exclu d ed  n o n n u c le a te d  ce lls. T o  
d e term in e  th e  n u m b e r  o f  n e u tro p h ils  (G r-D ), ce lls  were im m u n o la b e le d  
w ith  P E -co n ju g a ted  an ti-m o u se  L y 6 -G r-1  an d  co u n te d  u sin g  F lo w -C o u n t 
bead s (B e ck m a n  C o u lter).
Histology andimmunohistocbemistry. S ix - to  10-w eek-old  BA LB/c S C ID  m ice 
were in jec ted  i.p. w ith  107 B L 2  cells. T u m o rs  developed i.p. w ith in  2  m o n th s  
o f  in je c tio n . M ice  were sacrificed  an d  tu m o rs  excised. F o r  p o sitiv e  co n tro l, 
BALB/c m ice  were im m u n ized  w ith  sh eep  red b lo o d  ce lls an d  sp leen s h ar­
vested  an d  fro zen  7  days a fte r  i.p . in je c tio n . Im m u n o h is to c h e m is try  w as 
p erfo rm ed  o n  fro zen  ace to n e -fixe d  se c tio n s  (5 p m ) o f  B L  o r  sp leen  tissu es 
u s in g  b io tin y la te d  a n t i-m o u s e  G r-1 a n tib o d y  (1 0  pg/m l; B io L e g e n d ) o r  
iso ty p e co n tro l (A bD  S ero tec). N o n sp e c ific  a d s o rp tio n  o f  a n tib o d ie s  w as 
b lo ck ed  u sin g  seru m -free P ro te in  B lo ck  (D a k o ). R e a c tio n s  w ere a m p lified  
u sin g  V E C T A ST A IN  E lite  A B C  av id in -b io tin y la te d  p ero xid ase co m p lex e s  
(V ector L ab o ra to ries). H em ato x y lin  was used  as co u n te rs ta in .
Flow cytometry. U n le ss  o th e rw ise  s ta te d , ce lls  w ere su sp e n d e d  in  P B S  
c o n ta in in g  5%  n o rm a l m o u se  seru m  o r 0 .1%  BSA , an d  all a n tib o d y  in c u ­
b a t io n s  w ere p e rfo rm e d  fo r  2 0  m in u te s  o n  ice . M o u se  n e u tro p h ils  w ere 
d efin ed  based  o n  th e  ex p ressio n  o f  G r-1  e p ito p e  u s in g  P E -co n ju g a te d  ra t 
a n t i-m o u s e  L y 6G  (G r-1 ; eB io sc ie n ce ). F o r  th e  a s s e s s m e n t o f  n e u tro p h il  
a c tiv a tio n , th e  fo llo w in g  a n tib o d ie s  w ere u sed : F IT C -c o n ju g a te d  a n ti-  
C D 6 2 L  (F M C 4 6 , m Ig G 2 b ; A bD  S ero tec) an d  A P C -co n ju g a ted  a n ti-C D  l i b  
(IC R F 4 4 , m lg G l ;  B D ). Iso ty p e c o n tro ls  in c lu d ed  m o u se  Ig G L F IT C  (A bD  
Sero tec), m ou se Ig G L A P C  (B D ), an d  ra t Ig G 2b :P E  (eB ioscien ce). C ell apop- 
to s is  w as d e term in ed  by  la b e lin g  w ith  a n n e x in  V an d  p ro p id iu m  io d id e. 
S a m p les  were an aly zed  u sin g  a B D  F A C S C a lib u r o r  F A C S can  cy to m ete r, 
an d  d a ta  were analyzed  u sin g  B D  C e llQ u e st softw are.
Size fractionation and ion exchange chromatography. S ize fra c tio n a tio n  o f  BL 2 
cell co n d itio n e d  m ed ia  was p erfo rm ed  u sin g  filte rs  w ith  s p ec ific  m o le cu la r 
w eig h t c u to f f  sizes (A m ico n  C e n trifu g a l filte rs  Y M -5 0  an d  Y M -1 0 0 ; M illi- 
pore), fo llow in g  th e  m a n u fa ctu re r’s in s tru ctio n s . Io n  exch an g e c h ro m a to g ­
rap hy w as carried  o u t u sin g  Q  Sep h aro se  F a st F low  bead s (S ig m a-A ld rich ). 
B eads were w ashed  w ith  n eu tra liz in g  b u ffer, an d  b o u n d  p ro te in s  were th en  
e lu ted  by a d d itio n  o f  10 m M  N aA c, 0 .5  M  N aC l, pH  4 . B L 2  c e l l - c o n d i­
tio n e d  m ed iu m  o r co n tro l m ed iu m  ( R P M I1 6 4 0 ) w as m ixed  w ith  th e  bead s 
a n d  in cu b a te d  a t  ro o m  te m p era tu re  fo r  5 m in u te s . S a m p les  w ere c e n tr i­
fu g ed  (3 0 0 g , 5  m in u te s) an d  su p e rn a ta n ts  sto red . B ead s were w ash ed  w ith  
n e u tra liz in g  b u ffer , an d  b o u n d  p ro te in s  w ere th e n  e lu ted  by  a d d itio n  o f  
th e  co rre sp o n d in g  e lu tio n  b u ffe r  ( fo r  S  b ead s: 10  m M  T ris , 0 .5  M  N aC l, 
p H  10; fo r  Q  bead s: 10 m M  N aA c, 0 .5  M  N aC l, pH  4 ). A fte r a  5 -m in u te  
in cu b a tio n  a t ro o m  tem p eratu re , bead s were ce n trifu g e d  ( 3 0 0 g, 5 m in u tes) 
an d  su p e rn a ta n ts  co llec te d  and  analyzed. P r io r  to  ch e m o ta x is  an aly sis , th e 
s u p e rn a ta n ts  w ere d ilu ted  (1 :1 0 0 ) , an d  pH  w as a d ju s te d  to  7 .0 . P ro te in s  
w ere id e n tifie d  by p e p tid e  m ass fin g e rp r in tin g  u s in g  M A L D I-T O F  m ass 
sp ectro m etry . T h e  p roced u re w as carried  o u t by th e  S c o tt is h  In s tr u m e n ta ­
tio n  an d  R e so u rce  C e n tre  fo r  A d van ced  M ass  S p e c tro m e try  (S IR C A M S ), 
S c h o o l o f  C h em istry , U niversity  o f  E d in b u rg h .
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Immunoblotting. C o n d itio n e d  m ed ia  fro m  viable an d  a p o p to t ic  B L 2  and  
A549 cells w ere co llec te d , an d  th e ir  p ro te in  c o n te n t was T C A  p recip ita ted . 
Briefly, 1 00  p i T C A  w as add ed  in  1 m l co n d itio n e d  m ed iu m  a t  4 ° C . S a m ­
ples were ce n trifu g e d  a t  1 8 ,0 0 0  g  an d  th e  pelle ts w ashed in  ice -co ld  a ce to n e  
before re su sp e n sio n  in  sam p le b u ffe r  (N uP A G E ; In v itrog en ). N eu tro p h ils  
(5 x 106 cells/ m l) w ere lysed fo r  15 m in u te s  w ith  1% N P -4 0  in  T B S  c o n ­
taining p ro tease  in h ib ito r  c o c k ta il  (S ig m a A ld rich ), a p ro tin in , leu p ep tin , 
pepstatin A, 4 -(2 -a m in o e th y l)b en z en e su lfo n y l flu o rid e , so d iu m  o rth o v a n ­
adate, b e n z a m id in e , lev am iso le , an d  P -g ly ce ro p h o sp h ate . S a m p le s  were 
centrifuged (2 0 ,0 0 0  g, 4 ° C , 15 m in u te s) an d  resolved by S D S -P A G E  u sin g  
4%-12% B is-T ris  gels (N uPA G E; In vitrogen ). Protein s were th en  e le c tro b lo t­
ted o n to  a  n itro ce llu lo s e  m em b ran e  (N uPA G E ; In v itro g en ), b lo ck e d  w ith
0.5% (fo r la c to fe rr in )  o r  3% B SA  (fo r  E R K ), an d  p ro b ed  w ith  m o n o c lo n a l 
mouse a n t i -h u m a n  la c to fe r r in  (1 :1 0 0 ; L F .2 B 8 ; A b D  S e ro te c )  o r  m o u se  
m on o clon al a n ti-M A P K  a ctiv a te d  (d ip h o s p h o ry la te d  E R K 1  an d  E R K 2 ) 
antibody (1 :1 ,0 0 0 ; S ig m a -A ld r ic h ) o r  p o ly c lo n a l m o u se  E R K 2  ( 1 :1 ,0 0 0 ; 
Santa C ru z  B io te c h n o lo g y  In c .)  o r  r a b b it  m o n o c lo n a l a n t i - lK B a  (7 4 )  
(1:2,500; E 1 3 0 ; A b eam ) fo llo w ed  by H R P -co n ju g ate d  g o a t a n ti-m o u s e  IgG  
(1 :2 ,000; A m e rsh a m ) o r  H R P -c o n ju g a te d  g o a t a n t i - r a b b it  Ig G  (1 :2 ,5 0 0 ; 
Dako) an d  v isu alized  u sin g  E C L  (G E  H ealth care).
Binding studies. B io tin y la tio n  o f  h u m a n  m ilk -d eriv ed  lacto ferrin  w as per­
formed u sin g  E Z -L in k  S u lfo -N H S -L C -B io tin  (Pierce, T h e rm o  S c ie n tific ) . 
Fresh n eu trop h ils were exposed to  biotinylated  lacto ferrin  (1 0  (xg/ml) a t  3 7 °C  
for 1 hour, a fte r w h ich  th e  cells were w ashed and lysates prepared, resolved by 
SDS-PAGE, e lec tro b lo tte d , b lo ck ed  w ith  0.1%  PB S-Tw een, an d  p robed  w ith 
H R P-con jugated strep tav id in  (D ak o ). F o r S ca tc h a rd  analyses, 12SI-lab eled  
human m ilk -d eriv ed  lacto ferrin , prepared u sin g  Pierce Io d in a tio n  R eagen t 
(Thermo S c ie n tific ) , was added a t  a  c o n sta n t a m o u n t to  fresh  h u m an  n eu ­
trophils in  th e  presence o f  in creasin g  am o u n ts o f  cold , unlabeled  lactoferrin . 
After 3 0  m in u tes a t 4 °  C, cells were w ashed 3 tim es before g am m a co un tin g .
Measurement o f  [Ca2* ] M e a s u r e m e n t  o f  [C a2*]; w as p e rfo rm e d  as previ­
o u sly  describ ed  (75 ). B riefly , fresh ly  iso la ted  n e u tro p h ils  were resu sp end ed  
(1 0 7/m l) in  H B S S  (w ith o u t C a2i/ M g2+) a n d  w ere in c u b a te d  w ith  2  pM  
F U R A  2/AM (C a lb io ch em ) a t  3 7 ° C  fo r  3 0  m in u tes . T h e  ce lls were w ashed 
tw ice , re su sp e n d ed  a t  2  x 1 0 6/m l in  H B S S  (w ith  C a2+/M g2*), in c u b a te d  
fo r  an  a d d it io n a l 3 0  m in u te s  a t  3 7 ° C  in  th e  p re s e n c e  o f  la c to fe r r in  
(1 0  pg/m l), an d  th e n  s tim u la te d  w ith  fM L P  (1 n M  o r 10 n M ). [C a2+]i lev­
els were d eterm in ed  based  o n  3 4 0 :3 8 0  n m  d u a l w avelen gth  e x c ita tio n  in  a 
P e rk in E lm e r lu m in e sc e n ce  sp e c tro m e te r  a t  3 7  °C  w ith  c o n s ta n t  s tirr in g . 
C a lib ra tio n  was p erform ed  a fte r each  ex p erim e n t u s in g  T r ito n  X  (Rm„ )  and 
E G T A  (Rmi„) (Rmax an d  R,„,„ are th e  m a x im u m  an d  m in im u m  3 4 0 :3 8 0  f lu o ­
rescen ce ra tio s, respectively). [C a2+ ]j w as ca lcu la te d  based  o n  th e  3 4 0 :3 8 0  
n m  flu o re scen ce  ra tio .
Statistics. R esu lts fro m  m u ltip le  exp erim en ts are p resen ted  as m ean  ± SE M . 
O ne-w ay AN OVA was p erform ed , follow ed by B o n fe rro n i’s p o st-h o c  test. In  
all cases, P  values o f  0 .0 5  o r  less were co n sid ered  s ig n ifica n t.
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Association of FcyRIIa (CD32a) with Lipid Rafts Regulates 
Ligand Binding Activity1
Stylianos Bournazos,*+ Simon P. Hart,* Luke H. Chamberlain,8 Martin J . Glennie,11 
and Ian Dransfield2*
Binding of Igs to myeloid cells via FcR is a key event in the control of innate and acquired immunity. FcyRIIa (CD32a) is a 
receptor for multivalent IgG expressed predominantly by myeloid cells, and its association with microdomains rich in cholesterol 
and sphingolipids, termed as lipid rafts, has been reported to be essential for efficient signaling. However, for many myeloid cell 
types, ligand binding to CD32a is suppressed by as yet undefined mechanisms. In this study, we have examined the role of 
CD32a-lipid raft interactions in the regulation of IgG binding to CD32a. Disruption of lipid raft structure following depletion or 
sequestration of membrane cholesterol greatly inhibited CD32a-mediated IgG binding. Furthermore, specific CD32a mutants, 
which show reduced association with lipid rafts (A224S and C241A), displayed decreased levels of IgG binding compared with 
wild-type CD32a. In contrast, constitutively lipid raft-associated CD32a (GPI-anchored CD32a) exhibited increased capacity for 
IgG binding compared with the full-length transmembrane CD32a. Our findings clearly suggest a major role for lipid rafts in the 
regulation of IgG binding and, more specifically, that suppression of CD32a-mediated IgG binding in myeloid cells is achieved by
receptor exclusion from lipid raft membrane nucrodomains.
N eutrophils represent the most abundant population o f cir­culating leukocytes and mediate the earliest events of an inflammatory response to invading pathogens. In re­
sponse to a number of distinct chemoattractant stimuli, these 
phagocytic leukocytes are rapidly recruited to the sites of infection, 
where they deploy a range of effector functions aimed at the de­
struction and eradication of pathogens (1). These functions include 
the activation of NADPH oxidase producing reactive oxygen in­
termediates (RO I),3 the release of proteolytic enzymes and anti­
microbial molecules, and the phagocytosis o f invading pathogens 
(2). Recognition of pathogens is a key step in the initiation of all 
these processes and neutrophils have the capacity to recognize 
many diverse pathogens via the expression of specialized receptors 
for complement and pathogen-associated molecular patterns, in­
cluding T L R  and seven transmembrane spanning G protein-cou-
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pled receptors that recognize LPS, dsRNA, N-formylated peptides, 
and unmethylated CpG (3).
Neutrophils also express FcR that enable the recognition of di­
verse Ags via Ab-mediated molecular bridging, thereby linking the 
innate with the adaptive branches o f immunity. FcR  interaction 
with Igs has important biological consequences including — but 
not limited to— phagocytosis, Ab-dependent cellular cytotoxicity, 
degranulation, cytokine production, Ag presentation, and regula­
tion of Ab production (4). A number of FcR  have been identified 
and are categorized in terms of their interaction with Ab classes; 
particularly, FcyR, F caR , FceR , FcjuR, and FcSR recognize and 
bind to IgG, IgA, IgE, IgM, and IgD, respectively.
IgG represents the most abundant Ab class present in circula­
tion, and therefore, the role o f FcyR has been extensively studied. 
Three classes of FcyR  have been identified: CD 64 (FcyR I), a high- 
affinity receptor for monomeric IgG and two receptors that, despite 
their low affinity for IgG monomers, bind particularly well to ag­
gregated IgG via multivalent, high-avidity interactions, CD32 
(FcyRII) and CD 16 (FcyR III) (5). Neutrophils constitutively ex­
press CD32a (FcyRIIa) and CD 16b (FcyR IIIb) that are distinct in 
both their structure and function (6). In contrast, CD 64 (FcyRI) 
expression is only induced following stimulation with IFN -y (5). 
CD 16b is a GPI-anchored membrane protein that lacks intracellu­
lar domains requiring accessory signaling proteins (e.g., y- or 
f-chains) for the transduction o f signals following receptor en­
gagement. In contrast, CD32 represents the sole FcyR  that con­
tains distinct ITAM  within the cytoplasmic domain. CD32a may 
therefore represent the exclusive neutrophil FcyR  with the poten­
tial of transducing intrinsic signals upon engagement.
After recognition and binding of IgG complexes to CD32, the 
receptor becomes clustered and recruited to lipid raft microdo­
mains (7-9 ). These regions of the plasma membrane, also termed 
detergent-resistant membranes (DRM ) due to their characteristic 
insolubility following cold detergent extraction, act as docking 
sites for several intracellular signaling proteins. Association of a 
number of immunoreceptors with lipid rafts is necessary for re­
ceptor signaling and functional responses upon ligand binding
www.jimmunol.org/cgi/doi/10.4049/jimmunol.0900107
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(10), including AgR, such as B C R  (11), TCR (12), adhesion mol­
ecules, like P-selectin glycoprotein ligand 1 (13), E-selectin (14), 
LFA-1 (15, 16), chemokine and cytokine receptors, such as 
CXCR4 (17), IL-2R (18), as well as key signaling proteins, in­
cluding Ras (19), Kit (20), and Lyn (21) kinase.
It has been previously demonstrated that CD32a-lipid raft inter­
actions are essential for efficient signaling events initiated follow­
ing receptor cross-linking (22, 23). Mutations in key residues 
within the transmembrane region of CD32 that alter its association 
with lipid rafts have been reported to have a negative impact on its 
ability to transduce intracellular signals (24). Interactions of the 
ITAM of CD 32 molecules with kinases o f the Src and Syk family 
that preferentially reside within lipid raft microdomains lead to 
their phosphorylation and subsequently to downstream effector 
functions, including actin cytoskeletal rearrangements, initiation of 
respiratory burst, calcium mobilization, receptor endocytosis, and 
degradation (7, 9, 25).
Failure to control FcyR  engagement would lead to the excessive 
release of neutrophil-derived cytotoxic compounds, including my­
eloperoxidase, hydrogen peroxide, elastase, and matrix metallo- 
proteinases, that have destructive impacts on host tissue (26). In­
deed, inappropriate neutrophil activation is associated with several 
chronic inflammatory conditions, such as vasculitis, rheumatoid 
arthritis, and glomerulonephritis, that are also linked to elevated 
levels of IgG complexes (27, 28). Thus, it is likely that regulatory 
homeostatic mechanisms exist to restrict IgG binding to neutro­
phils. For many myeloid cell types, including neutrophils, there is 
evidence that ligand binding to CD32 is suppressed, as evidenced 
by its poor interaction with IgG complexes (29, 30). Flowever, the 
molecular mechanisms that account for this observed suppression 
still remain to be unraveled.
In this study, we hypothesized that the exclusion of CD32 from 
lipid raft microdomains might act as a regulatory mechanism that 
accounts for the observed suppression of CD32-mediated IgG 
binding to neutrophils. In this article, we have assessed the role of 
lipid rafts on IgG complex binding using chemical agents that alter 
lipid raft composition and structure. We have also examined the 
effect of specific mutations in the transmembrane and juxtamem- 
brane regions of CD32 that displayed decreased association with 
lipid rafts on IgG complex binding. Furthermore, we generated a 
GPI-anchored CD32, which constitutively associated with lipid 
rafts and exhibited increased IgG complex binding when compared 
with the wild-type (W T) transmembrane receptor. Our findings 
clearly support a major role of lipid rafts in the regulation of IgG 
complex binding and, more specifically, that suppression of CD32- 
mediated IgG binding in myeloid cells is achieved by receptor 
exclusion from membrane domains.
Materials and Methods
Abs and reagents
All chem ical reagents w ere obtained from  Sigm a-A ldrich  and ce ll culture 
reagents w ere from  Invitrogen and PA A  laboratories, unless otherw ise 
stated. B io tin -con ju gated  ch o lera  toxin B  subunit (C tx B ) and A lexa  Fluor 
647-streptavidin w ere from  M o lecu lar Probes-Invitrogen. Human leuko­
cyte elastase was obtained from  E lastin  Products Com pany. T h e follow ing 
mouse anti-hum an C D 3 2  m A bs w ere used in this study: IV .3  (Ig G 2b), 
A T-10 (F (a b ')2 from  I g G l)  and F L I8 .2 6  (Ig G 2b , F IT C -co n ju g ated ; B D  
Pharmingen). G oat p o lyclonal anti-hum an C D 32a  was obtained from  R & D  
Systems. Purified m ouse anti-hum an C D 6 4  (1 0 .1 , Ig G l)  and C D 16  (3G 8, 
IgG l) w ere obtained from  A b D  S erotec. Corresponding isotype control 
Abs were from  D akoC ytom ation , A bD  S erotec, or Sigm a-A ldrich . M ouse 
anti-human cav eolin -I (C 0 6 0 , Ig M  and 2 2 9 7 , Ig G l) ,  m ouse anti-human 
transferrin receptor/C D 71 (clo n e 2 , Ig G l) ,  m ouse anti-hum an flotillin-1 
(clone 18, Ig G l) ,  and m ouse anti-phosphotyrosine (P Y 2 0 , Ig G 2b ) were 
from B D  Transduction  L aboratories (B D  B io scien ce s). F IT C - or R -P E - 
conjugated goat anti-m ouse Ig G  F (a b ')2 fragm ents. H R P-con jugated goat
anti-m ouse Ig , and rabbit anti-goat Ig  w ere from  D akoC ytom ation . F IT C - 
con jugated  m ouse anti-biotin  (B N -3 4 , Ig G l)  and purified human Ig G  w ere 
obtained from  Sig m a-A ld rich . Im m une co m p lexes w ere generated as de­
scribed  previously (2 9 ). B riefly , for biotin— anti-biotin  co m p lexes (B x B ) , 
F IT C -co n ju g ated  anti-biotin  (m ouse I g G l ;  170 /xg - m l- 1 ) w as co incubated  
with b io tin-con ju gated  B S A  (5 0 0  p g  • m l- 1 ) at 4 °C . H um an IgG  co m ­
p lexes (hum an heat-aggregated Ig G ; hH A IgG ) w ere form ed by incubating 
m onom eric human IgG  for 2 0  min at 6 3 °C  and centrifuged  at 1 4 .0 0 0 X  g 
to rem ove precipitates.
Cell isolation and culture
Eth ical approval w as obtained from  the Lothian  L o ca l R esearch  E th ics  
C om m ittee, and polym orphonuclear leu kocytes w ere isolated from  periph­
eral venous blood o f  healthy donors as described previously (3 1 ) . B rie fly , 
after centrifugation  o f  citrated w hole blood (1 2 .9  m M  sodium  citrate final 
con cen tration ) at 3 5 0  X  g  fo r 2 0  m in, p latelet-rich  plasm a w as rem oved, 
and erythrocytes were sedim ented using 0 .6 %  w/v D extran T 5 0 0  (Ph ar­
m acia). Polym orp honuclear leukocytes w ere separated from  m ononuclear 
leu kocytes using discontinuous isotonic Percoll gradients (G E  H ealthcare) 
and w ere harvested from  the 73% / 61%  in terface. Purity w as routinely as­
sessed using m orphologic criteria, and neutrophils represented > 9 5 %  o f  
the polym orphonuclear leu kocyte population.
K 5 6 2  and Ju rk a t ce lls  (tran sfe cte d  w ith  W T  C D 3 2 a  as d escrib ed  in 
R e f . 3 2 )  w ere cu ltured  in R P M I 1 6 4 0  m edium  supplem ented  w ith 10%  
F C S , L -g iu tam in e (2  m M ), and p e n ic illin  (1 0 0  U  • m l- l )/streptom ycin 
(1 0 0  pig • m l- 1 ). C h in ese  h am ster o vary  (C H O -K 1 ) ce lls  w ere m ain ­
tain ed  in D M E M :F -1 2  (1 :1 )  (In v itro g en ) w ith  G lu ta M A X , 10%  F C S , 
and p en icillin / strep to m y cin . A ll ce lls  w ere in cu b ated  at 3 7 ° C , 5 %  C O , 
in a h um idified  a tm osp here.
Site-directed mutagenesis
F u ll-len gth  human C D 3 2 a  O R F  subcloned into a p S E L E C T -n e o -m c s  v ec­
tor was obtained from  In vivoG en and w as used as the tem plate for the 
site-m utagenesis reactions that w ere perform ed based on the Q uikC hange 
S ite  II K it (Stratagen e). M utated plasm id sequences w ere validated by di­
rect sequencing, perform ed by the Seq u encing  S erv ice  (C o lleg e  o f  L ife  
Sc ie n ces , U niversity o f  D undee) using A pplied B io system s B ig -D y e  3.1 
chem istry  on an Applied B io system s m odel 3 7 3 0  autom ated capillary  
D N A  sequencer.
Short hairpin RNA (shRNA) mediated C D 32 expression 
knockdown
C D 3 2 a  exp ression  w as dow n-regulated using shR N A  lentiviral vectors that 
w ere obtained from  Sig m a-A ld rich  (M IS S IO N  sh R N A  clo n es). A ll five 
sh R N A  plasm id clo n es supplied w ere validated for C D 3 2  knockdow n e f­
ficiency  by transient transfection  to C H O  ce lls  exp ressing  W T  C D 32a . O ne 
particular clo n e achieved > 7 0 %  gene exp ression  knockdow n (clo n e 
T R C N 0 2 9 5 7 8 ; recogn izin g  sequence 5 '-G A A G A A A C C A A C A A T G A C  
T A T -3 ')  and w as stably transfected to  W T  K 5 6 2  ce lls  as described below . 
C D 3 2 a  expression  and IgG  com plex binding w as assessed  in shR N A  e x ­
pressing K 5 6 2  ce lls  by flow  cytom etry.
Generation of GPI-anchored CD32
T he G P I m odification site was predicted in the C D 55  gene based on R ef. 
33 and the ch im eric C D 32/55 construct included the extracellu lar dom ains 
o f  C D 3 2 , follow ed by the G PI-anchored  consensus sequen ce o f  C D 5 5 , 
com prising the to site and dow nstream  consensus dom ains (see F ig . 6 C). 
C D 32/55 protein was designed based on R ef. 3 4  (P reL in k ) to m inim ize 
m isfolding o f  the ch im eric protein. Seq uence o f  the final construct was 
validated by d irect sequencing, as described above. C D 32/55 exp ressing  
plasm id was transfected in C H O -K 1 and K 5 6 2  ce lls , and the G P I m odifi­
cation  o f  the ch im eric protein was confirm ed by reduction in expression  
fo llow in g  treatm ent with p hosphatid ylinositol-specific phospholipase C 
(S ig m a-A ld rich ) fo r 2 0  min at 37°C .
Cell transfection
C H O  ce lls  w ere transfected using either je tP E I  T ran sfectio n  reagent 
(Polyplus T ran sfectio n ) or L ipofectam ine L T X  (Invitrogen), accord ing  to 
the m anufacturer’ s instructions. K 5 6 2  ce lls  w ere transfected using L ip o ­
fectam in e L T X  and L ipofectam ine Plus reagent (Invitrogen). F o r the gen ­
eration o f  stable transfectants, CH O  ce lls  w ere cultured in D M E M :F -1 2  
(1 0 %  F C S  +  G lu taM A X ) m edium  con tain in g  1 m g • m l-1  G 4 1 8  (In v itro ­
gen) fo r ~ 1 4  days. K 5 6 2  ce lls  were m aintained in R P M I 16 4 0  medium  
(1 0 %  F C S  +  2  m M  L-glutam ine) and selected  with either G 4 1 8  (in itia lly  
added at 1 m g • m l-1  fo r the first 4 8  h and then at 5 0 0  p g  ■ m l- 1 ) or
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puromycin (2  /xg • m l- 1 ; S ig m a-A ld rich ). S electio n  o f  positive clo n es was 
performed by F A C S  using a B D  F A C SV an tag e  SE/D iV a C ell sorter (B D  
B ioscien ces).
Flow cytometry
Immune co m p lex  binding was assessed based on a previously described 
assay (2 9 ) that m easures binding o f  aggregated Ig G  to C D 32 , a low -affinity 
receptor v ia  m ultiple binding sites that generate h igh-avidity interactions. 
Cells w ere incubated with the corresponding IgG  com p lexes (B x B  or 
hHAIgG) fo r 3 0  m in on ice  and under these conditions, IgG  binding is 
essentially at equilibrium , with > 7 0 %  o f  m axim al IgG  binding ( 2 0 - 6 0  
min) observed after 5  min (data not show n). S im ilar IgG  binding k inetics 
were also  evident fo llow in g  M 0 C D  treatm ent. F or b lockin g  experim ents, 
function blo ck in g  an ti-C D 32  A bs ( IV .3 or A T - 10 F (a b ')2; 10 /xg • m l- 1 ) or 
anti-CD 16 (3 G 8  F (a b ')2; 10 /xg ‘ m l- 1 ) w ere used 10 min before the ad­
dition o f  Ig G  com p lexes. A nalysis o f  F c R  expression w as perform ed by 
incubating the ce lls  with the corresponding m ouse m A bs (used at 10 /xg • 
ml- 1 ), fo llow ed by F IT C -co n ju g ated  goat F (a b ')2 anti-m ouse Ig  (1 0  /xg • 
ml- 1 ; D akoC ytom ation ). F lo w  cytom etric analysis o f  the sam ples w as per­
formed using a B D  F A C SC alib u r or F A C S can  cytom eter (B D  B io ­
sciences). D ata  w ere analyzed using B D  C ellQ uest (B D  B io sc ien ce s) or 
F low Jo (T ree  S tar) softw are, and all results are presented as the m edian 
fluorescence intensity.
DRM fractionation and immunoblot analysis
D RM  dom ain fractionation  w as perform ed essentially  as previously de­
scribed (8 , 14) using w ell-validated protocols and all procedures w ere co n ­
ducted at 4 °C . F o llo w in g  stim ulation o f  ce lls  (C H O , 2  X  107, or K 5 6 2 , 1 X  
107) with Ig G  co m p lexes (h H A Ig G ), ce lls  were w ashed with ice-co ld  P B S  
(Ca2+/Mg2+ free) and incubated for 10 min with T N E  buffer (5 0  m M  T ris, 
150 m M  N aC l, and 2  m M  E D T A  (pH 7 .5 ) )  at 4 °C . Then, ce ils  w ere ho­
m ogenized using a 25 -g au g e needle, and ce ll hom ogenates w ere incubated 
on ice for an additional 5  m in, before the addition o f  Triton  X -1 0 0  (0 .2 5 %  
v/v final con cen tration ). L ysates w ere incubated for 3 0  min on ice , Opti- 
Prep (A x is-S h ie ld ; S ig m a-A ld rich ) density gradient m edium  was added at 
a final concentration  o f  4 0 % , and m ixture (6 0 0  /xl) was applied to the 
bottom o f  p rech illed  2 .2 -m l ultracentrifuge tubes (U ltra-C lear; Beck m an  
Coulter). O n top, O ptiPrep solutions (6 0 0  /xl in T N E  buffer) at con cen tra­
tions o f  35  and 2 5 %  w ere sequentially layered, follow ed by 2 0 0  /xl o f  T N E  
buffer. Sam p les w ere centrifuged  at 5 4 ,0 0 0  rpm (1 9 4 ,0 0 0  X  g avg) for 2 h 
at 4°C  in an O p tim a-M A X  benchtop ultracentrifuge using a T L S -5 5  rotor 
(Beckm an C oulter). A fter centrifugation, fractions (2 0 0  /xl) w ere co llected  
and resolved by S D S -P A G E  using 4 - 1 2 %  B is -T ris  gels (N uP A G E ; In- 
vitrogen), accord in g  to the m anufacturer’ s instructions. Proteins were then 
electroblotted onto n itrocellu lose m em brane (A m ersham  B io sc ien ce s), 
blocked w ith 5 %  w/v fa t-free m ilk, and probed with the corresponding 
primary A b: goat anti-hum an C D 3 2 a  (1/500), m ouse anti-hum an caveo- 
lin-1 (1/500), m ou se anti-hum an transferrin-receptor (1/ 1000), and m ouse 
anti-human flotillin -1 (1/ 1000). B lo ts  were then incubated with H R P -con - 
jugated secondary A bs (either goat anti-m ouse or rabbit anti-goat Ig ; 
1/5000) and visualized using E C L  (A m ersham  B io sc ien ce s). F o r the quan­
tification o f  gel-band intensities, Im ag eJ softw are package was used (N a­
tional Institutes o f  H ealth).
Confocal immunofluorescence microscopy
CD32 and G M 1 im m unolabeling was perform ed using previously de­
scribed p rotocols (3 5 ) . B riefly , CH O  ce lls  were grown on sterile g lass 
coverslips fo r 2 4  h (3 7 °C ; 5 %  C O ,)  before im m unolabeling. C ells were 
washed tw ice w ith  ice -co ld  m edium  (D M E M  containing 2  m g • m l 1 B S A ) 
and incubated w ith the m ouse anti-hum an C D 3 2  A b ( IV .3 c lo n e; 2 0  /xg • 
ml- 1 ) and bio tin -con ju gated  C tx B  (1 0  /xg • m l ’ ) at 12°C  for 6 0  m in under 
gentle ro ck in g . T h e  sp ecificity  o f  C txB  fo r the G M 1 ganglioside w as val­
idated by W estern  b lo t analysis o f  CH O  and K 5 6 2  ce ll lysates. T hen , ce lls  
were w ashed w ith ice -co ld  P B S  and subsequently incubated with A lexa  
Fluor 6 4 7 -la b e led  streptavidin (1 0  /ig ■ ml ' )  and R -P E -co n ju g ated  goat 
F(ab’)2 anti-m ou se Ig  (1 0  /xg • m l- 1 ). C ells were fixed on ice  for 4  m in with 
3.8%  form aldehyde in P B S  follow ed by a 5-m in  incubation in m ethanol at 
~ 20°C . K 5 6 2  im m unolabeling was perform ed as described above with the 
exception that ce lls  w ere labeled in suspension and were then attached to 
poly-L-lysine (S ig m a-A ld rich )-coated  coverslips, according to the m anu­
facturer’ s instructions before fixation. C overslips were m ounted using the 
Fluorsave reagent (M erck -C alb io ch em ), slides w ere visualized ( X 1 0 0  o il- 
immersion o b jec tiv e ) using Z eiss  L S M 5 1 0 m eta  laser scanning co n foca l 
microscope (Z eiss) equipped w ith argon and helium/neon lasers, and dig­
ital im ages w ere prepared using the L S M  im age brow ser (Z eiss) and V o - 
locity (Im p rov ision ). F o r  the quantification o f  C D 32-G M 1 co localization , 
images (fro m  at least 5 0  ce lls  obtained fro m  random  fields) were analyzed
using the Z eiss  L S M  5 1 0  softw are p ackage, o r V o lo c ity  and co loca lizatio n  
is expressed as the percentage o f  p ixels from  the C D 3 2  channel co lo ca l- 
izing with p ixels from  the G M 1 channel.
Analysis of CD32 tyrosine phosphorylation
A fter stim ulation o f  C H O  ce lls  with Ig G  co m p lex es (1 0  /xg • m l- 1 , 5  min, 
3 7 °C ), ce lls  (3  X  107/ml) w ere w ashed exten sively  in ice -co ld  P B S  and 
lysed with 2 %  Triton X -1 0 0  in T B S ,  in the p resen ce o f  phosphatase and 
protease inhibitors (H alt protease and phosphatase inhibitor m ixture; 
Pierce/Therm o Scie n tific ) for 15 min on ice , fo llo w in g  by centrifugation 
(1 4 ,0 0 0  X  g , 15 m in, 4 °C ). L ysates w ere incubated with ag aro se-co n ju ­
gated goat anti-m ouse Ig  (S ig m a-A ld rich ) fo r  6 0  m in at 4 °C  to rem ove 
nonspecific protein interactions. A n ti-C D 3 2  A b ( IV .3 )  w as then added to 
the precleared lysates and incubated fo r 6 0  m in (4 °C ), fo llow in g  by goat 
anti-m ouse Ig  agarose for 9 0  m in. A g arose pellets w ere exten sively  
washed, and proteins w ere resolved by S D S -P A G E  using 4 - 1 2 %  B is -T ris  
gels (N u P A G E ; Invitrogen), accord in g  to  the m anufacturer’ s instructions. 
Proteins w ere then electrob lotted  onto n itro cellu lose m em brane (A m er­
sham B io sc ien ce s), b locked  with 0 .1 %  T w een  2 0 , and probed w ith biotin- 
conjugated m ouse anti-phosphotyrosine (1/ 7000). B lo ts  w ere then in cu­
bated with H R P-con jugated  streptavidin (1/ 5000) and visualized using 
E C L  (A m ersham  B io sc ien ce s). T o  assess total C D 3 2  con ten t, m em branes 
w ere stripped with 0.1 M  g lycin e (pH  2 .5 )  con tain in g  0 .1 %  T w een 2 0  and 
then blocked with 5 %  w/v fa t-free m ilk  and reprobed w ith goat anti-hum an 
C D 3 2 a  (1/500), follow ed by H R P -con ju g ated  rabbit anti-goat Ig  (1/5000).
Statistical analysis
U n less otherw ise stated, results from  m ultip le exp erim ents are presented as 
m ean ±  S D . O ne- or tw o-w ay A N O V A  w as perform ed follow ed by B o n - 
ferroni posthoc analysis. V alues o f  p  £  0 .0 5  w ere consid ered  to be statis­
tically  significant.
Results
Differential regulation of IgG  binding to CD32 receptor in 
various cell types
To determine whether IgG com plex binding to C D 32 is sup­
pressed in a cell context-dependent manner, we measured 
CD32-mediated IgG binding in diverse cell lineages, including 
K 562, an erythromyeloid cell line, and CD32-transfected hu­
man Jurkat T  cells (Jurkat:32) and Chinese hamster ovary 
(CH O :32) cells. Analysis o f F cy R  expression (C D 64, CD 32, 
and CD 16) by flow cytometry revealed that C D 32 was ex­
pressed by all the tested cell types (Fig. 1A). However, key 
differences were noted in terms o f CD32-m ediated IgG complex 
binding. In particular, although CD 32 was expressed at sub­
stantial levels by neutrophils and K 562 cells, IgG complex 
binding to these cells was essentially minimal. In contrast, 
CD32-transfected CHO and Jurkat cells displayed high levels of 
IgG complex binding (Fig. 15 ; data not shown). Comparison of 
CD32-mediated IgG complex binding to K 562 and Jurkat:32 
cells, both cell types expressing C D 32 at comparable levels, 
revealed that Jurkat cells were capable o f IgG binding at much 
lower concentrations (Fig. 1, C  and D ). Sim ilar analyses were 
performed in other cell types o f the myeloid lineage, including 
monocytes, eosinophils, platelets, and H L-60, a myeloleukae- 
mic cell line. In all these cell types, CD 32 was expressed at 
substantial levels; however, IgG com plex binding to CD 32 was 
at negligible levels (data not shown). These results suggest the 
existence o f common regulatory mechanisms that limit IgG 
binding to CD 32 in cells o f myeloid origin, such as neutrophils 
and K 562 cells.
Involvement of lipid rafts in the regulation of IgG binding to 
CD32
Although the CD32-lipid raft association has been suggested to be 
required for the initiation of signal transduction events in response 
to receptor cross-linking, the role of lipid rafts in the regulation of 
IgG complex binding to CD32 is not clear. W e therefore measured 
IgG complex binding to CHO:32 cells that were treated with a
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F IG U R E  1. D eferen tia l regulation 
of IgG  com plex binding to C D 3 2  re­
ceptor in various ce ll types. A, R ep ­
resentative flow  cytom etry h isto ­
grams o f  F c y R  expression  in 
neutrophils, K 5 6 2  ce lls, and in C D 3 2 - 
transfected C H O  and Jurkat ce lls. B, 
M easurem ent o f  Ig G  com plex bind­
ing (m lg G l; B x B ; 10 /xg • m l- 1 ) and 
CD 32 exp ression  in neutrophils, 
K 562 ce lls , and C D 32-tran sfected  Ju ­
rkat ce lls (Ju rk a t:32 ) w ere perform ed 
by flow cytom etry as described in 
Materials and M ethods. C , F IT C - 
conjugated human IgG  com plex 
(hH AIgG ) binding to  K 5 6 2  and Ju r- 
kat:32 ce lls  over a range o f  IgG  co n ­
centration w as determ ined by flow 
cytometry. R esu lts presented as the 
mean ( ± S D )  from  at least three inde­
pendent experim ents. D , R epresen ta­
tive flow cytom etry  h istogram s o f  
IgG com plex binding (B x B ; 10 /xg ■ 
ml- 1 ) to K 5 6 2  or Ju rk a t:3 2  ce lls. 
Control indicates the profile o f  ce lls  










cholesterol-depleting agent, methyl-/3-cyclodextrin (M/3CD; 10 
mM for 15 min at 37°C) to disrupt lipid raft microdomains. IgG 
complex binding to CD32 was greatly reduced following treatment 
with Mj3CD, whereas the inactive analog of M/3CD, a-cyclodextrin 
(a-CD), had no impact on IgG binding (Fig. 2, A-Q. In addition, 
cholesterol repletion (10 mM cholesterol-M/3CD, 30 min, 37°C) in 
M)3CD-treated cells abrogated any effects on IgG complex binding 
observed following M)3CD treatment (data not shown). Further evi­
dence in support of the requirement for intact lipid rafts for IgG com­
plex binding to CD32 was obtained using nystatin, a chemical agent 
that binds to cholesterol, thereby altering lipid organization of the 
plasma membrane (Fig. 2 C). In addition, reduced IgG complex bind­
ing to CD32 was observed following treatment of CHO:32 cells with 
short-chain ceramides (C2-ceramide and C6-ceramide) that also dis­
rupt lipid raft organization, whereas the inactive form of C2-cerarmde, 
C2-dihydroceramide, had no impact on IgG binding (Fig. 2D). It 
should be noted that disruption of lipid rafts had no effect on CD32 
expression (Fig. 2E), and none of the treatments had any impact on 
cell viability (data not shown). In summary, these results clearly in­
dicate that intact lipid raft microdomains are required for efficient IgG 
complex binding to CD32.
Although the precise characterization o f membrane lipid rafts is 
a topic o f great debate, it is widely accepted that at least part of 
these domains display insolubility following cold nonionic deter­
gent extraction, due to their cholesterol-enriched, low-density lipid 
environment. For this reason, a well-validated, commonly used 
technique for the isolation of lipid rafts, also adopted in this study, 
is the fractionation of detergent-insoluble regions termed as DRM 
by ultracentrifugation with density gradient media. W e analyzed 
the association o f CD32 with lipid raft domains and as it is evident 
in Fig. 2, F  and G, in the resting state, CD 32 is predominantly 
distributed within the detergent-soluble membrane fractions char­
acterized by the absence o f caveolin, with a small percentage of 
CD32 to be detergent insoluble. However, following cross-linking 
of CD32 with IgG complexes (10 /xg • m T 1; hHAIgG), we ob­
served redistribution o f CD32 to the caveolin-rich DRM  fractions 
of the membrane. Taken together, these results suggest that CD32 
translocation to lipid rafts is associated with efficient IgG binding.
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F IG U R E  2 . Involvem ent o f  lipid rafts in the regulation o f  IgG  binding to 
CD32. A, M easurem ent o f  FITC -conjugated IgG  com plex binding (hH A IgG ) 
to CD 32-transfected CH O  cells (C H O :32) follow ing treatment with (M J3CD) 
or without (control) M/3CD (1 0  m M ; 15 min, 37°C ) ( * ,  p  <  0 .0 1 ; * * ,  p  <  
0.05). B, Representative flow cytom etry histogram overlay o f  IgG binding to 
CHO:32 cells treated with (gray filled) or without (unfilled) 10 m M  M j3CD . C, 
IgG com plex binding (hH A IgG ; 10 p g  • m f 1) to C H O :32 cells following 
disruption o f  lipid rafts by nystatin (3 0  p g  • m l- 1 ; 15 min, 37°C ) or M/3CD (10  
mM; 15 min, 37°C ). a C D  (10  m M ), an inactive analog o f M/3CD, was used 
as control. Results presented the mean ( ± S D )  from  at least three independent 
experiments ( * ,  p  <  0 .0 1 ; * * ,  p  <  0 .05 ) com pared with untreated cells. D , 
Binding o f  human Ig G  com plexes (hH A IgG ; 10 p g  • m l- 1 ) to C H O :32 cells 
following treatment with short-chain ceram ides: C2-ceram ide (C 2 ; 100 p M , 
37°C, 60  min) and C 6-ceram ide (C 6 ; 5 0  /xM, 37°C , 6 0  min). Control indicates 
untreated cells, and C2-dihydroceram ide (C2-dh; 100 /xM, 37°C , 60  min) was 
used as the inactive form  o f  C 2  ceram ide. Results presented the mean ( ± S D )  
from at least three independent experiments; * ,  p  <  0.01 compared with un­
treated cells. E, Representative flow cytometry histogram o f C D 32 expression 
in control and in M|3CD-treated C H O :32 cells. Isotype represents isotype- 
matched control. F, A fter incubation o f  C H O :32 cells with (+ Ig G ) or without 
( - Ig G )  IgG  com plexes (hH A IgG ; 10 p g  • m l“ 1), D R M  regions were extracted 
from cell lysates by fractionation using discontinuous OptiPrep gradient, as de­
scribed in Materials and Methods. C D 32 distribution was assessed by Western blot 
analysis o f  the fractions obtained. The constitutively lipid raft-associated protein 
caveolin-1 was used to define lipid raft fractions. G, Quantification o f the percent­
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F I G U R E  3 . E lastase-m ediated  augm entation o f  Ig G  binding to  neutro­
phils is dependent on lipid rafts. B inding  o f  m urine Ig G l (B x B ; 10 p g  ■ 
m l“ ')  o r human IgG  (h H A Ig G ; 3 0  p g  ■ m l“ ')  co m p lex es w as m easured in 
neutrophils follow ing  treatm ent with H N E (4  ;xg • m l“ ' ;  2 0  m in, 3 7 °C ). 
C D 32-m ed iated  IgG  com plex binding w as determ ined using an ti-C D 32 
function b lockin g  A bs (A T -1 0  F (a b ')2; 10 p g  ■ m l“ 1) (A, graphical repre­
sentation; B, representative flow  cytom etry h istogram s). R esu lts represent 
the m ean ( ± S D )  from  at least three independent exp erim en ts; * ,  p  <  0 .01  
com pared with control ce lls. C , R epresen tative co n fo ca l im m unofluores­
cen ce  m icroscopy m icrographs o f  Ig G  binding to  con tro l and H N E-treated 
neutrophils. S ca le  bar: 10 pm . D , C D 3 2  and C D 1 6  exp ression  w as deter­
m ined by flow cytom etry in control ( ■ )  and H N E-treated ( □ )  neutrophils. 
R esu lts presented as m ean ( ± S D )  from  at least three independent deter­
m inations. £ ,  Ig G  com plex binding was m easured in control and H N E- 
treated neutrophils that w ere firstly incubated with ( □ )  or w ithout ( ■ )  10 
m M  M/3CD (15  m in, 3 7 °C ). R esu lts represent the m ean ( ± S D )  from  at 
least three independent exp erim ents; * ,  p  <  0 .01  com pared w ith the co r­
responding control. F, R epresentative flow  cytom etry histogram s o f  IgG  
com plex binding (B x B )  to H N E-treated neutrophils incubated w ith or w ith­
out M j3C D  (1 0  m M ; 15 m in, 3 7 °C ).
Elastase-mediated augmentation o f  IgG binding to neutrophils 
is dependent on lipid rafts
W e next assessed IgG complex binding to neutrophils treated with 
human neutrophil elastase (HNE), which has been previously 
shown to regulate several effector functions, including CD32-me- 
diated IgG complex binding (36). W e have determined the contri­
bution of the two types o f Fc-yR (CD32 and CD16; Fig. 1A) 
expressed by neutrophils in IgG complex binding, using function- 
blocking anti-CD32 and anti-CD 16 Abs. In addition, since mlgGl 
has specificity for CD32, we have used m lgGl complexes (B xB ) 
as a direct measure for CD32-mediated IgG binding. Blockade of 
CD32, but not of CD16, resulted in a complete inhibition of BxB  
binding demonstrating a specific binding to CD32 (Fig. 3A; data not 
shown), whereas both CD 16 and CD32 contributed to human IgG 
complex (human heat-aggregated IgG; hHAIgG) binding (Fig. 3A).
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F IG U R E  4 . E x clu sion  o f  C D 3 2  from  lipid rafts results in decreased IgG  binding in C D 32-tran sfected  C H O  ce lls. M u tagenesis o f  A 2 2 4 S  w ithin the 
transm em brane region o f  C D 32  resulted in decreased association  o f  C D 3 2  with lipid raft m icrodom ains. A and B, R epresentative co n fo ca l im m unofluo­
rescence m icrographs o f  C H O  ce lls  expressing C D 32  (W T  or A 2 2 4 S ) and co localizatio n  o f  C D 3 2  with G M 1, a m arker fo r lipid raft dom ains together with 
quantification o f  C D 32-G M 1 co loca lizatio n  (sca le  bar: 10 p m ). C ells w ere prepared and analyzed as described in M aterials and M ethods. C , D R M  
fractionation and analysis o f  C D 3 2  distribution in W T  and A 2 2 4 S  C D 32-exp ressin g  CH O  ce lls  to determ ine receptor localization  fo llow in g  Ig G  com plex 
binding (h H A Ig G ; 10 /xg • m T 1). C a v eo lin -1 was used as a m arker for D R M  fractions. D , Q uantification o f  C D 3 2  band intensities present in each  fraction. 
E, M easurem ent o f  IgG  co m p lex  binding (h H A IgG ) in W T  and A 2 2 4 S  C D 32-tran sfected  C H O  ce lls  that were treated with or without 10 m M  M/3CD (15  
min, 3 7 °C ). R esu lts are presented as the m ean from  at least three experim ents, and error bars indicate SD . * * ,  p  <  0 .0 5 , and * ,  p  <  0 .0 1 , com pared with 
W T C D 32 . F, R epresentative flow  cytom etry histogram  o f  C D 3 2  expression in W T  and A 2 2 4 S  C D 32-ex p ressin g  C H O  ce lls. G , A n alysis o f  tyrosine 
phosphorylation (p Y ) o f  W T  and A 2 2 4 S  C D 3 2  follow ing  stim ulation with IgG  com plexes (h H A IgG ; 10 /xg • m l- 1 , 5  m in, 3 7 °C ). C D 3 2  phosphorylation 
was analyzed as described in M aterials and M ethods , and as control, m em branes w ere reprobed for C D 32 .
Treatment of neutrophils with HNE (4 /xg • ml“ 1, 20 min, 37°C) 
resulted in a substantial increase in CD32-mediated IgG complex 
binding (Fig. 3, A -Q  without significant alteration in the levels of 
CD32 (Fig. 3D). Similar effects were also observed when other serine 
proteases were used, including proteinase K (data not shown). These 
data suggest that proteases increase the capacity for IgG complex 
binding to CD32, independently of effects on surface expression.
Since disruption o f lipid rafts resulted in a decreased IgG com­
plex binding to cells that display constitutive IgG complex binding 
(CHO:32), we investigated whether the observed elastase-medi- 
ated augmentation of IgG binding to neutrophils was also depen­
dent upon the presence o f intact lipid raft microdomains. As shown 
in Fig. 3, E  and F , IgG complex binding was also found to be 
markedly reduced following treatment of neutrophils with M/3CD 
in elastase-treated neutrophils. Similarly, nystatin also displayed 
an analogous effect, with no change in IgG complex binding ob­
served following cholesterol repletion in M|3CD-treated cells or 
upon treatment with a-CD  (data not shown). It should be noted 
that none of these treatments had any effect on neutrophil expres­
sion of CD 32 (data not shown). Taken together, these data dem­
onstrate that IgG binding to CD32 on neutrophils also required 
lipid raft integrity.
Exclusion o f  CD32 from lipid rafts results in decreased IgG 
binding
To further investigate the role of lipid rafts in the regulation of 
IgG complex binding, we examined a CD32 transmembrane mu­
tation (A 224S) that was previously shown to have impaired asso­
ciation with lipid rafts (24). We have generated the A 224S CD32 
mutation by site-directed mutagenesis and subsequently used 
transfection together with cell sorting to select a CHO cell popu­
lation expressing levels of CD32 similar to control CD32-trans- 
fected cells. The association of the A 224S mutant CD 32 with lipid 
rafts was determined by confocal immunofluorescence microscopy 
and DRM fractionation. As it is evident in Fig. 4, A and 5 , the 
A 224S mutant displayed decreased colocalization with the gangli- 
oside GM 1, a characteristic, well-established marker for lipid raft 
microdomains, compared with the W T receptor. Furthermore, un­
like W T CD32, A 224S failed to translocate to the detergent-insol­
uble fractions following cross-linking with IgG based on DRM 
fractionation analysis (Fig. 4, C and D). IgG complex binding were 
significantly reduced in A 224S CD32-expressing CHO cells com­
pared with W T CD32-CHO over a range of IgG concentrations, de­
spite expressing CD32 at comparable levels (Fig. 4, E  and F). More 
importantly, consistent with data shown in Fig. 2, treatment with 
M/3CD had minimal impact on IgG complex binding to the A224S, 
indicating that the observed reduction in IgG binding could be attrib­
uted to the exclusion of this mutant receptor from lipid rafts. As re­
ceptor association with lipid rafts is a key determinant for the initia­
tion of signaling cascades following receptor engagement, we have 
assessed and compared ITAM phosphorylation of W T and A224S 
CD32. As it is evident from Fig. 4G, reduced levels of phosphorylated 
CD32 were observed following IgG complex binding compared with 
the W T receptor, clearly indicating that exclusion of CD32 from lipid 
rafts could also have an impact on downstream signaling events.
Palmitoylation o f  CD32 promotes association with lipid rafts 
and regulates IgG binding
The CD 32 protein has one potential site (C 241) for palmitoyl­
ation, a posttranslational process that supports the association 
o f membrane proteins with lipid rafts. This site was previously 
shown to be essential for CD32 palmitoylation and its association
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F IG U R E  S . P alm itoylation  o f  C D 3 2  prom otes association  with lipid rafts and regulates IgG  binding. A, F IT C -lab e le d  IgG  co m p lex  binding (h H A IgG ) 
was assessed  in C D 32-tran sfected  C H O  ce lls  fo llow in g  treatm ent with 5 0  /xM 2-brom opalm itate (2 0  h, 3 7 °C ), a palm itoylation  inhibitor. R esu lts represent 
the m ean ( ± S D )  from  three independent experim ents. *, p  <  0 .0 1 . and * * ,  p  <  0 .0 5 , com pared with untreated ce lls. M utation  o f  the C D 3 2  palm itoylation 
site (C 2 4 1 A ) resulted in decreased association  o f  C D 3 2  with lipid rafts, as evidenced by con focal im m unofluorescence m icroscopy (B  and C) and D R M  
fractionation analysis (D  and E). B, Representative photom icrographs o f  C D 3 2 -G M  l-lab e led  CH O  ce lls  exp ressing  either the W T  or the palm itoylation 
mutant (C 2 4 1 A ) o f  C D 32 . S ca le  bar: 10 pm . C , Q uantification o f  C D 32  co localizatio n  with G M 1 in W T  and C 241 A -expressin g  C H O  ce lls. D R M  
fractionation (D ) and quantification (E ) o f  C D 3 2  distribution in CH O  ce lls  transfected with either the W T  or C 2 4 1 A  C D 32  upon binding o f  IgG  com p lexes 
(hH A IgG ; 10 p g  • m l- 1 ). C aveolin-1 was used to define D R M  fractions. F, Com parison o f  F IT C -co n ju g ated  Ig G  com plex binding (h H A IgG ) to W T  and 
C 241A  C D 3 2  fo llow in g  treatm ent with 10 m M  M/3CD (15  m in, 3 7 °C ). R esu lts are presented as the m ean from  three exp erim ents and error bars represent 
SD. * ,  p  <  0 .0 1 , and * * ,  p  <  0 .0 5 , com pared w ith W T  C D 32 . G , Flow  cytom etry histogram s o f  C D 3 2  exp ression  in W T  and C 2 4 1 A  C D 32-tran sfected  
CHO ce lls. 77, T yrosin e phosphorylation (p Y ) o f  C D 3 2  was assessed in CH O  ce lls  expressing either W T  or C 2 4 1 A  C D 32  follow ing  stim ulation with IgG  
com plexes (h H A Ig G ; 10 p g  ■ m l- 1 , 5 m in, 37 °C ). C D 3 2  phosphorylation was analyzed as described in M aterials and M ethods  and to determ ine equal 
protein loading, m em branes w ere reprobed for C D 32 .
with lipid raft microdomains (37). On the basis of our observation 
that exclusion of A 224S CD32 from lipid rafts leads to a substan­
tial decrease in IgG binding, we have next determined whether 
inhibition of CD32 palmitoylation had an impact on IgG binding.
First, the effect o f the palmitoylation inhibitor 2-bromopalmitate 
on IgG binding to W T CD32-expressing CHO cells was assessed. 
Treatment with 2-bromopalmitate (50 pM, 20 h; 37°C) resulted in 
a significant decrease in IgG complex binding (Fig. 5A); an effect 
that was not associated with any changes in CD32 expression (data 
not shown), implicating palmitoylation of CD32 in the regulation 
of IgG binding. Second, mutation of the predicted palmitoylation 
site (C241A) o f CD32 resulted in decreased CD32-GM1 colocal­
ization in the CHO-C241A mutant compared with its W T coun­
terpart (CHO:32) (Fig. 5, B and Q. Unlike W T CD32, the C241A 
mutant also failed to distribute to the detergent-resistant domains 
in the presence o f IgG complexes, suggesting possible exclusion 
from lipid rafts (Fig. 5, D and E). We next measured IgG binding 
in CHO-C241A cells, observing reduced levels of IgG complex 
binding when compared with CHO:32 W T cells (Fig. 5F), despite 
expressing CD32 at comparable levels (Fig. 5G). In addition, 
M/3CD treatment of C241A had minimal effect on IgG binding, 
highlighting the role o f CD32 palmitoylation in receptor-lipid raft
association. In addition, when we assessed ITAM  phosphorylation 
o f CD32 following binding of IgG complexes, the C241A mutant 
displayed reduced levels of tyrosine phosphorylation compared 
with the W T receptor (Fig. 5H), further highlighting the role of 
lipid raft-CD 32 association in the initiation of downstream signal­
ing processes.
Constitutively lipid raft-associated CD32 displays increased 
IgG binding
Chemical disruption o f lipid raft microdomains leads to de­
creased IgG binding to CD 32 and mutations that alter the as­
sociation o f CD 32 with detergent-insoluble domains have an 
analogous effect. Taken together, these findings indicate that 
translocation of CD 32 to lipid rafts is a m ajor process that reg­
ulates IgG binding in CHO cells, a cell type that displays un­
suppressed IgG binding to CD 32. W e hypothesized that the low 
levels of IgG complex binding observed in cell types o f myeloid 
origin, such as K 562 cells, could be attributed to constitutive 
CD 32 exclusion from lipid raft microdomains in these cell 
types. W e therefore investigated whether constitutive localiza­
tion o f CD 32 in lipid rafts would lead to an unsuppressed state 
in the myeloid environment o f K 562 cells.
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F IG U R E  6 . C onstitu tively  lipid raft-associated  C D 32  displays increased Ig G  binding in K 5 6 2  ce lls . A , Endogenous C D 3 2  expression  w as knocked down 
in K 5 6 2  fo llow in g  stable transfection  with an ti-C D 32 shR N A -expressing  plasm id vectors and surface expression  w as assessed by flow  cytom etry. Isotype 
represents isotype-m atched  control. R esu lts are presented as the m ean ( ± S D )  from  four independent experim ents. B, R epresen tative flow  cytom etry 
histogram s o f  Ig G  com plex binding ( B x B ; 10 p,g • m l- 1 ) to W T  or shR N A -transfected  K 5 6 2  ce lls  (sh R N A ). C , Sch em atic representation o f  a generated 
mutant form  o f  C D 3 2  with the extracellu lar dom ains o f  C D 32 , follow ed by the G P I m odification consensus sequen ce o f  the G P I-an chored  C D 5 5  that is 
predicted to  be prim arily localized  within lipid raft m icrodom ains. D , Representative flow  cytom etry histogram  o f  C D 3 2  exp ression  in sh R N A -K 5 6 2  ce lls  
that w ere stably  transfected  with either the W T , full-length  C D 3 2  (with synonym ous m utations in the shRN A  target reg ion ), or the C D 32/55 ch im eric 
construct. E  and F , A n aly sis and quantification o f  C D 32-G M 1 co localization  in C D 32  and C D 32/ 55-expressing K 5 6 2  ce lls  by co n fo ca l im m unofluorescence 
m icroscopy. C ells w ere prepared and analyzed as described in M aterials and M ethods  and are presented as extended focus three-d im ensional reconstructed 
images. S ca le  bar: 5 p.m. G , D R M  fractionation analysis o f  C D 3 2  localization  in W T  or C D 32/55 K 5 6 2  ce lls  revealed con stitu tive lipid raft association  
of CD 32/55 but not o f  W T  C D 3 2 . T ransferrin  receptor (T fR /C D 71) and flotillin-1 distribution w ere assessed as m arkers for raft-exclud ed  or raft-associated  
proteins, respectively . H, Q uantification o f  the presence o f  C D 3 2  in each  fraction. /, M easurem ent o f  F IT C -co n ju g ated  Ig G  co m p lex  binding (h H A IgG ) 
in W T  o r C D 32/ 55-transfected  K 5 6 2  ce lls  treated with o r without 10 m M  M j3C D  (1 5  m in, 3 7 °C ). R esu lts represent the m ean ( ± S D )  from  at least three 
independent experim ents. * ,  p  <  0 .0 1 , and * * ,  p  <  0 .0 5 , com pared with C D 32/55.
However, since K 562 cells constitutively express CD32, we had 
to knock down endogenous CD32 expression in K 562 cells using 
shRNA. K 562 cells were stably transfected with plasmid vectors 
expressing shRNA targeted against CD32, resulting in > 7 0 %  re­
duction in CD32 expression (Fig. 6A). Reduced expression of 
CD32 in these cells was associated with negligible levels of IgG 
complex binding (Fig. 65). These cells (K 562:C D 32low) were then 
stably transfected either with the W T CD32 (bearing synonymous 
mutations in the shRNA-recognizing sequence) or with a GPI- 
anchored version o f CD32, which like all GPI-anchored proteins, 
was expected to be primarily localized to lipid raft membrane do­
mains. This construct was engineered to comprise the extracellular 
domains o f CD32, followed by the GPI modification consensus 
site of CD55 (Fig. 6Q. Both W T CD32 and CD32/55 were ex­
pressed at similar levels (Fig. 6D) and the CD32/55 chimeric pro­
tein was found to be GPI-anchored, as evidenced by the reduction 
in expression following phosphatidylinositol-specific phospho- 
lipase C treatment (data not shown). Analysis of CD32/55 local­
ization by confocal immunofluorescence microscopy revealed sig­
nificantly higher colocalization with GM1 compared with the WT 
CD32 (Fig. 6, E and F). In contrast with W T CD32, which was 
excluded from rafts, CD32/55 was constitutively present in DRM
fractions (Fig. 6 , G and H). On the basis of these findings, we next 
investigated IgG binding to CD32/55 and to the W T counterpart. 
CD32/55 displayed markedly higher levels of IgG binding than 
W T CD32 (Fig. 61). In addition, a great proportion of the IgG 
binding was inhibited following treatment with M/3CD, suggesting 
that intact lipid rafts were necessary for the observed high levels of 
binding. In summary, all the presented data clearly indicate that in 
myeloid cells such as K 562, CD 32 is normally excluded from lipid 
raft microdomains, a process that accounts for the suppressed IgG 
binding observed.
Discussion
Several cell types of the myeloid origin, including monocytes and 
neutrophils are characterized by suppressed IgG complex binding 
to CD32, but the molecular mechanisms of suppression are poorly 
characterized. On the basis o f our findings that disruption of lipid 
raft architecture using chemical agents, such as M/3CD or nystatin, 
resulted also in decreased levels of IgG complex binding, we have 
tested the hypothesis that association o f CD 32 with lipid rafts are 
required for IgG complex binding and that exclusion of CD32 
from lipid rafts acts to inhibit IgG complex binding to myeloid 
cells.
8034 CD32a-LIPID RA FT INTERACTIONS REG U LA TE IgG BINDING
The heterogeneity o f the plasma membrane comprising of vari­
able-sized domains with distinct density and lipid composition can 
influence the activity and function of a range of membrane-bound 
proteins, controlling the interaction with downstream signaling 
components (10, 38). For this reason, the association o f a protein 
with lipid rafts is a highly regulated, dynamic process, and several 
determinants for the control of this process have already been de­
scribed, including the transmembrane domains. Interactions of the 
amino acid residues of these domains with complexes o f choles­
terol and sphingolipids present in lipid rafts influences the affinity 
for a protein for lipid rafts. Mutations within the transmembrane 
domains had an impact on their association with lipid rafts, pos­
sibly due to alterations in the overall three-dimensional structure 
(39).
For CD32, it has been demonstrated that alanine 224 within the 
transmembrane region of CD32 has a role on the receptor parti­
tioning within the plasma membrane following cross-linking and 
mutation o f this residue (A 224S) resulted in decreased association 
with lipid rafts (24). Decreased levels of IgG complex binding to 
A224S-expressing CHO cells when compared with the W T recep­
tor suggest that association of CD32 with lipid rafts is necessary 
for IgG complex binding. Association of CD32 with lipid rafts 
may be determined by a palmitoylation site that increases the af­
finity o f CD 32 for lipid rafts (37). We have clearly demonstrated 
that mutation o f this site or inhibition of palmitoylation using 
chemical inhibitors results in decreased binding o f IgG complexes; 
an effect that was attributed to the exclusion of CD32 from lipid 
rafts, further highlighting the role of lipid rafts in the regulation of 
IgG complex binding to CD32. The existence of a functional pal­
mitoylation site clearly suggests that CD32-lipid raft interactions 
play a key role in the regulation of receptor activity and function. 
Although the available techniques for the study of lipid rafts have 
their respective strengths and weaknesses, in the present study, we 
have used two well-characterized approaches to study association 
of CD32 with lipid rafts: confocal immunofluorescence using 
CtxB that is known to specifically interact with the ganglioside 
GM1, a characteristic component o f lipid rafts, as well as cold 
nonionic detergent extraction and fractionation. In addition, the 
efficiency o f the DRM fractionation was validated by assessing the 
localization of known lipid raft associated (caveolin-1) and non­
raft-associated (transferrin receptor) marker proteins.
Previous studies focusing on the importance of lipid raft do­
mains in the regulation o f CD32 effector functions have demon­
strated that either chemical disruption of lipid rafts or mutants (in 
the transmembrane domain or in the palmitoylation site) with de­
creased affinity for lipid rafts impairs signaling responses (7 -9 , 
22-24, 37). However, these studies did not measure binding of IgG 
complexes, and therefore, any impairment in receptor effector 
functions could be attributed to reduced ligand binding to CD32. 
Studies in which cross-linking of CD32 molecules with Abs or 
measuring the uptake of particles coated with anti-CD32 Abs as a 
surrogate of receptor engagement and activity may not represent a 
good model o f the multivalent, low-affinity interaction of CD32 
with IgG complexes, as they bypass normal physiological regula­
tory mechanisms.
A surprising observation of this study was the cell type-specific 
regulation o f IgG complex binding to CD32. We have shown that 
in a range of myeloid cell types, CD32 has limited capacity for IgG 
complex binding, despite being expressed at levels, which confer 
significant binding in nonmyeloid cells. Since a constitutively lipid 
raft-associated form of CD32 (GPI-anchored CD32) results in high 
levels of IgG complex binding relative to W T CD32, we propose 
that CD32 is actively excluded from lipid rafts in myeloid cells. 
Given the role of lipid rafts in the regulation IgG complex binding
F I G U R E  7 . Sch em atic representation o f  the proposed m odel o f  control 
o f  IgG  com plex binding to C D 3 2  by lipid raft dom ains. A , U nder resting 
conditions, C D 3 2  ex ists as a m onom eric protein either being associated 
with sm all sca le  rafts or residing predom inantly in the nonraft regions o f  
the m em brane. B , A fter recognition  o f  Ig G  co m p lexes, m ultiple low -affin­
ity, high-avidity m ultivalent in teractions o ccu r betw een C D 3 2  m olecules 
and Ig G  com plexes that induce receptor o ligom erization , lead ing co n se­
quently to increased affinity o f  C D 3 2  fo r lipid rafts and its redistribution to 
larger and m ore stable lipid rafts. D uring this process, the w eak interactions 
betw een IgG  and C D 3 2  o f  the initial phase o f  the binding (A) are greatly 
stabilized fo llow in g  m ultivalent in teractions and organization o f  C D 3 2  to 
high-order lipid raft dom ains. C lustering  o f  C D 3 2  w ithin these dom ains 
that are enriched with signaling  m olecu les is essen tia l for the interaction o f  
the IT A M  o f C D 3 2  with k inases (lik e S y k  k in ase) leading to the initiation 
o f  signaling cascad es follow ing  recep tor engagem ent.
we have already shown here, this exclusion may affect the stability 
of the CD32-IgG interactions. Cell type-specific association of 
molecules with lipid rafts has been previously described for the /32 
integrin, LFA-1 (15). LFA-1 functional activity is dependent on its 
association with lipid rafts and differential binding capacity for 
ICAM-1 was observed in monocytes and in dendritic cells (15, 
16). The ability of LFA-1 to become organized in nanoclusters 
within lipid raft domains was suggested to augment LFA-1 affinity 
for ligand. We propose that a similar principle applies also for the 
regulation of ligand binding to CD32, which in myeloid cells is 
excluded from rafts and thus unable to oligomerize and associate 
with high-order lipid rafts, leading consequently to decreased sta­
bility of CD32-IgG complex interactions. On the basis o f recent 
studies on the dynamics of lipid rafts, a model of lipid raft in­
volvement in control of IgG complex binding could be proposed 
(Fig. 7) (35, 40). In the absence o f IgG complexes, CD32 exists as 
a monomeric protein and is therefore associated with small-scale 
rafts or displays reduced affinity for rafts residing predominantly in 
the nonraft regions of the membrane with only a small fraction 
being raft associated (Fig. 2, E and F). After IgG complex binding 
to CD32, multiple low-affinity interactions with multivalent IgG 
complexes trigger receptor oligomerization and high-avidity bind­
ing, thereby stabilizing IgG complex binding to CD32. It is there­
fore highly possible that binding of IgG increases receptor local­
ization to lipid rafts and as a consequence, lipid raft-associated 
CD32 would enhance IgG binding.
Several regulatory mechanisms could restrict the association of 
CD32 with lipid rafts in myeloid cells. Such mechanisms have 
been previously suggested to be responsible for the exclusion of 
proteins from lipid rafts and include the regulation of lipid mem­
brane composition, protein palmitoylation, interaction of CD32
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with membrane proteins with low affinity for lipid rafts or associ­
ation of CD32 with cytoskeletal adaptor proteins, linking CD32 
with nonraft domains of the membrane (4 0 -4 3 ) . Furthermore, it is 
likely that variations in the lipid composition of raft domains be­
tween different cell types might regulate the ligand binding activity 
of CD32. Preliminary analysis o f the cholesterol content of lipid 
membranes o f K 562 and CHO cells revealed no major differences 
between these two cell types (K 562, 3.7 ±  0.33 ju.g/106 cells; 
CHO, 4.2 ±  0.68 p.g/106 cells). Similarly, previous studies on 
platelets and CHO cells— two cell types that display differential 
CD32 ligand binding activity— revealed similar cholesterol :phos- 
pholipid ratios (44, 45). Although it seems unlikely for the mem­
brane cholesterol content to have a regulatory role in the IgG bind­
ing to CD32, the amount o f specific phospholipid and glycolipid 
species within the lipid raft domains o f different cell types might 
be an important determinant for the ligand binding activity of 
CD32, as well as for other raft-associated proteins.
Our data suggest that the mechanisms responsible for the ex­
clusion of CD32 from lipid rafts are likely to be common in many 
myeloid cell types, including neutrophils, monocytes, and plate­
lets, acting as an important regulatory component that limit IgG 
complex binding to these cells. Since myeloid cells are the first 
type of cells that encounter IgG complexes during an inflammatory 
response, it seems reasonable that lipid raft-mediated regulatory 
control of receptor activity has evolved to restrict IgG complex 
binding, preventing inappropriate cell activation by low levels of 
IgG complexes. The clustering of CD32 molecules within these 
domains that are enriched in signaling molecules is essential for 
the initiation of signaling cascades following receptor engagement.
There is increasing evidence of a role for lipid rafts in the reg­
ulation o f other FcR  activity. For instance, FceR I binds mono­
meric IgE with high affinity and displays very low affinity for lipid 
rafts under resting conditions. Receptor activation following bind­
ing of oligomeric Ags cross-links two or more FceR I receptors 
together, leading consequently to their recruitment into high-order 
lipid rafts, favoring phosphorylation of ITAM through interaction 
with raft-associated Lyn kinases or through the exclusion o f phos­
phatases from lipid raft domains. CD64, the high-affinity receptor 
for IgG expressed predominantly in monocytes and macrophages, 
has also been reported to become constitutively associated with 
lipid rafts and changes in receptor partitioning to membrane mi­
crodomains may regulate IgG binding (46). Similarly, redistribu­
tion and colocalization o f FcyR IIIa (CD 16a) and IL-12R  has been 
reported to be a key step in the initiation of intracellular signaling 
cascades, including E R K  phosphorylation and subsequent effector 
functions, such as IFN -y production following ligand binding (47). 
Furthermore, recent studies characterized a polymorphism (I232T) 
within the transmembrane domain of CD32b, an isoform of CD32 
that contains an inhibitory ITIM  with decreased affinity for lipid 
rafts and defective signaling (48, 49). Interestingly, increased fre­
quency of the T 232 polymorphism was noted in patients with sys­
temic lupus erythematosus presumably because C D 32b ™ 2 fails to 
localize to lipid rafts and therefore exert inhibitory activity upon 
autoimmune responses.
In conclusion, in this study, we have presented a novel regula­
tory role for lipid rafts, as an integral and important component for 
IgG complex binding to CD32. Indeed, disruption of lipid raft 
structure or alteration of receptor affinity for lipid rafts is associ­
ated with impaired IgG complex binding. In addition, we have 
shown that myeloid cells exhibit suppressed CD32 activity in 
terms of IgG complex binding, and this effect clearly arises from 
the active exclusion o f CD 32 from lipid rafts in these cells.
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Glucocorticoids Induce Protein S-Dependent Phagocytosis of 
Apoptotic Neutrophils by Human Macrophages1
Aisleen McCoIl,* Stylianos Bournazos,* Sandra Franz,* Mauro Perretti,+ B. Paul Morgan,* 
Christopher Haslett,* and Ian Dransfield2*
During resolution of an inflammatory response, recruited neutrophil granulocytes undergo apoptosis and are removed by tissue 
phagocytes before induction of secondary necrosis without provoking proinflammatory cytokine production and release. Promo­
tion of physiological neutrophil clearance mechanisms may represent a viable therapeutic strategy for the treatment of inflam­
matory or autoimmune diseases in which removal of apoptotic cells is impaired. The mechanism underlying enhancement of 
macrophage capacity for phagocytosis of apoptotic cells by the powerful anti-inflammatory drugs of the glucocorticoid family has 
remained elusive. In this study, we report that human monocyte-derived macrophages cultured in the presence of dexamethasone 
exhibit augmented capacity for phagocytosis of membrane-intact, early apoptotic cells only in the presence of a serum factor. Our 
results eliminate a role for a number of potential opsonins, including complement, pentraxin-3, and fibronectin. Using ion- 
exchange and gel filtration chromatography, we identified a high molecular mass serum fraction containing C4-binding protein 
and protein S responsible for the augmentation of phagocytosis of apoptotic neutrophils. Because the apoptotic neutrophils used 
in this study specifically bind protein S, we suggest that glucocorticoid treatment of macrophages induces a switch to a protein 
S-dependent apoptotic cell recognition mechanism. Consistent with this suggestion, pretreatment of macrophages with Abs to Mer 
tyrosine kinase, a member of the Tyro3/Axl/Mer family of receptor tyrosine kinases, prevented glucocorticoid augmentation of 
phagocytosis. Induction of a protein S/Mer tyrosine kinase-dependent apoptotic cell clearance pathway may contribute to the 
potent anti-inflammatory effects of glucocorticoids, representing a potential target for promoting resolution of inflammatory 
responses. The Journal o f Immunology, 2009, 183: 2167-2175.
S uccessful restoration of a tissue to its original state after an inflammatory insult requires that large numbers of extrav- asated neutrophil granulocytes are cleared from the in­flamed site. During this resolution phase o f inflammation, recruited 
neutrophils undergo apoptosis and are subsequently removed by 
phagocytosis ( 1), a rapid and efficient process that does not stim­
ulate proinflammatory macrophage responses (2). Conversely, in­
efficient or defective clearance of membrane-intact apoptotic neu­
trophils may result in release of their histotoxic intracellular 
contents as a consequence of secondary necrosis, potentially caus­
ing local tissue damage and contributing to pathogenesis of in­
flammatory disease (3). An attractive approach for therapeutic 
intervention in inflammatory diseases would therefore be to ma­
nipulate the processes involved in physiological clearance of neu­
trophils from inflamed sites. Although promotion of neutrophil 
apoptosis may be achievable pharmacologically (4), under some 
circumstances in vivo it will be important to ensure that the ca­
pacity for apoptotic cell clearance within tissues is matched to
*Medical Research Council Centre for Inflammation Research, Queen’s Medical Re­
search Institute, Edinburgh, United Kingdom; tWilliam Harvey Research Institute 
Barts and London Queen Mary’s School o f Medicine and Dentistry, London, United 
Kingdom; and -Department of Medical Biochemistry and Immunology, School of 
Medicine, Cardiff University, Cardiff, United Kingdom
Received for publication October 17, 2008. Accepted for publication June 3, 2009.
The costs of publication of this article were defrayed in part by the payment of page 
charges. This article must therefore be hereby marked advertisement in accordance 
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by a European Community Grant (QLK3-CT-2002- 
02017), the British Heart Foundation, the Deutsche Forschungsgemeinschaft, and the 
Medical Research Council (United Kingdom).
2 Address correspondence and reprint requests to Dr. Ian Dransfield, Medical Re­
search Council Centre for Inflammation Research, Queen’s Medical Research Insti­
tute, 47 Little France Crescent, Edinburgh, United Kingdom. E-mail address: 
¡ dransfield@ed.ac.uk
avoid potential deleterious consequences of the presence of non- 
phagocytosed apoptotic cells (5).
We have previously reported that the powerful anti-inflammatory 
drugs of the glucocorticoid family (methylprednisolone, hydrocorti­
sone, or dexamethasone (Dex))3 specifically enhance noninflamma­
tory phagocytosis of apoptotic cells by human and murine macro­
phages (6, 7). Glucocorticoids have been shown to modulate the 
expression of over 100 genes, including those known to be associated 
with apoptotic cell phagocytosis, such as CD 163, FPR1, and Mer 
tyrosine kinase (Mertk) receptors and M FG-E8 and C lq  serum pro­
teins (8). Furthermore, we have shown that human monocytes differ­
entiated for 5 days in the presence of glucocorticoids exhibit a more 
homogeneous phenotype with reduced phosphorylation of molecules 
involved in integrin signaling and cytoskeletal rearrangement (7). 
However, the precise mechanism(s) by which glucocorticoids aug­
ment phagocytosis of apoptotic cells has remained elusive.
In this study, we have examined the mechanism underlying aug­
mentation o f human monocyte-derived macrophage (MDM</>) ca­
pacity for phagocytosis of early membrane-intact apoptotic human 
neutrophils following exposure to glucocorticoids. Apoptotic neu­
trophils display a distinct surface molecular phenotype important 
for attenuation o f functional responses (9) with additional surface 
changes that target dying cells for removal by phagocytes (10). A 
number of soluble factors present in serum, including complement 
C lq  and C3b, properdin, collectins, long pentraxin-3, M FG -E8, 
galectin-3, and a 2-macroglobulin, have been reported to bind to 
apoptotic human cells (1 1 -1 8 ) and consequently modulate their
3 Abbreviations used in this paper: Dex, dexamethasone; C4BP, C4-binding protein; 
CMFDA, 5-chloromethylfluorescein diacetate; MDM<i>, monocyte-derived macro­
phage; Mertk, Mer tyrosine kinase.
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recognition and uptake by macrophages via a number o f different 
surface receptors, including scavenger receptors, complement re­
ceptors, receptors for phosphatidylserine, and Mertk (1 9 -2 2 ). 
However, it is important to note that some of these opsonization 
events occur relatively late during the apoptotic process and ac­
company loss of membrane integrity (23).
In this study, we demonstrate that glucocorticoid augmentation 
of MDM<£ phagocytosis is associated with a switch from a serum- 
independent to a serum-dependent apoptotic cell recognition 
mechanism, which can be recapitulated with purified protein S, a 
75-kDa vitamin K-dependent anticoagulation factor that is present 
in plasma at a relatively high concentration of —25 /xg/ml (24), 
and involves macrophage Mertk, a member of the Tyro3/Axl/Mer 
family o f immunoregulatory receptor tyrosine kinases (25). Our 
data strongly suggest that glucocorticoids critically regulate a 
switch in apoptotic cell clearance mechanisms used by macro­
phages, potentially contributing to their potent anti-inflammatory 
effects and thus representing a target for promoting inflammatory 
resolution.
Materials and Methods
Sera, serum proteins, and other reagents
All ch em ica ls  w ere purchased from  Sigm a-A ld rich , unless otherw ise 
stated. Culture m edium  (IM D M ), buffers (H B S S  and P B S  without divalent 
cations), and try p sin -E D T A  w ere from  PA A  Laboratories. P erco ll was 
from G E  H ealthcare. D extran  T 5 0 0  was from  Pharm acosm os. D ex  was 
obtained from  O rganon. R o scov itin e was from  M erck. Serum , from  co ag ­
ulated w hole b lood , was obtained by cardiac puncture from  w ild-type, 
annexin I-d eficien t (2 6 ) , and C lq -d e fic ien t (2 7 ) m ice on a C 57B L / 6 back ­
ground. C lq -d e p leted  hum an serum  was obtained from  M erck . A  soluble 
recom binant form  o f  human com plem ent receptor 1 was used for inhibition 
o f C 3  activation  in serum  (2 8 ) . A  dose o f  2 5 0  /xg/ml com pletely  blocks 
com plem ent activ ity , as assessed  by hem olytic assays. Proteins purified 
from human serum/plasma w ere obtained from  the fo llow in g  sources: pro­
tein S (E n zy m e R esearch  Laboratories), C lq  (M erck ), and a 2-m acroglob- 
ulin (S ig m a-A ld rich ).
Antibodies
Primary A bs w ere from  the follow ing  sources: p o lyclonal rabbit anti­
protein S  A b (1 :5 0 0 0 ; D akoC ytom ation), anti-hum an M e r m A b (clone 
125508, m urine Ig G 2 b , 1 :5 0 ; R & D  Sy stem s), and C D 4 4  m A b (clo n e 5A 4 , 
Ig G l, 1 :5 0 ; provided by G. D ougherty, U niversity  o f  C aliforn ia , San Fran­
cisco, C A ). C ontrol m ouse Igs ( Ig G l, Ig G 2b ; 1 :50 ) w ere from  S erotec. 
H RP-conjugated goat anti-rabbit Igs ( 1 :2 5 0 0 ) and F IT C -co n ju g ated  F (a b ')2 
goat anti-m ou se Igs (1 :5 0 )  w ere from  D akoC ytom ation . PE -con ju gated  
anti-CD 16 m A b (c lo n e  3 G 8 , Ig G l)  was obtained from  B D  B io scien ce s . 
A garose-coupled goat anti-rabbit Ig  was obtained from  Sig m a-A ldrich .
Cell isolation
M ononuclear and polym orphonuclear leukocytes w ere isolated from  
freshly drawn, citrated human blood by dextran sedim entation and cen trif­
ugation over a discontinuous P ercoll gradient (final concentrations o f  55 , 
70, and 8 1 %  P e rco ll), as previously described (2 9 ). M on on u clear ce lls  
were aspirated from  the 55/70%  interface, and neutrophils from  the 70/81%  
interface. A u tologous serum  was prepared by recalcificatio n  o f  p latelet-rich  
plasma (final C a C l, concentration : 2 2  m M ), as previously described (2 4 ).
In vitro culture o f  human MDM<\>
M ononuclear ce lls  w ere resuspended at 4  X  106/ml in IM D M  and adhered 
to 48 -w e ll tissue cu lture plates for 1 h at 3 7 °C  in 5 %  C 0 2. N onadherent 
lym phocytes w ere rem oved by w ashing with IM D M , and adherent m ono­
cytes w ere cultured fo r  5 days in IM D M  containing 10%  autologous se­
rum ±  1 p M  D ex . T h ese  ce lls  are > 9 0 %  C D 1 4 + at 5  days with functional 
and phenotypic characteristics o f  m acrophages (D ex-M D M d>) (7 ).
In vitro culture o f  neutrophils to induce apoptosis
N eutrophils w ere cu ltu red  at 4  X  106/ml in  IM D M  e ith e r  in the a b sen ce  
o f serum  o r in the p resen ce  o f  10 %  autologous serum  at 3 7 ° C  in 5 %  
C 0 2 a tm o sp h ere fo r  2 0 - 2 4  h, during w hich  tim e a p rop ortion  o f  the 
cells und erw ent ap o p to sis  (1 ) . A p o p to sis  and secon d ary  n e cro sis  w ere 
determined by  an n exin  V -F IT C  b in din g  (R o ch e  A pp lied  S c ie n c e s )  and
propidium  iod ide sta in in g  (S ig m a -A ld ric h ), re sp e c tiv e ly . A lte rn a tiv e ly , 
n eu tro p h ils  w ere resuspend ed in IM D M  at 2  X  107/ml and lab e led  w ith 
th e flu o rescen t ce ll track er dye 5 -ch lo ro m e th y lflu o re sce in  d iace ta te  
(C M F D A ; In v itro g en ), 2  /xg/ml fo r 15 m in at 3 7 ° C  in 5 %  C 0 2. N eu ­
trop h ils  w ere then w ashed  and cu ltu red  fo r  2 0 - 2 4  h , as d escrib ed  
abo v e.
Apoptotic cell phagocytosis assay
Phagocytosis o f  apoptotic ce lls  w as assessed  essen tia lly  as described (3 0 ), 
using a m ethod that has been carefu lly  characterized  and show n to dis­
crim inate betw een bound and internalized apoptotic ce lls, com paring fa ­
vorably with m icroscopy analysis. C M F D A -lab ele d  apoptotic neutrophils 
w ere centrifuged at 2 0 0  X  g  and resuspended at 2 .5  X  lO'Vml in IM D M , 
and 0 .5  ml w as overlaid  onto MDM<() that had been cultured in 48-w ell 
plates ( —2 0 0 ,0 0 0  MDM<j>/well, a ratio  o f  — 10 neutrophils per m acro­
phage) and then coincubated for 3 0  min at 3 7 °C  in 5 %  C 0 2. M edium  was 
then gently aspirated from  the w ells, and all ce lls  w ere detached with 5 0 0  
/xl o f  tryp sin -E D T A  before determ ination o f  phagocytosis (percentage o f  
F L -1 -p o sitiv e  M DM cj), identified by their d istinct forw ard and side scatter 
properties) by flow  cytom etry using a F A C S ca n  (B D  B io sc ien ce s). F or 
assays conducted in the presence o f  serum  or purified proteins, neutrophils 
w ere resuspended in IM D M  con tain in g  eith er 1%  autologous serum , 10 
/xg/ml either purified protein, or 1 mg/ml protein fraction s from  ion -ex ­
change or gel filtration chrom atography, unless otherw ise stated in the 
figure legends. F or experim ents requiring preincubation w ith either A bs or 
other protein fractions from  ion -exch an ge or gel filtration chrom atography, 
MDM4> or neutrophils w ere incubated with saturating concentrations o f  
A bs (final concentration  o f  — 10 /xg/ml as determ ined by flow cytom etric 
an alysis) or 10 /xg/ml either purified protein or 1 mg/ml protein fractions 
from  ion-exchange or gel filtration chrom atography, unless otherw ise 
stated in the figure legends. C ells w ere w ashed and resuspended in IM D M  
before use in phagocytosis assays.
Serum fractionation
Human serum was dialyzed against 5 0  m M  H E P E S  buffer (pH 7 .0 ) containing
0 .1 4  M  N aCl overnight before anion-exchange chromatography using Q 
Sepharose (Sigm a-A ldrich). Proteins were eluted using 50  m M  H E P E S con­
taining 0 .2  M  N aCl, and fractions containing the highest amount o f  protein 
were com bined before dialysis against 5 0  m M  T ris (pH 7 .4 ) containing 0 .1 4  M  
N aCl (T B S ) and concentrated before gel filtration chrom atography using 
Sephacryl S -3 0 0  (G E  H ealthcare). T h e  protein concentration  in eluted frac­
tions w as estim ated by m easurem ent o f  absorbance at 2 8 0  nm  (A 2 8 0 ) using 
a spectrophotom eter or using a b ic in ch o n in ic acid  protein assay k it, as 
specified by the m anufacturer (P ierce). G el filtration fraction s containing 
phagocytic activity  were analyzed by S D S -P A G E , im m unoblotting, and 
m ass spectrom etry to  determ ine the proteins present (tw o separate analy­
ses; J .  Creanor, U niversity  o f  Edinburgh, Edinburgh, U .K .).
Immunodepletion and Western blotting
T h e  0 .2  M  N aC l elu ate  fro m  a n io n -e x c h a n g e  ch rom ato grap h y  w as in­
cu bated  w ith protein  S  A b (5  /xg/ml e lu a te ) fo r 1 h on ice . Im m u ­
nod epletion  w as ach iev ed  by in cu b ation  fo r  1 h w ith ag aro se-co u p led  
goat an ti-rab b it Ig G  at 4 ° C  on a ro tary  m ix er , fo llo w ed  by ce n trifu g a ­
tion  at 1 3 ,0 0 0  X  g fo r  1 m in to  p e lle t th e ag aro se . T o  en su re effic ien t 
protein  d ep letio n , the supernatant w as su b jec ted  to  three rounds o f  d e­
p le tion . Sam p les w ere reso lv ed  by  S D S -P A G E  u sin g  9 %  g e ls  under 
n on red u cin g  co n d itio n s, un less o th erw ise  stated , and transferred  e le c -  
tro p h o retica lly  (8 0  V  fo r  5 0  m in ) o nto  e ith e r  p o ly v in y lid en e  d ifluorid e 
or n itro ce llu lo se  m em b ran es (M illip o re ) . M em b ran es w ere b lo ck ed  
overn ig h t in T B S  co n ta in in g  0 .1 %  T w een  2 0  b e fo re  prob in g  w ith  A b s. 
B in d in g  o f  an ti-p ro te in  S A b  w as d etected  w ith H R P -co n ju g a te d  goat 
an ti-rab b it Ig s  to g eth er w ith E C L  (G E  H ea lth care ).
Flow cytometry
A ll incubations w ere perform ed on ice  to prevent in ternalization o f  A b. 
Adherent MDMcj> w ere detached by incubation  in H B S S  w ithout divalent 
cations containing 0 .1 %  B S A  and 3 m M  E D T A . A fter w ashing with ice - 
cold  H B S S  containing 2 %  F B S , ce lls  (1 0 5/assay) w ere incubated with sat­
urating concentrations o f  m A b for 3 0  m in. C e lls  w ere then washed tw ice 
in H B S S  containing 2 %  F B S  b efore incubation  with F IT C -co n ju g ated  
F (a b ')2 goat anti-m ouse Ig s  fo r 3 0  min b efore an alysis using a F A C S can  
flow  cytom eter (29 ).
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A n a lysis  o f  re su lts
Results are presented as m ean ±  S E M , and n =  num ber o f  independent 
experim ents using m acrophages from  different donors. R esu lts w ere ana­
lyzed by repeated m easures one-w ay A N O V A  w ith a B on ferron i posttest.
Results
G lu c o c o r t ic o id -a u g m e n te d  c l e a r a n c e  o f  a p o p to t ic  n e u tro p h ils  b y  
m a cro p h a g es  is  se ru m  d e p e n d e n t
Previous studies relating to glucocorticoid-enhanced phagocytosis 
of apoptotic cells used monocyte-derived macrophages and apo­
ptotic cell targets that had been cultured in the presence of serum 
(6 , 7). To evaluate the potential role o f serum opsonization in 
promoting apoptotic neutrophil clearance, human blood mono­
cytes were cultured for 5 days in the absence or presence of Dex, 
and neutrophils were rendered apoptotic by overnight culture in 
serum-free conditions (Fig. 1A). Neutrophil populations cultured 
in serum-free conditions for 20 h exhibit a slightly higher percent­
age (63-70% , n = 35, 95%  confidence limit) of annexin V +/pro- 
pidium iodide-  (apoptotic) cells when compared with neutrophils 
cultured in the presence of serum (5 0 -6 0 % , n = 10), consistent 
with the presence of a survival factor(s) in human serum. In ad­
dition, there were significantly higher percentages of annexin V +/ 
propidium iodide+ (secondarily necrotic) neutrophils in serum- 
free cultures (1 8 -2 6 % , n =  35) when compared with neutrophils 
cultured in the presence o f serum (8 -1 7 % , n  =  10).
When we determined the proportion of untreated MDM</> and 
Dex-MDM4> that were capable of phagocytosis o f neutrophils, we 
were surprised to find that there was no significant augmentation of 
phagocytosis o f serum-free apoptotic neutrophils observed for 
Dex-MDMc/> (Fig. 1, C and E). In contrast, in the presence of 10% 
autologous serum, we observed increased phagocytic capacity for 
Dex-MDMc/> (Fig. 1, D and £ ). The presence or absence of serum 
also had a small, but statistically significant stimulatory effect upon 
phagocytosis of apoptotic neutrophils by untreated M D M $ (Fig. 
1E). The effect of serum on phagocytosis by D ex-M D M $ was 
concentration dependent and reached significance at 1 % (data not 
shown). The possibility that the presence o f serum acts to promote 
phagocytic activity of M D M $ directly was excluded in a series of 
experiments in which preincubation of apoptotic neutrophils with se­
rum was found to confer augmentation of Dex-MDMtf> phagocytic 
capacity (data not shown), raising the possibility that a serum factor 
binds to the apoptotic neutrophil surface to promote phagocytosis by 
Dex-MDM$.
A u g m en ta tio n  o f  p h a g o c y to s i s  b y  se ru m  is  in d ep en d en t o f  th e  
p r e s e n c e  o f  n e c r o t i c  n eu tro p h ils
Neutrophils undergo apoptosis in a relatively heterogeneous man­
ner during in vitro culture (Fig. 1A), making it difficult to deter­
mine whether enhanced phagocytosis following opsonization de­
pends upon the presence of apoptotic or secondarily necrotic cells. 
We therefore treated neutrophils with roscovitine, a cyclin-depen- 
dent kinase inhibitor that induces neutrophil apoptosis rapidly and 
uniformly without induction of secondary necrosis (4). Neutrophil 
populations cultured with 20 /uM roscovitine in serum-free condi­
tions for 4  h exhibit a high percentage (8 0 -9 0 % ) of annexin V +/ 
propidium iodide-  (apoptotic) cells with less than 3% annexin 
V+/propidium iodide+ (secondarily necrotic) cells (Fig. IS ). Se­
rum-dependent enhancement o f phagocytosis of roscovitine- 
treated apoptotic neutrophils by Dex-MDM<£ confirmed that op­
sonization of early apoptotic cells was required (33.7 ±  9.3%  and 
51.8 ±  6.3%  for Dex-MDMc/» in the absence and presence of se­
rum, respectively). Data are mean percentage phagocytosis ±  
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F I G U R E  1 . A ugm entation o f  phagocytosis o f  apoptotic neutrophils by 
g lu cocortico id-treated  m acrophages is serum  dependent. S tain in g  with an­
nexin V  (A n x V )-F IT C  (F L -1 )  and propidium  iodide (F L -2 )  was used to 
determ ine the proportion o f  apoptotic (A n x V +/propidium iod ide- ) and 
secondarily n ecrotic (A n x V +/propidium iod ide+ ) ce lls  present in neutro­
phil populations used fo r phagocytosis assays. R epresen tative tw o-param ­
eter h istogram s o f  flow  cyto m etric data are show n fo r A, neutrophils cu l­
tured for 2 0  h in serum -free conditions (n =  3 5 ) , and B, neutrophils 
cultured fo r 4  h in serum -free conditions in the presence o f  2 0  /u.M ro sco ­
vitine In =  3 ). M ean  data for the proportion o f  v iable , apoptotic, and 
secondarily  n ecrotic ce lls  present for each  treatm ent are show n in the ap­
propriate quadrant together with 9 5 %  con fid en ce intervals. P h ag o cy tosis o f 
fluorescently  labeled neutrophils was determ ined by flow  cytom etry using 
forw ard scatter and flu orescen ce to define F L - l hlgh p hagocytic and F L - l low 
nonphagocytic MDM<£ populations. R epresentative dot plots for D ex - 
MDMc() incubated with C M F D A -lab eled  neutrophils in the absen ce (C ) or 
presen ce (D )  o f  10%  autologous serum  are show n. F S C , forw ard light 
scatter. E , Percentage o f  phagocytosis ( ± S E M )  recorded for untreated 
M D M <i ( □ )  and Dex-M DMc/i ( ■ )  follow ing  incubation with neutrophils 
fo r 3 0  min is show n. P h agocytosis o f  apoptotic neutrophils by D e x -M D M ^  
was significan tly  augm ented by 10%  autologous serum  (A S ). T h e  presence 
o f  serum  also  had a sm all, but statistically  significant stim ulatory effect 
upon ph agocytosis by untreated D ata are m ean percentage phago­
cy to sis  ±  S E M , n =  75 . * * * ,  p  <  0 .0 0 1 .
S er u m -d ep en d en t e n h a n ce m e n t o f  p h a g o c y to s i s  o f  a p o p to t i c  
n e u tro p h ils  d o e s  n o t  r e q u ir e  c o m p le m e n t  a c tiv a tio n
Down-regulation o f complement regulatory molecules CD55 (de­
cay-accelerating factor), CD46 (membrane cofactor protein), and 
CD35 (CR1) on the surface of human apoptotic neutrophils (31) 
may allow complement proteins present in serum to bind, and 
hence promote their removal by phagocytes (11). W e found that 
addition o f commercially available Clq-depleted human serum
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Serum: —  —  AS C1q —  Serum:—  —  AS C1qJ' C1qJ'
Add back:—  —  —  —  C1q T “
Pre-treatment:—  —  —  sCR1 PBS
F IG U R E  2 . G lu cocortico id -en h an ced  phagocytosis o f  apoptotic ce lls 
does not require com plem en t activation. Phagocytosis o f  apoptotic neutro­
phils by untreated MDM<)> ( □ )  and D ex-M D M cjt ( ■ )  was assessed in a 
30-m in assay by flow  cytom etry. A , Phagocytosis o f  apoptotic neutrophils 
by D ex-M D M 4> in the presence o f  serum  was not augm ented by C lq -  
depleted serum  (C lq d), w hereas addition o f  7 0  jug/ml C lq  failed  to restore 
augm entation o f  phagocytosis (n =  3 ; * * * ,  p  <  0 .0 0 1  com pared with 
Dex-MDMr#) in the presen ce o f  serum ). B, Serum  derived fro m  eith er 
male (M ) o r fem a le  (F )  C lq -d e f ic ie n t  m ice  restored  serum -depend ent 
augm entation o f  p h ag o cy to sis  o f  ap o p totic  n eu troph ils by D ex -M D M tj) 
(n =  3 ; * * ,  p  <  0 .0 1  co m p ared  w ith D e x -M D M ^  in the a b se n ce  o f  
serum ). C , A u tologous serum  (A S ) pretreated with 2 5 0  jug/ml solu ble hu­
man rC R l to  inhibit C 3  activation  o r with P B S  as a control for 10 min did 
not affect p h agocytosis o f  apoptotic neutrophils by Dex-MDM<j> in the 
presence o f  serum  (n =  4 ; N S ), and D, heat inactivation o f  autologous 
serum (H I A S ; 5 6 °C  for 3 0  m in) failed  to affect phagocytosis o f  apoptotic 
neutrophils by Dex-MDM<f> (n =  4 ; N S). D ata are m ean percentage phago­
cytosis ±  S E M .
failed to confer augmentation of phagocytosis (Fig. 2A), suggest­
ing that C lq  was the serum opsonin binding to apoptotic neutro­
phils. However, addition of 70 /ug/ml human C lq  alone (Fig. 2A) 
or to Clq-depleted serum (data not shown) did not restore phago­
cytosis by Dex-MDMtj> to levels observed in the presence of au­
tologous serum. In a series of experiments examining the effects of 
sera from different species, we noted that augmentation of phago­
cytosis by Dex-MDMt/t was also observed when apoptotic neutro­
phils were incubated in serum obtained from mice, allowing us to 
use specific knockouts to define serum components (data not 
shown). W e found that serum derived from either male or female 
Clq-deficient mice was able to significantly augment phagocytosis 
of apoptotic neutrophils by Dex-MDMt/>, demonstrating that C lq  
was not the serum opsonin required (Fig. 2B). We next inhibited 
complement activation and subsequent deposition of C3b on the 
surface o f apoptotic neutrophils by pretreating autologous serum 
with 250 p.g/ml C3 inhibitor for 10 min before the assay. The 
effects o f C3 inhibitor-treated serum were indistinguishable from 
control PBS-treated serum in enhancement of Dex-MDMcf> phago­
cytosis (Fig. 2 C). Further confirmation of a lack of requirement for 
complement activation and opsonization of targets was made 
through use o f heat-inactivated serum (Fig. 2D).
Identification o f  a serum component required fo r  augmentation 
of apoptotic neutrophil phagocytosis by Dex-MDMf>
A number of serum factors have been reported to modulate apo­
ptotic cell phagocytosis by macrophages, ranging from small mol­
ecules to very large protein complexes. A series of experiments 
using size fractionation of serum indicated the serum component to
T ab le  I. Effect o f  sera  and serum proteins on D ex-M D M (b  
phagocytosis"
Add Back (during phagocytosis)
Phagocytosis by Dex-MDMd: 
(as percentage o f phagocytosis 
by Dcx-MDM<J) in the absence 
o f serum)
A utologous serum 3 0 1 .4
U ltracentrifuged autologous serum 2 9 3 .8
M urine serum 491 .1
B o v in e  serum 2 4 1 .8
IgG 109 .8
Pentraxin-3 113 .4
Fibronectin 9 7 .9
Platelet releasate 8 4 .7
“ Data are shown as percentage o f phagocytosis relative to that recorded for Dex- 
MDM (/j in the absence of serum (equivalent to 100%) for at least three independent 
experiments.
be greater than 100 kDa (data not shown). W e initially sought to 
use an “add back” approach to evaluate the role o f well-charac­
terized serum proteins in the observed opsonization phenomenon. 
This strategy eliminated a role for IgG, pentraxin-3, fibronectin, 
platelet-derived factors, and immune complexes (Table I). An- 
nexin I and lipoxin A4 are anti-inflammatory mediators that are 
regulated by glucocorticoids and can act to stimulate phagocytosis 
o f apoptotic cells through the formyl-peptide receptor-like 1 (32). 
However, pretreatment of Dex-MDM<j> with 10 ju,M W RW 4 (a 
formyl-peptide receptor-like 1 antagonist) for 1 h before assess­
ment of phagocytosis of apoptotic neutrophils in the presence of 
10% autologous serum showed no inhibitory effects (50.5 ± 9 .1 %  
and 42.5 ±  6.5%  for Dex-MDMtf> with or without pretreatment; 
mean percentage phagocytosis ±  SD, n = 3). Similarly, compar­
ison of phagocytosis of apoptotic cells in the presence of either 
control or annexin I-deficient mouse serum demonstrated that this 
pathway is not used by Dex-MDM</> for recognition of apoptotic 
neutrophils (80.4 ±  6.3%  and 79.3 ±  3.23%  for Dex-MDMtj> in 
the presence of wild-type and annexin I knockout serum, respec­
tively; mean percentage phagocytosis ±  SD, n =  3).
Identification o f  a serum fraction with phagocytic activity
Preliminary experiments showed that the serum factor could be bound 
to Q Sepharose in a 50 mM HEPES buffer at pH 7.0 or above and 
eluted with 0.2 M NaCl (data not shown). Because fewer proteins 
would bind at pH 7.0, we ran subsequent separations at this pH to 
facilitate identification of the factor. Further fractionation of the 0.2 M 
NaCl eluate using Sephacryl S-300 column yielded two partially over­
lapping peaks of protein with descending size (Fig. 3, A and B), as 
might be expected for a crude protein fraction with the first peak, 
representing high molecular mass proteins (> 3 0 0  kDa), able to confer 
augmentation of phagocytosis (Fig. 3C).
Identification o f  the serum component using mass spectrometry
Mass spectrometry analysis of the major proteins present in the 
high molecular mass fraction revealed that the principal proteins 
present were IgM, a 2-macroglobulin, and C4-binding protein 
(C4BP), most likely in complex with protein S (33). The presence 
of protein S in the high molecular mass fractions isolated from gel 
filtration chromatography was confirmed by immunoblotting anal­
ysis (Fig. 3D). Previous work had eliminated a role for IgM in the 
augmentation of phagocytosis of apoptotic cells by Dex-MDM<j> 
(data not shown). Phagocytosis o f apoptotic neutrophils by Dex- 
MDMcj> in the presence of 20 /xg/ml a 2-macroglobulin was not 
augmented, suggesting that a 2-macroglobulin was not involved 
either (Fig. 4A), whereas addition of purified protein S during the
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F IG U R E  3 . Identification o f  a high m olecular m ass facto r required for 
augm entation o f  phagocytosis using an ion -exch ange chrom atography and 
gel filtration. Serum  proteins w ere fractionated using a com bination  o f  
anion-exchange chrom atography (Q  Sep harose) together with gel filtration 
(Sephacryl S -3 0 0 )  o f  a  0 .2  M  N aCI eluate from  the Q -Sep h arose colum n. 
A, Protein elution profile o f  a  typical gel filtration separation (o f  five that 
were perform ed) determ ined by m easurem ent o f  absorbance at 2 8 0  nm 
(A 280) reveals tw o partially overlapping peaks o f  protein. B, G el filtration 
samples (labeled  A -G )  w ere separated by S D S -P A G E  on a 9 %  gel under 
reducing conditions and stained with 0 .5 %  C oom assie blue (M , m olecular 
mass m arker; 0 .2 , 0 .2  M  N aCI elu ate). C , T h e effect o f  different protein 
fractions on phagocytosis o f  apoptotic neutrophils by Dex-M DM <)) ( ■ )  was 
determined using a 30-m in  phagocytosis assay. Sam ples w ere standardized 
for protein content, and phagocytosis o f  apoptotic neutrophils by untreated 
MDM</> ( □ )  is show n for com parison. S ig nificant augm entation o f  D ex- 
MDM<£ phagocytosis o f  apoptotic neutrophils w as observed for tw o frac­
tions. D ata  are m ean ±  S E M ; n =  3. * * * ,  p  <  0 .0 0 1 , and * * ,  p  <  0 .01  
compared with Dex-MDM<1> in the absen ce o f  serum . D , T h e  presence o f  
protein S  in the high m olecular m ass gel filtration fraction  (fraction  A ) was 
confirm ed by im m unoblotting, as described in M aterials and M ethods.
assay restored phagocytosis of apoptotic neutrophils by Dex- 
MDMc/> to levels similar to those observed in the presence of 10% 
serum (Fig. 45 ). We therefore tested whether immunodepletion of 
protein S from the 0.2 M NaCI eluate affected D ex-M D M $ phago­
cytosis of apoptotic neutrophils. As shown in Fig. 5A, immu­
nodepletion did not result in the nonspecific removal of proteins 
from the 0.2 M NaCI eluate as assessed by total protein staining. 
Confirmation of the depletion o f protein S from the 0.2M  NaCI 
eluate containing the prophagocytic activity was made by immu-
S e ru m : —  —  AS
P ro te in  S: —  —  —  25000 2500 750 250 75 25
(n g /m l)
F IG U R E  4 . Protein S , but not a 2-m acroglobulin , stim ulates phagocyto­
sis o f  apoptotic neutrophils by D ex -M D M cf. T h e effect o f  addition o f  e ither 
2 0  p-g/ml a 2-m acroglobulin  (A) or different concentrations o f  protein S (B) 
on phagocytosis o f  apoptotic neutrophils by Dex-MDM<f> ( ■ )  was assessed 
in a 30-m in  assay. P h agocytosis o f  apoptotic neutrophils by untreated 
M DM cp ( □ )  is show n for com parison. Addition o f  a 2-m acroglobulin  failed 
to restore augm ented ph agocytosis by D ex-M D M rf), w hereas protein S  sig ­
n ificantly augm ented m acrophage phagocytosis at concentrations o f  2 5 0  
ng/ml or higher. D ata are m ean ±  S E M ; n =  3 . * * * ,p  <  0 .0 0 1 , and * ,p  <  
0 .0 5  and N S, com pared with Dex-MDM<#> in the absen ce o f  serum .
noblotting (Fig. 55). In contrast to a mock Ab depletion o f the 0.2 
M NaCI eluate, protein S-depIeted 0.2 M NaCI eluate failed to 
confer augmentation of phagocytosis by Dex-MDM<(> (Fig. 5C). 
Together with data presented in Fig. 3C, these data suggested that 
protein S, possibly complexed with C4BP, was required to confer 
full phagocytic capacity o f Dex-MDMc(>. Interestingly, addition 
of 250 ng/ml purified human protein S (equivalent to the con­
centration o f protein S present in 1% serum) to protein S-de- 
pleted 0.2 M NaCI eluate from ion-exchange chromatography 
fully restored Dex-MDMc/> phagocytosis (Fig. 5C). These data 
raised the possibility that protein S acts as an opsonin, binding 
to the surface o f apoptotic neutrophils to specifically promote 
clearance by Dex-MDMc/>.
P ro te in  S b in d s to  a p o p to t ic  n e u tro p h ils  in a  c a lc iu m -d ep en d e n t  
m a n n er  to  m ed ia te  th e ir  r e m o v a l  b y  D ex -M D M cj)
To confirm that protein S was able to opsonize apoptotic neutro­
phils, we preincubated serum-free apoptotic neutrophils with either 
the high molecular mass fraction from gel filtration chromatogra­
phy or 2.5 /xg/ml human protein S before washing in IMDM with 
or without the addition of 5 mM EDTA. Binding of protein S to 
neutrophils in a Ca2+-dependent manner could be detected by flow 
cytometry using anti-protein S Ab together with CD 16 staining to 
define apoptotic and nonapoptotic cells (29). The possibility that 
anti-protein S Abs were binding nonspecifically through FcR-me- 
diated interactions was excluded by use o f a rabbit Ig control (Fig. 
6 A ) and by mAb blockade o f FcyRIIa (data not shown). In the 
presence of Ca2+, protein S binds to apoptotic (CD 16 low-express­
ing) and also nonapoptotic (CD 16 high-expressing) cells, but the
















I I Control 
l? I Dex
Serum: — —
Protein S: — —
F IG U R E  5 . Protein  S  depletion from  a 0 .2  M  N aCl elution fraction from  
Q -Sepharose abolished augm entation o f  phagocytosis by Dex-MDM</). Im - 
munodepletion o f  protein S  w as achieved by three rounds o f  depletion 
using a p o lyclon al rabbit anti-protein  S  A b and agarose-coupled goat anti­
rabbit Ig G , as detailed in M aterials and M ethods. A  m ock depletion was 
perform ed using agarose-coupled goat anti-rabbit IgG  alone. Sam ples were 
separated by S D S -P A G E  on a 9 %  gel under nonreducing conditions and 
then transferred to n itrocellu lose. A, T h e  presence o f  protein S  ( —85 kD a) 
in the 0 .2  M  N aC l eluate from  an ion-exchange chrom atography and in 
depleted fraction s was confirm ed by co llo id al gold labeling o f  transferred 
protein ( lane 1, 0 .2  M  N aCl elu ate; lane 2 , protein S-depleted 0 .2  M  N aCl 
eluate; lane 3, m ock  depletion o f  0 .2  M  eluate; lane 4, anti-protein S- 
im m unodepleted m aterial, to confirm  the presence o f  protein S ). B, Sp ecific  
depletion o f  protein S in the sam ples shown in A was confirm ed by im- 
m unoblotting, as described in M aterials and M ethods. In view  o f  the pres­
ence o f  A b in the im m unodepleted sam ple (lane  2 ) , only the outlined sec­
tion o f  the m em brane in A is show n. C, T h e effects o f  protein S depletion 
upon phagocytosis o f  apoptotic neutrophils by Dex-M DM d> ( ■ )  were as­
sessed in a 30-m in  assay. P h agocytosis o f  apoptotic neutrophils by un­
treated M D M e) ( D )  is show n for com parison. In contrast to  a m ock de­
pletion o f  protein S  (P S md), protein S  depletion from  a 0 .2  M  N aCl fraction 
(PSd) abolished augm entation o f  phagocytosis by Dex-M DM(f>, an effect 
that was restored by addition o f  2 5 0  ng/ml human protein S  (equivalent to 
level in 1%  autologous serum ). D ata are m ean ±  S E M ; n =  3 . * ,  p  <  0 .05  
compared with Dex-MDM</> in the presence o f  0 .2  M  N aC l eluate.
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F I G U R E  6 . Protein S  binds to neutrophils in a calciu m -dep endent m an­
ner and co n fers augm entation o f  phagocytosis by Dex-MDMc(>. N eutro­
phils cultured for 2 0  h in serum -free conditions w ere preincubated with 1% 
autologous serum  for 3 0  min in the presence o f  1.5 m M  C a C l2. During 
subsequent steps, incubations w ere perform ed in T B S  in either the presence 
or absen ce o f  1.5 m M  C aC l2 throughout. N eutrophils w ere w ashed before 
labeling  with either A, rabbit Igs (as co n tro l), or B  and C, rabbit anti-hum an 
protein S  for 3 0  m in. N eutrophils were then w ashed tw ice , labeled with 
PE -co n ju g ated  C D  16 m A b for 2 0  m in, and w ashed before flow  cy tom etric  
analysis. L ev els  o f  C D 1 6 expression  can  be used to  define apoptotic (low ), 
secondarily  necrotic (interm ediate), and nonapoptotic (h igh) neutrophils. 
R epresentative histogram s for binding in either the p resen ce (A and B) or 
absen ce (C ) o f  1.5 m M  C aC l2 are show n. D , C alcium -dependent effects o f 
protein S  upon phagocytosis o f  neutrophils cultured for 2 0  h in serum -free 
conditions. Preincubation o f  neutrophils with either 10%  autologous serum  
or 2 5 0  ng/ml purified protein S  for 1 h, follow ed by w ashing in either the 
presen ce (IM D M ) or absen ce (5 m M  E D T A ) o f  divalent cation s before 
assessm ent o f  phagocytosis o f  apoptotic neutrophils in a 30-m in  assay by 
untreated MDM<j) ( □ )  and D e x -M D M ^  ( ■ ) .  A ugm entation o f  p h agocy­
tosis o f  apoptotic neutrophils by D ex-M D M <j) follow ing  protein S  prein­
cubation  w as lost w hen neutrophils were w ashed in E D T A -co n ta in in g  
IM D M  before assessm ent o f  phagocytosis. D ata  are m ean ±  S E M ; n =  3. 
* * * ,  p  <  0 .0 0 1  com pared with D ex-M D M (j> in the presence o f  protein S.
level of binding to apoptotic cells was 2.3-fold higher relative to 
that observed for nonapoptotic cells (Fig. 65). In contrast, protein 
S binds poorly to cells in the absence of divalent cations (Fig. 6C). 
Interestingly, high levels o f protein S binding to secondarily ne­
crotic cells was observed (CD 16 intermediate cells; Fig 6A), as 
demonstrated for many other opsonins, including C-reactive pro­
tein and C lq  (23, 34). Apoptotic neutrophils bind protein S when 
washed in divalent cation-containing medium, but not when
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F IG U R E  7 . Protein S-enhanced phagocytosis by Dex-MDMc(> is depen­
dent on M ertk. A , Surface expression o f  M er on MDMc£> was assessed by 
indirect im m unofluorescence together with flow cytometry. Representative 
overlay histograms show expression o f  M ertk and C D 44 for untreated M D M ^  
(dotted lines) and D ex -M D M ^  (solid lines) compared with binding o f  control 
IgG l m Ab. Expression o f  M ertk (as determined by mean fluorescence inten­
sity) was increased 1.6-fold in five separate comparisons that were made. In 
contrast, C D 4 4  expression was down-regulated on the surface o f  Dex-MDM((>, 
as previously reported (7). Preincubation o f  Dex-MDMcJ> ( ■ )  with 10 /ag/ml 
anti-M er A b fo r 10 min inhibited subsequent phagocytosis o f  apoptotic 
neutrophils in the presen ce o f  either 2 .5  /xg/ml protein S  (B) or 10%  au­
tologous serum  (C ). Pretreatm ent w ith an ti-M er alone had no effect on 
phagocytosis by Dex-MDM(/> in the absen ce o f  protein S  or serum . D ata 
are m ean ±  S E M ; n =  3. * * * ,  p  <  0 .0 0 1 , and * ,  p  <  0 .0 5 .
washed in EDTA-containing medium, consistent with a calcium- 
dependent opsonization event (Fig. 6D). However, we also ob­
served low levels o f protein S binding to nonapoptotic neutrophils 
in the presence of divalent cations, suggesting that the prophago- 
cytic effect of protein S on uptake o f apoptotic neutrophils by 
Dex-MDM^) may require additional cell surface signals.
We also tested the effects o f preincubation of neutrophils with or 
without protein S and then anti-protein S Ab before assessment of 
phagocytosis. In two experiments that were performed, the results 
for glucocorticoid-treated macrophages were as follows: no serum 
(18%), 1% serum (56% ), and 1% serum plus anti-protein S (68%). 
One possibility is that binding of anti-protein S Ab to neutrophils 
(as shown in Fig. 6 , A -Q  may lead to their opsonization with IgG 
leading to phagocytosis by FcyR-mediated pathways. In the ab­
sence of commercially available Fab' preparations of anti-protein 
S Ab to test this possibility directly, we used function-blocking 
mAb, IV .3, to block the interaction of IgG bound to the neutrophil 
surface with macrophage FcyRII (CD32). Treatment with IV .3 did 
not influence phagocytosis (65%  phagocytosis for Dex MDM^) 
with 1% serum plus anti-protein S ; 62%  phagocytosis for 
DexMDM4> with 1% serum plus anti-protein S in the presence of 
IV.3; n = 2). These data may indicate either that the polyclonal Ab 
to protein S used in this study does not neutralize the prophago- 
cytic activity or that multiple FcyRs (FC7RIII and/or FcyR I) ex­
pressed by MDM(/> mediate the uptake of anti-protein S-opsonized 
neutrophils.
Protein S-enhanced phagocytosis by Dex-MDMcj) is dependent 
on Mertk
Surface expression of Mertk, a potential receptor for protein S 
(35), was increased (1.6-fold) on Dex-MDMc/> compared with un­
treated MDMc() (Fig. 7A), consistent with previous reports using
oligonucleotide arrays (8). The observed up-regulation of Mertk 
expression was not due to a nonspecific increase in receptor ex­
pression because CD44 was decreased on the surface of Dex- 
MDM<£ relative to untreated MDMc£ (Fig. 1A). To assess the 
contribution of Mertk to protein S-dependent phagocytosis, Dex- 
MDM(|> were pretreated with an anti-human Mer Ab for 10 min 
before phagocytosis. Although anti-Mer had no effect on phago­
cytosis in the absence o f protein S, anti-Mer significantly inhibited 
phagocytosis by Dex-MDMc^ in the presence of 2.5 p,g/ml protein 
S (Fig. IB). Similar experiments were undertaken to determine 
whether Abs to protein S would exert similar inhibitory effects on 
phagocytosis. However, pretreatment of neutrophils with anti­
protein S resulted in an augmentation o f macrophage phagocytosis, 
possibly through an opsonization event (see Fig. 6) leading to 
FcyR-mediated phagocytosis. In contrast, blockade of Mer also 
significantly inhibited phagocytosis in the presence of 10% autol­
ogous serum, implying that the Mertk pathway is critical for glu­
cocorticoid augmentation o f phagocytosis o f apoptotic neutrophils 
(Fig. 1C). We also examined the effects o f short-term treatment of 
MDMc/> with Dex upon the protein S dependency of phagocytosis 
of apoptotic neutrophils. MDM(/> that had been cultured in the 
absence of Dex for 96 h were then treated for 24 h with Dex. 
Compared with untreated MDM<£ (18 ±  5%  phagocytosis in the 
absence of protein S), 96- to 120-h Dex-treated MDM<£ had 
slightly higher basal levels o f phagocytosis o f apoptotic cells in the 
absence of protein S (25 ±  6%), but exhibited increased phago­
cytosis in the presence of protein S (60 ±  8%).
Discussion
In this study, we have examined the mechanisms that underlie the 
requirement for semm in augmentation of human macrophage 
phagocytosis of apoptotic neutrophils following treatment with 
glucocorticoids. We demonstrated that protein S opsonizes early 
apoptotic neutrophils (induced by treatment with roscovitine) to 
promote their internalization by Dex-MDM<i>, and that the pres­
ence of cells that had undergone secondary necrosis was not nec­
essary. This is an important observation because a number of se­
rum opsonins have been reported to bind to late apoptotic or 
secondary necrotic neutrophils, including C lq , and the pentraxins, 
C-reactive protein and pentraxin-3 (18, 23, 34). Restoration of 
phagocytic capacity o f Dex-M D M ^ by a high molecular mass se­
rum fraction raised the possibility o f a requirement for a C4BP- 
protein S complex, which has been reported to inhibit phagocytosis 
of apoptotic lymphocyte cell lines (36). Our data showing the pres­
ence of protein S in the high molecular mass fraction would imply 
that the C4BP-protein S com plex can augment phagocytosis 
under some circumstances. Because protein S binding can be 
demonstrated following incubation o f neutrophils cultured in 
the absence o f serum with either the high molecular mass frac­
tion from gel filtration or purified protein S, one possibility is 
that under certain conditions, protein S can dissociate from 
C4BP and subsequently oligom erize at the apoptotic neutrophil 
surface (35). Our data clearly demonstrate that protein S alone 
is able to confer the augmentation o f phagocytosis of apoptotic 
neutrophils that we observe.
The importance of complement proteins in apoptotic cell opso­
nization has been highlighted in studies o f complement deficiency. 
In C lq  deficiency, impaired clearance o f apoptotic cells is thought 
to contribute to the development of an systemic lupus erythema- 
tosus-like autoimmune disease (27). For Dex-MDM(/>, C lq  did not 
restore levels of phagocytosis to those observed in the presence of 
serum even when Clq-binding proteins such as pentraxin-3 or fi- 
bronectin (37, 38) were present. Moreover, Clq-deficient mouse 
serum was able to confer phagocytic activity, demonstrating that
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Clq was not required for efficient phagocytosis of apoptotic neu­
trophils by Dex-MDM<j>. W e were also unable to demonstrate a 
role for opsonization of apoptotic neutrophils with C3bi for re­
moval through CR3 and CR4, as reported by Elkon and colleagues
(11). Furthermore, the data presented in this study argue against a 
role for IgG, pentraxin-3, fibronectin, annexin I, platelet-derived 
factors, and immune complexes in phagocytosis o f apoptotic neu­
trophils by Dex-MDMc/).
We believe that this is the first report demonstrating a switch in 
the molecular mechanism used by human MDMc/> for apoptotic 
cell clearance. Our observations are clearly different from the in­
duction o f phosphatidylserine-dependent recognition of apoptotic 
murine thymocytes by bone marrow-derived murine macrophages 
treated with /31,3 glucan reported by Fadok et al. (39). Treatment 
with /31,3 glucan did not increase phagocytic potential when com­
pared with untreated bone marrow-derived macrophages, but did 
alter the molecular mechanism used. In contrast, our findings dem­
onstrate that phagocytosis o f apoptotic cells by Dex-MDM<j) is 
profoundly augmented by glucocorticoids, promoting a critical 
switch from a protein S-independent to a protein S-dependent rec­
ognition pathway.
The tissue microenvironment has the potential to influence the 
mechanisms involved in apoptotic cell removal and thus apoptotic 
cell clearance capacity. The cytokine and matrix composition will 
determine the differentiation status of phagocyte populations dur­
ing progression o f an inflammatory response. Interestingly, protein 
S-dependent recognition of an apoptotic B  cell line was previously 
characterized in MDM(j> generated by differentiation in M -CSF 
(35), which promotes the development of M2 macrophages that 
have anti-inflammatory phenotype properties and respond to TLR 
stimulation by producing IL-10 (40). W e find that when MDM<j> 
were cultured in the presence of autologous serum, apoptotic cell 
recognition pathways that are used are predominantly protein S 
dependent-independent (as shown in Fig. 1). In contrast with dex- 
treated MDM<j>, these MDMc/> have a more proinflammatory phe­
notype and release IL-12 in response to T L R  stimulation, suggest­
ing that protein S-dependent recognition pathways may be 
restricted to macrophage phenotypes associated with resolution of 
inflammation.
The production and release o f potential opsonins (complement 
components, pentraxins, annexins, protein S, etc.) are also regu­
lated during inflammation. A number o f reports indicate that in­
flammation and the coagulation cascade are closely regulated, par­
ticularly during the acute-phase response. Protein S is produced in 
the liver and by endothelial cells (41). Production o f both protein 
S and C4BP in the liver appears to be controlled by inflammatory 
mediators, including IL -6 (42, 43). Levels of protein S are reduced 
in patients with ischemic stroke (44) and in patients with sepsis 
(45), possibly via the effects of TNF on endothelial cells (46). In 
contrast, glucocorticoids have been reported to elevate levels of 
protein S (47). Based upon data presented in this work, we propose 
that a major effect of glucocorticoids on macrophage differentia­
tion is the induction of the capacity to recognize a distinct set of 
molecular cues that are presented on the apoptotic cell surface. 
Apoptotic cells display a complex surface molecular signature as a 
consequence o f cell death with altered expression of receptors to­
gether with binding (or opsonization) of a number of different pro­
teins. One implication of our observation is that the surface mo­
lecular signature of an apoptotic cell may be interpreted differently 
by different phagocyte populations.
We have also examined the effects o f treatment of differentiated 
MDM(j> with Dex for 24 h (6 ) upon acquisition of the capacity for 
protein S-dependent phagocytosis of apoptotic cells. Our data sug­
gest that augmentation of phagocytosis observed following short­
er-term treatment is also associated with use of a protein S-depen- 
dent pathway for recognition o f apoptotic cells. Because both 
untreated MDM</> and Dex-MDM(/> populations examined in this 
study express Mertk, the reason that Dex-MDMcj) are enabled to 
use a protein S-dependent clearance pathway is not clear. One 
possibility is that the observed up-regulation of Mertk expression 
on the surface of Dex-MDM<j> may be sufficient to confer phago­
cytic potential. Alternatively, Mertk may interact with other re­
ceptors on the cell membrane following glucocorticoid treatment. 
Ligand-activated Mertk forms dimers in the membrane, resulting 
in Mertk autophosphorylation and activation (48), and may het- 
erodimerize with other Tyro3/Axl/Mer family receptors or co ­
operate with other receptors involved in the phagocytic process, 
such as scavenger receptor A (49) or a vj35 (50). Induction of 
cooperative action o f receptors may allow regulation o f phago­
cytosis o f apoptotic cells in response to different environmental 
cues encountered during the inflammatory response.
Alternatively, glucocorticoids may influence engagement of 
downstream signaling pathways critical for Mertk-dependent 
phagocytosis. We have previously demonstrated that glucocorti­
coid-treated MDM(j> exhibited reduced phosphorylation and local­
ization of paxillin and pyk2 to podosome-like adhesion structures, 
together with increased Rac activity (7). Interestingly, Rac guanine 
nucleotide exchange factor Vavl is activated downstream of Mertk 
(51). Mertk has also been reported to induce FAK phosphorylation 
and recruitment to a v/35 and formation of pl30Cas/CrkII/Dockl 80 
complex (50, 52). One possibility is that phosphorylation of Mertk 
at Tyr867 in the absence o f assembly of adhesion structures pro­
motes MDM<j> phagocytic activity (52).
Induced expression of Mertk and protein S by glucocorticoids 
may promote acquisition of a negative-feedback pathway to both 
switch off proinflammatory cytokine production (53) and enhance 
phagocytic capacity for apoptotic cells. The efficacy of glucocor­
ticoids in treatment o f autoimmune diseases such as systemic lupus 
erythematosus that are characterized by impairment of apoptotic 
cell clearance may be due, in part, to engagement of these pro­
resolution mechanisms. Manipulation of the Mertk pathway may 
represent a novel approach to engage aspects of glucocorticoid 
action that favor resolution of inflammation without promoting 
deleterious side effects.
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Summary
Receptors for im munoglobulins (Fc receptors) play a central role during an 
im m une response, as they mediate the specific recognition o f antigens of 
almost infinite diversity by leucocytes, thereby linking the humoral and cel­
lular components o f immunity. Indeed, engagement o f  Fc receptors by im m u­
noglobulins initiates a range of im munoregulatory processes that might also 
play a role in disease pathogenesis. In the circulation, five main types of 
im m unoglobulins (Ig) exist -  namely IgG, IgA, IgE, IgM and IgD and recep­
tors with the ability to recognize and bind to IgG (Fey receptor family), IgE 
(FceRI and CD23), IgA (CD89; Fca/|iR ) and IgM (Fca/pR) have been iden­
tified and characterized. However, it is astonishing that nearly all the known 
human Fc receptors display extensive genetic variation with clear implications 
for their function, thus representing a substantial genetic risk factor for the 
pathogenesis o f a range o f chronic inflammatory disorders.
Keywords: Fc receptors, im m u noglobu lins, polym orphism s, copy nu m ber 
variation, chronic in flam m atory diseases
The Fey receptor family
Im m unoglobulin G (IgG) is the m ost abundant Ig class 
in serum, constituting over 75%  o f circulating im m uno­
globulin. It mediates key effector functions through interac­
tion with Fey receptors, which are encoded by eight different 
genes, each with multiple transcriptional isoform s and 
located in a locus on the long arm o f  chrom osom e 1 ( lq 21-  
23). Fey receptors are related structurally and belong to the Ig 
protein superfamily with multiple Ig-like domains. Fey 
receptors are divided generally into three main classes: FcyRI 
(C D 64), FcyRI I (C D 32) and FcyRIII (C D 16), each with 
distinct structural and functional properties (Fig. 1).
FcyRI is a high-affinity receptor for m onom eric IgG 
(Ka: 109- 1 0 lo/M) with three extracellular Ig-like domains 
expressed constitutively by monocytes and macrophages, as 
well as by many myeloid progenitor cells. Three genes coding 
for FcyRI have been characterized: FCGR1A, FCGR1B and 
FCGR1C [1]. However, it is generally accepted that only 
FcyRIa is capable o f  IgG binding, whereas FcyRIb and FcyRIc 
possibly represent truncated or soluble form s o f the receptor, 
with poorly characterized function. The a  ligand-binding 
chain o f FcyRI associates with a disulphide-bonded dimer o f
FcR y chain, a signal transducing polypeptide described 
originally as a com ponent o f the high affinity IgE receptor 
that associates with various Fc receptors. The y chain carries 
an activatory signalling m o tif (im m unoreceptor tyrosine- 
based activation motif: ITAM ), which mediates signal trans­
duction upon FcyRI engagement.
In contrast to FcyRI, the other two classes o f  Fey receptor, 
FcyRII and FcyRIII, display low affinity for m onom eric IgG. 
They are capable o f binding to aggregated IgG through 
m ultim eric low-affinity, high-avidity interactions, which are 
particularly im portant in the recognition and binding o f 
antibody-antigen complexes during an im m une response. 
IgG binding to low-affinity FcyR can trigger a range o f  effec­
tor and im m unoregulatory functions, including degranula­
tion, phagocytosis and regulation o f antibody production
[2]. Exam ination o f the genom ic organization o f  the FcyRII 
and FcyRIII locus suggests that these receptors arose as a 
consequence o f  multiple gene duplication and recom bina­
tion processes, followed by gain-of-function mutations. 
FcyRII is encoded by three genes: FCGR2A, FCGR2B and 
FCGR2C. All the mem bers o f  the FcyRII class share a char­
acteristic structure unique to FcyRII, that includes functional 
signalling m otifs in their cytoplasm ic domains, namely
244 © 2009 British Society for Immunology, Clinical and Experimental Immunology, 157 : 244-254
Fe receptor genetic variants and disease
F ig. 1. Overview  o f  th e Fey receptor family. 
M<p, m acrophages; D C , d en d ritic cells; PM N , 
p olym orph onu clear leucocytes; IFN -y, 
in terferon-y ; G -C SF, granulocyte 
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ITAM for FcyRlla and FcyRIIc and immunoreceptor 
tyrosine-based inhibition m otif (IT IM ) for FcyRIIb. FcyRII 
is expressed by diverse cell types: FcyRlla by myeloid cells, 
including polym orphonuclear leucocytes, monocytes, 
macrophages, platelets and certain types o f endothelial cells; 
FcyRIIb by B cells, m onocytes and macrophages; while 
FcyRIIc expression is restricted solely to natural killer (NK) 
cells.
The other low -affinity Fey receptor, FcyRIII, is encoded 
by genes FCGR3A and FCGR3B. Although FcyRllla and 
FcyR lllb share high levels o f  sequence homology, they 
exhibit distinct structural differences. FcyRllla is a trans­
m em brane protein that associates with the FcRy chain, 
whereas FcyR lllb  is processed post-translationally as a gly- 
cosylphosphatidylinositol (G PI)-anchored protein, lacking 
transm em brane and intracellular domains. This difference is 
thought to be the result o f  an original gene duplication o f the 
ancestral gene followed by point m utation in the mem brane 
proximal region o f  the extracellular domain that created a 
G PI-anchor signal sequence (serine at position 203 rather 
than the phenylalanine present in the transmem brane 
FcyR llla). The FcyR llla isoform  is expressed widely by 
several leucocyte cell types, including macrophages, NK cells 
and subsets o f  T  cells and m onocytes, while FcyRlllb is 
expressed constitutively only by neutrophils [2 ].
The Fee receptor family
Although norm ally present in serum at very low levels, IgE 
may be up-regulated in certain individuals where it associ­
ated with atopy, and in im m une responses to certain para­
sites where it is believed to play a protective role. Unlike Fey 
receptors, there are no structural similarities shared by the 
two classes o f  IgE receptors: FceRI, representing the high- 
affinity receptor for IgE, and FceRII (C D 23), a lower-affinity 
receptor. FceRI is a heterotetram eric structure that is com ­
prised o f one a  subunit, one P subunit and a hom odim er o f 
the FcRy subunit, encoded by FCERI A, MS4A2 and FCERI G 
genes, respectively. The a  subunit mediates IgE binding and 
its structure resembles closely those o f  the Fey receptors, as it 
consists o f two extracellular Ig-like domains with a trans­
m em brane and a cytoplasmic region. The P subunit o f  FceRI 
is a 4-CC helix m em brane-spanning protein with tyrosine 
phosphorylation motifs in its C-term inal cytoplasm ic 
region. Recent studies have dem onstrated that it exists in two 
splice variant form s, the P and pT, the latter having a role in 
the cellular targeting o f  FceRIa [3]. Finally, the y  subunit 
together with the p subunit facilitates signalling following 
engagement o f  FceRIa. FceRI is expressed constitutively by 
mast cells and basophils, whereas m onocytes, eosinophils 
and dendritic cells express FceRI, but only in its trim eric 
form (a,y-y), lacking the P subunit [3],
FceRII (C D 23) is the low-affinity receptor for IgE, having 
an affinity o f approximately 107/M. It is expressed constitu­
tively by B cells and is involved in the regulation o f  IgE 
production by B cells -  a role related to that o f  FcyRIIb. In 
addition, it has been dem onstrated that several cell types, 
including eosinophils, neutrophils, macrophages, m onocytes 
and T  cells, up-regulate FceRII expression upon treatm ent 
with interleukin (IL )-4  [4]. FceRII can also bind and interact 
with other molecules, such as CD 21, C D llb  and C D llc ,  
although the functional significance o f  these interactions is 
still being defined. FceRII displays susceptibility to pro­
teolytic cleavage by A disintegrin and m etalloproteinase 
(ADAM) sheddases and soluble FceRII has been reported to 
have mitogenic properties [5,6],
Receptors for IgM and IgA
A num ber o f  receptors specific for IgA and IgM have been 
characterized, including the polym eric im m unoglobulin 
receptor (plgR) and Fca/pR. These two receptors bind to 
IgA and IgM with intermediate affinity and are encoded by 
the PIGR and FCAMR genes present at the same locus on 
chrom osom e 1 (1 q32). Fca/|iR is expressed by mature B cells 
and macrophages, as well as in secondary lymphoid organs 
such as lymph nodes, intestine and appendix, and it is there­
fore anticipated that it possesses a range o f  im m unoregula- 
tory roles [7]. In contrast, plgR is expressed predom inantly 
on the basolateral surface o f  epithelial cells and is involved in 
the transport o f  mucosal IgA and IgM across the epithelia 
[ 8 ],
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T able 1. Fun ction al effects o f  genetic variants o f  Fc receptors.
R eceptor G ene Variant Effect Reference
FcyRIIa FCGR2A R 131H H 131: h igher affinity for IgG2 [12]
FcyR IIb FCGR2B I2 3 2 T T 2 3 2 : low er affin ity  for lipid rafts/decreased in h ib itory  activity 17,18
- 3 8 6 G  > C -3 8 6 C : h igher p rom oter activity [23]
- 3 4 3 G  > C -3 4 3 C : loss o f  AP-1 b in din g  site/transcriptionally repressed [24]
—120T  >  A -1 2 0 A : h igher p rom oter activity [23]
FcyRIIc FCGR2C Q 5 7 X T runcated n o n -fu n ction al protein [21]
- 3 8 6 G  > C -3 8 6 C : increased p rom oter activity [21]
—120C  > A -1 2 0 A : linked w ith h igher transcrip tional activity [21]
C N V [21]
FcyRIIIa FCGR3A V 158F V I 58: h igher affin ity  for Ig G l and 3, binds IgG 4 [14]
C N V [35]
F cyR IIIb FCGR3B NA1/2 NA1: h igher affin ity  for Ig G l and 3 [15]
SH/A78D U nknow n -  linked to  the NA2 allele [16]
C N V 33 ,108
F ceR I a  chain FCERI A —6 6 T  >  C - 6 6 T :  h igher p rom oter activity  -  additional GATA-1 b in din g  site [26]
-3 1 5 C  > T -3 1 5 T : increased transcrip tional activity  -  S p l site [27]
- 3 3 5 T  >  C -3 3 5 C : increased expression? [109]
FceR I P chain MS4A2 - 4 2 6 T  >  C -4 2 6 C : increased p rom oter activity [31]
-6 5 4 C  >  T -6 5 4 T : increased p rom oter activ ity -Y Y -1 binding 28,31
- 1 0 9 C  > T -1 0 9 T : unknow n/higher receptor expression [28]
E 237G G 237 : associated w ith h igher expression [88]
I181L L 181: unknow n/higher expression? [88]
V 183L L 183: unknow n/higher expression? [88]
FceR II FCER2 R 62W W 62: resistant to  proteolytic cleavage [5]
p lgR PIGR A 580V V 580 : near en d oproteolytic cleavage site/reduced efficiency o f  IgA release? [8]
F c a R I FCAR S248G G 248: enhanced  IgA -m ediated responses; increased cytokin e release [19]
Ig: im m un oglobulin .
Although plgR and Fca/|iR, along with several other m ol­
ecules, can bind specifically to IgA, the only ‘classical’ Fc 
receptor specific for IgA is FcaR I (C D 89) [9]. W hile the 
ligand-binding (a )  chain o f F caR I is related structurally to 
those o f  FcyR and FceRI it is a more distantly related 
m em ber o f the family, and the FCAR gene maps to chrom o­
som e 19, alongside genes for leucocyte Ig-like receptors and 
natural killer cell receptors (K IR s). Like many o f the FcyR 
and FceRI, the F ca R I a chain associates with a hom odimer, 
the FcRy chain, although it is often expressed in the absence 
o f FcRy chain pairing.
Fc receptor genetic variation -  implications 
for function
Single nucleotide polymorphisms (SNPs)
The vast m ajority o f  the Fc receptor encoding genes display 
genetic variation either in the form o f SNPs or alteration in 
their copy number. Although many SNPs have been identi­
fied for Fc receptors, for m ost o f them their precise impact 
upon receptor function remains unknown. Functionally rel­
evant genetically determined SNPs can be categorized into 
three m ain types, based on the effect they have on receptor
function: (i) augmenting the affinity o f Fey receptors for 
particular IgG subclasses; (ii) altering the receptor function 
and consequently downstream effector events; and (iii) 
affecting transcriptional prom oter activity or mechanisms 
that alter the levels o f receptor expression (Table 1).
One o f the first functional SNP identified for Fc receptors 
was the R131H  allelic variant for the low-affinity Fey receptor 
FcyRIIa. This point m utation (519G  > A) results in an amino 
acid substitution [arginine (R) to histidine (H )] at position 
131, which is located in the m em brane proximal Ig-like 
domain o f the extracellular region [10]. Recent crystallo- 
graphic studies, along with previous mutational analyses, 
indicated that this region is involved in the receptor interface 
interacting with the Fc portion o f  IgG [11] and the R131H  
variant determines the affinity o f FcyRIIa for hum an IgG2. In 
particular, while the R131 variant is not able to interact with 
hIgG2, H131 has been shown previously to bind and enable 
phagocytosis o f hIgG2-coated particles [12], The H131 
variant might be particularly im portant in conditions char­
acterized by high IgG2 antibody responses, where it may 
confer enhanced leucocyte activation by IgG2 and increased 
capacity for clearance o f circulating IgG2 complexes.
SNPs affecting the binding affinity for IgG subclasses 
have also been characterized for FcyRIII. There are two
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co-dom inantly expressed allelic variants o f FcyRIIIa having 
either a valine (V) or a phenylalanine (F) at position 158. 
This single amino acid substitution has been demonstrated 
to increase the affinity o f the V I 58 allotype for IgG l and 
IgG3 com pared to F I 58 and induce capacity for IgG4 
binding [13,14], Furtherm ore, IgG-induced NK cell activity 
has been found to be increased significantly in 158V/V rather 
than the 158F/F individuals.
FcyRIIIb is characterized by the presence o f the human 
neutrophil antigen (HNA or NA), a polym orphic variant 
that comprises four non-synonym ous and one synonymous 
m utation within the m em brane distal Ig-like domain o f the 
receptor. The four amino acid differences between the two 
NA allotypes (NA1 or H N A -la and NA2 or H N A -lb) have 
an im pact on the N -linked glycosylation o f the receptor, and 
as a consequence affect the affinity for IgG subclasses. In 
particular, the NA1 allotype displays increased binding and 
phagocytosis o f Ig G l- and IgG3-coated particles and it has 
been shown to exhibit higher affinity for IgG3 compared to 
the NA2 allotype [15]. Apart from NA-1 and NA-2, the SH 
polym orphism (also termed as H N A -lc) has been added to 
the NA family o f FcyRIIIb polymorphisms [16], The SH 
allele determines the substitution o f alanine at position 78 to 
aspartic acid (A 78D ) and is linked mainly to the NA2 allele; 
however, the precise role o f this polym orphism in IgG 
binding is unknown.
In addition to the polym orphism s augmenting receptor 
affinity for IgG subclasses, SNPs that have a profound 
im pact on the functional effector responses o f Fc receptors 
following im m unoglobulin binding have been described. 
For example, in the case o f the inhibitory Fey receptor 
FcyRIIb, it has been demonstrated that a change o f a non­
polar isoleucine to a polar threonine at position 232 
(I232T ) within the transm em brane region could affect 
receptor activity. The T232 variant has been shown to be 
translocated less efficiently to m em brane domains rich in 
cholesterol and sphingolipids, termed as lipid rafts [17,18]. 
As a consequence, reduced inhibitory activity was observed 
for the T 232, due possibly to impaired interaction with 
protein kinases that reside preferentially in lipid raft m em ­
brane domains.
A recently identified functional polym orphism in FceRII 
is the arginine (R) to tryptophan (W ) substitution at posi­
tion 62 (R 62W ). In contrast to the R62 variant, the W 62 
variant is resistant to proteolytic shedding following treat­
m ent with a broad range o f  different proteases, which might 
influence receptor function and mitogenic role [5]. Finally, a 
relatively com m on polym orphism identified in the coding 
region o f F ca R I is associated with impaired capacity to 
trigger mechanisms such as cytokine release [19]. This poly­
m orphism  (844A  > G) involves the change o f serine 248 to 
glycine (S248G ) within the cytoplasmic domain o f the recep­
tor’s a  chain [20]. IgA-mediated cross-linking o f FcocRI on 
neutrophils from individuals homozygous for the G248 
variant triggered significantly more IL-6 release than equiva­
lent cross-linking o f  receptor on neutrophils from donors 
homozygous for the S248 variant. In fact, the G 248 form , 
unlike the S248 variant, is capable o f  inducing cytokine 
release in the absence o f  the FcRy chain. This capacity is 
presumed to be due, at least in part, to its ability to interact 
directly with the Src family m em ber Lyn, an im portant com ­
ponent o f  the F ca R I signalling cascade.
A num ber o f  SNPs have been characterized that play a 
regulatory role in the expression o f  particular Fey and Fee 
receptors. For example, within exon 3 o f the FCGR2C gene, 
a single nucleotide substitution at position 202 results in the 
change o f a glutam ine residue to a stop codon at position 57 
(Q 57X ), resulting in the production o f a non-functional, 
truncated protein. Furtherm ore, NK cells from heterozygous 
57Q/X donors displayed reduced expression com pared to 
57Q/Q donors, while homozygous 57X/X donors were nega­
tive for NK cell surface receptor expression [21].
Another determ inant o f the levels o f  receptor expression 
are SNPs within the upstream prom oter sequences that may 
affect the transcriptional activity o f  the promoter. For 
example, two SNPs, -3 8 6 G  > C and -1 2 0 T  > A, have been 
identified within the almost identical prom oter regions o f the 
genes encoding the FcyRIIb and FcyRIIc receptors [21,22]. 
Using in vitro prom oter activity assays, it has been shown that 
the less frequent -3 8 6 C  and -1 2 0 A  haplotypes exhibit 
enhanced transcriptional activity com pared to th e -3 8 6 G  and 
—120T ones, due m ainly to the differential binding o f GATA-4 
and Yin-Yang 1 (YY-1) transcription factors [22,23]. In addi­
tion, genetic linkage was observed between the -3 8 6 C  and 
—120A alleles. Furtherm ore, an additional polym orphic site 
(G to C substitution at the -3 4 3  position; —343G  > C) within 
the prom oter o f  the FCGR2B gene enables the interaction 
o f the YY-1 transcription factor, leading to transcriptional 
repression o f FCGR2B via com petition for binding with the 
c-Jun/AP-1 transcription com plex [24,25]. Given the high 
sequence sim ilarity between the FCGR2B and the FCGR2C 
gene prom oters, the -3 4 3 G  > C polym orphism would also be 
predicted to be present w ithin the FCGR2C promoter.
Similarly, within the prom oter o f the gene coding for the a 
chain o f  the FceRI (FCER1A), a num ber o f SNPs, including 
- 66T  > C, —315C  > T  and —335C  > T, have been shown to 
regulate receptor expression through differential binding 
and transactivation o f transcription regulatory factors. For 
example, the - 66T variant displayed increased in vitro tran­
scriptional activity com pared to the - 66C form , because the 
form er has an additional GATA-1 binding m otif [26]. Sim i­
larly, the C to T  substitution at position -3 1 5  (also referred 
as -3 4 4 )  was associated with significantly higher prom oter 
activity, an effect that was attributed to the binding o f Sp l 
transcriptional regulator [27], Similar SNPs have been iden­
tified in the prom oter regions o f the gene encoding for the (3 
chain o f the FceRI receptor [2 8 -3 0 ]. Increased binding o f 
YY-1 and consequently higher prom oter activity has been 
observed for the -4 2 6 C  and -6 5 4 T  haplotypes, compared 
with the -4 2 6 T  and -6 5 4 C  haplotypes [31],
© 2009 British Society for Immunology, Clinical and Experimental Immunology, 157 : 244-254 247














Fig. 2. C opy n u m b er variation  o f  the Fey receptor locus revealed by 
genom e-w ide analysis. A rray com parative genom e hybridization 
data from  the W h ole G en om e T ilePath (W G T P ) p ro ject o f  the 
Sanger In stitu te (based  on R edon etal. [1 0 6 ], available at 
http://www.sanger.ac.uk/humgen/cnv/data/). Log intensity  ratios from  
2 70  H apM ap sam ples for n in e probes w ithin the lq23  region o f  
ch rom oso m e I ,  w here the Fey receptor locus is m apped. C ontrary  to 
o ther probes, d istin ct clusters o f  in tensity  ratios w ith in  the Fey 
receptor p robe (8 H 4 ) reveal extensive gene copy variation ranging 
from  zero to  m ore than  three copies. S im ilar analyses o f  the sam e 
exp erim en tal dataset for th e loci where o ther Fc receptor genes are 
m apped revealed m in im al variation  in  intensity  ratios am ong the 
H apM ap individuals (data n o t show n). A notable exception was the 
F c a R  locus (1 9 q l3 )  th at displays significant variation , due probably  to 
the close p roxim ity  o f  th e FCAR  gene w ith the KIR  fam ily genes, 
w hich have been  described previously to  exh ib it extensive 
co p y -n u m ber variation  [107].
Copy number variation
Apart from  SNPs, a num ber o f recent studies have dem on­
strated that genes coding for Fey receptors exhibit variation 
in their copy numbers. Indeed, whole genome scans revealed 
that over 12%  o f  the human genome is covered by copy 
num ber variation, accounting for a great proportion o f 
genetic diversity between individuals (reviewed in [32]). In 
addition, astonishingly high variation has been noted within 
the Fey receptor locus (Fig. 2), but not within the loci where 
the genes coding for other Fc receptors are mapped. Copy 
num ber variation has been demonstrated for FCGR3B, 
FCGR2C and FCGR3A genes, but not for FCGR2A or 
FCGR2B. For FCGR3B, W illcocks and co-workers [33] have 
dem onstrated recently an association between gene copy 
num ber and surface expression o f FcyRIIIb in neutrophils. 
In addition, neutrophils isolated from donors with more 
than two gene copies displayed enhanced IgG-induced effec­
tor responses as well as increased cell adherence in IgG-
coated surfaces compared with those from  donors with less 
than two [33]. Similarly, NK cells from individuals with two 
or three copies o f FCGR3A tend to express higher levels o f 
receptor and exhibit greater antibody-dependent killing 
capacity than those from individuals with one copy o f  the 
gene [21], Based on these findings, it is anticipated that 
higher copy numbers o f  the FcyRIIc gene may be associated 
with increased levels o f surface receptor expression and 
potentiation o f responses following stim ulation with IgG. 
Although a num ber o f studies have made use o f well- 
validated com plem entary techniques for the assessment o f 
copy num ber variation, there is controversy on the accuracy 
and sensitivity o f som e o f  these techniques, as they are still at 
an early stage o f technical development.
Fc receptor genetic variants as risk factors for 
chronic inflammatory diseases
The link between Fc receptor genetic variants and disease 
pathogenesis has been the subject for intensive investigation 
for a num ber o f decades and it is accepted widely that they 
play a crucial role in the pathogenesis o f  a range o f  chronic 
inflam m atory diseases, constituting significant genetic risk 
factors for disease development and prognosis. Based on the 
functional implications o f the Fey receptor polym orphic 
and copy num ber variants, they can be categorized into 
either low- or high-responder variants. Low-responder 
polym orphic variants o f Fey receptors, for example R131, 
F158 and NA2 for FCGR2A, FCGR3A and FCGR3B, respec­
tively, as well as a low num ber o f genom ic copies, are asso­
ciated usually with autoim m une pathologies that are 
characterized by the presence o f circulating IgG complexes 
[3 4 -3 6 ], Reduced efficiency o f  IgG -Fc interactions with 
these low-responder variants may com prom ise clearance o f 
IgG complexes from circulation, leading to their deposition 
in peripheral tissues; a process that initiates or exacerbates 
inflam m atory processes with detrim ental effects. Alter­
natively, high-responder variants are linked to chronic 
inflam m atory disorders characterized by excessive or inap­
propriate leucocyte activation [3 7 -3 9 ], These variants may 
result in more efficient and prolonged Fc-Ig G  interactions. 
Reduced threshold for IgG-m ediated cellular effector 
responses could prom ote leucocyte infiltration into tissues 
together with the release o f  histotoxic and cytotoxic com ­
pounds that amplify inflam m atory cell-m ediated tissue 
damage [40]. A num ber o f  chronic inflam m atory diseases 
(summarized in Table 2) have been shown to be associated 
with Fey receptor genetic variants and include (but are not 
lim ited to) autoim m une pathologies, such as systemic lupus 
erythematosus (SLE) [1 4 ,1 7 ,22 ,24 ,25 ,36 ,41 -60], rheum a­
toid arthritis [3 5 ,6 1 -6 6 ], myasthenia gravis [67,68], certain 
neuropathies[6 9 -7 2 ], acute allograft rejection [73] and 
vascular inflam m atory and throm botic disorders, such 
as coronary artery stenosis, peripheral atherosclerosis and 
vasculitis [37 ,38 ,74 -81].
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Table 2 . A ssociation  o f  Fey receptor variants w ith ch ron ic in flam m atory  diseases.
G ene V ariant Disease Reference
FCGR2A H 131 G BS [72]
R131 A cute renal allograft re jec tio n , A PS, g iant cell arteritis, H IT, 
ITP, IgA nephropathy, lupus nephritis, M G  severity, 
peripheral atherosclerosis, RA severity, RF, SLE, W G
[3 4 ,3 6 ,3 8 ,3 9 ,4 1 -4 4 ,4 6 ,4 7 ,4 9 ,5 2 ,5 7 ,6 4 ,6 6 ,6 8 ,
7 3 ,7 4 ,7 7 ,8 0 -8 2 ,1 1 0 -1 1 8 ]
FCGR2B - 1 2 0  A SLE, C ID P [22 ,71]
- 3 4 3 C SLE [24 ,25]
- 3 8 6 C SLE, C ID P [22 ,71]
T 232 SLE [1 7 ,5 3 ,5 7 -6 0 ]
FCGR2C H igh C N V IT P [21]
FCGR3A F 158 C o ron ary  artery  stenosis, g iant cell arteritis , lupus 
n ephritis, SLE, W G
[ 1 4 ,3 7 -3 9 ,4 6 ,5 0 -5 3 ,8 2 ,8 3 ,1 1 9 ]
V 158 ACPA-positive RA, allergic rh in itis, bron ch ial asthm a, H IT, 
ITP, IgA nephropathy severity, rheum atoid  factor 
p rod u ction , RA
[3 5 ,6 1 -6 3 ,6 5 ,7 5 ,7 8 ,1 1 0 ,1 2 0 ,1 2 1  ]
FCGR3B NA1 AN CA vasculitis, ITP, M G  severity [67 ,76 ,79 ]
NA2 G BS severity, lupus nephritis, SLE [5 5 -5 7 ,6 9 ,7 0 ]
H igh C N V A N CA -positive vasculitis [33]
Low CN V SLE, lupus nephritis [33 ,86 ,108 ]
ACPA: an ti-citru llin ated  protein/peptide an tibodies; AN CA: an ti-n eu trop h il cytoplasm ic antibodies; A PS: an ti-ph osph olip id  syndrom e; C ID P : 
ch ron ic in flam m atory  dem yelinating polyneuropathy; CN V: copy n um ber variation; G BS: G u illa in -B arre  syndrom e; H IT : h eparin -ind uced  th ro m b ­
ocytopen ia ; Ig: im m u n oglobu lin ; IT P : id iopathic th ro m bo cy top en ia  purpura; M G : m yasthenia gravis; NA: neu troph il antigen; RA: rheum atoid  arthritis; 
R F: rh eu m atic fever; SLE: system ic lupus erythem atosus; W G : W egener’s granulom atosis.
Although there is substantial evidence for the role o f Fey 
receptor variants with susceptibility to all these diseases, SLE 
represents a prototype, m ulti-organ, antibody-mediated 
autoim m une disorder, characterized classically by elevated 
circulating IgG complexes. SLE has been shown to be 
associated strongly with almost all known Fey receptor poly­
m orphic and copy num ber variants. Several groups have 
reported an increased frequency o f  the low-responder allele 
o f FcyRIIIa, F158 among SLE patients [14 ,46 ,50 -53 ,82 ,83 ], 
Furtherm ore, this allele displays preferential segregation 
with affected individuals from multiplex SLE families, indi­
cating clearly that it represents a significant risk factor for 
SLE susceptibility [84], For FcyRIIa, the R131 allele has been 
shown to be associated with SLE in several ethnic groups, an 
observation that was confirm ed further by recent m eta­
analyses [36,49]. Similarly, increased frequency am ong SLE 
patients o f  the low-responder allele o f  FcyRIIIb, NA2 has 
been reported widely [5 5 -5 7 ]. It should be noted that there 
have been several reports that describe the lack o f association 
o f these polym orphism s with SLE, due possibly to the high 
genetic variation o f these polymorphisms in populations o f 
different origin [50,51,56,85]. In addition, although autoan­
tibodies o f all three m ajor subclasses (Ig G l, IgG2 and IgG3) 
can be detected in SLE patients, heterogeneity o f  the anti­
body subclass responses and differential clinical exacerba­
tions am ong these patients could also constitute an 
additional determ inant that accounts for the lack o f associa­
tion between particular Fey receptor polymorphisms with 
disease susceptibility.
A num ber o f  polym orphism s within the FCGR2B coding 
and prom oter regions that are linked to the development of 
SLE have been identified. M any o f these variants exhibit 
decreased activity or expression o f FcyRIIb that would prob­
ably affect B cell function and antibody production, as well 
as the activity o f other cell types such as m onocytes and 
macrophages. A notable example is the transm em brane 
polymorphism T 232, which displays lower affinity for lipid 
rafts, and as a consequence it exhibits decreased inhibitory 
activity and has been shown to be associated with SLE, 
at least in Asian populations [1 7 ,5 3 ,57 -60]. Similarly, the 
—343C  allele that displayed repressed FCGR2B prom oter 
activity was enriched am ong SLE patients, compared to 
disease-free controls [24,25]. O ther SNPs within the pro­
moter o f FCGR2B are - 3 8 6 G > C  and - 1 2 0 T > A , which 
exhibit genetic linkage. Interestingly, Su and colleagues 
reported that the frequency o f  the -3 8 6 C  and -1 2 0 A  alleles, 
which exhibit enhanced transcriptional activity, was 
increased in Caucasian patients with SLE compared to eth­
nically matched controls [22]. The functional relevance o f 
this finding remains to be determined, but one possibility is 
that these polymorphisms (-3 8 6 G  > C ,-1 2 0 T  > A) m ight be 
linked genetically to other as-yet unidentified polym or­
phisms associated with SLE, or their over-representation in 
the SLE cohort to be due to their low haplotype frequency in 
the tested population. Finally, variation in the copy number 
o f FCGR3B has been identified as an additional determinant 
for the development o f  SLE. In two independent studies, low 
copy numbers o f the FCGR3B gene was associated strongly
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T able 3. Role o f  IgE, IgA and IgM  receptor SN Ps in disease pathogenesis.
Receptor SNP D isease Reference
FceR I a  chain - 6 6 T  >  C Atopy, high IgE levels in  asthm a [26]
- 3 1 5 C > T A sp irin-in to lerant ch ron ic urticaria , high IgE levels [98]
- 3 3 5 T > C H igh IgE levels [109]
FceR I ß chain E 237G A topic asthm a, high IgE levels, atopy, airway hyperresponsiveness, 
allergic rh in itis, asthm a
[8 8 ,9 0 -9 7 ,1 2 2 ]
I181L Atopy, asthm a [88,89]
- 1 0 9 C  > T H igh IgE levels [2 8 -3 0 ,9 5 ]
F c a R I S248G SLE [19]
p ig R A 580V IgA nephropathy [8]
Ig: im m u n oglobu lin ; SLE: system ic lupus erythem atosus; SN P: single nucleotid e polym orphism .
with SLE, as the percentage o f individuals with less than two 
genom ic copies o f FCGR3B was significantly higher in the 
SLE compared to the control study cohort [33,86]. Reduced 
surface expression o f FcyRIIIb in these individuals may com ­
promise the clearance o f IgG complexes, increasing the risk 
for the development o f SLE.
Apart from Fey receptors, polym orphism within FcaR I 
has been associated with SLE, in that the proinflam m atory 
G 248 allele has been found to be enriched in SLE popula­
tions [19] (Table 3). In addition, several Fee receptor poly­
morphism s have been linked with the development o f 
allergy-related chronic inflam m atory diseases, and new asso­
ciations continue to be reported [87] (Table 3). In particular, 
polymorphisms within the gene coding for the P subunit o f 
the FceRI (MS4A2) have been shown to be associated 
strongly with atopy, asthma, airway hyperresponsiveness, 
allergic rhinitis, serum IgE levels, atopic asthma and atopic 
dermatitis [2 8 -3 0 ,8 8 -9 7 ]. The extent o f  the im pact o f these 
polymorphisms on receptor function and properties is 
under investigation. M any atopy-associated SNPs within the 
prom oter o f FCER1A have been reported to determine tran­
scriptional activity and subsequently receptor expression. In 
particular, th e -6 6 T ,- 3 15T a n d -3 3 5 C  alleles, which differ in 
their frequency between atopic and non-atopic subjects, at 
least in som e populations, were associated strongly with 
increased serum IgE [26,27,98]. As the levels o f  IgE in circu­
lation are correlated greatly with the surface expression o f 
FceRI, these polymorphisms might affect receptor expres­
sion directly or indirectly and consequently the effectiveness 
o f  IgE-mediated cellular responses.
In summary, Fc receptors have a key role in the regulation 
o f im m une cell function and the polym orphic and copy 
num ber variants identified so far undoubtedly contribute to 
the development o f  a num ber o f chronic inflammatory 
diseases. Apart from these diseases, Fc receptor polym or­
phisms have also been shown to be associated strongly with 
susceptibility to pathogens, constituting a m ajor genetic risk 
factor for a num ber o f  infectious d iseases[99-103]. Further­
more, recent advances in the therapeutic use o f intravenous 
im m unoglobulins have highlighted the role o f Fc receptor
polymorphisms in the clinical outcom e and therapeutic 
responsiveness [104,105]. One o f the future challenges is to 
determine the precise role o f the different classes o f hum an 
Fc receptors in the control o f innate and acquired im m une 
responses and define how the observed genetic variation 
contributes to disease pathogenesis.
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Correspondence
Identification of Fibrocytes in Peripheral Blood
T o  t h e  E d i t o r .
Dr. M oeller and colleagues have concluded in their article on 
fibrocytes in idiopathic pulm onary fibrosis (IP F ) that fibrocytes 
comprise m ore than 10% o f circulating leukocytes (white blood 
cells) in many patients (1). H ow ever, the overriding question 
must be: W hat do they look like? It would have been a simple 
m atter to use fluorescence-activated cell sorting to separate these 
collagen 1-positive cells and look at them under a microscope. 
This would have been a key experim ent because in our opinion 
there has never been any convincing dem onstration that fibro­
cytes can be detected at all in peripheral blood.
In 1994 B ucala and cow orkers reported that spindle-shaped 
cells appeared in adherent populations o f human leukocytes 
after at least 14 d in culture (2). These fibrocytes stained with 
mesenchymal (connective tissue) m arkers, as well as the bone 
marrow stem  cell m arker C D 34. M oeller and cow orkers (1) used 
an antibody recognizing a single m esenchym al m arker (collagen 
1) to label freeze-thaw ed, fixed, perm eabilized peripheral blood 
leukocytes from patients with stable and exacerbating IPF . 
However, the broad spread of laser side-scatter o f the “positive” 
cells suggests that they are not a distinct population o f fibrocytes, 
but rather a m ixture of different leukocytes (Figure IE ) .
Positive staining with the rabbit polyclonal collagen 1 anti­
body might have been due to antibody cross-reactivity, aggrega­
tion of cells, or Fey receptor binding. A  polyclonal antibody is 
actually a m ixture o f antibody m olecules which bind to different 
protein epitopes. Polyclonal antibodies are prone to bind “non- 
specifically” to proteins other than the one used to immunize the 
animal (collagen 1 in this case). T herefore, positive staining 
should have been validated by using a panel o f antibodies that 
recognize other m esenchym al and leukocyte m arkers and CD 34. 
Also, we do not know w hether the antibody caused cell aggrega­
tion, which could also result in increased fluorescence.
A  further problem  is that the use o f a “control” antibody may 
be insufficient to control for the fact that antibody preparations 
contain variable amounts o f aggregated IgG , which exhibits high 
avidity binding to F ey receptors on m onocytes, granulocytes, and 
some lymphocytes. This problem  can be circumvented by using 
Fab ' or F (a b ')2 antibody fragm ents which lack the F c  region.
M oeller and cow orkers’ article suggests that there is som e­
thing different about the leukocytes o f patients with IPF. 
However, our technical concerns about the data presented in this 
article indicate that the existence o f the enigm atic fibrocytes in 
peripheral blood rem ains unproven.
Conflict o f Interest Statement: S.B. has no financial relationship with a commercial 
entity that has an interest in the subject of this manuscript. A.F. has no financial 
relationship with a commercial entity that has an interest in the subject of this 
manuscript. S.P.H. received up to $1,000 from Actelion for advisory board 
activities; he has received lecture fees from GlaxoSmithKline ($1,001-$5,000), 
and Boehringer Ingelheim (up to $1,000); he has received a grant from Argenta 
for a clinical trial ($10,001-$50,000).
S t y l i a n o s  B o u r n a z o s  
University o f  Edinburgh/MRC Centre fo r  
Inflammation Research 
Edinburgh, United Kingdom
A h m e d  F a h im  
S im o n  P. H a r t  
Hull York M edical School 
Cottingham, United Kingdom
References
1. M o elle r A , G ilp in  S E , A sk  K , C o x  G , C o o k  D , G auld ie J ,  M arg etts  P J ,
F ark as L , D ob ran o w sk i J ,  B o y lan  C , et al. C ircu latin g  fibrocytes are  an 
in d icato r o f  p o or prognosis in id iopathic pulm onary fibrosis. A m  J 
Respir Crit Care M ed  2 0 0 9 ;1 7 9 :5 8 8 -5 9 4 .
2. B u ca la  R , Sp iegel L A , C hesney  J ,  H ogan M , C eram i A . C irculating
fibrocytes define a new leu kocyte subpopulation that m ed iates tissue 
repair. M ol M ed  1 994 ;1 :71 -81 .
F r o m  t h e  A u t h o r s :
W e thank D rs. Bournazos, Fahim , and H art for their interest in 
our article (1). In their letter they com m ent that the “overriding 
question must be: W hat do they [fibrocytes] look lik e?” W e 
want to point out that the presence o f fibrocytes in the 
circulating blood and tissue o f animals and humans has been 
confirmed by several independent groups. Fibrocytes com prise 
a substantial proportion o f circulating leukocytes in pulm onary 
fibrosis both in human interstitial lung disease (2 ) and animal 
models o f pulmonary fibrosis (3, 4). In addition, the m orpho­
logical characteristics o f fibrocytes have been published pre­
viously, both in cells isolated from  the peripheral blood (5 ) and 
in the lungs of patients with idiopathic pulmonary fibrosis (IP F ) 
(6 ). W e therefore disagree with the statem ent that redem ons- 
trating the m icroscopic appearance o f fibrocytes would consti­
tute a “key experim ent” for our study.
Side-scatter on flow cytometry is proportional to the internal 
complexity of cells; as such, the spread of side-scatter in the 
collagen-1 positive cells is merely indicative o f the variability of 
their internal complexity. W e routinely exclude cell aggregates and 
preblock nonspecific binding with serum and human IgG , as should 
be done in all flow cytometry staining, so these are not a likely 
explanation for false-positive (nonspecific) staining. W hile it is true 
that affinity-purified polyclonal A bs are a mixture of several Abs 
that by definition bind different specific A g epitopes, negative 
staining with the control affinity-purified polyclonal A bs validates 
the specificity of the stain. E xternal validation, including staining of 
fibrocytes with other mesenchymal markers, has been published 
previously (6). In addition, these cells have been found to stain for 
procollagens in animal models, further validating their expansion 
in the context o f fibrosis (7).
The key observation in our article (1) was not to dem onstrate 
that the fibrocyte pool is expanded in patients with IP F  since this 
has been shown before. O ur intent was to dem onstrate that the 
circulating num ber o f fibrocytes was associated with both exac­
erbations o f IP F  and a predictor (biom arker) o f m ortality in these 
patients.
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